{"e0a778fcfc70c148e8e0a19a174d06b2a7f25958": [["IntroductionSpleen tyrosine kinase (Syk) is expressed widely in the immune system including in leukocytes, platelets and dendritic cells [1] .", [["immune system", "ANATOMY", 68, 81], ["leukocytes", "ANATOMY", 95, 105], ["platelets", "ANATOMY", 107, 116], ["dendritic cells", "ANATOMY", 121, 136], ["tyrosine", "CHEMICAL", 19, 27], ["tyrosine", "CHEMICAL", 19, 27], ["IntroductionSpleen tyrosine kinase", "GENE_OR_GENE_PRODUCT", 0, 34], ["Syk", "GENE_OR_GENE_PRODUCT", 36, 39], ["immune system", "ANATOMICAL_SYSTEM", 68, 81], ["leukocytes", "CELL", 95, 105], ["platelets", "CELL", 107, 116], ["dendritic cells", "CELL", 121, 136], ["IntroductionSpleen tyrosine kinase", "PROTEIN", 0, 34], ["Syk", "PROTEIN", 36, 39], ["leukocytes", "CELL_TYPE", 95, 105], ["platelets", "CELL_TYPE", 107, 116], ["dendritic cells", "CELL_TYPE", 121, 136], ["IntroductionSpleen tyrosine kinase (Syk)", "TREATMENT", 0, 40], ["leukocytes", "TEST", 95, 105], ["platelets", "TEST", 107, 116], ["dendritic cells", "PROBLEM", 121, 136], ["leukocytes", "ANATOMY", 95, 105], ["dendritic cells", "OBSERVATION", 121, 136]]], ["A wide variety of cell surface receptors on immune system cells and other cell types have been postulated to transduce signals via the binding and activation of Syk [2] [3] [4] [5] .", [["cell surface", "ANATOMY", 18, 30], ["immune system cells", "ANATOMY", 44, 63], ["cell", "ANATOMY", 74, 78], ["cell", "CELL", 18, 22], ["immune system cells", "CELL", 44, 63], ["cell", "CELL", 74, 78], ["Syk [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 161, 180], ["cell surface receptors", "PROTEIN", 18, 40], ["immune system cells", "CELL_TYPE", 44, 63], ["Syk", "PROTEIN", 161, 164], ["A wide variety of cell surface receptors", "PROBLEM", 0, 40], ["immune system cells", "PROBLEM", 44, 63], ["other cell types", "PROBLEM", 68, 84], ["Syk", "TEST", 161, 164], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["variety", "OBSERVATION_MODIFIER", 7, 14], ["cell", "OBSERVATION", 18, 22], ["surface", "OBSERVATION_MODIFIER", 23, 30], ["cell types", "OBSERVATION", 74, 84]]], ["For the most part these include receptors bearing the immunoreceptor tyrosine-based activation motif (ITAM) [2] .", [["tyrosine", "CHEMICAL", 69, 77], ["tyrosine", "CHEMICAL", 69, 77], ["immunoreceptor tyrosine-based activation motif", "PROTEIN", 54, 100], ["ITAM", "PROTEIN", 102, 106], ["receptors bearing the immunoreceptor tyrosine", "TREATMENT", 32, 77]]], ["However, other non-ITAM-bearing receptors such as those for IL-2, IL-15, erythropoietin and lipopolysaccharide (endotoxin/LPS) have also been postulated to signal via the activation of Syk [6] [7] [8] [9] .IntroductionThe FceRI receptor complex is expressed on mast cells, basophils and eosinophils and signal transduction following the binding of IgE/allergen leads to Syk binding and phosphorylation [3, 10] .", [["mast cells", "ANATOMY", 261, 271], ["basophils", "ANATOMY", 273, 282], ["eosinophils", "ANATOMY", 287, 298], ["lipopolysaccharide", "CHEMICAL", 92, 110], ["endotoxin", "CHEMICAL", 112, 121], ["LPS", "CHEMICAL", 122, 125], ["IL-2", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-15", "GENE_OR_GENE_PRODUCT", 66, 71], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 73, 87], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 92, 110], ["endotoxin", "SIMPLE_CHEMICAL", 112, 121], ["LPS", "SIMPLE_CHEMICAL", 122, 125], ["Syk [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 185, 204], ["FceRI receptor", "GENE_OR_GENE_PRODUCT", 222, 236], ["mast cells", "CELL", 261, 271], ["basophils", "CELL", 273, 282], ["eosinophils", "CELL", 287, 298], ["IgE", "GENE_OR_GENE_PRODUCT", 348, 351], ["Syk", "GENE_OR_GENE_PRODUCT", 370, 373], ["non-ITAM-bearing receptors", "PROTEIN", 15, 41], ["IL", "PROTEIN", 60, 62], ["IL-15", "PROTEIN", 66, 71], ["erythropoietin", "PROTEIN", 73, 87], ["endotoxin", "PROTEIN", 112, 121], ["Syk", "PROTEIN", 185, 188], ["FceRI receptor complex", "PROTEIN", 222, 244], ["mast cells", "CELL_TYPE", 261, 271], ["basophils", "CELL_TYPE", 273, 282], ["eosinophils", "CELL_TYPE", 287, 298], ["IgE", "PROTEIN", 348, 351], ["Syk", "PROTEIN", 370, 373], ["IL", "TEST", 60, 62], ["IL", "TREATMENT", 66, 68], ["erythropoietin", "TREATMENT", 73, 87], ["lipopolysaccharide (endotoxin/LPS", "TREATMENT", 92, 125], ["The FceRI receptor complex", "TREATMENT", 218, 244], ["basophils", "TEST", 273, 282], ["eosinophils", "TEST", 287, 298], ["signal transduction", "TREATMENT", 303, 322], ["IgE/allergen leads", "TREATMENT", 348, 366], ["Syk binding", "PROBLEM", 370, 381], ["mast cells", "OBSERVATION", 261, 271]]], ["Syk is then believed to mediate the direct phosphorylation several proteins within an inflammatory complex including linker for activator of T cells (LAT), SH2-domain-containing leukocyte protein-76 (SLP-76) and Vav [3] .", [["T cells", "ANATOMY", 141, 148], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["activator of T cells", "GENE_OR_GENE_PRODUCT", 128, 148], ["LAT", "GENE_OR_GENE_PRODUCT", 150, 153], ["SH2-domain-containing leukocyte protein-76", "GENE_OR_GENE_PRODUCT", 156, 198], ["SLP-76", "GENE_OR_GENE_PRODUCT", 200, 206], ["Vav", "GENE_OR_GENE_PRODUCT", 212, 215], ["Syk", "PROTEIN", 0, 3], ["inflammatory complex", "PROTEIN", 86, 106], ["linker for activator of T cells", "PROTEIN", 117, 148], ["LAT", "PROTEIN", 150, 153], ["SH2", "PROTEIN", 156, 159], ["leukocyte protein-76", "PROTEIN", 178, 198], ["SLP", "PROTEIN", 200, 203], ["Vav", "PROTEIN", 212, 215], ["the direct phosphorylation several proteins", "PROBLEM", 32, 75], ["an inflammatory complex", "PROBLEM", 83, 106], ["activator of T cells", "TEST", 128, 148], ["SH2", "TEST", 156, 159], ["leukocyte protein", "TEST", 178, 195], ["SLP", "TEST", 200, 203], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98], ["Vav", "ANATOMY", 212, 215]]], ["Following the assembly and activation of this complex of proteins, activation of MAPKs, calcium-flux and PLCc1 and PLCc2 phosphorylation lead to degranulation, lipid mediator and cytokine synthesis.", [["calcium", "CHEMICAL", 88, 95], ["calcium", "CHEMICAL", 88, 95], ["MAPKs", "GENE_OR_GENE_PRODUCT", 81, 86], ["calcium", "SIMPLE_CHEMICAL", 88, 95], ["PLCc1", "GENE_OR_GENE_PRODUCT", 105, 110], ["PLCc2", "GENE_OR_GENE_PRODUCT", 115, 120], ["lipid", "SIMPLE_CHEMICAL", 160, 165], ["MAPKs", "PROTEIN", 81, 86], ["PLCc2", "PROTEIN", 115, 120], ["cytokine", "PROTEIN", 179, 187], ["MAPKs", "TEST", 81, 86], ["calcium", "TEST", 88, 95], ["PLCc1", "TREATMENT", 105, 110], ["PLCc2 phosphorylation", "TREATMENT", 115, 136], ["degranulation", "TEST", 145, 158], ["lipid mediator", "TREATMENT", 160, 174], ["cytokine synthesis", "TREATMENT", 179, 197], ["cytokine synthesis", "OBSERVATION", 179, 197]]], ["Syk has gathered a great deal of attention as a potentially novel target for the treatment of allergic and other inflammatory disorders [3, 10, 11] .", [["allergic", "DISEASE", 94, 102], ["inflammatory disorders", "DISEASE", 113, 135], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["Syk", "PROTEIN", 0, 3], ["allergic", "PROBLEM", 94, 102], ["other inflammatory disorders", "PROBLEM", 107, 135], ["inflammatory", "OBSERVATION_MODIFIER", 113, 125]]], ["In particular, several small-molecule inhibitors of the Syk kinase domain have shown efficacy both human and animal models of allergic disease [12] [13] [14] [15] [16] .IntroductionRecent advances in the use of small interfering RNA (siRNA) technologies as a means of post-transcriptional gene silencing have provided a potential alternative to the use of small-molecule inhibitors for the inhibition of disease targets [17] [18] [19] .", [["allergic disease", "DISEASE", 126, 142], ["Syk", "GENE_OR_GENE_PRODUCT", 56, 59], ["human", "ORGANISM", 99, 104], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 143, 167], ["[17] [18] [19]", "SIMPLE_CHEMICAL", 420, 434], ["Syk kinase domain", "PROTEIN", 56, 73], ["small interfering RNA", "RNA", 211, 232], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["several small-molecule inhibitors", "TREATMENT", 15, 48], ["the Syk kinase domain", "PROBLEM", 52, 73], ["allergic disease", "PROBLEM", 126, 142], ["small interfering RNA (siRNA) technologies", "TREATMENT", 211, 253], ["post-transcriptional gene silencing", "TREATMENT", 268, 303], ["small-molecule inhibitors", "TREATMENT", 356, 381], ["disease targets", "PROBLEM", 404, 419], ["several", "OBSERVATION_MODIFIER", 15, 22], ["small", "OBSERVATION_MODIFIER", 23, 28]]], ["In this study, we designed a range of different Syk siRNA sequences and tested them for their ability to knockdown Syk in the rat basophilic RBL-2H3 cell line.", [["basophilic RBL-2H3 cell line", "ANATOMY", 130, 158], ["Syk", "GENE_OR_GENE_PRODUCT", 48, 51], ["Syk", "GENE_OR_GENE_PRODUCT", 115, 118], ["rat", "ORGANISM", 126, 129], ["basophilic RBL-2H3 cell line", "CELL", 130, 158], ["Syk siRNA sequences", "DNA", 48, 67], ["Syk", "PROTEIN", 115, 118], ["rat basophilic RBL-2H3 cell line", "CELL_LINE", 126, 158], ["rat", "SPECIES", 126, 129], ["this study", "TEST", 3, 13], ["different Syk siRNA sequences", "TREATMENT", 38, 67], ["2H3 cell line", "TREATMENT", 145, 158], ["basophilic RBL", "OBSERVATION", 130, 144], ["2H3 cell line", "OBSERVATION", 145, 158]]], ["Syk siRNAs were also tested for their specificity by investigating the induction of an interferon response, as analyzed by the expression of IFN-induced protein with tetratricopeptide repeats-1 (IFIT1/ISG56), which is a characteristic inflammatory response to viral dsRNA [20] .", [["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 141, 144], ["tetratricopeptide repeats-1", "GENE_OR_GENE_PRODUCT", 166, 193], ["IFIT1", "GENE_OR_GENE_PRODUCT", 195, 200], ["ISG56", "GENE_OR_GENE_PRODUCT", 201, 206], ["Syk", "PROTEIN", 0, 3], ["interferon", "PROTEIN", 87, 97], ["IFN", "PROTEIN", 141, 144], ["tetratricopeptide repeats-1", "PROTEIN", 166, 193], ["IFIT1", "PROTEIN", 195, 200], ["ISG56", "PROTEIN", 201, 206], ["Syk siRNAs", "TREATMENT", 0, 10], ["an interferon response", "TREATMENT", 84, 106], ["IFN", "TEST", 141, 144], ["tetratricopeptide repeats", "TEST", 166, 191], ["a characteristic inflammatory response", "PROBLEM", 218, 256], ["viral dsRNA", "PROBLEM", 260, 271], ["inflammatory", "OBSERVATION_MODIFIER", 235, 247], ["viral dsRNA", "OBSERVATION", 260, 271]]], ["Selected siRNAs displaying a combination of efficient and specific knockdown of Syk were compared with the previously published Syk kinase inhibitors R406 [14] , BAY61-3606 [15] and piceatannol [21] for their effect on FceRI signal transduction and basophilic degranulation.", [["basophilic", "ANATOMY", 249, 259], ["R406", "CHEMICAL", 150, 154], ["BAY61-3606", "CHEMICAL", 162, 172], ["piceatannol", "CHEMICAL", 182, 193], ["R406 [14] , BAY61-3606", "CHEMICAL", 150, 172], ["piceatannol", "CHEMICAL", 182, 193], ["Syk", "GENE_OR_GENE_PRODUCT", 80, 83], ["Syk", "GENE_OR_GENE_PRODUCT", 128, 131], ["R406 [14]", "SIMPLE_CHEMICAL", 150, 159], ["BAY61-3606 [15]", "SIMPLE_CHEMICAL", 162, 177], ["piceatannol [21]", "SIMPLE_CHEMICAL", 182, 198], ["FceRI", "SIMPLE_CHEMICAL", 219, 224], ["Syk", "PROTEIN", 80, 83], ["Syk kinase", "PROTEIN", 128, 138], ["FceRI", "PROTEIN", 219, 224], ["Selected siRNAs", "PROBLEM", 0, 15], ["Syk", "PROBLEM", 80, 83], ["the previously published Syk kinase inhibitors", "TREATMENT", 103, 149], ["BAY61", "TEST", 162, 167], ["piceatannol", "TEST", 182, 193], ["FceRI signal transduction", "TREATMENT", 219, 244], ["basophilic degranulation", "PROBLEM", 249, 273], ["basophilic degranulation", "OBSERVATION", 249, 273]]], ["The identification of specific and cellularly active Syk sequences in this study provides a basis for the development of Syk siRNAs in more complex in vivo models of inflammatory diseases.Reagents and siRNAsIndividual Duplex siRNAs were purchased from Thermo Fisher Scientific (Lafayette, CO) and Applied Biosystems/Ambion (Austin, TX).", [["inflammatory diseases", "DISEASE", 166, 187], ["Syk", "GENE_OR_GENE_PRODUCT", 53, 56], ["Syk", "GENE_OR_GENE_PRODUCT", 121, 124], ["Syk sequences", "DNA", 53, 66], ["Syk", "PROTEIN", 121, 124], ["specific and cellularly active Syk sequences", "PROBLEM", 22, 66], ["this study", "TEST", 70, 80], ["Syk siRNAs", "PROBLEM", 121, 131], ["inflammatory diseases", "PROBLEM", 166, 187], ["siRNAsIndividual Duplex siRNAs", "TREATMENT", 201, 231], ["Syk siRNAs", "OBSERVATION", 121, 131], ["more complex", "OBSERVATION_MODIFIER", 135, 147], ["inflammatory", "OBSERVATION", 166, 178]]], ["Antibodies to Syk (SYK-01), PLCc1 (1F1), b-actin (C4) and LAT (FL-233) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany).", [["FL-233", "CHEMICAL", 63, 69], ["Syk", "GENE_OR_GENE_PRODUCT", 14, 17], ["SYK-01", "GENE_OR_GENE_PRODUCT", 19, 25], ["PLCc1", "GENE_OR_GENE_PRODUCT", 28, 33], ["1F1", "GENE_OR_GENE_PRODUCT", 35, 38], ["b-actin", "GENE_OR_GENE_PRODUCT", 41, 48], ["C4", "GENE_OR_GENE_PRODUCT", 50, 52], ["LAT", "GENE_OR_GENE_PRODUCT", 58, 61], ["Syk", "PROTEIN", 14, 17], ["SYK", "PROTEIN", 19, 22], ["01", "PROTEIN", 23, 25], ["PLCc1", "PROTEIN", 28, 33], ["1F1", "PROTEIN", 35, 38], ["b-actin", "PROTEIN", 41, 48], ["C4", "PROTEIN", 50, 52], ["LAT", "PROTEIN", 58, 61], ["FL", "PROTEIN", 63, 65], ["Antibodies", "TEST", 0, 10], ["Syk", "TEST", 14, 17], ["SYK", "TEST", 19, 22], ["PLCc1", "TEST", 28, 33], ["b-actin (C4) and LAT (FL", "TEST", 41, 65]]], ["Antibodies to phospho-PLCc1 (Tyr783), phospho-Zap70 (Tyr319)/Syk (Tyr352), Phospho-Erk (Thr202/Tyr204) and p44/42 MAP Kinase were obtained from Cell Signaling Technology (Danvers, MA).", [["Cell", "ANATOMY", 144, 148], ["Tyr783", "CHEMICAL", 29, 35], ["phospho", "CHEMICAL", 38, 45], ["phospho-PLCc1", "GENE_OR_GENE_PRODUCT", 14, 27], ["Tyr783", "GENE_OR_GENE_PRODUCT", 29, 35], ["phospho-Zap70 (Tyr319)", "GENE_OR_GENE_PRODUCT", 38, 60], ["Syk", "GENE_OR_GENE_PRODUCT", 61, 64], ["Tyr352", "GENE_OR_GENE_PRODUCT", 66, 72], ["Phospho-Erk", "GENE_OR_GENE_PRODUCT", 75, 86], ["Thr202", "GENE_OR_GENE_PRODUCT", 88, 94], ["Tyr204", "GENE_OR_GENE_PRODUCT", 95, 101], ["p44/42 MAP Kinase", "GENE_OR_GENE_PRODUCT", 107, 124], ["Cell", "CELL", 144, 148], ["phospho-PLCc1", "PROTEIN", 14, 27], ["Tyr783", "PROTEIN", 29, 35], ["phospho", "PROTEIN", 38, 45], ["Zap70", "PROTEIN", 46, 51], ["Tyr319", "PROTEIN", 53, 59], ["Syk", "PROTEIN", 61, 64], ["Tyr352", "PROTEIN", 66, 72], ["Phospho", "PROTEIN", 75, 82], ["Erk", "PROTEIN", 83, 86], ["Thr202", "PROTEIN", 88, 94], ["Tyr204", "PROTEIN", 95, 101], ["p44/42 MAP Kinase", "PROTEIN", 107, 124], ["Antibodies", "TEST", 0, 10], ["phospho-", "TEST", 14, 22], ["PLCc1", "TEST", 22, 27], ["phospho", "TEST", 38, 45], ["Zap70", "TEST", 46, 51], ["Syk", "TEST", 61, 64], ["Phospho", "TEST", 75, 82], ["Erk", "TEST", 83, 86], ["MAP Kinase", "TEST", 114, 124], ["Syk", "ANATOMY", 61, 64]]], ["The SLP-76 (Tyr128), SLP-76, and high affinity IgE receptor (FceRI) (BC4) antibodies were from BD Biosciences (San Jose, CA).", [["SLP-76", "GENE_OR_GENE_PRODUCT", 4, 10], ["Tyr128", "GENE_OR_GENE_PRODUCT", 12, 18], ["SLP-76", "GENE_OR_GENE_PRODUCT", 21, 27], ["high affinity IgE receptor", "GENE_OR_GENE_PRODUCT", 33, 59], ["FceRI", "GENE_OR_GENE_PRODUCT", 61, 66], ["SLP", "PROTEIN", 4, 7], ["SLP", "PROTEIN", 21, 24], ["high affinity IgE receptor (FceRI) (BC4) antibodies", "PROTEIN", 33, 84], ["BD Biosciences", "PROTEIN", 95, 109], ["The SLP", "TEST", 0, 7], ["SLP", "TEST", 21, 24], ["high affinity IgE receptor (FceRI) (BC4) antibodies", "PROBLEM", 33, 84]]], ["The phospho-LAT (Tyr226) and phosphotyrosine (4G10) antibodies were purchased from Millipore (Billerica, MA).", [["phospho", "CHEMICAL", 4, 11], ["Tyr226", "CHEMICAL", 17, 23], ["phosphotyrosine", "CHEMICAL", 29, 44], ["phospho-LAT", "GENE_OR_GENE_PRODUCT", 4, 15], ["Tyr226", "GENE_OR_GENE_PRODUCT", 17, 23], ["phosphotyrosine", "GENE_OR_GENE_PRODUCT", 29, 44], ["4G10", "GENE_OR_GENE_PRODUCT", 46, 50], ["phospho", "PROTEIN", 4, 11], ["LAT", "PROTEIN", 12, 15], ["Tyr226", "PROTEIN", 17, 23], ["phosphotyrosine (4G10) antibodies", "PROTEIN", 29, 62], ["The phospho-LAT", "TEST", 0, 15], ["phosphotyrosine", "TEST", 29, 44], ["antibodies", "TEST", 52, 62]]], ["The mouse anti-DNP IgE antibody (clone TIB142) was a kind gift from Dr. Takeshi Kono (Nippon Boehringer Ingelheim Co., LTD, Tokyo).", [["mouse", "ORGANISM", 4, 9], ["anti-DNP IgE antibody", "GENE_OR_GENE_PRODUCT", 10, 31], ["mouse anti-DNP IgE antibody", "PROTEIN", 4, 31], ["clone TIB142", "PROTEIN", 33, 45], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["The mouse anti-DNP IgE antibody", "TEST", 0, 31]]], ["Bovine serum albumin-2,4-dinitrophenyl (DNP-BSA) was purchased from Invitrogen (Karlsruhe, Germany).", [["serum", "ANATOMY", 7, 12], ["albumin-2,4-dinitrophenyl", "CHEMICAL", 13, 38], ["DNP-BSA", "CHEMICAL", 40, 47], ["2,4-dinitrophenyl", "CHEMICAL", 21, 38], ["DNP", "CHEMICAL", 40, 43], ["Bovine", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["albumin-2,4-dinitrophenyl", "SIMPLE_CHEMICAL", 13, 38], ["DNP-BSA", "SIMPLE_CHEMICAL", 40, 47], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine serum albumin", "TEST", 0, 20], ["dinitrophenyl (DNP-BSA)", "TREATMENT", 25, 48]]], ["Piceatannol was purchased from Merck (Darmstadt, Germany).Culture and treatment of RBL-2H3 cells with pharmacological agentsRBL-2H3 cells (ATCC: CRL-2256) were routinely cultured in minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS).", [["RBL-2H3 cells", "ANATOMY", 83, 96], ["RBL-2H3 cells", "ANATOMY", 124, 137], ["ATCC", "ANATOMY", 139, 143], ["CRL-2256", "ANATOMY", 145, 153], ["fetal calf serum", "ANATOMY", 235, 251], ["Piceatannol", "CHEMICAL", 0, 11], ["CRL-2256", "CHEMICAL", 145, 153], ["Piceatannol", "CHEMICAL", 0, 11], ["Piceatannol", "SIMPLE_CHEMICAL", 0, 11], ["RBL-2H3 cells", "CELL", 83, 96], ["RBL-2H3 cells", "CELL", 124, 137], ["ATCC: CRL-2256", "CELL", 139, 153], ["fetal calf", "ORGANISM_SUBSTANCE", 235, 245], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["FCS", "ORGANISM_SUBSTANCE", 253, 256], ["RBL-2H3 cells", "CELL_LINE", 83, 96], ["RBL", "CELL_LINE", 124, 127], ["2H3 cells", "CELL_LINE", 128, 137], ["ATCC: CRL-2256", "CELL_LINE", 139, 153], ["calf", "SPECIES", 241, 245], ["ATCC: CRL-2256", "SPECIES", 139, 153], ["Piceatannol", "TREATMENT", 0, 11], ["Culture", "TEST", 58, 65], ["RBL", "TEST", 83, 86], ["pharmacological agents", "TREATMENT", 102, 124], ["RBL", "TEST", 124, 127], ["ATCC", "TEST", 139, 143], ["CRL", "TEST", 145, 148], ["2H3 cells", "OBSERVATION", 128, 137]]], ["For the treatment of cells with pharmacological agents for later analysis of proteins by Western blotting, 5 \u00c2 10 5 cells were seeded into 24-well plates and cultured overnight.", [["cells", "ANATOMY", 21, 26], ["cells", "ANATOMY", 116, 121], ["cells", "CELL", 21, 26], ["cells", "CELL", 116, 121], ["the treatment of cells", "TREATMENT", 4, 26], ["pharmacological agents", "TREATMENT", 32, 54]]], ["Cells were then washed once with phosphate buffered saline (PBS) and then incubated for 30 min in MEM without FBS plus either inhibitors or the vehicle dimethyl sulfoxide (DMSO).", [["Cells", "ANATOMY", 0, 5], ["phosphate", "CHEMICAL", 33, 42], ["MEM", "CHEMICAL", 98, 101], ["FBS", "CHEMICAL", 110, 113], ["dimethyl sulfoxide", "CHEMICAL", 152, 170], ["DMSO", "CHEMICAL", 172, 176], ["phosphate", "CHEMICAL", 33, 42], ["dimethyl sulfoxide", "CHEMICAL", 152, 170], ["DMSO", "CHEMICAL", 172, 176], ["Cells", "CELL", 0, 5], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 33, 58], ["FBS", "ORGANISM_SUBSTANCE", 110, 113], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 152, 170], ["DMSO", "SIMPLE_CHEMICAL", 172, 176], ["phosphate buffered saline (PBS", "TREATMENT", 33, 63], ["FBS", "TREATMENT", 110, 113], ["either inhibitors", "TREATMENT", 119, 136], ["the vehicle dimethyl sulfoxide (DMSO", "TREATMENT", 140, 176]]], ["Cells were then activated for 10 min by the addition of the anti-FceRI (BC4) antibody (0.02 lg/ml).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-FceRI", "GENE_OR_GENE_PRODUCT", 60, 70], ["BC4", "SIMPLE_CHEMICAL", 72, 75], ["anti-FceRI (BC4) antibody", "PROTEIN", 60, 85], ["the anti-FceRI (BC4", "TREATMENT", 56, 75], ["antibody", "TEST", 77, 85]]], ["Cells were then washed once with ice-cold PBS and lysed at 4\u00b0C for 30 min in Lysis Buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 1% NP40, 5 mM EDTA, 50 mM NaF, 20 lM Na 3 VO 4 ) supplemented with Halt Protease Inhibitor Cocktail and Halt Phosphatase Inhibitor Cocktail (both from Thermo Fisher Scientific, Rockford, IL).", [["Cells", "ANATOMY", 0, 5], ["NaCl", "CHEMICAL", 98, 102], ["NaF", "CHEMICAL", 150, 153], ["Na", "CHEMICAL", 161, 163], ["NaCl", "CHEMICAL", 98, 102], ["Tris", "CHEMICAL", 110, 114], ["NP40", "CHEMICAL", 127, 131], ["EDTA", "CHEMICAL", 138, 142], ["NaF", "CHEMICAL", 150, 153], ["Na 3 VO 4", "CHEMICAL", 161, 170], ["Cells", "CELL", 0, 5], ["EDTA", "SIMPLE_CHEMICAL", 138, 142], ["NaF", "SIMPLE_CHEMICAL", 150, 153], ["Halt Phosphatase", "GENE_OR_GENE_PRODUCT", 228, 244], ["ice-cold PBS", "TREATMENT", 33, 45], ["Lysis Buffer", "TREATMENT", 77, 89], ["NaCl", "TEST", 98, 102], ["Tris", "TEST", 110, 114], ["pH", "TEST", 116, 118], ["EDTA", "TEST", 138, 142], ["NaF", "TEST", 150, 153], ["Halt Protease Inhibitor Cocktail", "TREATMENT", 191, 223], ["Halt Phosphatase Inhibitor Cocktail", "TREATMENT", 228, 263]]], ["Lysates were then cleared by centrifugation and prepared for Western blotting by the addition of NuPAGE \u00d2 Sample Reducing Agent and LDS Sample Buffer (both from Invitrogen).Transfection of RBL-2H3 and MEF cells with siRNAsThe Nucleofector L Kit (#VCA-1005) (Lonza Cologne AG, Germany) was used for electroporation of RBL-2H3 cells with siRNAs.", [["Lysates", "ANATOMY", 0, 7], ["RBL-2H3", "ANATOMY", 189, 196], ["MEF cells", "ANATOMY", 201, 210], ["RBL-2H3 cells", "ANATOMY", 317, 330], ["NuPAGE", "CHEMICAL", 97, 103], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["RBL-2H3", "CELL", 189, 196], ["MEF cells", "CELL", 201, 210], ["Nucleofector L Kit", "GENE_OR_GENE_PRODUCT", 226, 244], ["RBL-2H3 cells", "CELL", 317, 330], ["RBL", "CELL_LINE", 189, 192], ["2H3", "CELL_LINE", 193, 196], ["MEF cells", "CELL_LINE", 201, 210], ["RBL-2H3 cells", "CELL_LINE", 317, 330], ["Lysates", "TEST", 0, 7], ["NuPAGE \u00d2 Sample Reducing Agent", "TREATMENT", 97, 127], ["LDS Sample Buffer", "TREATMENT", 132, 149], ["RBL", "TEST", 189, 192], ["MEF cells", "TEST", 201, 210], ["siRNAs", "TEST", 216, 222], ["The Nucleofector L Kit", "TEST", 222, 244], ["VCA", "TEST", 247, 250], ["RBL", "TEST", 317, 320], ["siRNAs", "PROBLEM", 336, 342], ["RBL", "ANATOMY", 189, 192], ["RBL", "ANATOMY", 317, 320], ["2H3 cells", "OBSERVATION", 321, 330]]], ["1 \u00c2 10 6 cells were electroporated in cuvettes in Nucleofector L Solution with 420 nM of each siRNA using a Nucleofector \u00d2 Device (Lonza, #AAD-1001) with program L-029.", [["cells", "ANATOMY", 9, 14], ["L-029", "CHEMICAL", 162, 167], ["L-029", "CHEMICAL", 162, 167], ["cells", "CELL", 9, 14], ["L-029", "SIMPLE_CHEMICAL", 162, 167], ["1 \u00c2 10 6 cells", "CELL_LINE", 0, 14], ["Nucleofector L Solution", "TREATMENT", 50, 73], ["each siRNA", "TREATMENT", 89, 99], ["a Nucleofector \u00d2 Device", "TREATMENT", 106, 129]]], ["Cells were then diluted in 6 well plates with MEM/10% FCS to give a final siRNA concentration of 20 nM.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["a final siRNA concentration", "TREATMENT", 66, 93]]], ["Cells were cultivated for a further 2 days prior to application in cellular assays or for the analysis of Syk mRNA levels by TaqMan PCR as described in the following section.Transfection of RBL-2H3 and MEF cells with siRNAsDharmaFECT 2 siRNA Transfection Reagent (#T-2002-01) (Thermo Fisher Scientific) was used for the transfection of mouse embryonic fibroblast (MEF) cells for the analysis of the induction of the interferon (IFN)-inducible gene IFIT1.", [["Cells", "ANATOMY", 0, 5], ["cellular", "ANATOMY", 67, 75], ["RBL-2H3", "ANATOMY", 190, 197], ["MEF cells", "ANATOMY", 202, 211], ["embryonic fibroblast (MEF) cells", "ANATOMY", 342, 374], ["Cells", "CELL", 0, 5], ["cellular", "CELL", 67, 75], ["Syk", "GENE_OR_GENE_PRODUCT", 106, 109], ["RBL-2H3", "CELL", 190, 197], ["MEF cells", "CELL", 202, 211], ["siRNAsDharmaFECT 2", "CELL", 217, 235], ["mouse", "ORGANISM", 336, 341], ["embryonic fibroblast (MEF) cells", "CELL", 342, 374], ["interferon (IFN)-inducible", "GENE_OR_GENE_PRODUCT", 416, 442], ["IFIT1", "GENE_OR_GENE_PRODUCT", 448, 453], ["Syk mRNA", "RNA", 106, 114], ["RBL", "CELL_LINE", 190, 193], ["2H3", "CELL_LINE", 194, 197], ["MEF cells", "CELL_LINE", 202, 211], ["mouse embryonic fibroblast (MEF) cells", "CELL_LINE", 336, 374], ["interferon (IFN)-inducible gene", "DNA", 416, 447], ["IFIT1", "DNA", 448, 453], ["mouse", "SPECIES", 336, 341], ["mouse", "SPECIES", 336, 341], ["cellular assays", "TEST", 67, 82], ["the analysis", "TEST", 90, 102], ["Syk mRNA levels", "TEST", 106, 121], ["TaqMan PCR", "TEST", 125, 135], ["RBL", "TEST", 190, 193], ["MEF cells", "TEST", 202, 211], ["siRNAsDharmaFECT 2 siRNA Transfection Reagent", "TREATMENT", 217, 262], ["the transfection of mouse embryonic fibroblast (MEF) cells", "TREATMENT", 316, 374], ["the analysis", "TEST", 379, 391], ["the interferon (IFN)", "TREATMENT", 412, 432], ["inducible gene IFIT1", "PROBLEM", 433, 453], ["RBL", "ANATOMY", 190, 193]]], ["MEF cells were routinely cultured in DMEM/10% FCS and seeded at a concentration of 4.2 \u00c2 10 5 in 6-well plates and grown overnight until they reached 90% confluence.", [["MEF cells", "ANATOMY", 0, 9], ["MEF cells", "CELL", 0, 9], ["MEF cells", "CELL_LINE", 0, 9], ["MEF cells", "PROBLEM", 0, 9]]], ["Cells were then transfected with 20 nM of each siRNA mixed with DharmaFECT 2 siRNA Transfection Reagent.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["each siRNA", "TREATMENT", 42, 52], ["DharmaFECT 2 siRNA Transfection Reagent", "TREATMENT", 64, 103]]], ["Following 24 h of culture, mRNA was analyzed by TaqMan PCR.Gene expression analysisFor quantitative analysis of gene expression total RNA was isolated from cell culture lysates according to the RNeasy protocol (Qiagen, Hilden, Germany).", [["cell culture lysates", "ANATOMY", 156, 176], ["cell culture lysates", "ORGANISM_SUBSTANCE", 156, 176], ["mRNA", "RNA", 27, 31], ["culture", "TEST", 18, 25], ["mRNA", "TEST", 27, 31], ["TaqMan PCR", "TEST", 48, 58], ["Gene expression analysis", "TEST", 59, 83], ["quantitative analysis", "TEST", 87, 108], ["gene expression total RNA", "PROBLEM", 112, 137], ["cell culture lysates", "TEST", 156, 176], ["the RNeasy protocol", "TREATMENT", 190, 209]]], ["The purified total RNA was stored at \u00c020\u00b0C. The gene expression levels were determined by TaqMan \u00d2 analysis in a 7900HT Sequence Detection System (Applied Biosystems Inc., Foster City, CA) using the TaqMan \u00d2 EZ RT-PCR reagent kit (Applied Biosystems) for reverse transcription and PCR amplification in ABI PRISM 384-well optical reaction plates (Applied Biosystems).", [["The purified total RNA", "TREATMENT", 0, 22], ["The gene expression levels", "TEST", 44, 70], ["the TaqMan", "TEST", 195, 205], ["EZ RT", "TREATMENT", 208, 213], ["reverse transcription", "TREATMENT", 255, 276], ["PCR amplification", "TEST", 281, 298], ["ABI PRISM", "TEST", 302, 311], ["well optical reaction plates", "TREATMENT", 316, 344], ["total", "OBSERVATION_MODIFIER", 13, 18], ["RNA", "OBSERVATION", 19, 22]]], ["For the detection of the respective transcripts, the following primers and probes were used: Syk_rat (Applied Biosystems, # Rn00562684_m1), Syk_mouse (Applied Biosystems, # Mm0 0441649_m1), RNA PolII_rat: forward primer: 5 0 -GCAGGCGAG AGCGTTGAG-3 0 , reverse primer: For the presentation of the expression levels, normalized relative quantities of a transcript were divided by the mean value of the respective control group and displayed as%-control values.Western blot analysis of proteinsCell lysates were loaded onto NuPAGE \u00d2 4-12% Bis-Tris gels (Invitrogen) and transferred to Immobilon-P Transfer Membranes (Millipore, Billerica, MA) by wet blotting.", [["Cell lysates", "ANATOMY", 491, 503], ["Bis-Tris", "CHEMICAL", 536, 544], ["NuPAGE", "CHEMICAL", 521, 527], ["Bis-Tris gels", "CHEMICAL", 536, 549], ["Cell lysates", "ORGANISM_SUBSTANCE", 491, 503], ["Bis-Tris gels", "SIMPLE_CHEMICAL", 536, 549], ["Invitrogen", "SIMPLE_CHEMICAL", 551, 561], ["RNA PolII_rat", "DNA", 190, 203], ["forward primer: 5 0 -GCAGGCGAG AGCGTTGAG-3 0", "DNA", 205, 249], ["reverse primer", "DNA", 252, 266], ["the following primers", "TREATMENT", 49, 70], ["AGCGTTGAG", "TEST", 236, 245], ["the expression levels", "TEST", 292, 313], ["a transcript", "TREATMENT", 349, 361], ["Cell lysates", "TEST", 491, 503]]], ["After blocking with blocking buffer (5% non-fat milk in TBS), membranes were incubated under gentle agitation with the respective primary antibodies diluted in blocking buffer for 1 h at room temperature.", [["fat milk", "ANATOMY", 44, 52], ["membranes", "ANATOMY", 62, 71], ["fat milk", "TISSUE", 44, 52], ["membranes", "CELLULAR_COMPONENT", 62, 71], ["primary antibodies", "PROTEIN", 130, 148], ["blocking buffer", "TREATMENT", 20, 35], ["5% non-fat milk in TBS", "TREATMENT", 37, 59], ["membranes", "TREATMENT", 62, 71], ["gentle agitation", "PROBLEM", 93, 109], ["the respective primary antibodies", "TREATMENT", 115, 148], ["blocking buffer", "TREATMENT", 160, 175]]], ["Membranes were then washed four times for 10 min with TBS-T (TBS with 0.05% Tween 20) and then incubated with peroxidaseconjugated secondary antibodies (Jackson ImmunoResearch Europe Ltd., Suffolk, UK) at a dilution of 1/5000 in blocking buffer (Jackson ImmunoResearch Europe Ltd, Suffolk, UK).", [["Membranes", "ANATOMY", 0, 9], ["Tween 20", "CHEMICAL", 76, 84], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["peroxidaseconjugated secondary antibodies", "PROTEIN", 110, 151], ["TBS", "TEST", 54, 57], ["TBS", "TEST", 61, 64]]], ["Membranes were then washed again in TBS-T as described above and then Western blots developed using the Enhanced Chemiluminescence (ECL) reagents (PerkinElmer, Waltham, MA) according to the manufacturer's instructions.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["the Enhanced Chemiluminescence", "TREATMENT", 100, 130]]], ["Membranes were in some cases stripped with Restore Western Blot Stripping Buffer (Thermo Fisher Scientific) and then analyzed with additional antibodies.b-Hexosaminidase assayThe release of b-hexosaminidase enzyme activity from RBL-2H3 cells was used as a quantifiable readout for degranulation [22] .", [["Membranes", "ANATOMY", 0, 9], ["RBL-2H3 cells", "ANATOMY", 228, 241], ["b-Hexosaminidase", "CHEMICAL", 153, 169], ["b-Hexosaminidase", "CHEMICAL", 153, 169], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["b-Hexosaminidase", "GENE_OR_GENE_PRODUCT", 153, 169], ["b-hexosaminidase", "GENE_OR_GENE_PRODUCT", 190, 206], ["RBL-2H3 cells", "CELL", 228, 241], ["antibodies", "PROTEIN", 142, 152], ["b-hexosaminidase enzyme", "PROTEIN", 190, 213], ["RBL-2H3 cells", "CELL_LINE", 228, 241], ["Restore Western Blot Stripping Buffer", "TREATMENT", 43, 80], ["additional antibodies", "TREATMENT", 131, 152], ["Hexosaminidase assay", "TEST", 155, 175], ["b-hexosaminidase enzyme activity", "PROBLEM", 190, 222], ["RBL", "TEST", 228, 231], ["2H3 cells", "PROBLEM", 232, 241], ["2H3 cells", "OBSERVATION", 232, 241]]], ["One day following transfection of cells with siRNAs, media was re-TNFa and histamine measurementsFollowing transfection with siRNAs, cells were incubated as described above with the mouse anti-DNP IgE antibody.", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 133, 138], ["histamine", "CHEMICAL", 75, 84], ["histamine", "CHEMICAL", 75, 84], ["cells", "CELL", 34, 39], ["re-TNFa", "SIMPLE_CHEMICAL", 63, 70], ["histamine", "SIMPLE_CHEMICAL", 75, 84], ["cells", "CELL", 133, 138], ["mouse", "ORGANISM", 182, 187], ["anti-DNP IgE antibody", "GENE_OR_GENE_PRODUCT", 188, 209], ["mouse anti-DNP IgE antibody", "PROTEIN", 182, 209], ["mouse", "SPECIES", 182, 187], ["mouse", "SPECIES", 182, 187], ["transfection of cells", "TREATMENT", 18, 39], ["siRNAs, media", "TREATMENT", 45, 58], ["re-TNFa", "TREATMENT", 63, 70], ["histamine measurements", "TEST", 75, 97], ["siRNAs, cells", "TREATMENT", 125, 138], ["the mouse anti-DNP IgE antibody", "TEST", 178, 209]]], ["The following day, cells were washed and then cultured for 6 h in MEM/10% FCS plus DNP-BSA (100 ng/ml).", [["cells", "ANATOMY", 19, 24], ["DNP-BSA", "CHEMICAL", 83, 90], ["cells", "CELL", 19, 24], ["FCS", "SIMPLE_CHEMICAL", 74, 77], ["DNP-BSA", "SIMPLE_CHEMICAL", 83, 90], ["cells", "PROBLEM", 19, 24], ["BSA", "TEST", 87, 90]]], ["Supernatants were then cleared by centrifugation and analyzed for levels of rat TNFa using the rat TNFa Immunoassay (R&D Systems, Minneapolis, MN) and histamine using a specific enzyme immunoassay (EIA) (IMMUNO-TECH, Czech Republic), according to the manufacture's instructions.Design of siRNAs against SykTen siRNA sequences (A-J) were designed against Syk with the aim of knocking down Syk in the rat RBL-2H3 cell line (Fig. 1 ).", [["Supernatants", "ANATOMY", 0, 12], ["RBL-2H3 cell line", "ANATOMY", 403, 420], ["histamine", "CHEMICAL", 151, 160], ["histamine", "CHEMICAL", 151, 160], ["Supernatants", "CELL", 0, 12], ["rat", "ORGANISM", 76, 79], ["TNFa", "GENE_OR_GENE_PRODUCT", 80, 84], ["rat", "ORGANISM", 95, 98], ["TNFa", "GENE_OR_GENE_PRODUCT", 99, 103], ["histamine", "SIMPLE_CHEMICAL", 151, 160], ["SykTen", "GENE_OR_GENE_PRODUCT", 303, 309], ["Syk", "GENE_OR_GENE_PRODUCT", 354, 357], ["Syk", "GENE_OR_GENE_PRODUCT", 388, 391], ["rat", "ORGANISM", 399, 402], ["RBL-2H3 cell line", "CELL", 403, 420], ["Fig. 1", "CELL", 422, 428], ["rat TNFa", "PROTEIN", 76, 84], ["SykTen siRNA sequences", "DNA", 303, 325], ["Syk", "PROTEIN", 354, 357], ["Syk", "PROTEIN", 388, 391], ["rat RBL-2H3 cell line", "CELL_LINE", 399, 420], ["rat", "SPECIES", 76, 79], ["rat", "SPECIES", 95, 98], ["rat", "SPECIES", 399, 402], ["rat", "SPECIES", 76, 79], ["rat", "SPECIES", 95, 98], ["rat", "SPECIES", 399, 402], ["levels of rat TNFa", "TREATMENT", 66, 84], ["the rat TNFa Immunoassay", "TEST", 91, 115], ["histamine", "TREATMENT", 151, 160], ["a specific enzyme immunoassay", "TEST", 167, 196], ["Design of siRNAs", "TREATMENT", 278, 294], ["SykTen siRNA sequences", "TREATMENT", 303, 325], ["2H3 cell line", "TREATMENT", 407, 420], ["rat RBL", "ANATOMY", 399, 406], ["2H3 cell line", "OBSERVATION", 407, 420]]], ["Sequences were based on the RefSeq information for human (NM_003177), mouse (NM_011518) and rat (NM_012758) Syk mRNAs.", [["human", "ORGANISM", 51, 56], ["mouse", "ORGANISM", 70, 75], ["rat", "ORGANISM", 92, 95], ["Syk", "GENE_OR_GENE_PRODUCT", 108, 111], ["rat (NM_012758)", "DNA", 92, 107], ["Syk mRNAs", "RNA", 108, 117], ["human", "SPECIES", 51, 56], ["mouse", "SPECIES", 70, 75], ["rat", "SPECIES", 92, 95], ["human", "SPECIES", 51, 56], ["mouse", "SPECIES", 70, 75], ["rat", "SPECIES", 92, 95], ["Syk mRNAs", "PROBLEM", 108, 117]]], ["Sequences A-F had 100% homology with rat Syk alone, whereas sequences G-J were pan siRNAs with complete homology to the rat, mouse and human Syk transcripts.Identification of active siRNAs against rat SykRBL-2H3 cells were transfected with each siRNA as described in Section 2.", [["SykRBL-2H3 cells", "ANATOMY", 201, 217], ["rat", "ORGANISM", 37, 40], ["Syk", "GENE_OR_GENE_PRODUCT", 41, 44], ["G-J", "GENE_OR_GENE_PRODUCT", 70, 73], ["rat", "ORGANISM", 120, 123], ["mouse", "ORGANISM", 125, 130], ["human", "ORGANISM", 135, 140], ["Syk", "GENE_OR_GENE_PRODUCT", 141, 144], ["rat", "ORGANISM", 197, 200], ["SykRBL-2H3 cells", "CELL", 201, 217], ["rat Syk", "PROTEIN", 37, 44], ["G-J", "DNA", 70, 73], ["rat, mouse and human Syk transcripts", "RNA", 120, 156], ["rat SykRBL-2H3 cells", "CELL_LINE", 197, 217], ["rat", "SPECIES", 37, 40], ["rat", "SPECIES", 120, 123], ["mouse", "SPECIES", 125, 130], ["human", "SPECIES", 135, 140], ["rat", "SPECIES", 197, 200], ["rat", "SPECIES", 37, 40], ["rat", "SPECIES", 120, 123], ["mouse", "SPECIES", 125, 130], ["human", "SPECIES", 135, 140], ["rat", "SPECIES", 197, 200], ["Sequences A-F", "TEST", 0, 13], ["active siRNAs", "PROBLEM", 175, 188], ["2H3 cells", "PROBLEM", 208, 217], ["each siRNA", "TREATMENT", 240, 250], ["Syk transcripts", "OBSERVATION", 141, 156], ["active", "OBSERVATION_MODIFIER", 175, 181], ["siRNAs", "OBSERVATION", 182, 188], ["2H3 cells", "OBSERVATION", 208, 217], ["siRNA", "OBSERVATION", 245, 250]]], ["Syk mRNA levels were determined using TaqMan PCR ( Fig. 2A) .", [["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["Syk mRNA", "RNA", 0, 8], ["Syk mRNA levels", "TEST", 0, 15], ["TaqMan PCR", "TEST", 38, 48]]], ["Syk levels were normalized to RNA Polymerase II in each sample.", [["sample", "ANATOMY", 56, 62], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["RNA Polymerase II", "GENE_OR_GENE_PRODUCT", 30, 47], ["Syk", "PROTEIN", 0, 3], ["RNA Polymerase II", "PROTEIN", 30, 47], ["Syk levels", "TEST", 0, 10], ["RNA Polymerase II in each sample", "PROBLEM", 30, 62]]], ["An siRNA against GAPDH, as well as cells electroporated in the absence of siRNAs were used as negative controls.", [["cells", "ANATOMY", 35, 40], ["GAPDH", "GENE_OR_GENE_PRODUCT", 17, 22], ["cells", "CELL", 35, 40], ["GAPDH", "PROTEIN", 17, 22], ["An siRNA", "TEST", 0, 8], ["GAPDH", "PROBLEM", 17, 22], ["siRNAs", "PROBLEM", 74, 80], ["siRNA", "OBSERVATION", 3, 8], ["siRNAs", "OBSERVATION", 74, 80]]], ["These two controls led to a minor decrease in Syk mRNA levels compared to untreated cells.", [["cells", "ANATOMY", 84, 89], ["Syk", "GENE_OR_GENE_PRODUCT", 46, 49], ["cells", "CELL", 84, 89], ["Syk mRNA", "RNA", 46, 54], ["untreated cells", "CELL_TYPE", 74, 89], ["a minor decrease in Syk mRNA levels", "PROBLEM", 26, 61], ["minor", "OBSERVATION_MODIFIER", 28, 33], ["decrease", "OBSERVATION_MODIFIER", 34, 42], ["Syk mRNA", "OBSERVATION", 46, 54]]], ["Sequence A was the most potent siRNA with regards to Syk mRNA knockdown.", [["Syk", "GENE_OR_GENE_PRODUCT", 53, 56], ["Syk mRNA", "RNA", 53, 61], ["Syk mRNA knockdown", "TREATMENT", 53, 71], ["Syk mRNA knockdown", "OBSERVATION", 53, 71]]], ["Meanwhile sequence D, was the least potent.", [["potent", "OBSERVATION_MODIFIER", 36, 42]]], ["Whole cell protein extracts were also analyzed for Syk expression by Western blotting with a specific antibody ( Fig. 2B) .", [["cell", "ANATOMY", 6, 10], ["extracts", "ANATOMY", 19, 27], ["cell", "CELL", 6, 10], ["extracts", "ORGANISM_SUBSTANCE", 19, 27], ["Syk", "GENE_OR_GENE_PRODUCT", 51, 54], ["Syk", "PROTEIN", 51, 54], ["specific antibody", "PROTEIN", 93, 110], ["Fig. 2B", "PROTEIN", 113, 120], ["Whole cell protein extracts", "TREATMENT", 0, 27], ["a specific antibody", "TEST", 91, 110]]], ["As a control, levels of b-actin were also examined to ensure equal loading of cellular proteins for each sample.", [["cellular", "ANATOMY", 78, 86], ["sample", "ANATOMY", 105, 111], ["b-actin", "CHEMICAL", 24, 31], ["b-actin", "GENE_OR_GENE_PRODUCT", 24, 31], ["cellular", "CELL", 78, 86], ["b-actin", "PROTEIN", 24, 31], ["cellular proteins", "PROTEIN", 78, 95], ["b-actin", "TREATMENT", 24, 31]]], ["Syk protein levels were reduced in a manner consistent with the potency of each siRNA towards Syk mRNA levels, with sequence A displaying the most potent knockdown of Syk protein.siRNASpecies specificityInduction of the interferon-responsive gene IFIT1 by active Syk siRNAsInduction of interferon (IFN) expression by double stranded RNA (dsRNA) comprises a first line of cellular defense against viral infection [20] .", [["cellular", "ANATOMY", 371, 379], ["viral infection", "DISEASE", 396, 411], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["Syk", "GENE_OR_GENE_PRODUCT", 94, 97], ["Syk", "GENE_OR_GENE_PRODUCT", 167, 170], ["interferon", "GENE_OR_GENE_PRODUCT", 220, 230], ["IFIT1", "GENE_OR_GENE_PRODUCT", 247, 252], ["Syk", "GENE_OR_GENE_PRODUCT", 263, 266], ["interferon", "GENE_OR_GENE_PRODUCT", 286, 296], ["IFN", "GENE_OR_GENE_PRODUCT", 298, 301], ["cellular", "CELL", 371, 379], ["Syk", "PROTEIN", 0, 3], ["Syk mRNA", "RNA", 94, 102], ["Syk", "PROTEIN", 167, 170], ["interferon-responsive gene", "DNA", 220, 246], ["IFIT1", "DNA", 247, 252], ["Syk", "PROTEIN", 263, 266], ["interferon", "PROTEIN", 286, 296], ["IFN", "PROTEIN", 298, 301], ["double stranded RNA", "RNA", 317, 336], ["Syk protein levels", "TEST", 0, 18], ["each siRNA", "PROBLEM", 75, 85], ["Syk mRNA levels", "TEST", 94, 109], ["the interferon-responsive gene IFIT1", "TREATMENT", 216, 252], ["active Syk siRNAsInduction of interferon (IFN) expression", "TREATMENT", 256, 313], ["double stranded RNA (dsRNA", "TREATMENT", 317, 343], ["viral infection", "PROBLEM", 396, 411], ["siRNA", "OBSERVATION", 80, 85], ["active", "OBSERVATION_MODIFIER", 256, 262], ["Syk", "OBSERVATION", 263, 266]]], ["Viral dsRNA activates a range of cellular pathways including the dsRNA recognition protein PKR [23] , toll-like receptor 3 (TLR3) [24] and the 2 0 -5 0 -oligoadenylate-dependent ribonuclease L (RNase L) [25, 26] leading to inhibition of cellular translation and the expression of stress response genes including IFNs.", [["cellular", "ANATOMY", 33, 41], ["cellular", "ANATOMY", 237, 245], ["cellular", "CELL", 33, 41], ["PKR [23]", "GENE_OR_GENE_PRODUCT", 91, 99], ["toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 102, 122], ["TLR3", "GENE_OR_GENE_PRODUCT", 124, 128], ["2 0 -5 0 -oligoadenylate", "SIMPLE_CHEMICAL", 143, 167], ["ribonuclease L", "GENE_OR_GENE_PRODUCT", 178, 192], ["RNase L", "GENE_OR_GENE_PRODUCT", 194, 201], ["cellular", "CELL", 237, 245], ["IFNs", "GENE_OR_GENE_PRODUCT", 312, 316], ["dsRNA recognition protein", "PROTEIN", 65, 90], ["PKR", "PROTEIN", 91, 94], ["toll-like receptor 3", "PROTEIN", 102, 122], ["TLR3", "PROTEIN", 124, 128], ["ribonuclease L", "PROTEIN", 178, 192], ["RNase L", "PROTEIN", 194, 201], ["stress response genes", "DNA", 280, 301], ["IFNs", "PROTEIN", 312, 316], ["Viral dsRNA", "PROBLEM", 0, 11], ["the dsRNA recognition protein", "TEST", 61, 90], ["PKR", "TEST", 91, 94], ["cellular translation", "TREATMENT", 237, 257], ["stress response genes", "PROBLEM", 280, 301]]], ["Following IFN signaling, a wave of other genes are expressed including the IFN-stimulated genes (ISG), which function to block viral replication [20, 27] .", [["IFN", "GENE_OR_GENE_PRODUCT", 10, 13], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 75, 95], ["ISG", "GENE_OR_GENE_PRODUCT", 97, 100], ["IFN", "PROTEIN", 10, 13], ["IFN-stimulated genes", "DNA", 75, 95], ["ISG", "DNA", 97, 100], ["IFN signaling", "PROBLEM", 10, 23], ["a wave of other genes", "PROBLEM", 25, 46], ["block viral replication", "PROBLEM", 121, 144]]], ["Activation of the IFN response has also been demonstrated in siRNA transfected cells and this complicates the therapeutic potential of these molecules [28, 29] .", [["cells", "ANATOMY", 79, 84], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["cells", "CELL", 79, 84], ["IFN", "PROTEIN", 18, 21], ["siRNA transfected cells", "CELL_LINE", 61, 84], ["siRNA transfected cells", "PROBLEM", 61, 84], ["siRNA transfected cells", "OBSERVATION", 61, 84]]], ["In particular, Syk is considered a major target for inflammatory disorders and an induction of inflammatory mediators due to an anti-viral cellular response would be an unacceptable side-effect when designing Syk siRNA therapeutics.Induction of the interferon-responsive gene IFIT1 by active Syk siRNAsThe expression of IFN-induced protein with tetratricopeptide repeats-1 (IFIT1/ISG56) was analyzed in mouse embryonic fibroblast (MEF) cells transfected with a selection of active Syk siRNAs (A, B, C, G, H, I and J) in order to determine if these siRNAs activated anti-viral cellular pathways.", [["cellular", "ANATOMY", 139, 147], ["embryonic fibroblast (MEF) cells", "ANATOMY", 409, 441], ["cellular", "ANATOMY", 576, 584], ["inflammatory disorders", "DISEASE", 52, 74], ["Syk", "GENE_OR_GENE_PRODUCT", 15, 18], ["cellular", "CELL", 139, 147], ["Syk", "GENE_OR_GENE_PRODUCT", 209, 212], ["interferon", "GENE_OR_GENE_PRODUCT", 249, 259], ["IFIT1", "GENE_OR_GENE_PRODUCT", 276, 281], ["Syk", "GENE_OR_GENE_PRODUCT", 292, 295], ["IFN", "GENE_OR_GENE_PRODUCT", 320, 323], ["tetratricopeptide repeats-1", "GENE_OR_GENE_PRODUCT", 345, 372], ["IFIT1", "GENE_OR_GENE_PRODUCT", 374, 379], ["ISG56", "GENE_OR_GENE_PRODUCT", 380, 385], ["mouse", "ORGANISM", 403, 408], ["embryonic fibroblast (MEF) cells", "CELL", 409, 441], ["Syk", "GENE_OR_GENE_PRODUCT", 481, 484], ["B", "GENE_OR_GENE_PRODUCT", 496, 497], ["cellular", "CELL", 576, 584], ["Syk", "PROTEIN", 15, 18], ["inflammatory mediators", "PROTEIN", 95, 117], ["Syk", "PROTEIN", 209, 212], ["interferon-responsive gene", "DNA", 249, 275], ["IFIT1", "DNA", 276, 281], ["Syk siRNAs", "RNA", 292, 302], ["IFN", "PROTEIN", 320, 323], ["tetratricopeptide repeats-1", "PROTEIN", 345, 372], ["IFIT1", "PROTEIN", 374, 379], ["ISG56", "PROTEIN", 380, 385], ["mouse embryonic fibroblast (MEF) cells", "CELL_LINE", 403, 441], ["Syk siRNAs", "PROTEIN", 481, 491], ["B", "PROTEIN", 496, 497], ["mouse", "SPECIES", 403, 408], ["mouse", "SPECIES", 403, 408], ["inflammatory disorders", "PROBLEM", 52, 74], ["inflammatory mediators", "PROBLEM", 95, 117], ["an anti-viral cellular response", "PROBLEM", 125, 156], ["Syk siRNA therapeutics", "TREATMENT", 209, 231], ["the interferon-responsive gene IFIT1", "TREATMENT", 245, 281], ["active Syk siRNAs", "PROBLEM", 285, 302], ["IFN", "TEST", 320, 323], ["tetratricopeptide repeats", "TEST", 345, 370], ["mouse embryonic fibroblast (MEF) cells", "TREATMENT", 403, 441], ["these siRNAs activated anti-viral cellular pathways", "PROBLEM", 542, 593], ["Syk", "OBSERVATION", 15, 18], ["inflammatory", "OBSERVATION", 52, 64], ["Syk siRNAs", "OBSERVATION", 292, 302], ["active", "OBSERVATION_MODIFIER", 474, 480], ["Syk siRNAs", "OBSERVATION", 481, 491]]], ["MEF cells have previously been shown to express interferon-responsive genes in response to siRNAs and therefore represent a valid experimental system [28, 30] .", [["MEF cells", "ANATOMY", 0, 9], ["MEF cells", "CELL", 0, 9], ["interferon", "GENE_OR_GENE_PRODUCT", 48, 58], ["MEF cells", "CELL_LINE", 0, 9], ["interferon-responsive genes", "DNA", 48, 75], ["MEF cells", "PROBLEM", 0, 9], ["siRNAs", "TREATMENT", 91, 97]]], ["Syk siR-NAs C, H and I increased the expression of IFIT1 by twofold suggestive of an activation of the IFN response (Fig. 3) .", [["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["C", "SIMPLE_CHEMICAL", 12, 13], ["H", "SIMPLE_CHEMICAL", 15, 16], ["IFIT1", "GENE_OR_GENE_PRODUCT", 51, 56], ["Syk", "PROTEIN", 0, 3], ["IFIT1", "PROTEIN", 51, 56], ["IFN", "PROTEIN", 103, 106]]], ["The GAPDH siRNA as well as Syk siRNAs A, B, G and J were without effect on IFIT1 expression.Knockdown of Syk reduces FceRI-mediated signal transduction in a manner similar to Syk kinase inhibitorsThe ability of a selection of active Syk siRNAs (A, G and J) to block FceRI-mediated signal transduction was examined in RBL-2H3 cells.", [["RBL-2H3 cells", "ANATOMY", 317, 330], ["GAPDH", "GENE_OR_GENE_PRODUCT", 4, 9], ["Syk", "GENE_OR_GENE_PRODUCT", 27, 30], ["B", "CELL", 41, 42], ["IFIT1", "GENE_OR_GENE_PRODUCT", 75, 80], ["Syk", "GENE_OR_GENE_PRODUCT", 105, 108], ["FceRI", "GENE_OR_GENE_PRODUCT", 117, 122], ["Syk", "GENE_OR_GENE_PRODUCT", 175, 178], ["Syk", "GENE_OR_GENE_PRODUCT", 233, 236], ["FceRI", "GENE_OR_GENE_PRODUCT", 266, 271], ["RBL-2H3 cells", "CELL", 317, 330], ["GAPDH siRNA", "RNA", 4, 15], ["Syk siRNAs", "PROTEIN", 27, 37], ["IFIT1", "PROTEIN", 75, 80], ["Syk", "PROTEIN", 105, 108], ["FceRI", "PROTEIN", 117, 122], ["Syk kinase inhibitors", "PROTEIN", 175, 196], ["Syk siRNAs", "PROTEIN", 233, 243], ["FceRI", "PROTEIN", 266, 271], ["RBL-2H3 cells", "CELL_LINE", 317, 330], ["RBL-2H3", "SPECIES", 317, 324], ["The GAPDH siRNA", "TREATMENT", 0, 15], ["Syk siRNAs", "TREATMENT", 27, 37], ["Syk", "PROBLEM", 105, 108], ["FceRI-mediated signal transduction", "TREATMENT", 117, 151], ["Syk kinase inhibitors", "TREATMENT", 175, 196], ["active Syk siRNAs", "TREATMENT", 226, 243], ["A, G and J) to block FceRI-mediated signal transduction", "TREATMENT", 245, 300], ["GAPDH siRNA", "OBSERVATION", 4, 15], ["Syk siRNAs", "OBSERVATION", 27, 37], ["Syk", "OBSERVATION", 105, 108], ["active", "OBSERVATION_MODIFIER", 226, 232], ["Syk siRNAs", "OBSERVATION", 233, 243], ["2H3 cells", "OBSERVATION", 321, 330]]], ["Crosslinking of the FceRI receptor in these cells led to a rapid phosphorylation Syk at tyrosine 346 (Fig. 4A ).", [["cells", "ANATOMY", 44, 49], ["tyrosine", "CHEMICAL", 88, 96], ["tyrosine", "CHEMICAL", 88, 96], ["FceRI receptor", "GENE_OR_GENE_PRODUCT", 20, 34], ["cells", "CELL", 44, 49], ["Syk", "GENE_OR_GENE_PRODUCT", 81, 84], ["tyrosine", "AMINO_ACID", 88, 96], ["346", "AMINO_ACID", 97, 100], ["FceRI receptor", "PROTEIN", 20, 34], ["Syk", "PROTEIN", 81, 84], ["tyrosine 346", "PROTEIN", 88, 100], ["the FceRI receptor", "TREATMENT", 16, 34], ["a rapid phosphorylation Syk at tyrosine", "TREATMENT", 57, 96]]], ["In addition, the Syk substrates LAT (tyrosine 226) and SLP-76 (tyrosine 128) as well as the associated protein PLCc1 (tyrosine 783) and downstream protein Erk (threonine 202/tyrosine 204) were also phosphorylated.", [["tyrosine", "CHEMICAL", 37, 45], ["tyrosine", "CHEMICAL", 63, 71], ["tyrosine", "CHEMICAL", 118, 126], ["threonine 202", "CHEMICAL", 160, 173], ["tyrosine", "CHEMICAL", 174, 182], ["tyrosine", "CHEMICAL", 37, 45], ["tyrosine", "CHEMICAL", 63, 71], ["tyrosine", "CHEMICAL", 118, 126], ["threonine", "CHEMICAL", 160, 169], ["tyrosine", "CHEMICAL", 174, 182], ["Syk", "GENE_OR_GENE_PRODUCT", 17, 20], ["LAT", "GENE_OR_GENE_PRODUCT", 32, 35], ["tyrosine", "AMINO_ACID", 37, 45], ["226", "AMINO_ACID", 46, 49], ["SLP-76", "GENE_OR_GENE_PRODUCT", 55, 61], ["tyrosine", "AMINO_ACID", 63, 71], ["128", "AMINO_ACID", 72, 75], ["PLCc1", "GENE_OR_GENE_PRODUCT", 111, 116], ["tyrosine", "AMINO_ACID", 118, 126], ["783", "AMINO_ACID", 127, 130], ["Erk", "GENE_OR_GENE_PRODUCT", 155, 158], ["threonine 202", "AMINO_ACID", 160, 173], ["tyrosine", "AMINO_ACID", 174, 182], ["204", "AMINO_ACID", 183, 186], ["Syk substrates", "PROTEIN", 17, 31], ["LAT", "PROTEIN", 32, 35], ["SLP", "PROTEIN", 55, 58], ["tyrosine 128", "PROTEIN", 63, 75], ["PLCc1", "PROTEIN", 111, 116], ["tyrosine 783", "PROTEIN", 118, 130], ["Erk", "PROTEIN", 155, 158], ["threonine 202", "PROTEIN", 160, 173], ["the Syk substrates LAT (tyrosine", "TEST", 13, 45], ["SLP", "TEST", 55, 58], ["tyrosine", "TEST", 63, 71], ["the associated protein PLCc1", "TEST", 88, 116], ["tyrosine", "TEST", 118, 126], ["downstream protein Erk", "TEST", 136, 158], ["threonine", "TEST", 160, 169], ["tyrosine", "TEST", 174, 182]]], ["A general activation of protein tyrosine phosphorylation with predominant signals at 100, 70-75 and 55 kDa was also observed in response to FceRI receptor crosslinking.", [["tyrosine", "CHEMICAL", 32, 40], ["tyrosine", "CHEMICAL", 32, 40], ["tyrosine", "AMINO_ACID", 32, 40], ["FceRI receptor", "GENE_OR_GENE_PRODUCT", 140, 154], ["FceRI receptor", "PROTEIN", 140, 154], ["protein tyrosine phosphorylation", "TREATMENT", 24, 56], ["FceRI receptor crosslinking", "TREATMENT", 140, 167]]], ["Consistent with results presented above (Fig. 2) , Syk siRNA A was the most potent in reducing levels of Syk protein.", [["Syk", "GENE_OR_GENE_PRODUCT", 51, 54], ["Syk", "GENE_OR_GENE_PRODUCT", 105, 108], ["Syk", "PROTEIN", 51, 54], ["Syk protein", "PROTEIN", 105, 116], ["Syk siRNA A", "PROBLEM", 51, 62], ["Syk protein", "TREATMENT", 105, 116], ["Syk siRNA", "OBSERVATION", 51, 60], ["most potent", "OBSERVATION_MODIFIER", 71, 82], ["Syk protein", "OBSERVATION", 105, 116]]], ["Sequences J and H were respectively less potent than sequence A. The phosphorylation of LAT, SLP-76, PLCc1 and Erk was decreased by Syk siRNAs in a manner that directly correlated with their effects on Syk expression.", [["LAT", "GENE_OR_GENE_PRODUCT", 88, 91], ["SLP-76", "GENE_OR_GENE_PRODUCT", 93, 99], ["PLCc1", "GENE_OR_GENE_PRODUCT", 101, 106], ["Erk", "GENE_OR_GENE_PRODUCT", 111, 114], ["Syk", "GENE_OR_GENE_PRODUCT", 132, 135], ["Syk", "GENE_OR_GENE_PRODUCT", 202, 205], ["LAT", "PROTEIN", 88, 91], ["SLP", "PROTEIN", 93, 96], ["PLCc1", "PROTEIN", 101, 106], ["Erk", "PROTEIN", 111, 114], ["Syk", "PROTEIN", 132, 135], ["Syk", "PROTEIN", 202, 205], ["The phosphorylation of LAT", "TEST", 65, 91], ["SLP", "TEST", 93, 96], ["PLCc1", "TEST", 101, 106], ["Erk", "TEST", 111, 114], ["decreased", "OBSERVATION_MODIFIER", 119, 128], ["Syk siRNAs", "OBSERVATION", 132, 142], ["Syk expression", "OBSERVATION", 202, 216]]], ["Interestingly, whilst the tyrosine phosphorylation of proteins at 100 and 70-75 kDa was reduced by Syk siRNAs, the phosphorylation of the 55 kDa protein was slightly enhanced.", [["tyrosine", "CHEMICAL", 26, 34], ["tyrosine", "CHEMICAL", 26, 34], ["tyrosine", "AMINO_ACID", 26, 34], ["Syk", "GENE_OR_GENE_PRODUCT", 99, 102], ["55 kDa", "GENE_OR_GENE_PRODUCT", 138, 144], ["Syk", "PROTEIN", 99, 102], ["55 kDa protein", "PROTEIN", 138, 152], ["the tyrosine phosphorylation", "TEST", 22, 50], ["proteins", "TEST", 54, 62], ["the phosphorylation", "TEST", 111, 130], ["the 55 kDa protein", "TEST", 134, 152], ["slightly enhanced", "PROBLEM", 157, 174], ["Syk siRNAs", "OBSERVATION", 99, 109], ["slightly", "OBSERVATION_MODIFIER", 157, 165], ["enhanced", "OBSERVATION_MODIFIER", 166, 174]]], ["This suggests that the phosphorylation of this unidentified 55 kDa protein could be negatively regulated by Syk in response to FceRI receptor crosslinking.", [["55 kDa", "GENE_OR_GENE_PRODUCT", 60, 66], ["Syk", "GENE_OR_GENE_PRODUCT", 108, 111], ["FceRI receptor", "GENE_OR_GENE_PRODUCT", 127, 141], ["55 kDa protein", "PROTEIN", 60, 74], ["Syk", "PROTEIN", 108, 111], ["FceRI receptor", "PROTEIN", 127, 141], ["kDa protein", "TEST", 63, 74], ["FceRI receptor crosslinking", "TREATMENT", 127, 154]]], ["The total levels of LAT, SLP-76, PLCc1, Erk and b-actin were not affected by the Syk siRNAs indicating that the observed reduction in their respective phospho-forms was due to a decrease in their phosphorylation and not a decrease in their stability or expression.Knockdown of Syk reduces FceRI-mediated signal transduction in a manner similar to Syk kinase inhibitorsWe used the small-molecule inhibitors of the Syk kinase domain BAY61-3606, R406 and piceatannol to investigate if a similar inhibition of FceRI signaling could be observed with Syk inhibitors and Syk siRNAs.", [["BAY61-3606", "CHEMICAL", 431, 441], ["piceatannol", "CHEMICAL", 452, 463], ["phospho", "CHEMICAL", 151, 158], ["BAY61-3606", "CHEMICAL", 431, 441], ["piceatannol", "CHEMICAL", 452, 463], ["LAT", "GENE_OR_GENE_PRODUCT", 20, 23], ["SLP-76", "GENE_OR_GENE_PRODUCT", 25, 31], ["PLCc1", "GENE_OR_GENE_PRODUCT", 33, 38], ["Erk", "GENE_OR_GENE_PRODUCT", 40, 43], ["b-actin", "GENE_OR_GENE_PRODUCT", 48, 55], ["Syk", "GENE_OR_GENE_PRODUCT", 81, 84], ["Syk", "GENE_OR_GENE_PRODUCT", 277, 280], ["FceRI", "GENE_OR_GENE_PRODUCT", 289, 294], ["Syk", "GENE_OR_GENE_PRODUCT", 347, 350], ["Syk", "GENE_OR_GENE_PRODUCT", 413, 416], ["R406", "SIMPLE_CHEMICAL", 443, 447], ["piceatannol", "SIMPLE_CHEMICAL", 452, 463], ["FceRI", "GENE_OR_GENE_PRODUCT", 506, 511], ["Syk", "GENE_OR_GENE_PRODUCT", 545, 548], ["Syk", "GENE_OR_GENE_PRODUCT", 564, 567], ["LAT", "PROTEIN", 20, 23], ["SLP", "PROTEIN", 25, 28], ["PLCc1", "PROTEIN", 33, 38], ["Erk", "PROTEIN", 40, 43], ["b-actin", "PROTEIN", 48, 55], ["Syk", "PROTEIN", 81, 84], ["phospho", "PROTEIN", 151, 158], ["Syk", "PROTEIN", 277, 280], ["FceRI", "PROTEIN", 289, 294], ["Syk kinase inhibitors", "PROTEIN", 347, 368], ["Syk kinase domain BAY61-3606", "PROTEIN", 413, 441], ["FceRI", "PROTEIN", 506, 511], ["Syk", "PROTEIN", 545, 548], ["Syk", "PROTEIN", 564, 567], ["The total levels", "TEST", 0, 16], ["LAT", "TEST", 20, 23], ["SLP", "TEST", 25, 28], ["PLCc1", "TEST", 33, 38], ["Erk", "TEST", 40, 43], ["b-actin", "TEST", 48, 55], ["the observed reduction", "PROBLEM", 108, 130], ["a decrease in their phosphorylation", "PROBLEM", 176, 211], ["Syk", "PROBLEM", 277, 280], ["FceRI-mediated signal transduction", "TREATMENT", 289, 323], ["Syk kinase inhibitors", "TREATMENT", 347, 368], ["the small-molecule inhibitors", "TREATMENT", 376, 405], ["piceatannol", "TREATMENT", 452, 463], ["FceRI signaling", "PROBLEM", 506, 521], ["Syk inhibitors", "TREATMENT", 545, 559], ["Syk siRNAs", "PROBLEM", 564, 574], ["Syk siRNAs", "OBSERVATION", 81, 91], ["reduction", "OBSERVATION_MODIFIER", 121, 130], ["decrease", "OBSERVATION_MODIFIER", 178, 186], ["decrease", "OBSERVATION_MODIFIER", 222, 230], ["Syk", "OBSERVATION", 277, 280], ["Syk siRNAs", "OBSERVATION", 564, 574]]], ["The FceRI-induced phosphorylation of LAT, SLP-76, PLCc1, Erk and proteins at 100, 70-75 and 55 kDa were dosedependently inhibited by the BAY61-3606 and R406 compounds (Fig. 4B) .", [["FceRI", "CHEMICAL", 4, 9], ["BAY61-3606", "CHEMICAL", 137, 147], ["BAY61-3606", "CHEMICAL", 137, 147], ["R406", "CHEMICAL", 152, 156], ["FceRI", "SIMPLE_CHEMICAL", 4, 9], ["LAT", "GENE_OR_GENE_PRODUCT", 37, 40], ["SLP-76", "GENE_OR_GENE_PRODUCT", 42, 48], ["PLCc1", "GENE_OR_GENE_PRODUCT", 50, 55], ["Erk", "GENE_OR_GENE_PRODUCT", 57, 60], ["BAY61-3606", "SIMPLE_CHEMICAL", 137, 147], ["FceRI", "PROTEIN", 4, 9], ["LAT", "PROTEIN", 37, 40], ["SLP", "PROTEIN", 42, 45], ["PLCc1", "PROTEIN", 50, 55], ["Erk", "PROTEIN", 57, 60], ["The FceRI", "TEST", 0, 9], ["SLP", "TEST", 42, 45], ["PLCc1", "TEST", 50, 55], ["Erk", "TEST", 57, 60], ["proteins", "TEST", 65, 73], ["kDa", "TEST", 95, 98]]], ["Interestingly, in contrast to the effects of Syk siRNAs, the phosphorylation of the 55 kDa protein decreased with BAY61-3606 and R406.", [["BAY61-3606", "CHEMICAL", 114, 124], ["BAY61-3606", "CHEMICAL", 114, 124], ["R406", "CHEMICAL", 129, 133], ["Syk", "GENE_OR_GENE_PRODUCT", 45, 48], ["55 kDa", "GENE_OR_GENE_PRODUCT", 84, 90], ["BAY61-3606", "GENE_OR_GENE_PRODUCT", 114, 124], ["Syk", "PROTEIN", 45, 48], ["55 kDa protein", "PROTEIN", 84, 98], ["BAY61", "PROTEIN", 114, 119], ["Syk siRNAs", "TREATMENT", 45, 55], ["the phosphorylation", "TEST", 57, 76], ["kDa protein", "TEST", 87, 98], ["BAY61", "TEST", 114, 119], ["Syk siRNAs", "OBSERVATION", 45, 55]]], ["This may represent a discrepancy in the mechanism of action of these two inhibitory approaches.", [["a discrepancy", "PROBLEM", 19, 32], ["these two inhibitory approaches", "TREATMENT", 63, 94], ["may represent", "UNCERTAINTY", 5, 18], ["discrepancy", "OBSERVATION", 21, 32]]], ["The phosphorylation of Syk at tyrosine 346 was unaffected by these inhibitors suggesting that although it is activated following FceRI crosslinking, that it is not a substrate for Syk autocatalytic activity.Knockdown of Syk reduces FceRI-mediated signal transduction in a manner similar to Syk kinase inhibitorsWhen used at 20 lM, piceatannol led to a minor decrease in the phosphorylation of LAT, SLP-76, PLCc1, Erk and the 100, 70-75 and 55 kDa proteins, yet the inhibitor was without effect at the lower concentrations of 10 and 1 lM.Syk siRNAs and inhibitors block degranulation and TNFa expressionThe activation of mast cells and basophils via IgE complexes leads to degranulation and secretion of cytokines.", [["mast cells", "ANATOMY", 620, 630], ["basophils", "ANATOMY", 635, 644], ["tyrosine", "CHEMICAL", 30, 38], ["piceatannol", "CHEMICAL", 331, 342], ["tyrosine", "CHEMICAL", 30, 38], ["piceatannol", "CHEMICAL", 331, 342], ["Syk", "GENE_OR_GENE_PRODUCT", 23, 26], ["tyrosine", "AMINO_ACID", 30, 38], ["346", "AMINO_ACID", 39, 42], ["FceRI", "GENE_OR_GENE_PRODUCT", 129, 134], ["Syk", "GENE_OR_GENE_PRODUCT", 180, 183], ["Syk", "GENE_OR_GENE_PRODUCT", 220, 223], ["FceRI", "GENE_OR_GENE_PRODUCT", 232, 237], ["Syk", "GENE_OR_GENE_PRODUCT", 290, 293], ["piceatannol", "SIMPLE_CHEMICAL", 331, 342], ["LAT", "GENE_OR_GENE_PRODUCT", 393, 396], ["SLP-76", "GENE_OR_GENE_PRODUCT", 398, 404], ["PLCc1", "GENE_OR_GENE_PRODUCT", 406, 411], ["Erk", "GENE_OR_GENE_PRODUCT", 413, 416], ["Syk", "GENE_OR_GENE_PRODUCT", 537, 540], ["TNFa", "GENE_OR_GENE_PRODUCT", 587, 591], ["mast cells", "CELL", 620, 630], ["basophils", "CELL", 635, 644], ["IgE", "GENE_OR_GENE_PRODUCT", 649, 652], ["Syk", "PROTEIN", 23, 26], ["FceRI", "PROTEIN", 129, 134], ["Syk", "PROTEIN", 180, 183], ["Syk", "PROTEIN", 220, 223], ["FceRI", "PROTEIN", 232, 237], ["Syk kinase inhibitors", "PROTEIN", 290, 311], ["LAT", "PROTEIN", 393, 396], ["SLP", "PROTEIN", 398, 401], ["PLCc1", "PROTEIN", 406, 411], ["Erk", "PROTEIN", 413, 416], ["100, 70-75 and 55 kDa proteins", "PROTEIN", 425, 455], ["Syk", "PROTEIN", 537, 540], ["TNFa", "PROTEIN", 587, 591], ["mast cells", "CELL_TYPE", 620, 630], ["basophils", "CELL_TYPE", 635, 644], ["IgE complexes", "PROTEIN", 649, 662], ["cytokines", "PROTEIN", 703, 712], ["The phosphorylation of Syk at tyrosine", "TREATMENT", 0, 38], ["these inhibitors", "TREATMENT", 61, 77], ["FceRI crosslinking", "TREATMENT", 129, 147], ["Syk autocatalytic activity", "PROBLEM", 180, 206], ["Syk", "PROBLEM", 220, 223], ["FceRI-mediated signal transduction", "TREATMENT", 232, 266], ["Syk kinase inhibitors", "TREATMENT", 290, 311], ["piceatannol", "TREATMENT", 331, 342], ["a minor decrease", "PROBLEM", 350, 366], ["SLP", "TEST", 398, 401], ["PLCc1", "TEST", 406, 411], ["Erk", "TEST", 413, 416], ["kDa proteins", "TEST", 443, 455], ["Syk siRNAs", "TREATMENT", 537, 547], ["inhibitors block degranulation", "TREATMENT", 552, 582], ["TNFa expression", "TREATMENT", 587, 602], ["mast cells", "PROBLEM", 620, 630], ["basophils via IgE complexes", "TREATMENT", 635, 662], ["degranulation", "PROBLEM", 672, 685], ["secretion of cytokines", "PROBLEM", 690, 712], ["Syk", "OBSERVATION", 220, 223], ["minor", "OBSERVATION_MODIFIER", 352, 357], ["decrease", "OBSERVATION_MODIFIER", 358, 366], ["siRNAs", "OBSERVATION", 541, 547], ["mast cells", "OBSERVATION", 620, 630], ["IgE complexes", "OBSERVATION", 649, 662]]], ["We tested the ability of Syk siRNAs A, G and J and the Syk inhibitors to block these cellular responses in RBL-2H3 cells.", [["cellular", "ANATOMY", 85, 93], ["RBL-2H3 cells", "ANATOMY", 107, 120], ["Syk", "GENE_OR_GENE_PRODUCT", 25, 28], ["Syk", "GENE_OR_GENE_PRODUCT", 55, 58], ["cellular", "CELL", 85, 93], ["RBL-2H3 cells", "CELL", 107, 120], ["Syk siRNAs", "RNA", 25, 35], ["Syk", "PROTEIN", 55, 58], ["RBL-2H3 cells", "CELL_LINE", 107, 120], ["Syk siRNAs", "PROBLEM", 25, 35], ["A, G and J and the Syk inhibitors", "TREATMENT", 36, 69], ["Syk siRNAs", "OBSERVATION", 25, 35], ["Syk", "ANATOMY", 55, 58], ["2H3 cells", "OBSERVATION", 111, 120]]], ["All three Syk siRNAs potently blocked the release of b-hexosaminidase from activated RBL-2H3 cells (Fig. 5A) .", [["RBL-2H3 cells", "ANATOMY", 85, 98], ["Syk", "GENE_OR_GENE_PRODUCT", 10, 13], ["b-hexosaminidase", "GENE_OR_GENE_PRODUCT", 53, 69], ["RBL-2H3 cells", "CELL", 85, 98], ["Fig. 5A", "CELL", 100, 107], ["Syk", "PROTEIN", 10, 13], ["b-hexosaminidase", "PROTEIN", 53, 69], ["activated RBL-2H3 cells", "CELL_LINE", 75, 98], ["All three Syk siRNAs", "TREATMENT", 0, 20], ["b-hexosaminidase", "TREATMENT", 53, 69], ["activated RBL", "TREATMENT", 75, 88], ["Syk siRNAs", "OBSERVATION", 10, 20]]], ["Sequence G was shown above to knockdown Syk protein to a lesser extent than siRNAs A and J. Consistent with this, the release of b-hexosaminidase was inhibited to a lesser extent.", [["Syk", "GENE_OR_GENE_PRODUCT", 40, 43], ["b-hexosaminidase", "GENE_OR_GENE_PRODUCT", 129, 145], ["Syk protein", "PROTEIN", 40, 51], ["b-hexosaminidase", "PROTEIN", 129, 145], ["Sequence G", "TEST", 0, 10], ["Syk protein", "TEST", 40, 51], ["b-hexosaminidase", "TREATMENT", 129, 145], ["lesser extent", "OBSERVATION_MODIFIER", 57, 70], ["Consistent with", "UNCERTAINTY", 92, 107], ["lesser extent", "OBSERVATION_MODIFIER", 165, 178]]], ["The BAY61-3606 and R406 Syk inhibitors also blocked b-hexosaminidase release (Fig. 5B) .", [["BAY61-3606", "CHEMICAL", 4, 14], ["BAY61-3606", "CHEMICAL", 4, 14], ["BAY61-3606", "GENE_OR_GENE_PRODUCT", 4, 14], ["R406", "GENE_OR_GENE_PRODUCT", 19, 23], ["Syk", "GENE_OR_GENE_PRODUCT", 24, 27], ["b-hexosaminidase", "SIMPLE_CHEMICAL", 52, 68], ["Syk", "PROTEIN", 24, 27], ["b-hexosaminidase", "PROTEIN", 52, 68], ["The BAY61", "TEST", 0, 9], ["R406 Syk inhibitors", "TREATMENT", 19, 38], ["b-hexosaminidase release", "TREATMENT", 52, 76]]], ["Interestingly, although 10 and 1 lM piceatannol was shown above to have no impact on FceRI signal transduction, these concentrations effectively blocked b-hexosaminidase release.", [["piceatannol", "CHEMICAL", 36, 47], ["piceatannol", "CHEMICAL", 36, 47], ["piceatannol", "SIMPLE_CHEMICAL", 36, 47], ["FceRI", "SIMPLE_CHEMICAL", 85, 90], ["b-hexosaminidase", "SIMPLE_CHEMICAL", 153, 169], ["FceRI", "PROTEIN", 85, 90], ["b-hexosaminidase", "PROTEIN", 153, 169], ["1 lM piceatannol", "TREATMENT", 31, 47], ["FceRI signal transduction", "TREATMENT", 85, 110], ["b-hexosaminidase release", "TREATMENT", 153, 177]]], ["This indicates that although piceatannol has no impact on Syk-mediated signal transduction, it exerts unrelated anti-inflammatory effects in activated RBL-2H3 cells.", [["RBL-2H3 cells", "ANATOMY", 151, 164], ["piceatannol", "CHEMICAL", 29, 40], ["piceatannol", "CHEMICAL", 29, 40], ["piceatannol", "SIMPLE_CHEMICAL", 29, 40], ["Syk-", "SIMPLE_CHEMICAL", 58, 62], ["RBL-2H3 cells", "CELL", 151, 164], ["activated RBL-2H3 cells", "CELL_LINE", 141, 164], ["piceatannol", "TREATMENT", 29, 40], ["Syk-mediated signal transduction", "TREATMENT", 58, 90], ["anti-inflammatory effects", "OBSERVATION", 112, 137], ["RBL", "OBSERVATION", 151, 154], ["2H3 cells", "OBSERVATION", 155, 164]]], ["Each Syk siR-NA and inhibitor also blocked the release of TNFa and histamine by RBL-2H3 cells activated via FceRI-crosslinking (Table 1) .DiscussionSyk is widely expressed in the immune system where it is implicated in the transmission of signals via Fc receptors and other cell surface proteins [1] .", [["RBL-2H3 cells", "ANATOMY", 80, 93], ["immune system", "ANATOMY", 179, 192], ["cell surface", "ANATOMY", 274, 286], ["histamine", "CHEMICAL", 67, 76], ["histamine", "CHEMICAL", 67, 76], ["Syk", "GENE_OR_GENE_PRODUCT", 5, 8], ["siR-NA", "GENE_OR_GENE_PRODUCT", 9, 15], ["TNFa", "GENE_OR_GENE_PRODUCT", 58, 62], ["histamine", "SIMPLE_CHEMICAL", 67, 76], ["RBL-2H3 cells", "CELL", 80, 93], ["FceRI", "GENE_OR_GENE_PRODUCT", 108, 113], ["immune system", "ANATOMICAL_SYSTEM", 179, 192], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 251, 263], ["cell surface", "CELLULAR_COMPONENT", 274, 286], ["Syk", "PROTEIN", 5, 8], ["TNFa", "PROTEIN", 58, 62], ["RBL-2H3 cells", "CELL_LINE", 80, 93], ["FceRI", "PROTEIN", 108, 113], ["DiscussionSyk", "PROTEIN", 138, 151], ["Fc receptors", "PROTEIN", 251, 263], ["cell surface proteins", "PROTEIN", 274, 295], ["inhibitor", "TREATMENT", 20, 29], ["the release of TNFa", "TREATMENT", 43, 62], ["histamine", "TREATMENT", 67, 76], ["other cell surface proteins", "TEST", 268, 295]]], ["This has led to Syk gaining a great deal of interest as a potential therapeutic target for the treatment of inflammatory diseases such as asthma [3] , rheumatoid arthritis (RA) [31] and lupus [32] .", [["inflammatory diseases", "DISEASE", 108, 129], ["asthma", "DISEASE", 138, 144], ["rheumatoid arthritis", "DISEASE", 151, 171], ["RA", "DISEASE", 173, 175], ["lupus", "DISEASE", 186, 191], ["Syk", "GENE_OR_GENE_PRODUCT", 16, 19], ["Syk", "PROTEIN", 16, 19], ["inflammatory diseases", "PROBLEM", 108, 129], ["asthma", "PROBLEM", 138, 144], ["rheumatoid arthritis", "PROBLEM", 151, 171], ["lupus", "PROBLEM", 186, 191], ["inflammatory", "OBSERVATION", 108, 120], ["rheumatoid arthritis", "OBSERVATION", 151, 171], ["RA", "ANATOMY", 173, 175]]], ["Meanwhile, recent reports have sug- gested that Syk may represent a novel therapeutic target for the treatment of B and T cell lymphomas [33, 34] .", [["B", "ANATOMY", 114, 115], ["T cell lymphomas", "ANATOMY", 120, 136], ["T cell lymphomas", "DISEASE", 120, 136], ["Syk", "GENE_OR_GENE_PRODUCT", 48, 51], ["B", "CELL", 114, 115], ["T cell lymphomas", "CANCER", 120, 136], ["Syk", "PROTEIN", 48, 51], ["sug", "TEST", 31, 34], ["the treatment", "TREATMENT", 97, 110], ["B and T cell lymphomas", "PROBLEM", 114, 136], ["may represent", "UNCERTAINTY", 52, 65], ["cell lymphomas", "OBSERVATION", 122, 136]]], ["Current approaches towards Syk inhibition include the use of small molecule kinase domain inhibitors and in particular the R406 compound has shown efficacy in animal and human models of RA [16, 32] and immune thrombocytopenic purpura (ITP) [35] .DiscussionA novel approach towards Syk inhibition could be realized in the blockage of Syk expression using techniques such as anti-sense oligonucleotides or RNAi.", [["RA", "DISEASE", 186, 188], ["immune thrombocytopenic purpura", "DISEASE", 202, 233], ["ITP", "DISEASE", 235, 238], ["Syk", "GENE_OR_GENE_PRODUCT", 27, 30], ["human", "ORGANISM", 170, 175], ["Syk", "GENE_OR_GENE_PRODUCT", 281, 284], ["Syk", "GENE_OR_GENE_PRODUCT", 333, 336], ["Syk", "PROTEIN", 27, 30], ["Syk", "PROTEIN", 281, 284], ["Syk", "PROTEIN", 333, 336], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["Syk inhibition", "PROBLEM", 27, 41], ["small molecule kinase domain inhibitors", "TREATMENT", 61, 100], ["immune thrombocytopenic purpura", "PROBLEM", 202, 233], ["ITP", "TEST", 235, 238], ["Syk inhibition", "TREATMENT", 281, 295], ["techniques", "TREATMENT", 354, 364], ["anti-sense oligonucleotides", "TREATMENT", 373, 400], ["thrombocytopenic purpura", "OBSERVATION", 209, 233]]], ["These approaches potentially enable the reduction of gene expression as a means of target modulation as an alternative to the action of small-molecule inhibitors for which there are only a limited number of 'druggable' targets.", [["gene expression", "PROBLEM", 53, 68], ["small-molecule inhibitors", "TREATMENT", 136, 161]]], ["Aerolized Syk anti-sense oligonucleotides have been show to reduce Syk expression in alveolar macrophages and also blocked IgG/antigen-complex induced nitric oxide and TNFa release, pulmonary infiltration of inflammatory cells and allergic contraction of the trachea [36] [37] [38] .", [["alveolar macrophages", "ANATOMY", 85, 105], ["pulmonary", "ANATOMY", 182, 191], ["inflammatory cells", "ANATOMY", 208, 226], ["trachea", "ANATOMY", 259, 266], ["nitric oxide", "CHEMICAL", 151, 163], ["allergic contraction", "DISEASE", 231, 251], ["nitric oxide", "CHEMICAL", 151, 163], ["Syk", "GENE_OR_GENE_PRODUCT", 10, 13], ["Syk", "GENE_OR_GENE_PRODUCT", 67, 70], ["alveolar macrophages", "CELL", 85, 105], ["IgG/antigen", "GENE_OR_GENE_PRODUCT", 123, 134], ["nitric oxide", "SIMPLE_CHEMICAL", 151, 163], ["TNFa", "GENE_OR_GENE_PRODUCT", 168, 172], ["pulmonary", "ORGAN", 182, 191], ["inflammatory cells", "CELL", 208, 226], ["trachea", "ORGAN", 259, 266], ["Syk", "PROTEIN", 10, 13], ["Syk", "PROTEIN", 67, 70], ["alveolar macrophages", "CELL_TYPE", 85, 105], ["IgG", "PROTEIN", 123, 126], ["TNFa", "PROTEIN", 168, 172], ["inflammatory cells", "CELL_TYPE", 208, 226], ["Aerolized Syk anti-sense oligonucleotides", "TREATMENT", 0, 41], ["Syk expression in alveolar macrophages", "PROBLEM", 67, 105], ["IgG/antigen-complex induced nitric oxide", "TREATMENT", 123, 163], ["TNFa release", "TREATMENT", 168, 180], ["pulmonary infiltration", "PROBLEM", 182, 204], ["inflammatory cells", "PROBLEM", 208, 226], ["allergic contraction of the trachea", "PROBLEM", 231, 266], ["alveolar macrophages", "OBSERVATION", 85, 105], ["nitric oxide", "OBSERVATION", 151, 163], ["pulmonary", "ANATOMY", 182, 191], ["infiltration", "OBSERVATION", 192, 204], ["inflammatory cells", "OBSERVATION", 208, 226], ["allergic contraction", "OBSERVATION", 231, 251], ["trachea", "ANATOMY", 259, 266]]], ["These studies highlight the potential efficacy of targeting Syk expression levels as a novel therapeutic principle in airway inflammatory diseases.", [["airway", "ANATOMY", 118, 124], ["airway inflammatory diseases", "DISEASE", 118, 146], ["Syk", "GENE_OR_GENE_PRODUCT", 60, 63], ["airway", "MULTI-TISSUE_STRUCTURE", 118, 124], ["Syk", "PROTEIN", 60, 63], ["These studies", "TEST", 0, 13], ["targeting Syk expression levels", "PROBLEM", 50, 81], ["airway inflammatory diseases", "PROBLEM", 118, 146], ["airway", "ANATOMY", 118, 124], ["inflammatory", "OBSERVATION", 125, 137]]], ["Yet the potency of different siRNAa towards Syk knockdown and also the specificity of these sequences have not been directly investigated.DiscussionIn this study, we designed a range of different Syk siRNA sequences and tested their ability to knockdown Syk in the rat basophilic RBL-2H3 cell line.", [["basophilic RBL-2H3 cell line", "ANATOMY", 269, 297], ["Syk", "GENE_OR_GENE_PRODUCT", 44, 47], ["Syk", "GENE_OR_GENE_PRODUCT", 196, 199], ["Syk", "GENE_OR_GENE_PRODUCT", 254, 257], ["rat", "ORGANISM", 265, 268], ["basophilic RBL-2H3 cell line", "CELL", 269, 297], ["siRNAa", "PROTEIN", 29, 35], ["Syk", "PROTEIN", 44, 47], ["Syk siRNA sequences", "DNA", 196, 215], ["Syk", "PROTEIN", 254, 257], ["rat basophilic RBL-2H3 cell line", "CELL_LINE", 265, 297], ["rat", "SPECIES", 265, 268], ["these sequences", "TEST", 86, 101], ["this study", "TEST", 151, 161], ["different Syk siRNA sequences", "TREATMENT", 186, 215], ["2H3 cell line", "TREATMENT", 284, 297], ["potency", "OBSERVATION_MODIFIER", 8, 15], ["basophilic RBL", "OBSERVATION", 269, 283], ["2H3 cell line", "OBSERVATION", 284, 297]]], ["Syk siRNAs A-C and E-J all knocked down Syk mRNA and protein expression and each tested siRNA was also able to block FceRI-induced signal transduction, degranulation and TNFa release in a manner similar to the Syk inhibitors BAY61-3606 and R406.", [["FceRI", "CHEMICAL", 117, 122], ["BAY61-3606", "CHEMICAL", 225, 235], ["BAY61-3606", "CHEMICAL", 225, 235], ["R406", "CHEMICAL", 240, 244], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["E-J", "GENE_OR_GENE_PRODUCT", 19, 22], ["Syk", "GENE_OR_GENE_PRODUCT", 40, 43], ["FceRI", "GENE_OR_GENE_PRODUCT", 117, 122], ["TNFa", "GENE_OR_GENE_PRODUCT", 170, 174], ["Syk", "GENE_OR_GENE_PRODUCT", 210, 213], ["BAY61-3606", "GENE_OR_GENE_PRODUCT", 225, 235], ["R406", "SIMPLE_CHEMICAL", 240, 244], ["Syk", "PROTEIN", 0, 3], ["Syk mRNA", "RNA", 40, 48], ["FceRI", "PROTEIN", 117, 122], ["TNFa", "PROTEIN", 170, 174], ["Syk", "PROTEIN", 210, 213], ["Syk siRNAs", "TEST", 0, 10], ["A-C", "TEST", 11, 14], ["E-J", "TREATMENT", 19, 22], ["Syk mRNA and protein expression", "TREATMENT", 40, 71], ["each tested siRNA", "TREATMENT", 76, 93], ["signal transduction", "PROBLEM", 131, 150], ["degranulation", "PROBLEM", 152, 165], ["TNFa release", "TREATMENT", 170, 182], ["the Syk inhibitors", "TEST", 206, 224]]], ["Interestingly, the commonly used and published Syk inhibitor piceatannol was shown to block RBL-2H3 cell degranulation and TNFa release at concentrations which did not affect Sykmediated signal transduction.", [["RBL-2H3 cell", "ANATOMY", 92, 104], ["piceatannol", "CHEMICAL", 61, 72], ["piceatannol", "CHEMICAL", 61, 72], ["Syk", "GENE_OR_GENE_PRODUCT", 47, 50], ["piceatannol", "SIMPLE_CHEMICAL", 61, 72], ["RBL-2H3 cell", "CELL", 92, 104], ["TNFa", "GENE_OR_GENE_PRODUCT", 123, 127], ["Syk", "PROTEIN", 47, 50], ["TNFa", "PROTEIN", 123, 127], ["published Syk inhibitor piceatannol", "TREATMENT", 37, 72], ["RBL", "TEST", 92, 95], ["2H3 cell degranulation", "TREATMENT", 96, 118], ["TNFa release", "TREATMENT", 123, 135], ["2H3 cell degranulation", "OBSERVATION", 96, 118]]], ["This highlights the Syk-independent anti-inflammatory properties of this compound that must be considered in future studies.", [["Syk", "GENE_OR_GENE_PRODUCT", 20, 23], ["Syk", "PROTEIN", 20, 23], ["Syk", "OBSERVATION", 20, 23], ["anti-inflammatory properties", "OBSERVATION_MODIFIER", 36, 64]]], ["The blockage of FceRI signaling by each siRNA was directly proportional to their effect on Syk expression.", [["FceRI", "GENE_OR_GENE_PRODUCT", 16, 21], ["Syk", "GENE_OR_GENE_PRODUCT", 91, 94], ["FceRI", "PROTEIN", 16, 21], ["Syk", "PROTEIN", 91, 94], ["The blockage of FceRI signaling", "PROBLEM", 0, 31], ["blockage", "OBSERVATION", 4, 12], ["Syk expression", "OBSERVATION", 91, 105]]], ["These results not only suggest a fundamental role of Syk in FceRI signaling, but also demonstrate the efficacy of the siRNA approach in the targeting of FceRI-dependent allergic responses.DiscussionThe clinical potential of siRNAs is somewhat limited by complications associated with activation of cellular anti-viral interferoninducible genes and unanticipated off-target effects on other mRNAs.", [["cellular", "ANATOMY", 298, 306], ["allergic", "DISEASE", 169, 177], ["Syk", "GENE_OR_GENE_PRODUCT", 53, 56], ["FceRI", "GENE_OR_GENE_PRODUCT", 60, 65], ["FceRI", "GENE_OR_GENE_PRODUCT", 153, 158], ["cellular", "CELL", 298, 306], ["interferoninducible", "GENE_OR_GENE_PRODUCT", 318, 337], ["Syk", "PROTEIN", 53, 56], ["FceRI", "PROTEIN", 60, 65], ["FceRI", "PROTEIN", 153, 158], ["cellular anti-viral interferoninducible genes", "DNA", 298, 343], ["mRNAs", "RNA", 390, 395], ["the siRNA approach", "TREATMENT", 114, 132], ["dependent allergic responses", "PROBLEM", 159, 187], ["siRNAs", "PROBLEM", 224, 230], ["complications", "PROBLEM", 254, 267], ["cellular anti-viral interferoninducible genes", "TREATMENT", 298, 343], ["not only suggest", "UNCERTAINTY", 14, 30], ["Syk", "OBSERVATION", 53, 56], ["siRNA approach", "OBSERVATION", 118, 132], ["dependent", "OBSERVATION_MODIFIER", 159, 168], ["allergic", "OBSERVATION", 169, 177]]], ["Syk siRNA A was a unique sequence in that it displayed the most potent knockdown of Syk expression and reduction of FceRI-activated signaling and cellular responses, coupled with a lack of effect on the cellular IFN response.", [["cellular", "ANATOMY", 146, 154], ["cellular", "ANATOMY", 203, 211], ["Syk", "GENE_OR_GENE_PRODUCT", 0, 3], ["Syk", "GENE_OR_GENE_PRODUCT", 84, 87], ["FceRI", "GENE_OR_GENE_PRODUCT", 116, 121], ["cellular", "CELL", 146, 154], ["cellular", "CELL", 203, 211], ["Syk", "PROTEIN", 0, 3], ["Syk", "PROTEIN", 84, 87], ["FceRI", "PROTEIN", 116, 121], ["IFN", "PROTEIN", 212, 215], ["Syk expression", "PROBLEM", 84, 98], ["siRNA", "OBSERVATION", 4, 9], ["Syk expression", "OBSERVATION", 84, 98], ["reduction", "OBSERVATION_MODIFIER", 103, 112]]], ["Furthermore, Affymetrics analysis of the effect of Syk siRNA A on the global expression of rat mRNAs in RBL-2H3 cells revealed no off-target regulatory effects (data not shown).", [["RBL-2H3 cells", "ANATOMY", 104, 117], ["Syk", "GENE_OR_GENE_PRODUCT", 51, 54], ["rat", "ORGANISM", 91, 94], ["RBL-2H3 cells", "CELL", 104, 117], ["Syk", "PROTEIN", 51, 54], ["rat mRNAs", "RNA", 91, 100], ["RBL-2H3 cells", "CELL_LINE", 104, 117], ["rat", "SPECIES", 91, 94], ["rat", "SPECIES", 91, 94], ["Affymetrics analysis", "TEST", 13, 33], ["Syk siRNA", "PROBLEM", 51, 60], ["RBL", "TEST", 104, 107], ["2H3 cells", "TEST", 108, 117], ["Syk siRNA", "OBSERVATION", 51, 60], ["no", "UNCERTAINTY", 127, 129]]], ["The identification of this sequence and its desirable in vitro profile, raises the possibility of this sequence becoming a candidate for progress into Syk-dependent diseases models in vivo.", [["Syk", "GENE_OR_GENE_PRODUCT", 151, 154], ["Syk", "PROTEIN", 151, 154], ["this sequence", "TEST", 22, 35], ["Syk-dependent diseases models", "PROBLEM", 151, 180], ["raises the possibility", "UNCERTAINTY", 72, 94], ["dependent", "OBSERVATION_MODIFIER", 155, 164], ["diseases", "OBSERVATION", 165, 173]]], ["Other limiting factors for potential siRNA therapeutics include complications regarding the efficient delivery to specific target cells and the maintenance of siRNA in vivo stability.", [["cells", "ANATOMY", 130, 135], ["cells", "CELL", 130, 135], ["target cells", "CELL_TYPE", 123, 135], ["potential siRNA therapeutics", "TREATMENT", 27, 55], ["complications", "PROBLEM", 64, 77], ["the efficient delivery", "TREATMENT", 88, 110], ["siRNA in vivo stability", "TREATMENT", 159, 182], ["siRNA", "OBSERVATION", 159, 164]]], ["Airway delivery of siRNAs via inhalation has the advantage of potentially limiting systemic distribution of the molecules, whilst locally targeting airway cells and their genes [39] [40] [41] .", [["Airway", "ANATOMY", 0, 6], ["airway cells", "ANATOMY", 148, 160], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["airway cells", "CELL", 148, 160], ["airway cells", "CELL_TYPE", 148, 160], ["Airway delivery of siRNAs via inhalation", "TREATMENT", 0, 40], ["airway", "ANATOMY", 148, 154]]], ["Airway siR-NAs have already demonstrated efficient local knockdown of targets including heme oxygenase-1 [42] , glyceraldehyde-3phosphate dehydrogenase (GAPDH) [43] as well as the blockage of the replication and pathogenicity influenza virus A [44] , respiratory syncytial virus (RSV) [45, 46] and SARS coronavirus (SCV) [47] .", [["Airway", "ANATOMY", 0, 6], ["siR-NAs", "CHEMICAL", 7, 14], ["glyceraldehyde-3phosphate", "CHEMICAL", 112, 137], ["respiratory syncytial virus", "DISEASE", 251, 278], ["SARS coronavirus", "DISEASE", 298, 314], ["glyceraldehyde", "CHEMICAL", 112, 126], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 88, 104], ["glyceraldehyde-3phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 112, 151], ["GAPDH", "GENE_OR_GENE_PRODUCT", 153, 158], ["influenza virus A [44]", "ORGANISM", 226, 248], ["respiratory syncytial virus", "ORGANISM", 251, 278], ["RSV", "ORGANISM", 280, 283], ["SARS coronavirus", "ORGANISM", 298, 314], ["heme oxygenase-1 [42]", "PROTEIN", 88, 109], ["glyceraldehyde-3phosphate dehydrogenase", "PROTEIN", 112, 151], ["GAPDH", "PROTEIN", 153, 158], ["influenza virus A", "SPECIES", 226, 243], ["respiratory syncytial virus", "SPECIES", 251, 278], ["influenza virus A", "SPECIES", 226, 243], ["respiratory syncytial virus", "SPECIES", 251, 278], ["RSV", "SPECIES", 280, 283], ["SARS coronavirus", "SPECIES", 298, 314], ["SCV", "SPECIES", 316, 319], ["heme oxygenase", "TEST", 88, 102], ["glyceraldehyde", "TEST", 112, 126], ["3phosphate dehydrogenase (GAPDH)", "PROBLEM", 127, 159], ["the replication", "PROBLEM", 192, 207], ["pathogenicity influenza virus A", "PROBLEM", 212, 243], ["respiratory syncytial virus", "PROBLEM", 251, 278], ["SARS coronavirus (SCV)", "PROBLEM", 298, 320], ["syncytial virus", "OBSERVATION", 263, 278], ["SCV", "ANATOMY", 316, 319]]], ["Future studies are warranted to clarify the potential of inhaled Syk siRNAs in models of airway inflammatory cells in vivo.AcknowledgmentsWe would like to thank the following people at Boehringer Ingelheim Pharma for their excellent technical assistance and support of this work; Andreas Grieser, Bernd Guilliard, Susanne M\u00fcller, Christine Pischzan, Margit Ried, Christine Strasser and Eva Wex.", [["airway inflammatory cells", "ANATOMY", 89, 114], ["Syk", "GENE_OR_GENE_PRODUCT", 65, 68], ["airway inflammatory cells", "CELL", 89, 114], ["people", "ORGANISM", 175, 181], ["Syk", "PROTEIN", 65, 68], ["airway inflammatory cells", "CELL_TYPE", 89, 114], ["people", "SPECIES", 175, 181], ["Future studies", "TEST", 0, 14], ["inhaled Syk siRNAs", "TREATMENT", 57, 75], ["airway inflammatory cells", "PROBLEM", 89, 114], ["Syk siRNAs", "OBSERVATION", 65, 75], ["airway", "ANATOMY", 89, 95], ["inflammatory cells", "OBSERVATION", 96, 114]]], ["We would also like to thank the following academic staff members at Boehringer Ingelheim Pharma for their support and contributions; Drs. Thierry Bouyssou, Florian Gantner, Matthias RBL-2H3 cells were treated with Syk siRNAs (A) and kinase inhibitors (B) and then activated by overnight incubation in the mouse anti-DNP IgE antibody followed by addition of DNP-BSA. b-Hexosaminidase activity was measure in culture supernatants as described in Section 2.", [["RBL-2H3 cells", "ANATOMY", 182, 195], ["supernatants", "ANATOMY", 415, 427], ["DNP", "CHEMICAL", 357, 360], ["b-", "CHEMICAL", 366, 368], ["DNP", "CHEMICAL", 357, 360], ["Matthias RBL-2H3 cells", "CELL", 173, 195], ["Syk", "GENE_OR_GENE_PRODUCT", 214, 217], ["B", "CELL", 252, 253], ["mouse", "ORGANISM", 305, 310], ["DNP-BSA", "SIMPLE_CHEMICAL", 357, 364], ["b-", "SIMPLE_CHEMICAL", 366, 368], ["Hexosaminidase", "SIMPLE_CHEMICAL", 368, 382], ["Matthias RBL-2H3 cells", "CELL_LINE", 173, 195], ["Syk", "PROTEIN", 214, 217], ["mouse anti-DNP IgE antibody", "PROTEIN", 305, 332], ["mouse", "SPECIES", 305, 310], ["mouse", "SPECIES", 305, 310], ["2H3 cells", "TREATMENT", 186, 195], ["Syk siRNAs (A) and kinase inhibitors", "TREATMENT", 214, 250], ["the mouse anti-DNP IgE antibody", "TREATMENT", 301, 332], ["DNP-BSA", "TREATMENT", 357, 364], ["b-Hexosaminidase activity", "PROBLEM", 366, 391], ["culture supernatants", "TEST", 407, 427], ["Hexosaminidase activity", "OBSERVATION", 368, 391]]], ["Error bars represent the standard deviation of the mean for quadruplicate determinations.", [["quadruplicate determinations", "TEST", 60, 88], ["standard deviation", "OBSERVATION", 25, 43]]], ["A paired Student's t-test was used to compare the statistical significance of the difference between data points.", [["A paired Student's t-test", "TEST", 0, 25]]], ["All treatments with Syk siRNAs and inhibitors led to a significantly reduced secretion of b-hexosaminidase compared to the control with a p-value of less than 0.05.Table 1Syk Knockdown and kinase inhibitors block TNFa expression and degranulation of histamine.", [["histamine", "CHEMICAL", 250, 259], ["histamine", "CHEMICAL", 250, 259], ["Syk", "GENE_OR_GENE_PRODUCT", 20, 23], ["b-hexosaminidase", "GENE_OR_GENE_PRODUCT", 90, 106], ["1Syk", "GENE_OR_GENE_PRODUCT", 170, 174], ["TNFa", "GENE_OR_GENE_PRODUCT", 213, 217], ["histamine", "SIMPLE_CHEMICAL", 250, 259], ["Syk", "PROTEIN", 20, 23], ["b-hexosaminidase", "PROTEIN", 90, 106], ["TNFa", "PROTEIN", 213, 217], ["All treatments", "TREATMENT", 0, 14], ["Syk siRNAs", "TREATMENT", 20, 30], ["inhibitors", "TREATMENT", 35, 45], ["a significantly reduced secretion of b-hexosaminidase", "PROBLEM", 53, 106], ["a p-value", "TEST", 136, 145], ["Table 1Syk Knockdown", "TREATMENT", 164, 184], ["kinase inhibitors block TNFa expression", "TREATMENT", 189, 228], ["degranulation of histamine", "TREATMENT", 233, 259], ["Syk siRNAs", "OBSERVATION", 20, 30]]], ["RBL-2H3 cells were treated with the small-molecule inhibitors and siRNAs prior to activation of the FceRI receptor with IgE and DNP-albumin as described in Section 2.", [["RBL-2H3 cells", "ANATOMY", 0, 13], ["DNP", "CHEMICAL", 128, 131], ["RBL-2H3 cells", "CELL", 0, 13], ["FceRI receptor", "GENE_OR_GENE_PRODUCT", 100, 114], ["IgE", "GENE_OR_GENE_PRODUCT", 120, 123], ["DNP-albumin", "GENE_OR_GENE_PRODUCT", 128, 139], ["RBL-2H3 cells", "CELL_LINE", 0, 13], ["FceRI receptor", "PROTEIN", 100, 114], ["IgE", "PROTEIN", 120, 123], ["DNP", "PROTEIN", 128, 131], ["albumin", "PROTEIN", 132, 139], ["RBL", "TEST", 0, 3], ["the small-molecule inhibitors", "TREATMENT", 32, 61], ["siRNAs", "TREATMENT", 66, 72], ["the FceRI receptor with IgE", "TREATMENT", 96, 123], ["DNP-albumin", "TREATMENT", 128, 139], ["2H3 cells", "OBSERVATION", 4, 13]]], ["The percentage release of TNFa and histamine compared to IgE/DNP alone is presented.", [["TNFa", "CHEMICAL", 26, 30], ["histamine", "CHEMICAL", 35, 44], ["DNP", "CHEMICAL", 61, 64], ["TNFa", "CHEMICAL", 26, 30], ["histamine", "CHEMICAL", 35, 44], ["TNFa", "GENE_OR_GENE_PRODUCT", 26, 30], ["histamine", "SIMPLE_CHEMICAL", 35, 44], ["IgE", "GENE_OR_GENE_PRODUCT", 57, 60], ["DNP", "SIMPLE_CHEMICAL", 61, 64], ["TNFa", "PROTEIN", 26, 30], ["IgE", "PROTEIN", 57, 60], ["The percentage release of TNFa", "TREATMENT", 0, 30], ["histamine", "TREATMENT", 35, 44], ["IgE/DNP", "TREATMENT", 57, 64]]]], "4bd7744e1fc4a121de2f9161a459cbf33d57f5ac": [["Tel: +34 934896604.INTRODUCTIONThe Coronavirus 19 disease (COVID-19) caused by the SARS-CoV-2 virus has been declared a global health emergency in 2020.", [["COVID-19", "CHEMICAL", 59, 67], ["SARS", "DISEASE", 83, 87], ["Coronavirus 19 disease", "CANCER", 35, 57], ["SARS-CoV-2 virus", "ORGANISM", 83, 99], ["CoV-2 virus", "SPECIES", 88, 99], ["SARS-CoV-2 virus", "SPECIES", 83, 99], ["Coronavirus 19 disease", "PROBLEM", 35, 57], ["COVID", "TEST", 59, 64], ["the SARS", "PROBLEM", 79, 87], ["CoV-2 virus", "PROBLEM", 88, 99]]], ["Health systems around the globe are struggling to find efficacious treatments against COVID-19 and the associated acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 120, 131], ["COVID-19", "CHEMICAL", 86, 94], ["acute respiratory distress syndrome", "DISEASE", 114, 149], ["ARDS", "DISEASE", 151, 155], ["efficacious treatments", "TREATMENT", 55, 77], ["COVID", "TEST", 86, 91], ["the associated acute respiratory distress syndrome", "PROBLEM", 99, 149], ["ARDS", "PROBLEM", 151, 155], ["globe", "ANATOMY", 26, 31], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory distress", "OBSERVATION", 120, 140], ["ARDS", "OBSERVATION", 151, 155]]], ["Previous experience with SARS and MERS-CoV infection demonstrated a marked pro-inflammatory response (Th1 and Th17) in patients with ARDS which is also seen in COVID-19 (1) (2) (3) .", [["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 43, 52], ["ARDS", "DISEASE", 133, 137], ["MERS-CoV", "ORGANISM", 34, 42], ["patients", "ORGANISM", 119, 127], ["Th1", "CELL_TYPE", 102, 105], ["Th17", "CELL_TYPE", 110, 114], ["patients", "SPECIES", 119, 127], ["MERS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 25, 29], ["MERS", "PROBLEM", 34, 38], ["CoV infection", "PROBLEM", 39, 52], ["a marked pro-inflammatory response", "PROBLEM", 66, 100], ["ARDS", "PROBLEM", 133, 137], ["COVID", "TEST", 160, 165], ["marked", "OBSERVATION_MODIFIER", 68, 74], ["pro-inflammatory response", "OBSERVATION", 75, 100], ["ARDS", "OBSERVATION", 133, 137]]], ["This evidence has prompted the off-label use of IL-6 inhibitors in severe COVID-19 disease as well as the initiation of randomised clinical trials to test these drugs (clinicaltrials.gov, NCT04320615).", [["COVID-19 disease", "DISEASE", 74, 90], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-6 inhibitors", "TREATMENT", 48, 63], ["severe COVID-19 disease", "PROBLEM", 67, 90], ["randomised clinical trials", "TREATMENT", 120, 146], ["these drugs", "TREATMENT", 155, 166]]], ["Additionally, other inflammatory cytokine pathways such as the IL-1 pathway are currently being explored (clinicaltrials.gov, NCT04324021).INTRODUCTIONHydroxychloroquine, a commonly used antirheumatic medication, has been shown to have in vitro protective effects against SARS-CoV-2 infection (4), although its clinical efficacy still needs to be adequately assessed via randomized clinical trials (5) .", [["INTRODUCTIONHydroxychloroquine", "CHEMICAL", 139, 169], ["SARS-CoV-2 infection", "DISEASE", 272, 292], ["INTRODUCTIONHydroxychloroquine", "CHEMICAL", 139, 169], ["IL-1", "GENE_OR_GENE_PRODUCT", 63, 67], ["SARS-CoV-2", "ORGANISM", 272, 282], ["inflammatory cytokine", "PROTEIN", 20, 41], ["IL", "PROTEIN", 63, 65], ["SARS-CoV-2", "SPECIES", 272, 282], ["other inflammatory cytokine pathways", "PROBLEM", 14, 50], ["the IL-1 pathway", "TREATMENT", 59, 75], ["INTRODUCTIONHydroxychloroquine", "TREATMENT", 139, 169], ["antirheumatic medication", "TREATMENT", 187, 211], ["vitro protective effects", "TREATMENT", 239, 263], ["SARS", "PROBLEM", 272, 276], ["CoV-2 infection", "PROBLEM", 277, 292], ["inflammatory", "OBSERVATION_MODIFIER", 20, 32], ["infection", "OBSERVATION", 283, 292]]], ["A recently approved RA drug, JAK1/2 inhibitor baricitinib, could also be protective by reducing the ability of the virus to infect lung cells (6) .", [["lung cells", "ANATOMY", 131, 141], ["baricitinib", "CHEMICAL", 46, 57], ["baricitinib", "CHEMICAL", 46, 57], ["JAK1/2", "GENE_OR_GENE_PRODUCT", 29, 35], ["baricitinib", "SIMPLE_CHEMICAL", 46, 57], ["lung cells", "CELL", 131, 141], ["JAK1", "PROTEIN", 29, 33], ["lung cells", "CELL_TYPE", 131, 141], ["A recently approved RA drug", "TREATMENT", 0, 27], ["JAK1/2 inhibitor baricitinib", "TREATMENT", 29, 57], ["the virus to infect lung cells", "PROBLEM", 111, 141], ["RA", "ANATOMY", 20, 22]]], ["Therefore, patients with rheumatic diseases provide an opportunity to rapidly learn the impact of immunosuppressive agents as protective drugs against SARS-CoV-2 infection and against the development of more severe outcomes in COVID-19 disease.INTRODUCTIONTargeted biological and synthetic disease modifying antirheumatic drugs (tDMARDs) could also have a detrimental effect in COVID-19 disease.", [["rheumatic diseases", "DISEASE", 25, 43], ["SARS-CoV-2 infection", "DISEASE", 151, 171], ["patients", "ORGANISM", 11, 19], ["SARS-CoV-2", "ORGANISM", 151, 161], ["COVID-19 disease", "CANCER", 227, 243], ["tDMARDs", "SIMPLE_CHEMICAL", 329, 336], ["COVID-19 disease", "CANCER", 378, 394], ["patients", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 151, 159], ["COVID-19", "SPECIES", 227, 235], ["rheumatic diseases", "PROBLEM", 25, 43], ["immunosuppressive agents", "TREATMENT", 98, 122], ["protective drugs", "TREATMENT", 126, 142], ["SARS", "PROBLEM", 151, 155], ["CoV-2 infection", "PROBLEM", 156, 171], ["more severe outcomes in COVID-19 disease", "PROBLEM", 203, 243], ["biological and synthetic disease modifying antirheumatic drugs", "TREATMENT", 265, 327], ["COVID-19 disease", "PROBLEM", 378, 394], ["severe", "OBSERVATION_MODIFIER", 208, 214]]], ["There is a major need in the rheumatological community to determine which, if any, tDMARDs increase the vulnerability to infection and should therefore be stopped.", [["infection", "DISEASE", 121, 130], ["the vulnerability to infection", "PROBLEM", 100, 130], ["infection", "OBSERVATION", 121, 130]]], ["The European League Against Rheumatism (EULAR), American College of Rheumatology (ACR), National Institute for Health and Care Excellence (NICE) and the Paediatric Rheumatology European Society (PRES) have published preliminary guidance in this scenario (7) (8) (9) (10) .", [["Rheumatism", "DISEASE", 28, 38], ["PRES", "DISEASE", 195, 199], ["Rheumatism", "OBSERVATION", 28, 38]]], ["EULAR and PRES suggest that patients should discuss treatment discontinuation with their rheumatologists.", [["PRES", "DISEASE", 10, 14], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment discontinuation", "TREATMENT", 52, 77]]], ["ACR recommendations also favour to temporarily stop treatment with tDMARDs if exposure to SARS-CoV-2.", [["tDMARDs", "CHEMICAL", 67, 74], ["SARS", "DISEASE", 90, 94], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["treatment", "TREATMENT", 52, 61], ["CoV", "TEST", 95, 98]]], ["NICE and ACR advocate the suspension of tDMARDs if COVID-19 is confirmed or suspected with the ACR considering IL-6 inhibitors an exception, which may be continued under specific circumstances.", [["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 51, 59], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["COVID", "TEST", 51, 56], ["the ACR", "TEST", 91, 98], ["IL-6 inhibitors", "TREATMENT", 111, 126]]], ["So far, these recommendations are based on expert opinion as there is yet very limited epidemiological evidence on the potential risk conferred by tDMARDs with regards to severe COVID-19 disease complications in patients with rheumatic diseases.INTRODUCTIONRecent reports from Italy show no evidence of increased risk in a cohort of 320 adult rheumatic patients and in a cohort of 123 patients with connective tissue diseases (11, 12) .INTRODUCTIONTo date, only one report from a paediatric centre in Milan (Italy) shows no confirmed COVID-19 cases in children (13) .", [["connective tissue", "ANATOMY", 399, 416], ["rheumatic diseases", "DISEASE", 226, 244], ["connective tissue diseases", "DISEASE", 399, 425], ["patients", "ORGANISM", 212, 220], ["patients", "ORGANISM", 353, 361], ["patients", "ORGANISM", 385, 393], ["connective tissue", "TISSUE", 399, 416], ["children", "ORGANISM", 552, 560], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 353, 361], ["patients", "SPECIES", 385, 393], ["children", "SPECIES", 552, 560], ["severe COVID-19 disease complications", "PROBLEM", 171, 208], ["rheumatic diseases", "PROBLEM", 226, 244], ["increased risk", "PROBLEM", 303, 317], ["connective tissue diseases", "PROBLEM", 399, 425], ["rheumatic", "OBSERVATION", 226, 235], ["no evidence of", "UNCERTAINTY", 288, 302], ["increased", "OBSERVATION_MODIFIER", 303, 312], ["connective tissue", "ANATOMY", 399, 416]]], ["With this scant evidence, rheumatologists worldwide are in the dark as to how to manage patients on immunosuppressive therapies during the pandemic and more information is urgently needed (14) .", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["immunosuppressive therapies", "TREATMENT", 100, 127]]], ["Among them, the best positioned to lead this objective is the COVID-19 Global Rheumatology Alliance, an international coalition that is collecting data on rheumatic patients affected with COVID19.", [["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["COVID19", "TREATMENT", 188, 195]]], ["At present, however, they have published an initial report of only 110 rheumatic patients with COVID-19 disease outlining their characteristics and comorbidities (15) .", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["COVID-19 disease", "PROBLEM", 95, 111]]], ["The aim of our study was to report the incidence of COVID-19 in a large cohort of adult and a cohort of paediatric patients with rheumatic diseases receiving tDMARDs from a reference tertiary hospital in Spain, and to explore the possible effect of these treatments in the expression of COVID-19.Study designA cross-sectional study consisting of a telephone interview followed by a comprehensive review of electronic health records was conducted in a tertiary centre hospital in Barcelona, Spain, during the 2020 COVID-19 pandemic.", [["rheumatic diseases", "DISEASE", 129, 147], ["patients", "ORGANISM", 115, 123], ["COVID-19", "DNA", 287, 295], ["patients", "SPECIES", 115, 123], ["our study", "TEST", 11, 20], ["COVID", "TEST", 52, 57], ["rheumatic diseases", "PROBLEM", 129, 147], ["these treatments", "TREATMENT", 249, 265], ["COVID", "TEST", 287, 292], ["pandemic", "PROBLEM", 522, 530]]], ["All patients had a diagnosed inflammatory rheumatic disease treated with tDMARDs attending the Rheumatology Department in Vall d'Hebron University Hospital, Barcelona, Spain.", [["inflammatory rheumatic disease", "DISEASE", 29, 59], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a diagnosed inflammatory rheumatic disease", "PROBLEM", 17, 59], ["inflammatory", "OBSERVATION_MODIFIER", 29, 41], ["rheumatic disease", "OBSERVATION", 42, 59]]], ["Vall d'Hebron University Hospital is the largest hospital complex in the Catalonia region and one of the most important in Spain being a reference centre for adult and paediatric rheumatology.Study populationAll adult and paediatric patients with the following clinical diagnosis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), juvenile idiopathic arthritis (JIA) and autoinflammatory syndromes (AIS) who were receiving any of the following treatments: anti-TNF alpha drugs (etanercept, adalimumab, infliximab, golimumab and certolizumab), IL-1 inhibitors (anakinra), IL-6 inhibitors (tocilizumab and sarilumab), IL 12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab and ixekizumab), CTLA4-Ig (abatacept), JAK inhibitors (tofacitinib, baricitinib and ruxolitinib) and PDE4 inhibitors (apremilast) at the time of the study were invited to take part.Demographic, clinical and questionnaire dataThe following variables were retrieved from the hospital electronic health record: age, sex, For this analysis, we considered \"confirmed\" cases when the SARS-CoV-2 polymerase chain reaction (PCR) was performed and resulted positive.", [["rheumatoid arthritis", "DISEASE", 281, 301], ["RA", "DISEASE", 303, 305], ["psoriatic arthritis", "DISEASE", 308, 327], ["PsA", "DISEASE", 329, 332], ["axial spondyloarthritis", "DISEASE", 335, 358], ["axSpA", "DISEASE", 360, 365], ["juvenile idiopathic arthritis", "DISEASE", 368, 397], ["JIA", "DISEASE", 399, 402], ["autoinflammatory syndromes", "DISEASE", 408, 434], ["AIS", "DISEASE", 436, 439], ["etanercept", "CHEMICAL", 515, 525], ["adalimumab", "CHEMICAL", 527, 537], ["infliximab", "CHEMICAL", 539, 549], ["golimumab", "CHEMICAL", 551, 560], ["certolizumab", "CHEMICAL", 565, 577], ["anakinra", "CHEMICAL", 597, 605], ["tocilizumab", "CHEMICAL", 625, 636], ["sarilumab", "CHEMICAL", 641, 650], ["ustekinumab", "CHEMICAL", 674, 685], ["secukinumab", "CHEMICAL", 706, 717], ["ixekizumab", "CHEMICAL", 722, 732], ["tofacitinib", "CHEMICAL", 773, 784], ["baricitinib", "CHEMICAL", 786, 797], ["ruxolitinib", "CHEMICAL", 802, 813], ["apremilast", "CHEMICAL", 836, 846], ["golimumab", "CHEMICAL", 551, 560], ["certolizumab", "CHEMICAL", 565, 577], ["secukinumab", "CHEMICAL", 706, 717], ["ixekizumab", "CHEMICAL", 722, 732], ["tofacitinib", "CHEMICAL", 773, 784], ["baricitinib", "CHEMICAL", 786, 797], ["ruxolitinib", "CHEMICAL", 802, 813], ["patients", "ORGANISM", 233, 241], ["anti-TNF alpha", "GENE_OR_GENE_PRODUCT", 493, 507], ["etanercept", "SIMPLE_CHEMICAL", 515, 525], ["adalimumab", "SIMPLE_CHEMICAL", 527, 537], ["infliximab", "SIMPLE_CHEMICAL", 539, 549], ["golimumab", "SIMPLE_CHEMICAL", 551, 560], ["certolizumab", "SIMPLE_CHEMICAL", 565, 577], ["IL-1", "GENE_OR_GENE_PRODUCT", 580, 584], ["anakinra", "SIMPLE_CHEMICAL", 597, 605], ["IL-6 inhibitors", "SIMPLE_CHEMICAL", 608, 623], ["tocilizumab", "SIMPLE_CHEMICAL", 625, 636], ["sarilumab", "SIMPLE_CHEMICAL", 641, 650], ["IL 12/23 inhibitors", "SIMPLE_CHEMICAL", 653, 672], ["ustekinumab", "SIMPLE_CHEMICAL", 674, 685], ["IL-17 inhibitors", "SIMPLE_CHEMICAL", 688, 704], ["secukinumab", "SIMPLE_CHEMICAL", 706, 717], ["ixekizumab", "SIMPLE_CHEMICAL", 722, 732], ["CTLA4-Ig", "GENE_OR_GENE_PRODUCT", 735, 743], ["abatacept", "SIMPLE_CHEMICAL", 745, 754], ["JAK", "GENE_OR_GENE_PRODUCT", 757, 760], ["tofacitinib", "SIMPLE_CHEMICAL", 773, 784], ["baricitinib", "SIMPLE_CHEMICAL", 786, 797], ["ruxolitinib", "SIMPLE_CHEMICAL", 802, 813], ["PDE4", "GENE_OR_GENE_PRODUCT", 819, 823], ["apremilast", "SIMPLE_CHEMICAL", 836, 846], ["CTLA4", "PROTEIN", 735, 740], ["Ig", "PROTEIN", 741, 743], ["JAK", "PROTEIN", 757, 760], ["patients", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 1096, 1104], ["Study population", "TEST", 192, 208], ["rheumatoid arthritis", "PROBLEM", 281, 301], ["psoriatic arthritis (PsA)", "PROBLEM", 308, 333], ["axial spondyloarthritis (axSpA)", "PROBLEM", 335, 366], ["juvenile idiopathic arthritis", "PROBLEM", 368, 397], ["JIA)", "PROBLEM", 399, 403], ["autoinflammatory syndromes", "PROBLEM", 408, 434], ["the following treatments", "TREATMENT", 467, 491], ["anti-TNF alpha drugs", "TREATMENT", 493, 513], ["etanercept", "TREATMENT", 515, 525], ["adalimumab", "TREATMENT", 527, 537], ["infliximab", "TREATMENT", 539, 549], ["golimumab", "TREATMENT", 551, 560], ["certolizumab)", "TREATMENT", 565, 578], ["IL", "TREATMENT", 580, 582], ["anakinra)", "TREATMENT", 597, 606], ["IL", "TREATMENT", 608, 610], ["tocilizumab", "TREATMENT", 625, 636], ["sarilumab)", "TREATMENT", 641, 651], ["IL 12/23 inhibitors (ustekinumab)", "TREATMENT", 653, 686], ["IL", "TREATMENT", 688, 690], ["secukinumab", "TREATMENT", 706, 717], ["ixekizumab", "TREATMENT", 722, 732], ["CTLA4", "TREATMENT", 735, 740], ["Ig (abatacept)", "TREATMENT", 741, 755], ["JAK inhibitors", "TREATMENT", 757, 771], ["tofacitinib", "TREATMENT", 773, 784], ["baricitinib", "TREATMENT", 786, 797], ["ruxolitinib", "TREATMENT", 802, 813], ["PDE4 inhibitors", "TREATMENT", 819, 834], ["apremilast", "TREATMENT", 836, 846], ["the study", "TEST", 863, 872], ["questionnaire data", "TEST", 925, 943], ["this analysis", "TEST", 1040, 1053], ["the SARS", "TEST", 1092, 1100], ["CoV", "TEST", 1101, 1104], ["2 polymerase chain reaction", "PROBLEM", 1105, 1132], ["PCR", "TEST", 1134, 1137], ["largest", "OBSERVATION_MODIFIER", 41, 48], ["rheumatoid arthritis", "OBSERVATION", 281, 301], ["RA", "ANATOMY", 303, 305], ["psoriatic", "ANATOMY", 308, 317], ["arthritis", "OBSERVATION", 318, 327], ["spondyloarthritis", "OBSERVATION", 341, 358], ["juvenile", "OBSERVATION_MODIFIER", 368, 376], ["idiopathic", "OBSERVATION_MODIFIER", 377, 387], ["arthritis", "OBSERVATION", 388, 397], ["autoinflammatory syndromes", "OBSERVATION", 408, 434]]], ["Due to regional health policies(16), SARS-CoV-2 PCR testing was restricted to patients that had to be admitted to the hospital due to lung involvement.", [["lung", "ANATOMY", 134, 138], ["patients", "ORGANISM", 78, 86], ["lung", "ORGAN", 134, 138], ["patients", "SPECIES", 78, 86], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["PCR testing", "TEST", 48, 59], ["lung involvement", "PROBLEM", 134, 150], ["lung", "ANATOMY", 134, 138], ["involvement", "OBSERVATION", 139, 150]]], ["Additionally, clinical and radiological features, blood analysis results and outcome were investigated in patients with confirmed COVID-19 disease.Demographic, clinical and questionnaire dataFollowing the World Health Organisation (WHO) guidance(17), we considered \"suspected\" cases when patients reported fever plus one other respiratory symptom (dyspnoea, persistent cough or odynophagia) OR presented 1 of the previous symptoms (fever, dyspnoea, persistent cough or odynophagia) and had had a contact with a confirmed or probable case.Statistical analysisData are presented for both adult and paediatric subjects, defining adults as subjects above 18 years old.", [["blood", "ANATOMY", 50, 55], ["respiratory", "ANATOMY", 327, 338], ["fever", "DISEASE", 306, 311], ["respiratory symptom", "DISEASE", 327, 346], ["dyspnoea", "DISEASE", 348, 356], ["cough", "DISEASE", 369, 374], ["odynophagia", "DISEASE", 378, 389], ["fever", "DISEASE", 432, 437], ["dyspnoea", "DISEASE", 439, 447], ["cough", "DISEASE", 460, 465], ["odynophagia", "DISEASE", 469, 480], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 288, 296], ["adults", "ORGANISM", 626, 632], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 288, 296], ["blood analysis", "TEST", 50, 64], ["COVID-19 disease", "PROBLEM", 130, 146], ["fever", "PROBLEM", 306, 311], ["one other respiratory symptom", "PROBLEM", 317, 346], ["dyspnoea", "PROBLEM", 348, 356], ["persistent cough", "PROBLEM", 358, 374], ["odynophagia", "PROBLEM", 378, 389], ["the previous symptoms", "PROBLEM", 409, 430], ["fever", "PROBLEM", 432, 437], ["dyspnoea", "PROBLEM", 439, 447], ["persistent cough", "PROBLEM", 449, 465], ["odynophagia", "PROBLEM", 469, 480]]], ["Descriptive statistics were used to compare patient and disease characteristics according to classification as suspected cases.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["The association between disease activity and suspected cases was explored considering active disease when DAS28>2.6 in RA, BASDAI \u22654 in axSpA and DAPSA >14 in PsA.", [["RA", "DISEASE", 119, 121], ["axSpA", "CANCER", 136, 141], ["disease activity", "PROBLEM", 24, 40], ["active disease", "PROBLEM", 86, 100], ["DAS28", "TEST", 106, 111], ["RA", "TEST", 119, 121], ["BASDAI", "TEST", 123, 129], ["axSpA", "TEST", 136, 141], ["DAPSA", "TEST", 146, 151], ["RA", "ANATOMY", 119, 121]]], ["Pearson's chi square, Fisher's exact test, Student's t-test and Wilcoxon rank sum test were used for comparisons as appropriate.", [["Fisher's exact test", "TEST", 22, 41], ["Student's t-test", "TEST", 43, 59], ["Wilcoxon rank sum test", "TEST", 64, 86]]], ["Odds ratio (OR) for being classified as suspected were calculated using anti-TNF as reference (most prevalent treatment in our cohort) for tDMARDs and stratified by rheumatic disease.", [["rheumatic disease", "DISEASE", 165, 182], ["anti-TNF", "PROTEIN", 72, 80], ["anti-TNF", "TREATMENT", 72, 80], ["tDMARDs", "PROBLEM", 139, 146], ["rheumatic disease", "PROBLEM", 165, 182], ["rheumatic disease", "OBSERVATION", 165, 182]]], ["A test for linear trend was used to explore the relationship between the level of contact exposure with the proportion of suspected cases.Statistical analysisCumulative incidence was adjusted for sex and age by direct standardisation, using a COVID-19 epidemiological database from Barcelona generated by the local health institution (18) .Statistical analysisThis database is updated daily and contains district-level information of COVID-19 confirmed cases.", [["A test", "TEST", 0, 6], ["a COVID", "TEST", 241, 248], ["Statistical analysis", "TEST", 340, 360], ["COVID", "TEST", 434, 439]]], ["For this analysis we selected the data from the most frequent postal codes within our cohort, globally representing 50% of the patients.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["this analysis", "TEST", 4, 17], ["the data", "TEST", 30, 38]]], ["An additional analysis only considering confirmed cases who presented pneumonia in the chest x-ray hence requiring hospital admission (same testing criteria as for general population) was performed.", [["chest", "ANATOMY", 87, 92], ["pneumonia", "DISEASE", 70, 79], ["An additional analysis", "TEST", 0, 22], ["pneumonia", "PROBLEM", 70, 79], ["the chest x-ray", "TEST", 83, 98], ["same testing criteria", "TEST", 135, 156], ["pneumonia", "OBSERVATION", 70, 79], ["chest", "ANATOMY", 87, 92]]], ["Analyses were performed with STATA v 16.0 and RStudio v.3.5.1.Ethical approvalThe study was approved by the Hospital Universitari Vall d'Hebron Clinical Research Ethics Committee (Approval Number 5633).", [["Analyses", "TEST", 0, 8], ["STATA v", "TEST", 29, 36], ["RStudio", "TEST", 46, 53], ["Ethical approval", "TREATMENT", 62, 78], ["The study", "TEST", 78, 87]]], ["This study was conducted according to the principles of the Declaration of Helsinki and patient consent was obtained.RESULTSA total of 1,045 patients with rheumatic diseases currently taking tDMARDs were contacted, and n=959 completed the survey.", [["rheumatic diseases", "DISEASE", 155, 173], ["patient", "ORGANISM", 88, 95], ["patients", "ORGANISM", 141, 149], ["patient", "SPECIES", 88, 95], ["patients", "SPECIES", 141, 149], ["This study", "TEST", 0, 10], ["rheumatic diseases", "PROBLEM", 155, 173], ["rheumatic", "OBSERVATION_MODIFIER", 155, 164], ["diseases", "OBSERVATION", 165, 173]]], ["Following the WHO criteria, 95 patients were classified as suspected cases for COVID-19 infection, 11 of whom were subsequently confirmed to have a positive SARS-CoV-2 PCR test.Confirmed COVID-19 casesClinical characteristics of the 11 COVID-19 confirmed cases are summarised in Table 1 .", [["infection", "DISEASE", 88, 97], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["COVID-19", "SPECIES", 79, 87], ["COVID-19 infection", "PROBLEM", 79, 97], ["a positive SARS", "PROBLEM", 146, 161], ["CoV", "TEST", 162, 165], ["PCR test", "TEST", 168, 176], ["COVID", "TEST", 187, 192], ["COVID", "TEST", 236, 241]]], ["No confirmed cases were identified in the paediatric cohort.", [["cases", "OBSERVATION", 13, 18]]], ["Patients had a median age of 45 years (IQR 30-63) and there was a 54.6% male prevalence.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["IQR", "TEST", 39, 42]]], ["Briefly, the most commonly reported symptom was fever (82%), followed by persistent cough (73%) and malaise (55%).Confirmed COVID-19 casesSix patients had radiographic findings of pneumonia on admission.", [["fever", "DISEASE", 48, 53], ["cough", "DISEASE", 84, 89], ["pneumonia", "DISEASE", 180, 189], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["symptom", "PROBLEM", 36, 43], ["fever", "PROBLEM", 48, 53], ["persistent cough", "PROBLEM", 73, 89], ["malaise", "PROBLEM", 100, 107], ["COVID", "TEST", 124, 129], ["pneumonia", "PROBLEM", 180, 189], ["persistent", "OBSERVATION_MODIFIER", 73, 83], ["cough", "OBSERVATION", 84, 89], ["pneumonia", "OBSERVATION", 180, 189]]], ["All patients successfully recovered from COVID-19 disease after a median stay of 9.5 days (IQR 5-20 days) and only 1 patient required intensive unit care being the one with more comorbidities.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 117, 124], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 117, 124], ["COVID-19 disease", "PROBLEM", 41, 57], ["intensive unit care", "TREATMENT", 134, 153]]], ["The tDMARD was not administered during the admission in the cases with COVID-19 pneumonia, although in 50% of cases the usual treatment dose did not coincide with that timepoint.", [["tDMARD", "CHEMICAL", 4, 10], ["pneumonia", "DISEASE", 80, 89], ["tDMARD", "SIMPLE_CHEMICAL", 4, 10], ["The tDMARD", "TREATMENT", 0, 10], ["COVID", "TEST", 71, 76], ["pneumonia", "PROBLEM", 80, 89], ["pneumonia", "OBSERVATION", 80, 89]]], ["Of the remaining 5 cases who did not require admission, the tDMARD was maintained in 4 of them with further successful recovery and no disease flare.", [["tDMARD", "DISEASE", 60, 66], ["disease flare", "PROBLEM", 135, 148], ["no", "UNCERTAINTY", 132, 134], ["disease", "OBSERVATION", 135, 142]]], ["Most patients had a contact with a confirmed or suspected case either at home (2 patients had contact with a confirmed case and 5 patients with a suspected case), at work (2 patients had contact with a confirmed case and 4 patients with a suspected case) or both (1 patient).Cumulative incidence ratesCrude and adjusted incidence rates stratified by sex and age group are presented in Table 2 .Cumulative incidence ratesWhen adjusted for same age, sex and city districts, the cumulative incidence rate in our population was found to be 1.21% (95% CI 0.42-19.94%) compared to 0.58% (95% CI 5.62-5.99%) in the general population.", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 223, 231], ["patient", "ORGANISM", 266, 273], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 223, 231], ["patient", "SPECIES", 266, 273], ["Cumulative incidence ratesCrude", "TREATMENT", 275, 306], ["Cumulative incidence rates", "PROBLEM", 394, 420], ["CI", "TEST", 547, 549], ["CI", "TEST", 586, 588]]], ["If restricting to those confirmed cases with pneumonia, the adjusted cumulative incidence rate of rheumatic patients was found to be more similar to that of the general population [0.48% (95% CI 0.09-8.65%) vs 0.58% (95% CI 5.62-5.99%)].Suspected vs. non-suspected casesComparing the clinical characteristics of the suspected cases in the adult and paediatric cohorts with those of unaffected patients without these symptoms (Table 3)Disease activityRA patients with active disease (DAS28>2.6) were more likely to be classified as suspectedDISCUSSIONSpain is one of the countries in the world where the SARS-CoV-2 expanded more rapidly on the first trimester of 2020.", [["pneumonia", "DISEASE", 45, 54], ["active disease", "DISEASE", 467, 481], ["SARS", "DISEASE", 603, 607], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 393, 401], ["patients", "ORGANISM", 453, 461], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 393, 401], ["patients", "SPECIES", 453, 461], ["SARS-CoV", "SPECIES", 603, 611], ["pneumonia", "PROBLEM", 45, 54], ["rheumatic patients", "PROBLEM", 98, 116], ["CI", "TEST", 192, 194], ["CI", "TEST", 221, 223], ["these symptoms", "PROBLEM", 410, 424], ["active disease", "PROBLEM", 467, 481], ["DAS28", "TEST", 483, 488], ["the SARS", "TEST", 599, 607], ["CoV", "TEST", 608, 611], ["pneumonia", "OBSERVATION", 45, 54], ["rheumatic", "OBSERVATION", 98, 107], ["active", "OBSERVATION_MODIFIER", 467, 473], ["disease", "OBSERVATION", 474, 481]]], ["People receiving immunosuppressant therapies are considered more susceptible to viral and bacterial infections and, consequently, a major concern for rheumatologists worldwide is to know if rheumatic patients receiving these therapies have an increased risk of COVID-19.", [["viral and bacterial infections", "DISEASE", 80, 110], ["COVID-19", "CHEMICAL", 261, 269], ["People", "ORGANISM", 0, 6], ["patients", "ORGANISM", 200, 208], ["People", "SPECIES", 0, 6], ["patients", "SPECIES", 200, 208], ["immunosuppressant therapies", "TREATMENT", 17, 44], ["viral and bacterial infections", "PROBLEM", 80, 110], ["these therapies", "TREATMENT", 219, 234], ["COVID", "TEST", 261, 266], ["bacterial", "OBSERVATION_MODIFIER", 90, 99], ["infections", "OBSERVATION", 100, 110], ["increased", "OBSERVATION_MODIFIER", 243, 252]]], ["In this study, we performed an epidemiological survey of the COVID-19 incidence in rheumatic patients receiving tDMARD therapy from a large tertiary hospital from Barcelona, Spain.", [["tDMARD", "CHEMICAL", 112, 118], ["tDMARD", "CHEMICAL", 112, 118], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["this study", "TEST", 3, 13], ["the COVID", "TEST", 57, 66], ["tDMARD therapy", "TREATMENT", 112, 126], ["rheumatic", "OBSERVATION_MODIFIER", 83, 92], ["large", "OBSERVATION_MODIFIER", 134, 139], ["tertiary", "OBSERVATION_MODIFIER", 140, 148]]], ["From a total of 959 IMID patients treated with tDMARDs, we identified 11 confirmed COVID-19 cases in adults and no cases in the paediatric population.DISCUSSIONWhen comparing our cohort to the epidemiological data from the same city districts and tested with the same criteria, we found that the cumulative incidence for rheumatic patients is highly similar to that of the general population.", [["IMID", "DISEASE", 20, 24], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 331, 339], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 331, 339], ["tDMARDs", "TREATMENT", 47, 54], ["COVID", "TEST", 83, 88], ["rheumatic patients", "PROBLEM", 321, 339], ["rheumatic", "OBSERVATION", 321, 330]]], ["In our patient cohort, 10% of patients had COVID-19 compatible symptoms according to the WHO criteria.", [["patient", "ORGANISM", 7, 14], ["patients", "ORGANISM", 30, 38], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 30, 38], ["COVID", "TEST", 43, 48], ["compatible symptoms", "PROBLEM", 52, 71]]], ["Analysing the tDMARD distribution in these at-risk cases, we found significant differences in tDMARDs proportions between the suspected and non-suspected cases.", [["significant differences in tDMARDs proportions", "PROBLEM", 67, 113], ["significant", "OBSERVATION_MODIFIER", 67, 78]]], ["To our knowledge, this is the largest study outlining the extent of COVID-19 in rheumatic patients treated with tDMARDs to date.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["COVID", "TEST", 68, 73], ["rheumatic", "OBSERVATION_MODIFIER", 80, 89]]], ["Importantly, this study provides additional evidence that rheumatic patients on immunosuppressant therapies are not at a higher risk of COVID-19 infection than the general population.", [["infection", "DISEASE", 145, 154], ["patients", "ORGANISM", 68, 76], ["COVID-19", "GENE_OR_GENE_PRODUCT", 136, 144], ["patients", "SPECIES", 68, 76], ["this study", "TEST", 13, 23], ["immunosuppressant therapies", "TREATMENT", 80, 107], ["COVID-19 infection", "PROBLEM", 136, 154], ["rheumatic", "OBSERVATION_MODIFIER", 58, 67], ["infection", "OBSERVATION", 145, 154]]], ["The number of confirmed cases in our cohort is comparable to that recently reported from one of the focal regions in Italy (1.2% vs. 1.2%) (11) .", [["focal", "OBSERVATION_MODIFIER", 100, 105]]], ["If considering all cases, the adjusted incidence rate appears to be higher in our patients compared to the general population (1.21% vs 0.58%).", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["However, these results need to be contextualised.DISCUSSIONFollowing hospital and regional health guidance (16) , SARS-CoV-2 PCR confirmation should be only performed in patients with pneumonia and hospital admission requirements.", [["pneumonia", "DISEASE", 184, 193], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["SARS-CoV-2 PCR confirmation", "TEST", 114, 141], ["pneumonia", "PROBLEM", 184, 193], ["pneumonia", "OBSERVATION", 184, 193]]], ["In our cohort, however, 5 additional patients with normal chest x-ray and without inpatient admission criteria were PCR-tested for SARS-CoV-2 PCR.", [["patients", "ORGANISM", 37, 45], ["SARS-CoV-2 PCR", "DNA", 131, 145], ["patients", "SPECIES", 37, 45], ["PCR", "TEST", 116, 119], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["PCR", "TEST", 142, 145], ["chest", "ANATOMY", 58, 63]]], ["These patients were health workers from the same hospital (n=2) or patients who were tested as considered to be vulnerable population by the treating clinician (n=3).", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 67, 75]]], ["Once these subjects are excluded from the analysis, the incidence rate is analogous to the population from the same city area.DISCUSSIONReassuringly, tDMARD-treated inflammatory rheumatic disease patients do not seem to present a more severe clinical presentation of COVID-19, although our sample of confirmed cases is small.", [["tDMARD", "CHEMICAL", 150, 156], ["inflammatory rheumatic disease", "DISEASE", 165, 195], ["tDMARD", "SIMPLE_CHEMICAL", 150, 156], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["the analysis", "TEST", 38, 50], ["the incidence rate", "PROBLEM", 52, 70], ["inflammatory rheumatic disease", "PROBLEM", 165, 195], ["COVID", "TEST", 267, 272], ["our sample", "TEST", 286, 296], ["inflammatory", "OBSERVATION_MODIFIER", 165, 177], ["rheumatic disease", "OBSERVATION", 178, 195], ["small", "OBSERVATION_MODIFIER", 319, 324]]], ["This result is in concordance with the low occurrence of COVID-19 reported for children from the general population (19) .DISCUSSIONAt present, as outlined in the introduction EULAR, ACR, NICE and PRES guidance regarding patient management during the COVID-19 pandemic propose individualised decisions on tDMARDs (7-10).", [["PRES", "DISEASE", 197, 201], ["children", "ORGANISM", 79, 87], ["patient", "ORGANISM", 221, 228], ["children", "SPECIES", 79, 87], ["patient", "SPECIES", 221, 228], ["COVID", "TEST", 57, 62], ["patient management", "TREATMENT", 221, 239]]], ["ACR and NICE also advocate for a tDMARD stop if COVID-19 is suspected or confirmed.", [["COVID", "TEST", 48, 53]]], ["In our rheumatology department, tDMARD treatment discontinuation was performed individually, based on the specific patient characteristics.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["tDMARD treatment discontinuation", "TREATMENT", 32, 64]]], ["Of note, in most of the confirmed cases that were not admitted (i.e. normal chest x-ray), treatment was not stopped and all patients completely recovered from the infection.", [["infection", "DISEASE", 163, 172], ["chest", "ORGANISM_SUBDIVISION", 76, 81], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["treatment", "TREATMENT", 90, 99], ["the infection", "PROBLEM", 159, 172], ["chest", "ANATOMY", 76, 81], ["infection", "OBSERVATION", 163, 172]]], ["This is in line with the recently published guidelines of the German Society of Rheumatology that in a situation of a positive SARS-CoV-2 PCR without signs of infection, only recommend a tDMARD pause or delay for 5-6 days (20) .", [["infection", "DISEASE", 159, 168], ["a positive SARS", "PROBLEM", 116, 131], ["CoV-2 PCR", "TEST", 132, 141], ["infection", "PROBLEM", 159, 168], ["infection", "OBSERVATION", 159, 168]]], ["Altogether, our data supports a tDMARD maintenance strategy during the pandemic, although more evidence from different registries is needed.DISCUSSIONSimilar to recent reports (21), we found that most COVID-19 infected cases do not require secondary care.", [["our data", "TEST", 12, 20], ["a tDMARD maintenance strategy", "TREATMENT", 30, 59], ["the pandemic", "PROBLEM", 67, 79]]], ["This situation clearly hinders the estimation of the true population incidence.", [["true", "OBSERVATION_MODIFIER", 53, 57], ["population", "OBSERVATION", 58, 68]]], ["In our study, to better explore the clinical and epidemiologic characteristics of the suspected cases we decided to identify which patients had compatible symptoms based on the current WHO guidance (17).", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["our study", "TEST", 3, 12], ["compatible symptoms", "PROBLEM", 144, 163]]], ["The most frequent symptoms in both confirmed and suspected cases were fever and persistent cough as outlined in a recent meta-analysis (22) .DISCUSSIONPatients with compatible symptoms were significantly younger in the adult population.DISCUSSIONFactors that could contribute to this increase could be that younger patients tend to live with a higher number of cohabitants and are more likely to leave home for work and, therefore, have an increased risk of infection exposure.", [["fever", "DISEASE", 70, 75], ["cough", "DISEASE", 91, 96], ["infection", "DISEASE", 458, 467], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["The most frequent symptoms", "PROBLEM", 0, 26], ["fever", "PROBLEM", 70, 75], ["persistent cough", "PROBLEM", 80, 96], ["a recent meta-analysis", "TEST", 112, 134], ["compatible symptoms", "PROBLEM", 165, 184], ["infection exposure", "PROBLEM", 458, 476], ["persistent", "OBSERVATION_MODIFIER", 80, 90], ["cough", "OBSERVATION", 91, 96], ["increased", "OBSERVATION_MODIFIER", 440, 449], ["infection", "OBSERVATION", 458, 467]]], ["We found no differences in comorbidities between groups.", [["differences in comorbidities between groups", "PROBLEM", 12, 55], ["no", "UNCERTAINTY", 9, 11], ["differences", "OBSERVATION_MODIFIER", 12, 23]]], ["This is in apparent contradiction to data suggesting that comorbidities have an important role in COVID-19 severity (23).", [["comorbidities", "PROBLEM", 58, 71], ["COVID", "TEST", 98, 103]]], ["However, it is possible that comorbidities influence the severity of the disease rather than the probability of infection (24).", [["infection", "DISEASE", 112, 121], ["comorbidities", "PROBLEM", 29, 42], ["the disease", "PROBLEM", 69, 80], ["infection", "PROBLEM", 112, 121], ["disease", "OBSERVATION", 73, 80], ["infection", "OBSERVATION", 112, 121]]], ["Finally, in our cohort active RA patients were more likely to be classified as suspected cases.", [["RA", "DISEASE", 30, 32], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["There is evidence that RA patients are at an increased risk of infections particularly if they present high disease activity and depending on the concomitant glucocorticoids dose (25) (26) (27) .", [["RA", "DISEASE", 23, 25], ["infections", "DISEASE", 63, 73], ["glucocorticoids", "CHEMICAL", 158, 173], ["patients", "ORGANISM", 26, 34], ["glucocorticoids", "SIMPLE_CHEMICAL", 158, 173], ["patients", "SPECIES", 26, 34], ["infections", "PROBLEM", 63, 73], ["high disease activity", "PROBLEM", 103, 124], ["the concomitant glucocorticoids dose", "TREATMENT", 142, 178], ["RA", "OBSERVATION_MODIFIER", 23, 25], ["infections", "OBSERVATION", 63, 73]]], ["Also, when exploring the characteristics of these active patients, we found they were older, more obese and had more diabetes suggesting an effect of comorbidity in this finding (28) .DISCUSSIONAlthough treatment data should be interpreted with caution, we identified significant differences in tDMARDs proportions between the suspected and non-suspected cases.DISCUSSIONCTLA4-Ig and anti-IL-6 treated patients were less likely to be classified as suspected cases.DISCUSSIONWhen restricting the analysis to RA patients, we found suspected cases being less treated with abatacept or IL-6 inhibitors, although this difference did not reach statistical significance.", [["diabetes", "DISEASE", 117, 125], ["RA", "DISEASE", 507, 509], ["patients", "ORGANISM", 57, 65], ["DISCUSSIONCTLA4-Ig", "GENE_OR_GENE_PRODUCT", 361, 379], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 384, 393], ["patients", "ORGANISM", 402, 410], ["patients", "ORGANISM", 510, 518], ["abatacept", "SIMPLE_CHEMICAL", 569, 578], ["IL-6", "GENE_OR_GENE_PRODUCT", 582, 586], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 402, 410], ["patients", "SPECIES", 510, 518], ["diabetes", "PROBLEM", 117, 125], ["comorbidity", "PROBLEM", 150, 161], ["treatment data", "TEST", 203, 217], ["abatacept", "TREATMENT", 569, 578], ["IL", "TREATMENT", 582, 584], ["active", "OBSERVATION_MODIFIER", 50, 56], ["significant", "OBSERVATION_MODIFIER", 268, 279]]], ["This data suggests a protective effect of these two therapies.", [["these two therapies", "TREATMENT", 42, 61]]], ["IL-6 is one of the cytokines more highly expressed in severe forms of COVID-19, and has been associated to the reported cytokine storms (29) .", [["COVID-19", "CHEMICAL", 70, 78], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "PROTEIN", 0, 4], ["cytokines", "PROTEIN", 19, 28], ["cytokine", "PROTEIN", 120, 128], ["the cytokines", "TREATMENT", 15, 28], ["COVID", "TEST", 70, 75], ["severe", "OBSERVATION_MODIFIER", 54, 60]]], ["For this reason, IL-6 inhibitors are currently being used in the treatment of severe COVID disease (30) .", [["COVID disease", "DISEASE", 85, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["IL-6 inhibitors", "TREATMENT", 17, 32], ["severe COVID disease", "PROBLEM", 78, 98], ["severe", "OBSERVATION_MODIFIER", 78, 84]]], ["Our results are in line with a possible protective role of IL-6 inhibition in the progression of disease severity and suggest this could be applied preventively, at earlier stages of the infection (31) .", [["infection", "DISEASE", 187, 196], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["IL-6", "PROTEIN", 59, 63], ["IL-6 inhibition", "TREATMENT", 59, 74], ["disease severity", "PROBLEM", 97, 113], ["the infection", "PROBLEM", 183, 196], ["disease", "OBSERVATION", 97, 104], ["infection", "OBSERVATION", 187, 196]]], ["There is preliminary evidence that inhibition of the CD80/86 co-stimulation by abatacept as well as IL-6 inhibition could be useful to treat interstitial lung disease (32, 33) .", [["interstitial lung", "ANATOMY", 141, 158], ["abatacept", "CHEMICAL", 79, 88], ["interstitial lung disease", "DISEASE", 141, 166], ["CD80/86", "GENE_OR_GENE_PRODUCT", 53, 60], ["abatacept", "SIMPLE_CHEMICAL", 79, 88], ["IL-6", "GENE_OR_GENE_PRODUCT", 100, 104], ["lung", "ORGAN", 154, 158], ["CD80", "PROTEIN", 53, 57], ["IL-6", "PROTEIN", 100, 104], ["the CD80", "TEST", 49, 57], ["abatacept", "TREATMENT", 79, 88], ["IL-6 inhibition", "TREATMENT", 100, 115], ["interstitial lung disease", "PROBLEM", 141, 166], ["interstitial", "ANATOMY_MODIFIER", 141, 153], ["lung", "ANATOMY", 154, 158], ["disease", "OBSERVATION", 159, 166]]], ["Moreover, abatacept has been associated with a lower risk of serious infections which adds up as a possible explanation of these findings (34) .", [["abatacept", "CHEMICAL", 10, 19], ["infections", "DISEASE", 69, 79], ["abatacept", "SIMPLE_CHEMICAL", 10, 19], ["abatacept", "TREATMENT", 10, 19], ["serious infections", "PROBLEM", 61, 79], ["serious", "OBSERVATION_MODIFIER", 61, 68], ["infections", "OBSERVATION", 69, 79]]], ["Very recently, a case series of 86 COVID-19 affected patients with immunemediated inflammatory diseases (IMID) from New York showed that the percentage of patients treated with tDMARDs (72% of the cohort) was higher in the ambulatory managed patients compared to those that required admission (15) .", [["inflammatory diseases", "DISEASE", 82, 103], ["IMID", "DISEASE", 105, 109], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 242, 250], ["a case series", "TEST", 15, 28], ["COVID", "TEST", 35, 40], ["immunemediated inflammatory diseases", "PROBLEM", 67, 103], ["tDMARDs", "TREATMENT", 177, 184], ["inflammatory diseases", "OBSERVATION", 82, 103]]], ["Despite the small sample size, this study is in line with our findings, supporting the observation that some tDMARDs might have a protective effect.", [["tDMARDs", "CHEMICAL", 109, 116], ["tDMARDs", "SIMPLE_CHEMICAL", 109, 116], ["the small sample size", "PROBLEM", 8, 29], ["this study", "TEST", 31, 41], ["small", "OBSERVATION_MODIFIER", 12, 17], ["sample", "OBSERVATION_MODIFIER", 18, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["protective", "OBSERVATION_MODIFIER", 130, 140], ["effect", "OBSERVATION_MODIFIER", 141, 147]]], ["Together, these data should encourage the initiation of well-designed randomised controlled trials to corroborate the protective effect of these treatments in COVID-19.DISCUSSIONSome limitations of this study need to be addressed.", [["randomised controlled trials", "TREATMENT", 70, 98], ["these treatments", "TREATMENT", 139, 155], ["this study", "TEST", 198, 208]]], ["First, we designed an observational study based on a telephone survey with different date completion and filled by distinct operators.", [["an observational study", "TEST", 19, 41]]], ["Patient reporting could have been influenced by the operator and symptoms could have been missed as these could have appeared after the date of completion.", [["Patient", "SPECIES", 0, 7], ["symptoms", "PROBLEM", 65, 73]]], ["To address this potential bias, we reviewed the electronic health records of all patients to detect possible cases and asked all our patients to actively contact us if any of the compatible symptoms occurred.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 133, 141], ["the compatible symptoms", "PROBLEM", 175, 198]]], ["Secondly, we only included rheumatic patients treated with tDMARDs without a control group, either treated with other type of DMARDs or untreated patients.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 146, 154], ["tDMARDs", "TREATMENT", 59, 66], ["DMARDs", "TREATMENT", 126, 132]]], ["While including also rheumatic patients without these therapies would have also been useful information, the exceptional workload during the lockdown period compelled us to prioritise the group of patients who were initially considered to be the most vulnerable.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 197, 205], ["these therapies", "TREATMENT", 48, 63]]], ["Thirdly, our study is mainly focused on chronic inflammatory arthritis and we did not include, for example, patients with systemic lupus erythematosus or giant cell arteritis that could provide additional insights into the protective effect of hydroxychloroquine and anti-IL6 therapies.", [["giant cell", "ANATOMY", 154, 164], ["inflammatory arthritis", "DISEASE", 48, 70], ["systemic lupus erythematosus", "DISEASE", 122, 150], ["giant cell arteritis", "DISEASE", 154, 174], ["hydroxychloroquine", "CHEMICAL", 244, 262], ["hydroxychloroquine", "CHEMICAL", 244, 262], ["patients", "ORGANISM", 108, 116], ["giant cell", "CELL", 154, 164], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 244, 262], ["anti-IL6", "SIMPLE_CHEMICAL", 267, 275], ["patients", "SPECIES", 108, 116], ["our study", "TEST", 9, 18], ["chronic inflammatory arthritis", "PROBLEM", 40, 70], ["systemic lupus erythematosus", "PROBLEM", 122, 150], ["giant cell arteritis", "PROBLEM", 154, 174], ["hydroxychloroquine", "TREATMENT", 244, 262], ["anti-IL6 therapies", "TREATMENT", 267, 285], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["inflammatory", "OBSERVATION_MODIFIER", 48, 60], ["arthritis", "OBSERVATION", 61, 70], ["systemic", "OBSERVATION_MODIFIER", 122, 130], ["lupus erythematosus", "OBSERVATION", 131, 150], ["giant cell arteritis", "OBSERVATION", 154, 174]]], ["Further, the lockdown effect might be more pronounced in IMID patients since they are considered an immunosuppressed cohort protecting them from possible exposure to infection and, therefore, distorting their comparison with general population.DISCUSSIONWith regards to the analysis, the small number of cases did not allow for the adjustment for potential confounders other than age and sex.", [["infection", "DISEASE", 166, 175], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["infection", "PROBLEM", 166, 175], ["the analysis", "TEST", 270, 282], ["more pronounced", "OBSERVATION_MODIFIER", 38, 53], ["immunosuppressed", "OBSERVATION", 100, 116], ["infection", "OBSERVATION", 166, 175], ["small", "OBSERVATION_MODIFIER", 288, 293]]], ["Lastly, due to limited availability of SARS-CoV-2 testing in our setting, the estimate of COVID-19 incidence is inaccurate, thereby prompting the health community to rely on suspect cases definitions that might not precisely identify all cases.DISCUSSIONIn conclusion, adult and paediatric patients with rheumatic diseases treated with tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome compared to the general population.", [["rheumatic diseases", "DISEASE", 304, 322], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["SARS", "TEST", 39, 43], ["CoV-2 testing", "TEST", 44, 57], ["COVID", "TEST", 90, 95], ["rheumatic diseases", "PROBLEM", 304, 322], ["tDMARDs", "TREATMENT", 336, 343], ["COVID", "TEST", 384, 389], ["a more severe disease outcome", "PROBLEM", 396, 425], ["severe", "OBSERVATION_MODIFIER", 403, 409], ["disease", "OBSERVATION", 410, 417]]], ["These data suggest that tDMARDs should not be stopped in these patients during the pandemic.", [["tDMARDs", "SIMPLE_CHEMICAL", 24, 31], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["These data", "TEST", 0, 10], ["tDMARDs", "TREATMENT", 24, 31]]], ["Our study also suggests that tDMARDs show different levels of protection against COVID-19 and supports the development of randomized clinical trials to adequately assess their individual effect.", [["COVID-19", "CHEMICAL", 81, 89], ["COVID-19", "CHEMICAL", 81, 89], ["tDMARDs", "SIMPLE_CHEMICAL", 29, 36], ["Our study", "TEST", 0, 9], ["COVID", "TEST", 81, 86], ["randomized clinical trials", "TREATMENT", 122, 148]]], ["International initiatives currently under way, such as the Global Rheumatology Alliance and the EULAR COVID-19 database will provide invaluable data for rheumatic disease management, but epidemiological studies from large national reference centres can be extremely helpful as an interim guidance (14, 35) .", [["rheumatic disease", "DISEASE", 153, 170], ["the EULAR COVID", "TEST", 92, 107], ["rheumatic disease management", "TREATMENT", 153, 181], ["epidemiological studies", "TEST", 187, 210]]], ["In this unprecedented time, when therapies commonly used in rheumatic diseases could prove useful to manage a pandemic disease, rheumatologists are required to provide all their expertise to accelerate the generation of scientific data to protect the lives of people, not only those affected by rheumatic diseases, but also for the global population.", [["rheumatic diseases", "DISEASE", 60, 78], ["rheumatic diseases", "DISEASE", 295, 313], ["people", "ORGANISM", 260, 266], ["people", "SPECIES", 260, 266], ["therapies", "TREATMENT", 33, 42], ["rheumatic diseases", "PROBLEM", 60, 78], ["a pandemic disease", "PROBLEM", 108, 126], ["rheumatic diseases", "PROBLEM", 295, 313], ["rheumatic", "OBSERVATION", 295, 304]]]], "37b82d83204211c2042fe81d41edd371303537d4": [["IntroductionThe primary function of the human red blood cell (RBC) is to deliver oxygen to the tissues of the body.", [["red blood cell", "ANATOMY", 46, 60], ["RBC", "ANATOMY", 62, 65], ["tissues", "ANATOMY", 95, 102], ["body", "ANATOMY", 110, 114], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 81, 87], ["human", "ORGANISM", 40, 45], ["red blood cell", "CELL", 46, 60], ["RBC", "CELL", 62, 65], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["tissues", "TISSUE", 95, 102], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["human red blood cell", "CELL_TYPE", 40, 60], ["RBC", "CELL_TYPE", 62, 65], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["the human red blood cell (RBC)", "TREATMENT", 36, 66], ["oxygen", "TREATMENT", 81, 87], ["body", "ANATOMY", 110, 114]]], ["From a physiological perspective there are multiple scales at which a red blood cell interacts with the human body.", [["red blood cell", "ANATOMY", 70, 84], ["body", "ANATOMY", 110, 114], ["red blood cell", "CELL", 70, 84], ["human", "ORGANISM", 104, 109], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["red blood cell", "CELL_TYPE", 70, 84], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["multiple scales", "PROBLEM", 43, 58], ["a red blood cell", "TREATMENT", 68, 84], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["scales", "OBSERVATION_MODIFIER", 52, 58], ["human body", "ANATOMY_MODIFIER", 104, 114]]], ["On the largest scales is a healthy human, typical size \u2248 1-2 m, which is maintained though the constant supply of oxygen via the oxygen diffusion from the red blood which occurs on scales of \u00b5m.", [["red blood", "ANATOMY", 155, 164], ["oxygen", "CHEMICAL", 114, 120], ["oxygen", "CHEMICAL", 129, 135], ["oxygen", "CHEMICAL", 114, 120], ["oxygen", "CHEMICAL", 129, 135], ["human", "ORGANISM", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 114, 120], ["oxygen", "SIMPLE_CHEMICAL", 129, 135], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["oxygen", "TREATMENT", 114, 120], ["the oxygen diffusion", "TEST", 125, 145], ["the red blood", "PROBLEM", 151, 164], ["largest", "OBSERVATION_MODIFIER", 7, 14], ["scales", "OBSERVATION_MODIFIER", 15, 21], ["healthy human", "OBSERVATION_MODIFIER", 27, 40], ["typical", "OBSERVATION_MODIFIER", 42, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["constant", "OBSERVATION_MODIFIER", 95, 103], ["supply", "OBSERVATION_MODIFIER", 104, 110], ["oxygen diffusion", "OBSERVATION", 129, 145], ["red blood", "OBSERVATION", 155, 164]]], ["The physiological processes that maintains a healthy oxygenated human being is a connection of multiple heterogeneous systems that exists and operate on multiple spatial scales.", [["human", "ORGANISM", 64, 69], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["multiple heterogeneous systems", "PROBLEM", 95, 125], ["multiple", "OBSERVATION_MODIFIER", 95, 103], ["heterogeneous", "OBSERVATION", 104, 117]]], ["Mutli-scale computational models are being developed in order to understand how these individual processes are coupled together to maintain a working healthy human being [17, 18] .", [["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163]]], ["From a rheological perspective whole blood, which travels the through the cardiovascular system, is a multi-scale process in itself.", [["whole blood", "ANATOMY", 31, 42], ["cardiovascular system", "ANATOMY", 74, 95], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["cardiovascular", "ANATOMICAL_SYSTEM", 74, 88], ["system", "ANATOMICAL_SYSTEM", 89, 95], ["a multi-scale process", "TREATMENT", 100, 121], ["cardiovascular system", "ANATOMY", 74, 95]]], ["On the smallest scales (\u00b5m), are the deformations of a RBC and the corresponding interactions with the suspending blood plasma.", [["RBC", "ANATOMY", 55, 58], ["blood plasma", "ANATOMY", 114, 126], ["deformations", "DISEASE", 37, 49], ["RBC", "CELL", 55, 58], ["blood plasma", "ORGANISM_SUBSTANCE", 114, 126], ["RBC", "CELL_TYPE", 55, 58], ["a RBC", "TEST", 53, 58], ["the suspending blood plasma", "TEST", 99, 126], ["smallest", "OBSERVATION_MODIFIER", 7, 15], ["scales", "OBSERVATION_MODIFIER", 16, 22]]], ["Because of the cell nature of whole blood, typically dominated by the deformable RBCs, blood flow on scales below 300 \u00b5m exhibits non-Newtonian Behavior.", [["cell", "ANATOMY", 15, 19], ["whole blood", "ANATOMY", 30, 41], ["RBCs", "ANATOMY", 81, 85], ["blood", "ANATOMY", 87, 92], ["cell", "CELL", 15, 19], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["RBCs", "CELL", 81, 85], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["deformable RBCs", "CELL_TYPE", 70, 85], ["whole blood", "PROBLEM", 30, 41], ["the deformable RBCs", "TEST", 66, 85], ["blood flow on scales", "TEST", 87, 107], ["non-Newtonian Behavior", "PROBLEM", 130, 152], ["cell", "OBSERVATION", 15, 19], ["deformable RBCs", "OBSERVATION", 70, 85], ["non-Newtonian Behavior", "OBSERVATION", 130, 152]]], ["Such a hallmark of this behavior is the F\u00e5hraeus-Lindqvist effect [13] , which is the decrease in the relative apparent viscosity of whole blood that has been contributed by the lubrication layer on the vessel wall provided by the existence of a red blood cell-free layer (CFL) [14] .", [["blood", "ANATOMY", 139, 144], ["vessel wall", "ANATOMY", 203, 214], ["red blood cell", "ANATOMY", 246, 260], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 203, 214], ["red blood cell", "CELL_TYPE", 246, 260], ["whole blood", "PROBLEM", 133, 144], ["a red blood cell", "TEST", 244, 260], ["decrease", "OBSERVATION_MODIFIER", 86, 94], ["lubrication", "OBSERVATION", 178, 189], ["vessel", "ANATOMY", 203, 209], ["wall", "ANATOMY_MODIFIER", 210, 214]]], ["Migration of RBCs away from the vessel wall has been since observed in multiple in vitro studies, and has been shown to create two phases over the cross section of a tube; a central region of mainly RBCs, and an on average a cell depleted region, the CFL [10] .", [["RBCs", "ANATOMY", 13, 17], ["vessel wall", "ANATOMY", 32, 43], ["tube", "ANATOMY", 166, 170], ["RBCs", "ANATOMY", 199, 203], ["cell", "ANATOMY", 225, 229], ["RBCs", "CELL", 13, 17], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 32, 43], ["tube", "TISSUE", 166, 170], ["RBCs", "CELL", 199, 203], ["cell", "CELL", 225, 229], ["RBCs", "CELL_TYPE", 13, 17], ["RBCs", "CELL_TYPE", 199, 203], ["Migration of RBCs", "TREATMENT", 0, 17], ["vitro studies", "TEST", 83, 96], ["a tube", "TREATMENT", 164, 170], ["mainly RBCs", "PROBLEM", 192, 203], ["a cell depleted region", "TREATMENT", 223, 245], ["RBCs", "OBSERVATION", 13, 17], ["vessel", "ANATOMY", 32, 38], ["wall", "ANATOMY_MODIFIER", 39, 43], ["multiple", "OBSERVATION_MODIFIER", 71, 79], ["tube", "OBSERVATION", 166, 170], ["central", "ANATOMY_MODIFIER", 174, 181], ["mainly RBCs", "OBSERVATION", 192, 203], ["cell depleted", "OBSERVATION", 225, 238]]], ["The shear thinning behavior of whole blood however is not only limited to the F\u00e5hraeus-Lindqvist effect and may not only occur on the microvascular scale.", [["whole blood", "ANATOMY", 31, 42], ["microvascular", "ANATOMY", 134, 147], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["microvascular", "TISSUE", 134, 147], ["The shear thinning behavior of whole blood", "PROBLEM", 0, 42], ["the microvascular scale", "TEST", 130, 153], ["shear", "OBSERVATION_MODIFIER", 4, 9], ["thinning", "OBSERVATION_MODIFIER", 10, 18]]], ["There are also prominent shear thinning effects of whole blood and has been found to be affected by many things; such as the break up of rouleaux structures [6] , RBC alignment, and RBC stretching in flow [11, 16] .", [["whole blood", "ANATOMY", 51, 62], ["RBC", "ANATOMY", 163, 166], ["RBC", "ANATOMY", 182, 185], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["RBC", "SIMPLE_CHEMICAL", 182, 185], ["RBC", "CELL_TYPE", 182, 185], ["prominent shear thinning effects of whole blood", "PROBLEM", 15, 62], ["rouleaux structures", "PROBLEM", 137, 156], ["RBC alignment", "TEST", 163, 176], ["RBC stretching in flow", "TEST", 182, 204], ["prominent", "OBSERVATION_MODIFIER", 15, 24], ["shear", "OBSERVATION_MODIFIER", 25, 30], ["thinning", "OBSERVATION", 31, 39], ["RBC alignment", "OBSERVATION", 163, 176], ["RBC stretching", "OBSERVATION", 182, 196]]], ["These phenomena have given rise to the fact that whole blood viscosity is also dependent on shear rate [9] .IntroductionIn order to properly resolve the non-Newtonian phenomena, cell resolved blood flow models are required [5, 14, 27] , as they account for the mechanical deformations of the red blood cells and the subsequent influence on the suspension rheology.", [["blood", "ANATOMY", 55, 60], ["cell", "ANATOMY", 178, 182], ["blood", "ANATOMY", 192, 197], ["red blood cells", "ANATOMY", 292, 307], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["cell", "CELL", 178, 182], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["red blood cells", "CELL", 292, 307], ["red blood cells", "CELL_TYPE", 292, 307], ["These phenomena", "PROBLEM", 0, 15], ["whole blood viscosity", "TEST", 49, 70], ["shear rate", "TEST", 92, 102], ["IntroductionIn", "TREATMENT", 108, 122], ["the non-Newtonian phenomena", "PROBLEM", 149, 176], ["blood flow models", "TEST", 192, 209], ["the mechanical deformations of the red blood cells", "PROBLEM", 257, 307], ["the suspension rheology", "TREATMENT", 340, 363], ["non-Newtonian phenomena", "OBSERVATION", 153, 176], ["mechanical deformations", "OBSERVATION", 261, 284]]], ["The transport of other blood cells types on these scales are also influenced by the presence of red blood cells such as the margination of platelets [28] and white blood cells [15] to the vessel wall.", [["blood cells", "ANATOMY", 23, 34], ["red blood cells", "ANATOMY", 96, 111], ["platelets", "ANATOMY", 139, 148], ["white blood cells", "ANATOMY", 158, 175], ["vessel wall", "ANATOMY", 188, 199], ["blood cells", "CELL", 23, 34], ["red blood cells", "CELL", 96, 111], ["platelets", "CELL", 139, 148], ["white blood cells", "CELL", 158, 175], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 188, 199], ["blood cells", "CELL_TYPE", 23, 34], ["red blood cells", "CELL_TYPE", 96, 111], ["platelets", "CELL_TYPE", 139, 148], ["white blood cells", "CELL_TYPE", 158, 175], ["these scales", "TEST", 44, 56], ["red blood cells", "TEST", 96, 111], ["platelets", "TEST", 139, 148], ["white blood cells", "TEST", 158, 175], ["margination", "OBSERVATION_MODIFIER", 124, 135], ["vessel", "ANATOMY", 188, 194], ["wall", "ANATOMY_MODIFIER", 195, 199]]], ["Currently numerical models that adequately resolve the transport and rheological properties of whole blood have large amounts of computational overhead and require high performance computing [3, 23] .IntroductionBlood flow on scales larger than 300 \u00b5m is consistently modeled as a continuous fluid, as it is computationally more convenient because models no longer include the individual cell dynamics [20, 24, 25] , which greatly reduces the computational overhead.", [["whole blood", "ANATOMY", 95, 106], ["Blood", "ANATOMY", 212, 217], ["cell", "ANATOMY", 388, 392], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["Blood", "ORGANISM_SUBSTANCE", 212, 217], ["cell", "CELL", 388, 392], ["large amounts of computational overhead", "PROBLEM", 112, 151], ["Blood flow on scales", "TEST", 212, 232], ["a continuous fluid", "TREATMENT", 279, 297], ["the individual cell dynamics", "TEST", 373, 401], ["large", "OBSERVATION_MODIFIER", 112, 117], ["amounts", "OBSERVATION_MODIFIER", 118, 125]]], ["Continuous models either assume whole blood as a Newtonian fluid on larger scales or use a non-Newtonian blood viscosity model to approximate the departure of whole from the Newtonian description.", [["blood", "ANATOMY", 38, 43], ["blood", "ANATOMY", 105, 110], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["a Newtonian fluid on larger scales", "TREATMENT", 47, 81], ["a non-Newtonian blood viscosity model", "TREATMENT", 89, 126]]], ["Non-Newtonian models describe the change in blood viscosity with a dependency either on shear rate like a power law fluid [22] or Carreau-Yasuda [2] , or depends on yield stress like the Casson model [19] .", [["blood", "ANATOMY", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["Non-Newtonian models", "PROBLEM", 0, 20], ["the change in blood viscosity", "PROBLEM", 30, 59], ["a dependency", "PROBLEM", 65, 77], ["shear rate", "TEST", 88, 98], ["change", "OBSERVATION_MODIFIER", 34, 40], ["blood viscosity", "OBSERVATION_MODIFIER", 44, 59]]], ["Since such models do not include the dynamics of the cells they may over estimate the transport behaviors which are a result of cell-cell collisions within whole blood suspensions.", [["cells", "ANATOMY", 53, 58], ["cell", "ANATOMY", 128, 132], ["cell", "ANATOMY", 133, 137], ["blood", "ANATOMY", 162, 167], ["cells", "CELL", 53, 58], ["cell", "CELL", 128, 132], ["cell", "CELL", 133, 137], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["the transport behaviors", "PROBLEM", 82, 105], ["cell-cell collisions", "PROBLEM", 128, 148], ["whole blood suspensions", "TREATMENT", 156, 179], ["cell collisions", "OBSERVATION", 133, 148]]], ["This may lead to an invalid description of particle diffusivities within whole blood.IntroductionIn order to capture both the non-Newtonian viscosity change of whole blood along with the proper treatment of the transport of suspended blood cells a multi-scale model must be developed in order to correctly account for both processes on all scales of the cardiovascular system.", [["whole blood", "ANATOMY", 73, 84], ["blood", "ANATOMY", 166, 171], ["blood cells", "ANATOMY", 234, 245], ["cardiovascular", "ANATOMY", 354, 368], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["blood cells", "CELL", 234, 245], ["cardiovascular", "ANATOMICAL_SYSTEM", 354, 368], ["system", "ANATOMICAL_SYSTEM", 369, 375], ["suspended blood cells", "CELL_TYPE", 224, 245], ["particle diffusivities", "PROBLEM", 43, 65], ["suspended blood cells", "TREATMENT", 224, 245], ["a multi-scale model", "TREATMENT", 246, 265], ["non-Newtonian viscosity", "OBSERVATION", 126, 149], ["cardiovascular system", "ANATOMY", 354, 375]]], ["Because systems of the body are heterogeneous across multiple scales present in the body we chose to develop a heterogeneous multi-scale model (HMM) for blood flow.", [["body", "ANATOMY", 23, 27], ["body", "ANATOMY", 84, 88], ["blood", "ANATOMY", 153, 158], ["body", "ORGANISM_SUBDIVISION", 23, 27], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["blood flow", "TEST", 153, 163], ["body", "ANATOMY_MODIFIER", 23, 27], ["heterogeneous", "OBSERVATION", 32, 45], ["multiple", "OBSERVATION_MODIFIER", 53, 61], ["scales", "OBSERVATION_MODIFIER", 62, 68], ["body", "ANATOMY_MODIFIER", 84, 88], ["heterogeneous", "OBSERVATION_MODIFIER", 111, 124]]], ["Though this research is focused primarily on the rheology and transport properties of blood, HMM is a more general method for modeling multi scale problems and can be useful for future development as it can incorporate model beyond strictly fluid dynamic problems.Heterogeneous Multi-scale ModelThe Heterogeneous Multi-scale Method [1] is a modeling technique used to numerically solve multi-scale problems by coupling multiple sub-models together that each solve a component separately, but by combining each separate submodel together an overall macro model emerges.", [["blood", "ANATOMY", 86, 91], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["modeling multi scale problems", "PROBLEM", 126, 155], ["fluid dynamic problems", "PROBLEM", 241, 263], ["a modeling technique", "TREATMENT", 339, 359], ["fluid dynamic", "OBSERVATION", 241, 254], ["Heterogeneous", "OBSERVATION_MODIFIER", 299, 312], ["macro model", "OBSERVATION", 548, 559]]], ["HMM relies on efficient coupling between macro and micro models [12] .", [["macro and micro models", "TEST", 41, 63]]], ["A macro scale model can be either limited or too computational expensive to numerical solve an entire problem on its own; therefore micro models are employed to resolve each component of the problem separately and return the result to the macro model.", [["A macro scale model", "TEST", 0, 19], ["micro models", "TREATMENT", 132, 144]]], ["Scale separation is a common exploitation in HMM as many numerical problems are difficult to capture solely with one single model.", [["a common exploitation in HMM", "PROBLEM", 20, 48], ["many numerical problems", "PROBLEM", 52, 75]]], ["A benefit of such an HMM model applied to blood flow is that on the largest scales a continuous blood flow solver will be informed by a micro scale cell resolved blood flow solver, resolving the cell nature of whole blood by keeping computational overhead in mind.", [["blood", "ANATOMY", 42, 47], ["blood", "ANATOMY", 96, 101], ["cell", "ANATOMY", 148, 152], ["blood", "ANATOMY", 162, 167], ["cell", "ANATOMY", 195, 199], ["whole blood", "ANATOMY", 210, 221], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["cell", "CELL", 148, 152], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["cell", "CELL", 195, 199], ["blood", "ORGANISM_SUBSTANCE", 216, 221], ["an HMM model", "TREATMENT", 18, 30], ["blood flow", "TEST", 42, 52], ["a continuous blood flow solver", "TREATMENT", 83, 113], ["blood flow solver", "TEST", 162, 179], ["whole blood", "TEST", 210, 221], ["cell", "OBSERVATION", 195, 199]]], ["The heterogeneity of the models allows for extension to be added, such as the diffusion of chemicals.", [["heterogeneity", "OBSERVATION_MODIFIER", 4, 17]]], ["A schematic highlighting the different numerical models and physical scales present in the HMM model is shown in Fig. 1 , and a flow chart of the operations through one time-step of this model is highlighted in Fig. 2.", [["the operations", "TREATMENT", 142, 156]]], ["Workflow of the HMM blood flow model.Macro ModelOn the largest scales in this model (Macro-scale) blood flow is modelled as a continuous fluid using the lattice Boltzmann method (LBM) [7] .", [["blood", "ANATOMY", 20, 25], ["blood", "ANATOMY", 98, 103], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["the HMM blood flow model", "TEST", 12, 36], ["blood flow", "TEST", 98, 108], ["a continuous fluid", "TREATMENT", 124, 142], ["the lattice Boltzmann method (LBM)", "TREATMENT", 149, 183], ["largest", "OBSERVATION_MODIFIER", 55, 62], ["scales", "OBSERVATION_MODIFIER", 63, 69]]], ["Fluid will be driven by an external body force through a straight vessel geometry.", [["body", "ANATOMY", 36, 40], ["vessel", "ANATOMY", 66, 72], ["body", "ORGANISM_SUBDIVISION", 36, 40], ["vessel", "MULTI-TISSUE_STRUCTURE", 66, 72], ["Fluid", "TREATMENT", 0, 5], ["an external body force", "TREATMENT", 24, 46], ["straight vessel geometry", "OBSERVATION", 57, 81]]], ["After a time-step of the LBM fluid solver the velocity field across the macroscopic domain will be passed as input to an LBM advection-diffusion solver, which is also on the macro scale and will compute the transport of RBCs (hematocrit) given the underlying fluid flow.", [["RBCs", "ANATOMY", 220, 224], ["fluid", "ANATOMY", 259, 264], ["RBCs", "CELL", 220, 224], ["fluid", "ORGANISM_SUBSTANCE", 259, 264], ["RBCs", "CELL_TYPE", 220, 224], ["the LBM fluid solver", "TEST", 21, 41], ["an LBM advection", "TEST", 118, 134], ["diffusion solver", "TEST", 135, 151], ["the macro scale", "TEST", 170, 185], ["hematocrit", "TEST", 226, 236], ["the underlying fluid flow", "PROBLEM", 244, 269], ["fluid flow", "OBSERVATION", 259, 269]]], ["After this step the Hematocrit field from the advection diffusion solver and the velocity field (shear rate) from the fluid solver will be sent to a surrogate model.", [["the advection diffusion solver", "TEST", 42, 72], ["the velocity field", "TEST", 77, 95], ["shear rate", "TEST", 97, 107], ["the fluid solver", "TEST", 114, 130], ["velocity", "OBSERVATION_MODIFIER", 81, 89], ["fluid", "OBSERVATION", 118, 123]]], ["Here the surrogate model it will determine, via interpolation, whether a viscosity and diffusion coefficient is known for the shear rate and hematocrit combination.", [["a viscosity and diffusion coefficient", "TEST", 71, 108], ["the shear rate", "TEST", 122, 136], ["hematocrit combination", "TREATMENT", 141, 163]]], ["If there is no such parameter, either viscosity or diffusion coefficient, then a cell resolved blood flow model is spawned which will compute the diffusion coefficient and viscosity directly.", [["cell", "ANATOMY", 81, 85], ["blood", "ANATOMY", 95, 100], ["cell", "CELL", 81, 85], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["such parameter", "PROBLEM", 15, 29], ["diffusion coefficient", "TEST", 51, 72], ["a cell resolved blood flow model", "TEST", 79, 111], ["the diffusion coefficient", "TEST", 142, 167], ["no such", "UNCERTAINTY", 12, 19]]], ["The macro scale model will wait for either the surrogate model or the micro-scale model to return viscosities and diffusion coefficients for the entire domain.", [["the surrogate model", "TEST", 43, 62], ["diffusion coefficients", "TEST", 114, 136]]], ["The viscosity field will be return to the fluid solver and the diffusion field will be returned to the advection diffusion solver.", [["the fluid solver", "TEST", 38, 54], ["the advection diffusion solver", "TEST", 99, 129]]], ["The time-step will then be incremented and the process will begin again.Coupling Between Micro and MacroTo avoid duplicating shear rate and local hematocrit micro-scale simulations for each iteration of the HMM, we aim to build a surrogate model.", [["MacroTo", "TREATMENT", 99, 106], ["duplicating shear rate", "TREATMENT", 113, 135], ["local hematocrit micro-scale simulations", "TREATMENT", 140, 180], ["a surrogate model", "TREATMENT", 228, 245], ["shear", "OBSERVATION_MODIFIER", 125, 130]]], ["This process will decrease the required number of micro-scale models requested, which in turn will decrease computation time.", [["micro-scale models", "TREATMENT", 50, 68], ["decrease", "OBSERVATION_MODIFIER", 18, 26]]], ["Hematocrit fields and shear rate fields will be passed down from the macro scale.", [["Hematocrit fields", "TEST", 0, 17], ["shear rate fields", "TEST", 22, 39], ["the macro scale", "TEST", 65, 80], ["shear", "OBSERVATION_MODIFIER", 22, 27]]], ["First local hematocrit values and shear rate values will be combined, then the surrogate will query a database if there already exists a known viscosity and diffusion coefficient for the combination of hematocrit and shear rate.", [["First local hematocrit values", "TEST", 0, 29], ["shear rate values", "TEST", 34, 51], ["a known viscosity and diffusion coefficient", "PROBLEM", 135, 178], ["hematocrit", "TEST", 202, 212], ["shear rate", "TEST", 217, 227], ["hematocrit", "OBSERVATION", 12, 22], ["hematocrit", "OBSERVATION", 202, 212], ["shear rate", "OBSERVATION", 217, 227]]], ["If the is a known viscosity and diffusion coefficients then it will return them to the macro scale.", [["a known viscosity and diffusion coefficients", "PROBLEM", 10, 54], ["the macro scale", "TEST", 83, 98]]], ["If there are missing viscosities and/or diffusion coefficients then a micro model will be spawned for each unknown shear rate and hematocrit combination.", [["missing viscosities and/or diffusion coefficients", "PROBLEM", 13, 62], ["a micro model", "TREATMENT", 68, 81], ["hematocrit", "TEST", 130, 140]]], ["A heterogeneous multiscale computing framework has recently been developed to handle the scheduling and sub-model synchronization of such an application in order to efficiently use computational resources [4] .Micro ModelThe micro scale is modelled with the cell resolved blood flow model HemoCell, in which plasma is modelled by the LBM, the mechanical model of the RBCs are described by a discrete element method and are couple to the plasma via the immersed boundary method [26, 27] .", [["cell", "ANATOMY", 258, 262], ["blood", "ANATOMY", 272, 277], ["plasma", "ANATOMY", 308, 314], ["RBCs", "ANATOMY", 367, 371], ["plasma", "ANATOMY", 437, 443], ["cell", "CELL", 258, 262], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["HemoCell", "SIMPLE_CHEMICAL", 289, 297], ["plasma", "ORGANISM_SUBSTANCE", 308, 314], ["RBCs", "CELL", 367, 371], ["plasma", "ORGANISM_SUBSTANCE", 437, 443], ["RBCs", "CELL_TYPE", 367, 371], ["A heterogeneous multiscale computing framework", "PROBLEM", 0, 46], ["sub-model synchronization", "TREATMENT", 104, 129], ["an application", "TREATMENT", 138, 152], ["The micro scale", "TEST", 221, 236], ["heterogeneous", "OBSERVATION_MODIFIER", 2, 15], ["multiscale", "OBSERVATION", 16, 26], ["blood flow", "OBSERVATION", 272, 282], ["LBM", "OBSERVATION", 334, 337]]], ["From each local hematocrit and shear rate combination on the macro scale, a cell resolved micro scale will simulate perfect sheared environments using Lees-Edwards boundary conditions [21] .", [["cell", "ANATOMY", 76, 80], ["cell", "CELL", 76, 80], ["each local hematocrit", "TEST", 5, 26], ["shear rate", "TEST", 31, 41], ["the macro scale", "TREATMENT", 57, 72], ["a cell", "PROBLEM", 74, 80]]], ["A single simulation will be spawned for each unknown diffusivity and shear rate pair, this will likely result in multiple spawns if there are multiple unknown input parameters.", [["A single simulation", "TREATMENT", 0, 19], ["shear rate pair", "PROBLEM", 69, 84]]], ["The resulting diffusion coefficients and viscosities will be computed from each cell resolved simulation.", [["cell", "ANATOMY", 80, 84], ["cell", "CELL", 80, 84], ["The resulting diffusion coefficients", "TEST", 0, 36], ["viscosities", "TEST", 41, 52]]], ["As the HMM model progresses through time however a smaller amount of micro model will be spawned due to the surrogate model.DiscussionThe immediate focus of this work is to implement the HMM model for blood flow in a 3D straight vessel.", [["blood", "ANATOMY", 201, 206], ["vessel", "ANATOMY", 229, 235], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["vessel", "MULTI-TISSUE_STRUCTURE", 229, 235], ["micro model", "TREATMENT", 69, 80], ["blood flow", "TEST", 201, 211], ["smaller", "OBSERVATION_MODIFIER", 51, 58], ["amount", "OBSERVATION_MODIFIER", 59, 65], ["straight", "ANATOMY_MODIFIER", 220, 228], ["vessel", "ANATOMY", 229, 235]]], ["Validation to known blood quantities such as the F\u00e5hraeus-Lindqvist effect is needed.", [["blood", "ANATOMY", 20, 25], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["known blood quantities", "PROBLEM", 14, 36], ["the F\u00e5hraeus-Lindqvist effect", "TREATMENT", 45, 74]]], ["A correct physical implementation of this model will allow the determination of the minimum spatial size required from the cell resolved micro models, in order to preserve accurate viscosity and diffusivity measurements that will maximize computational efficiency.", [["cell", "ANATOMY", 123, 127], ["cell", "CELL", 123, 127], ["micro models", "TEST", 137, 149], ["diffusivity measurements", "TEST", 195, 219], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["The determination of the minimum spatial resolution of local viscosity and diffusivity is also required on the macro scale in order to accurately and efficiently model blood flow.DiscussionThe novelty of developing an HMM model for blood flow is that it can be extended to include models that are not limited to only model fluid dynamics.", [["blood", "ANATOMY", 168, 173], ["blood", "ANATOMY", 232, 237], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 232, 237], ["the macro scale", "TEST", 107, 122], ["blood flow", "TEST", 232, 242], ["model fluid dynamics", "PROBLEM", 317, 337], ["minimum", "OBSERVATION_MODIFIER", 25, 32], ["spatial", "OBSERVATION_MODIFIER", 33, 40], ["resolution", "OBSERVATION_MODIFIER", 41, 51], ["local viscosity", "OBSERVATION", 55, 70], ["blood flow", "OBSERVATION", 168, 178], ["fluid", "OBSERVATION", 323, 328]]], ["Given the heterogeneous nature of this model, computational models which include the reaction and perfusion of chemical species in the human microbiome, as well as the models for the smooth muscle cells, for example, can also be included to contribute to a more complete HMM model for the physiological human.", [["smooth muscle cells", "ANATOMY", 183, 202], ["human", "ORGANISM", 135, 140], ["smooth muscle cells", "CELL", 183, 202], ["human", "ORGANISM", 303, 308], ["smooth muscle cells", "CELL_TYPE", 183, 202], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 303, 308], ["the reaction", "PROBLEM", 81, 93], ["chemical species in the human microbiome", "PROBLEM", 111, 151], ["heterogeneous", "OBSERVATION_MODIFIER", 10, 23], ["chemical species", "OBSERVATION", 111, 127], ["human microbiome", "ANATOMY", 135, 151], ["smooth muscle cells", "OBSERVATION", 183, 202]]]], "358aa3873fbce1c441988b9a777b5fe16b9c53cb": [["BackgroundIn these first months of coronavirus disease-19 (COVID-19) pandemic, a mainstream pathogenetic hypothesis, likely stemming from early clinico-therapeutic observations, has been suggesting that severe COVID-19 may represent a sort of hyperimmune disorder, akin, in particular, to secondary hemophagocytic lymphohistiocytosis (sHLH) and macrophage activation syndrome (MAS) [1] [2] [3] .", [["macrophage", "ANATOMY", 345, 355], ["coronavirus disease", "DISEASE", 35, 54], ["hyperimmune disorder", "DISEASE", 243, 263], ["hemophagocytic lymphohistiocytosis", "DISEASE", 299, 333], ["sHLH", "DISEASE", 335, 339], ["coronavirus", "ORGANISM", 35, 46], ["hyperimmune", "ORGANISM", 243, 254], ["sHLH", "CANCER", 335, 339], ["macrophage", "CELL", 345, 355], ["coronavirus disease", "PROBLEM", 35, 54], ["COVID", "TEST", 59, 64], ["pandemic", "PROBLEM", 69, 77], ["a mainstream pathogenetic hypothesis", "PROBLEM", 79, 115], ["severe COVID", "PROBLEM", 203, 215], ["hyperimmune disorder", "PROBLEM", 243, 263], ["secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 289, 333], ["macrophage activation syndrome", "PROBLEM", 345, 375], ["coronavirus disease", "OBSERVATION", 35, 54], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["hyperimmune disorder", "OBSERVATION", 243, 263], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 299, 333], ["macrophage activation syndrome", "OBSERVATION", 345, 375]]], ["In this view, COVID-19-associated cytokine storm, with elevated plasma levels of IL-6, IL-1, and TNF-\u03b1, as well as ferritin and other inflammatory biomarkers, has been considered as a typical sign of sHLH/ MAS, but the other \"key feature\" of COVID-19-the progressive lymphopenia with T cell exhaustion [4] [5] [6] has largely been neglected.", [["plasma", "ANATOMY", 64, 70], ["T cell", "ANATOMY", 284, 290], ["MAS", "DISEASE", 206, 209], ["lymphopenia", "DISEASE", 267, 278], ["COVID-19", "CHEMICAL", 242, 250], ["COVID-19", "GENE_OR_GENE_PRODUCT", 14, 22], ["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 97, 102], ["ferritin", "GENE_OR_GENE_PRODUCT", 115, 123], ["sHLH", "GENE_OR_GENE_PRODUCT", 200, 204], ["COVID-19", "GENE_OR_GENE_PRODUCT", 242, 250], ["T cell", "CELL", 284, 290], ["COVID-19", "DNA", 14, 22], ["cytokine", "PROTEIN", 34, 42], ["IL-6", "PROTEIN", 81, 85], ["IL", "PROTEIN", 87, 89], ["TNF", "PROTEIN", 97, 100], ["ferritin", "PROTEIN", 115, 123], ["this view", "TEST", 3, 12], ["COVID", "TEST", 14, 19], ["cytokine storm", "PROBLEM", 34, 48], ["elevated plasma levels", "PROBLEM", 55, 77], ["IL", "TEST", 81, 83], ["IL", "TEST", 87, 89], ["TNF", "TEST", 97, 100], ["ferritin", "TEST", 115, 123], ["other inflammatory biomarkers", "TEST", 128, 157], ["sHLH", "PROBLEM", 200, 204], ["MAS", "PROBLEM", 206, 209], ["COVID", "TEST", 242, 247], ["the progressive lymphopenia", "PROBLEM", 251, 278], ["T cell exhaustion", "PROBLEM", 284, 301], ["cytokine storm", "OBSERVATION", 34, 48], ["TNF", "ANATOMY", 97, 100], ["inflammatory", "OBSERVATION", 134, 146], ["progressive", "OBSERVATION_MODIFIER", 255, 266], ["lymphopenia", "OBSERVATION", 267, 278]]], ["Of note, both CD4+ and CD8+ T lymphocytes were found to be remarkably decreased in severe cases (median 177.5 and 89.0 \u00d7 10 6 /L, respectively), when compared to moderate ones (median 381.5 and 254.0 \u00d7 10 6 /L, respectively), thus suggesting T cell lymphopenia may constitute a potential prognostic marker to be included in the monitoring of COVID-19 patients [4] .", [["CD4+ and CD8+", "ANATOMY", 14, 27], ["T lymphocytes", "ANATOMY", 28, 41], ["T cell", "ANATOMY", 242, 248], ["lymphopenia", "DISEASE", 249, 260], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["T lymphocytes", "CELL", 28, 41], ["T cell", "CELL", 242, 248], ["patients", "ORGANISM", 351, 359], ["CD4", "PROTEIN", 14, 17], ["CD8", "PROTEIN", 23, 26], ["T lymphocytes", "CELL_TYPE", 28, 41], ["patients", "SPECIES", 351, 359], ["CD4", "TEST", 14, 17], ["CD8", "TEST", 23, 26], ["T lymphocytes", "TEST", 28, 41], ["T cell lymphopenia", "PROBLEM", 242, 260], ["COVID", "TEST", 342, 347], ["found to be", "UNCERTAINTY", 47, 58], ["remarkably", "OBSERVATION_MODIFIER", 59, 69], ["decreased", "OBSERVATION_MODIFIER", 70, 79], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["moderate", "OBSERVATION_MODIFIER", 162, 170], ["suggesting", "UNCERTAINTY", 231, 241], ["T cell lymphopenia", "OBSERVATION", 242, 260]]], ["Frequencies of IFN-\u03b3-producing CD4+ T cells (i.e., cytotoxic Th1 subset) tended to be lower in severe than in moderate illness (median 14.1% versus 22.8%, respectively), possibly indicating a progressive skew of the Th1/Th2 balance toward a tolerogenic response [4] .", [["CD4+ T cells", "ANATOMY", 31, 43], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 15, 21], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["IFN", "PROTEIN", 15, 18], ["CD4", "PROTEIN", 31, 34], ["T cells", "CELL_TYPE", 36, 43], ["cytotoxic Th1 subset", "CELL_TYPE", 51, 71], ["IFN", "TEST", 15, 18], ["CD4+ T cells", "PROBLEM", 31, 43], ["moderate illness", "PROBLEM", 110, 126], ["lower", "OBSERVATION_MODIFIER", 86, 91], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["illness", "OBSERVATION", 119, 126], ["possibly indicating", "UNCERTAINTY", 170, 189], ["progressive", "OBSERVATION_MODIFIER", 192, 203]]], ["In addition, the percentages of both memory Th cells and regulatory T cells were found to decrease in severe cases [5] .BackgroundNonetheless, in patients with severe systemic hyperinflammatory diseases driven by other viral infections, hemophagocytic syndrome can be expected as a rare but life-threatening event, and, indeed, sHLH has been recognized to occur in up to 4.3% of sepsis cases [1] .", [["memory Th cells", "ANATOMY", 37, 52], ["regulatory T cells", "ANATOMY", 57, 75], ["hyperinflammatory diseases", "DISEASE", 176, 202], ["viral infections", "DISEASE", 219, 235], ["hemophagocytic syndrome", "DISEASE", 237, 260], ["sHLH", "DISEASE", 328, 332], ["sepsis", "DISEASE", 379, 385], ["memory Th cells", "CELL", 37, 52], ["regulatory T cells", "CELL", 57, 75], ["patients", "ORGANISM", 146, 154], ["sHLH", "CANCER", 328, 332], ["memory Th cells", "CELL_TYPE", 37, 52], ["regulatory T cells", "CELL_TYPE", 57, 75], ["patients", "SPECIES", 146, 154], ["regulatory T cells", "TEST", 57, 75], ["severe systemic hyperinflammatory diseases", "PROBLEM", 160, 202], ["other viral infections", "PROBLEM", 213, 235], ["hemophagocytic syndrome", "PROBLEM", 237, 260], ["sepsis cases", "PROBLEM", 379, 391], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["systemic", "OBSERVATION_MODIFIER", 167, 175], ["hyperinflammatory diseases", "OBSERVATION", 176, 202], ["viral", "OBSERVATION_MODIFIER", 219, 224], ["infections", "OBSERVATION", 225, 235], ["hemophagocytic syndrome", "OBSERVATION", 237, 260]]], ["Hence, in those COVID-19 patients showing massive hyperinflammation, a clinical diagnosis of sHLH/MAS may be appropriate and deserves further investigation at the histological level.BackgroundMore recently, COVID-19 clinical syndrome and related immunopathogenesis have been compared with sepsis, recalling the need to target the underlying and shared impairment of protective T cell immunity, while suppressing the emergent cytokine storm [7] [8] [9] .", [["T cell", "ANATOMY", 377, 383], ["hyperinflammation", "DISEASE", 50, 67], ["MAS", "DISEASE", 98, 101], ["sepsis", "DISEASE", 289, 295], ["patients", "ORGANISM", 25, 33], ["sHLH", "ORGANISM", 93, 97], ["T cell", "CELL", 377, 383], ["cytokine", "PROTEIN", 425, 433], ["patients", "SPECIES", 25, 33], ["massive hyperinflammation", "PROBLEM", 42, 67], ["sHLH/MAS", "PROBLEM", 93, 101], ["further investigation", "TEST", 134, 155], ["COVID", "TEST", 207, 212], ["clinical syndrome", "PROBLEM", 216, 233], ["related immunopathogenesis", "PROBLEM", 238, 264], ["sepsis", "PROBLEM", 289, 295], ["protective T cell immunity", "TREATMENT", 366, 392], ["the emergent cytokine storm", "TREATMENT", 412, 439], ["massive", "OBSERVATION_MODIFIER", 42, 49], ["hyperinflammation", "OBSERVATION", 50, 67]]], ["In fact, severe COVID-19 has appeared as a peculiar clinicopathologic entity-yet poorly understood from a mechanistic viewpoint-which however, by definition, may represent a novel form of viral sepsis, being characterized by (a) T cell deficiencies, with early and progressive lymphopenia; (b) systemic hyperinflammation, with a peculiar time-course, often increasing at a late phase, when coagulopathy and fatal organ damage may eventually occur; and (c) COVID-19-associated coagulopathy, displaying some unique clinical and laboratory findings, compared with either disseminated intravascular coagulation or sepsis-induced coagulopathy [10] .", [["T cell", "ANATOMY", 229, 235], ["organ", "ANATOMY", 413, 418], ["intravascular", "ANATOMY", 581, 594], ["viral sepsis", "DISEASE", 188, 200], ["lymphopenia", "DISEASE", 277, 288], ["hyperinflammation", "DISEASE", 303, 320], ["coagulopathy", "DISEASE", 390, 402], ["organ damage", "DISEASE", 413, 425], ["coagulopathy", "DISEASE", 476, 488], ["intravascular coagulation", "DISEASE", 581, 606], ["sepsis", "DISEASE", 610, 616], ["coagulopathy", "DISEASE", 625, 637], ["T cell", "CELL", 229, 235], ["organ", "ORGAN", 413, 418], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 581, 594], ["severe COVID", "PROBLEM", 9, 21], ["a peculiar clinicopathologic entity", "PROBLEM", 41, 76], ["viral sepsis", "PROBLEM", 188, 200], ["a) T cell deficiencies", "PROBLEM", 226, 248], ["progressive lymphopenia", "PROBLEM", 265, 288], ["(b) systemic hyperinflammation", "PROBLEM", 290, 320], ["coagulopathy", "PROBLEM", 390, 402], ["fatal organ damage", "PROBLEM", 407, 425], ["COVID", "TEST", 456, 461], ["coagulopathy", "PROBLEM", 476, 488], ["disseminated intravascular coagulation", "PROBLEM", 568, 606], ["sepsis", "PROBLEM", 610, 616], ["induced coagulopathy", "PROBLEM", 617, 637], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["may represent", "UNCERTAINTY", 158, 171], ["viral", "OBSERVATION_MODIFIER", 188, 193], ["sepsis", "OBSERVATION", 194, 200], ["cell deficiencies", "OBSERVATION", 231, 248], ["progressive", "OBSERVATION_MODIFIER", 265, 276], ["lymphopenia", "OBSERVATION", 277, 288], ["systemic", "OBSERVATION_MODIFIER", 294, 302], ["hyperinflammation", "OBSERVATION", 303, 320], ["late phase", "OBSERVATION_MODIFIER", 373, 383], ["fatal", "OBSERVATION_MODIFIER", 407, 412], ["organ", "ANATOMY", 413, 418], ["damage", "OBSERVATION", 419, 425], ["coagulopathy", "OBSERVATION", 476, 488], ["disseminated", "OBSERVATION_MODIFIER", 568, 580], ["intravascular coagulation", "OBSERVATION", 581, 606], ["sepsis", "OBSERVATION", 610, 616], ["coagulopathy", "OBSERVATION", 625, 637]]], ["Further investigations are required to shed light on the relationships between these clinic-immunologic features and organ failure, possibly paving the way to the treatment (or even prevention) of severe COVID-19, by modulation of host immune system with targeted immunotherapeutic drugs.BackgroundDuring the last few years, cancer immunotherapy with immune checkpoint inhibitors (ICIs), such as anti-PD1/ PD-L1 and anti-CTLA-4 monoclonal antibodies (e.g., nivolumab and ipilimumab, respectively), has allowed impressive restoration of T cell immunity against neoplastic cells, which commonly induce overexpression of PD-1/CTLA-4 ligands to foster T cell exhaustion/anergy and break anti-tumor immune surveillance.", [["organ", "ANATOMY", 117, 122], ["cancer", "ANATOMY", 325, 331], ["T cell", "ANATOMY", 536, 542], ["neoplastic cells", "ANATOMY", 560, 576], ["T cell", "ANATOMY", 648, 654], ["organ failure", "DISEASE", 117, 130], ["cancer", "DISEASE", 325, 331], ["nivolumab", "CHEMICAL", 457, 466], ["ipilimumab", "CHEMICAL", 471, 481], ["COVID-19", "CHEMICAL", 204, 212], ["ipilimumab", "CHEMICAL", 471, 481], ["organ", "ORGAN", 117, 122], ["cancer", "CANCER", 325, 331], ["PD1", "GENE_OR_GENE_PRODUCT", 401, 404], ["PD-L1", "GENE_OR_GENE_PRODUCT", 406, 411], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 416, 427], ["nivolumab", "SIMPLE_CHEMICAL", 457, 466], ["ipilimumab", "SIMPLE_CHEMICAL", 471, 481], ["T cell", "CELL", 536, 542], ["neoplastic cells", "CELL", 560, 576], ["PD-1", "GENE_OR_GENE_PRODUCT", 618, 622], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 623, 629], ["T cell", "CELL", 648, 654], ["anti-tumor", "CANCER", 683, 693], ["PD1", "PROTEIN", 401, 404], ["PD", "PROTEIN", 406, 408], ["L1", "PROTEIN", 409, 411], ["anti-CTLA-4 monoclonal antibodies", "PROTEIN", 416, 449], ["neoplastic cells", "CELL_TYPE", 560, 576], ["CTLA", "PROTEIN", 623, 627], ["Further investigations", "TEST", 0, 22], ["organ failure", "PROBLEM", 117, 130], ["the treatment", "TREATMENT", 159, 172], ["severe COVID", "PROBLEM", 197, 209], ["host immune system", "TREATMENT", 231, 249], ["targeted immunotherapeutic drugs", "TREATMENT", 255, 287], ["cancer immunotherapy", "TREATMENT", 325, 345], ["immune checkpoint inhibitors", "TREATMENT", 351, 379], ["anti-PD1/ PD", "TREATMENT", 396, 408], ["L1", "TREATMENT", 409, 411], ["anti-CTLA", "TEST", 416, 425], ["4 monoclonal antibodies", "TREATMENT", 426, 449], ["nivolumab", "TREATMENT", 457, 466], ["ipilimumab", "TREATMENT", 471, 481], ["T cell immunity", "TREATMENT", 536, 551], ["neoplastic cells", "PROBLEM", 560, 576], ["PD", "TEST", 618, 620], ["CTLA", "TEST", 623, 627], ["T cell exhaustion", "PROBLEM", 648, 665], ["anergy", "PROBLEM", 666, 672], ["break anti-tumor immune surveillance", "TREATMENT", 677, 713], ["organ", "ANATOMY", 117, 122], ["failure", "OBSERVATION", 123, 130], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["immunotherapeutic drugs", "OBSERVATION", 264, 287], ["cancer", "OBSERVATION", 325, 331], ["L1", "ANATOMY", 409, 411], ["neoplastic cells", "OBSERVATION", 560, 576], ["cell exhaustion", "OBSERVATION", 650, 665]]], ["Intriguingly, several human viruses have been demonstrated to adopt such \"cancer-like\" immune-evasion strategies, mainly by upregulation of PD-L1 in infected cells, in order to hamper antiviral T cell responses and make a productive infection [11] .", [["cancer", "ANATOMY", 74, 80], ["cells", "ANATOMY", 158, 163], ["T cell", "ANATOMY", 194, 200], ["cancer", "DISEASE", 74, 80], ["infection", "DISEASE", 233, 242], ["human", "ORGANISM", 22, 27], ["cancer", "CANCER", 74, 80], ["PD-L1", "GENE_OR_GENE_PRODUCT", 140, 145], ["cells", "CELL", 158, 163], ["T cell", "CELL", 194, 200], ["PD-L1", "PROTEIN", 140, 145], ["infected cells", "CELL_TYPE", 149, 163], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["several human viruses", "PROBLEM", 14, 35], ["such \"cancer", "PROBLEM", 68, 80], ["immune-evasion strategies", "TREATMENT", 87, 112], ["PD-L1 in infected cells", "TREATMENT", 140, 163], ["antiviral T cell responses", "TREATMENT", 184, 210], ["a productive infection", "PROBLEM", 220, 242], ["viruses", "OBSERVATION", 28, 35], ["infected cells", "OBSERVATION", 149, 163], ["productive", "OBSERVATION_MODIFIER", 222, 232], ["infection", "OBSERVATION", 233, 242]]], ["Recently, in the attempt to improve antiviral T cell immunity in COVID-19 patients, clinical trials have started to test such T cell activating treatments.", [["T cell", "ANATOMY", 46, 52], ["T cell", "ANATOMY", 126, 132], ["T cell", "CELL", 46, 52], ["COVID-19", "CELL", 65, 73], ["patients", "ORGANISM", 74, 82], ["T cell", "CELL", 126, 132], ["patients", "SPECIES", 74, 82], ["antiviral T cell immunity", "TREATMENT", 36, 61], ["clinical trials", "TREATMENT", 84, 99], ["T cell activating treatments", "TREATMENT", 126, 154]]], ["Of note, an ongoing Spanish phase 2 study (NCT04335305) seems the first to evaluate the attractive strategy of combining anti-cytokine treatments with ICIs (namely, tocilizumab plus pembrolizumab).", [["ICIs", "CHEMICAL", 151, 155], ["tocilizumab", "CHEMICAL", 165, 176], ["pembrolizumab", "CHEMICAL", 182, 195], ["pembrolizumab", "CHEMICAL", 182, 195], ["anti-cytokine", "SIMPLE_CHEMICAL", 121, 134], ["ICIs", "SIMPLE_CHEMICAL", 151, 155], ["tocilizumab", "SIMPLE_CHEMICAL", 165, 176], ["pembrolizumab", "SIMPLE_CHEMICAL", 182, 195], ["combining anti-cytokine treatments", "TREATMENT", 111, 145], ["ICIs (namely, tocilizumab plus pembrolizumab", "TREATMENT", 151, 195]]], ["Alongside monoclonal antibodies activating T lymphocytes, it has also been suggested that the infusion of SARS-CoV-2-specific cytotoxic T lymphocytes, deriving from HLA-matched convalescent donors, could be explored as innovative cell therapy for COVID-19 [12] .", [["T lymphocytes", "ANATOMY", 43, 56], ["cytotoxic T lymphocytes", "ANATOMY", 126, 149], ["cell", "ANATOMY", 230, 234], ["SARS", "DISEASE", 106, 110], ["COVID-19", "CHEMICAL", 247, 255], ["T lymphocytes", "CELL", 43, 56], ["SARS-CoV-2", "ORGANISM", 106, 116], ["cytotoxic T lymphocytes", "CELL", 126, 149], ["convalescent", "ORGANISM", 177, 189], ["donors", "ORGANISM", 190, 196], ["cell", "CELL", 230, 234], ["monoclonal antibodies", "PROTEIN", 10, 31], ["T lymphocytes", "CELL_TYPE", 43, 56], ["cytotoxic T lymphocytes", "CELL_TYPE", 126, 149], ["Alongside monoclonal antibodies activating T lymphocytes", "PROBLEM", 0, 56], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["specific cytotoxic T lymphocytes", "PROBLEM", 117, 149], ["HLA", "TEST", 165, 168], ["convalescent donors", "TREATMENT", 177, 196], ["innovative cell therapy", "TREATMENT", 219, 242], ["COVID", "TEST", 247, 252]]], ["Actually, to maximize potential benefits of different immunotherapeutic approaches against COVID-19, adequate patients' selection is warranted, possibly performed on the basis of putative biomarkers and immune profiles predictive of response.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["different immunotherapeutic approaches", "TREATMENT", 44, 82], ["COVID", "TEST", 91, 96], ["putative biomarkers", "TEST", 179, 198]]], ["In addition, by considering the typical disease course, often prolonged for several weeks, the optimal timing for these treatments should be defined.BackgroundThus, it seems conceivable that, during SARS-CoV-2 infection, especially in elderly patients and less frequently in young people, something can go wrong at the delicate interface between effective viral clearance and T cell tolerance.", [["T cell", "ANATOMY", 376, 382], ["SARS-CoV-2 infection", "DISEASE", 199, 219], ["SARS-CoV-2", "ORGANISM", 199, 209], ["patients", "ORGANISM", 243, 251], ["people", "ORGANISM", 281, 287], ["T cell", "CELL", 376, 382], ["patients", "SPECIES", 243, 251], ["people", "SPECIES", 281, 287], ["SARS-CoV-2", "SPECIES", 199, 209], ["these treatments", "TREATMENT", 114, 130], ["SARS", "PROBLEM", 199, 203], ["CoV-2 infection", "PROBLEM", 204, 219], ["typical", "OBSERVATION_MODIFIER", 32, 39], ["disease", "OBSERVATION", 40, 47], ["infection", "OBSERVATION", 210, 219]]], ["Indeed, COVID-19 may be characterized by different clinical pictures, ranging from almost asymptomatic/mild infections in children and young individuals to lethal \"sepsis-like\" illness with SARS, particularly in advanced age.", [["infections", "DISEASE", 108, 118], ["sepsis", "DISEASE", 164, 170], ["SARS", "DISEASE", 190, 194], ["COVID-19", "GENE_OR_GENE_PRODUCT", 8, 16], ["children", "ORGANISM", 122, 130], ["COVID-19", "DNA", 8, 16], ["children", "SPECIES", 122, 130], ["COVID", "TEST", 8, 13], ["mild infections", "PROBLEM", 103, 118], ["lethal \"sepsis", "PROBLEM", 156, 170], ["SARS", "PROBLEM", 190, 194], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["infections", "OBSERVATION", 108, 118], ["sepsis", "OBSERVATION", 164, 170]]], ["What differs between these two distinct stages of life, with regard to the antiviral response toward SARS-CoV-2 infection?", [["SARS-CoV-2 infection", "DISEASE", 101, 121], ["SARS-CoV-2", "ORGANISM", 101, 111], ["SARS-CoV-2", "SPECIES", 101, 111], ["the antiviral response", "PROBLEM", 71, 93], ["SARS", "PROBLEM", 101, 105], ["CoV-2 infection", "PROBLEM", 106, 121], ["infection", "OBSERVATION", 112, 121]]], ["Generally, in young subjects and even more in children, T cell immunity is known to be more pronounced and active, especially in terms of lymphocyte counts and adequate antiviral responses, while aged individuals typically undergo a well-described decline in T cell functions, which correlates with higher susceptibility to lifethreatening infections, autoimmunity, and cancer [13] .", [["T cell", "ANATOMY", 56, 62], ["lymphocyte", "ANATOMY", 138, 148], ["T cell", "ANATOMY", 259, 265], ["cancer", "ANATOMY", 370, 376], ["infections", "DISEASE", 340, 350], ["autoimmunity", "DISEASE", 352, 364], ["cancer", "DISEASE", 370, 376], ["children", "ORGANISM", 46, 54], ["T cell", "CELL", 56, 62], ["lymphocyte", "CELL", 138, 148], ["T cell", "CELL", 259, 265], ["cancer", "CANCER", 370, 376], ["children", "SPECIES", 46, 54], ["lymphocyte counts", "TEST", 138, 155], ["a well-described decline in T cell functions", "PROBLEM", 231, 275], ["higher susceptibility to lifethreatening infections", "PROBLEM", 299, 350], ["autoimmunity", "PROBLEM", 352, 364], ["cancer", "PROBLEM", 370, 376], ["more pronounced", "OBSERVATION_MODIFIER", 87, 102], ["active", "OBSERVATION_MODIFIER", 107, 113], ["well-described", "OBSERVATION_MODIFIER", 233, 247], ["cell functions", "OBSERVATION", 261, 275]]], ["Susceptibility to SARS-CoV-2 infection, related to the different functions and proportions of CD27 dull and Fig. 1 Working model for COVID-19 immunopathogenesis and related immunomodulatory treatments.", [["SARS", "DISEASE", 18, 22], ["infection", "DISEASE", 29, 38], ["SARS-CoV-2", "ORGANISM", 18, 28], ["CD27", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD27", "PROTEIN", 94, 98], ["CoV-2", "SPECIES", 23, 28], ["SARS-CoV-2", "SPECIES", 18, 28], ["SARS", "TEST", 18, 22], ["2 infection", "PROBLEM", 27, 38], ["CD27 dull", "PROBLEM", 94, 103], ["COVID", "TEST", 133, 138], ["immunopathogenesis", "PROBLEM", 142, 160], ["immunomodulatory treatments", "TREATMENT", 173, 200], ["infection", "OBSERVATION", 29, 38], ["CD27 dull", "OBSERVATION", 94, 103], ["immunomodulatory treatments", "OBSERVATION", 173, 200]]], ["Acronyms: SARS-CoV-2 severe acute respiratory syndrome-coronavirus-2, SARS severe acute respiratory syndrome, SIRS severe inflammatory response syndrome, sHLH secondary hemophagocytic lymphohistiocytosis, MAS macrophage activation syndrome, CRS cytokine release syndrome, KICS Kaposi sarcoma herpesvirusassociated inflammatory cytokine syndrome, COVID-19 coronavirus disease-19, DIC disseminated intravascular coagulation CD27 bright memory B cells, throughout life, has also recently been suggested [14] .BackgroundIn the fight against SARS-CoV-2 pandemic, a more comprehensive vision of COVID-19 immunopathogenesis and related clinical manifestations is warranted to reconcile COVID-19 hyper-inflammatory features-similarly observed in sepsis, sHLH/MAS, and cytokine release syndrome (CRS) [3] induced by chimeric antigen receptor (CAR) T cell therapy, as well as in Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome (KICS) [15] occurring in immunocompromised patients-with a renewed pivotal role played by the impairment of antiviral T cell functions.", [["intravascular", "ANATOMY", 396, 409], ["memory B cells", "ANATOMY", 434, 448], ["T cell", "ANATOMY", 839, 845], ["T cell", "ANATOMY", 1056, 1062], ["SARS", "DISEASE", 10, 14], ["acute respiratory syndrome-coronavirus", "DISEASE", 28, 66], ["SARS", "DISEASE", 70, 74], ["acute respiratory syndrome", "DISEASE", 82, 108], ["SIRS", "DISEASE", 110, 114], ["inflammatory response syndrome", "DISEASE", 122, 152], ["hemophagocytic lymphohistiocytosis", "DISEASE", 169, 203], ["Kaposi sarcoma", "DISEASE", 277, 291], ["coronavirus disease", "DISEASE", 355, 374], ["DIC", "DISEASE", 379, 382], ["intravascular coagulation", "DISEASE", 396, 421], ["SARS-CoV-2 pandemic", "DISEASE", 537, 556], ["sepsis", "DISEASE", 738, 744], ["CRS", "DISEASE", 787, 790], ["Kaposi sarcoma", "DISEASE", 869, 883], ["KICS", "DISEASE", 939, 943], ["SARS-CoV-2", "ORGANISM", 10, 20], ["COVID-19 coronavirus", "ORGANISM", 346, 366], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 396, 409], ["CD27", "GENE_OR_GENE_PRODUCT", 422, 426], ["memory B cells", "CELL", 434, 448], ["SARS-CoV-2", "ORGANISM", 537, 547], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 807, 832], ["Kaposi sarcoma herpesvirus", "ORGANISM", 869, 895], ["patients", "ORGANISM", 981, 989], ["T cell", "CELL", 1056, 1062], ["cytokine", "PROTEIN", 245, 253], ["cytokine", "PROTEIN", 327, 335], ["CD27", "PROTEIN", 422, 426], ["memory B cells", "CELL_TYPE", 434, 448], ["cytokine", "PROTEIN", 760, 768], ["chimeric antigen receptor", "PROTEIN", 807, 832], ["CAR", "PROTEIN", 834, 837], ["-coronavirus", "SPECIES", 54, 66], ["Kaposi sarcoma herpesvirus", "SPECIES", 869, 895], ["patients", "SPECIES", 981, 989], ["SARS-CoV-2 severe acute respiratory syndrome-coronavirus", "SPECIES", 10, 66], ["COVID-19 coronavirus", "SPECIES", 346, 366], ["SARS-CoV", "SPECIES", 537, 545], ["Kaposi sarcoma herpesvirus", "SPECIES", 869, 895], ["SARS", "PROBLEM", 10, 14], ["CoV", "TEST", 15, 18], ["severe acute respiratory syndrome", "PROBLEM", 21, 54], ["coronavirus", "PROBLEM", 55, 66], ["SARS severe acute respiratory syndrome", "PROBLEM", 70, 108], ["SIRS severe inflammatory response syndrome", "PROBLEM", 110, 152], ["sHLH", "PROBLEM", 154, 158], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 169, 203], ["MAS macrophage activation syndrome", "PROBLEM", 205, 239], ["CRS cytokine release syndrome", "PROBLEM", 241, 270], ["KICS Kaposi sarcoma", "PROBLEM", 272, 291], ["inflammatory cytokine syndrome", "PROBLEM", 314, 344], ["COVID", "TEST", 346, 351], ["coronavirus disease", "PROBLEM", 355, 374], ["DIC disseminated intravascular coagulation", "PROBLEM", 379, 421], ["SARS", "PROBLEM", 537, 541], ["CoV", "TEST", 542, 545], ["pandemic", "PROBLEM", 548, 556], ["COVID", "TEST", 589, 594], ["clinical manifestations", "PROBLEM", 629, 652], ["COVID", "TEST", 679, 684], ["hyper-inflammatory features", "PROBLEM", 688, 715], ["sepsis", "PROBLEM", 738, 744], ["sHLH", "PROBLEM", 746, 750], ["MAS", "PROBLEM", 751, 754], ["cytokine release syndrome", "PROBLEM", 760, 785], ["chimeric antigen receptor (CAR) T cell therapy", "TREATMENT", 807, 853], ["Kaposi sarcoma herpesvirus", "PROBLEM", 869, 895], ["inflammatory cytokine syndrome", "PROBLEM", 907, 937], ["antiviral T cell functions", "TREATMENT", 1046, 1072], ["SARS", "OBSERVATION", 10, 14], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory syndrome", "OBSERVATION", 34, 54], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory syndrome", "OBSERVATION", 88, 108], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["inflammatory response syndrome", "OBSERVATION", 122, 152], ["secondary", "OBSERVATION_MODIFIER", 159, 168], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 169, 203], ["MAS macrophage activation syndrome", "OBSERVATION", 205, 239], ["Kaposi sarcoma", "OBSERVATION", 277, 291], ["inflammatory cytokine syndrome", "OBSERVATION", 314, 344], ["coronavirus disease", "OBSERVATION", 355, 374], ["disseminated", "OBSERVATION_MODIFIER", 383, 395], ["inflammatory", "OBSERVATION", 694, 706], ["sepsis", "OBSERVATION", 738, 744], ["Kaposi sarcoma", "OBSERVATION", 869, 883], ["inflammatory", "OBSERVATION_MODIFIER", 907, 919], ["cytokine syndrome", "OBSERVATION", 920, 937], ["antiviral T cell", "OBSERVATION", 1046, 1062]]], ["In this perspective (Fig. 1 ), in parallel with targeted immunosuppressive strategies, an effective reversal of T cell impairment by immune-activating treatments should allow to improve viral clearance and promote a better disease control with faster resolution, probably more akin to what naturally occurs in children infected with SARS-CoV-2.BackgroundConclusions SARS-COV-2 has arisen as a new pathogen frequently inducing sepsis-like manifestations in the host.", [["T cell", "ANATOMY", 112, 118], ["SARS", "DISEASE", 333, 337], ["sepsis", "DISEASE", 426, 432], ["T cell", "CELL", 112, 118], ["children", "ORGANISM", 310, 318], ["SARS-CoV-2", "ORGANISM", 333, 343], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 366, 376], ["children", "SPECIES", 310, 318], ["SARS-CoV", "SPECIES", 333, 341], ["targeted immunosuppressive strategies", "TREATMENT", 48, 85], ["T cell impairment", "PROBLEM", 112, 129], ["immune-activating treatments", "TREATMENT", 133, 161], ["viral clearance", "TREATMENT", 186, 201], ["a better disease control", "TREATMENT", 214, 238], ["BackgroundConclusions SARS", "PROBLEM", 344, 370], ["a new pathogen", "PROBLEM", 391, 405], ["sepsis", "PROBLEM", 426, 432], ["cell", "OBSERVATION", 114, 118], ["more akin", "OBSERVATION_MODIFIER", 272, 281], ["sepsis", "OBSERVATION", 426, 432]]], ["Indeed, based on actual evidence showing hyperinflammation as well as T cell deficiencies and coagulation abnormalities, associated with life-threatening organ dysfunction, severe COVID-19 may be well consistent with a clinical diagnosis of viral sepsis, rather than with a mere hyperinflammatory disease.", [["T cell", "ANATOMY", 70, 76], ["organ", "ANATOMY", 154, 159], ["hyperinflammation", "DISEASE", 41, 58], ["coagulation abnormalities", "DISEASE", 94, 119], ["organ dysfunction", "DISEASE", 154, 171], ["viral sepsis", "DISEASE", 241, 253], ["COVID-19", "CHEMICAL", 180, 188], ["T cell", "CELL", 70, 76], ["organ", "ORGAN", 154, 159], ["hyperinflammation", "PROBLEM", 41, 58], ["T cell deficiencies", "PROBLEM", 70, 89], ["coagulation abnormalities", "PROBLEM", 94, 119], ["life-threatening organ dysfunction", "PROBLEM", 137, 171], ["severe COVID", "PROBLEM", 173, 185], ["viral sepsis", "PROBLEM", 241, 253], ["a mere hyperinflammatory disease", "PROBLEM", 272, 304], ["hyperinflammation", "OBSERVATION", 41, 58], ["cell deficiencies", "OBSERVATION", 72, 89], ["dysfunction", "OBSERVATION", 160, 171], ["viral", "OBSERVATION_MODIFIER", 241, 246], ["sepsis", "OBSERVATION", 247, 253], ["hyperinflammatory disease", "OBSERVATION", 279, 304]]], ["This conceptual framing may help to improve clinical management of severe COVID-19 patients, by providing a rationale for the development of novel balanced immunomodulatory approaches, combining both suppressive and activating immunotherapies.", [["COVID", "DISEASE", 74, 79], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["severe COVID", "PROBLEM", 67, 79], ["novel balanced immunomodulatory approaches", "TREATMENT", 141, 183], ["activating immunotherapies", "TREATMENT", 216, 242]]]], "PMC7152063": [["Bacteria ::: Etiology and Pathogenesis", [["Pathogenesis", "DISEASE", 26, 38], ["Pathogenesis", "PROBLEM", 26, 38]]]], "PMC4766880": [["Case ReportOn November 19, 2013, a 32-year-old woman residing in Abu-Dhabi, United Arab Emirates, sought medical care for fever and back pain of 4 days\u2019 duration.", [["fever", "DISEASE", 122, 127], ["back pain", "DISEASE", 132, 141], ["woman", "ORGANISM", 47, 52], ["woman", "SPECIES", 47, 52], ["fever", "PROBLEM", 122, 127], ["back pain", "PROBLEM", 132, 141], ["back", "ANATOMY", 132, 136]]], ["The woman, a school teacher from Jordan, was 32 weeks pregnant; she reported 3 earlier pregnancies (2 live births) and no concurrent conditions.", [["woman", "ORGANISM", 4, 9], ["woman", "SPECIES", 4, 9], ["3 earlier pregnancies", "PROBLEM", 77, 98], ["concurrent conditions", "PROBLEM", 122, 143]]], ["Emergency department (ED) and obstetric physicians suspected urinary tract infection.", [["urinary tract", "ANATOMY", 61, 74], ["urinary tract infection", "DISEASE", 61, 84], ["urinary tract", "ORGANISM_SUBDIVISION", 61, 74], ["urinary tract infection", "PROBLEM", 61, 84], ["urinary tract", "ANATOMY", 61, 74], ["infection", "OBSERVATION", 75, 84]]], ["The patient declined admission but returned to the ED on November 22 with worsening fever, cough, and shortness of breath.", [["fever", "DISEASE", 84, 89], ["cough", "DISEASE", 91, 96], ["shortness of breath", "DISEASE", 102, 121], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["worsening fever", "PROBLEM", 74, 89], ["cough", "PROBLEM", 91, 96], ["shortness of breath", "PROBLEM", 102, 121], ["worsening", "OBSERVATION_MODIFIER", 74, 83], ["fever", "OBSERVATION", 84, 89], ["cough", "OBSERVATION", 91, 96]]], ["She denied recent travel, sick contacts, or animal exposure within the previous 2 weeks.", [["sick contacts", "PROBLEM", 26, 39]]], ["Lung examination results were within normal limits; the patient had no signs of active labor or fetal distress.", [["Lung", "ANATOMY", 0, 4], ["fetal", "ANATOMY", 96, 101], ["fetal distress", "DISEASE", 96, 110], ["Lung", "ORGAN", 0, 4], ["patient", "ORGANISM", 56, 63], ["fetal", "ORGAN", 96, 101], ["patient", "SPECIES", 56, 63], ["Lung examination", "TEST", 0, 16], ["active labor", "PROBLEM", 80, 92], ["fetal distress", "PROBLEM", 96, 110], ["within normal limits", "OBSERVATION", 30, 50], ["no signs of", "UNCERTAINTY", 68, 79], ["active", "OBSERVATION_MODIFIER", 80, 86], ["labor", "OBSERVATION", 87, 92], ["fetal distress", "OBSERVATION", 96, 110]]], ["Chest computed tomography scan revealed bilateral consolidation; pulmonary embolus was not seen.Case ReportThe patient was admitted to the medical unit with suspected community-acquired pneumonia.", [["pulmonary embolus", "ANATOMY", 65, 82], ["pulmonary embolus", "DISEASE", 65, 82], ["pneumonia", "DISEASE", 186, 195], ["pulmonary", "ORGAN", 65, 74], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["Chest computed tomography scan", "TEST", 0, 30], ["bilateral consolidation", "PROBLEM", 40, 63], ["pulmonary embolus", "PROBLEM", 65, 82], ["acquired pneumonia", "PROBLEM", 177, 195], ["bilateral", "ANATOMY_MODIFIER", 40, 49], ["consolidation", "OBSERVATION", 50, 63], ["pulmonary", "ANATOMY", 65, 74], ["embolus", "OBSERVATION", 75, 82], ["not seen", "UNCERTAINTY", 87, 95], ["pneumonia", "OBSERVATION", 186, 195]]], ["Ceftriaxone and azithromycin were initiated.", [["Ceftriaxone", "CHEMICAL", 0, 11], ["azithromycin", "CHEMICAL", 16, 28], ["Ceftriaxone", "CHEMICAL", 0, 11], ["azithromycin", "CHEMICAL", 16, 28], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["azithromycin", "SIMPLE_CHEMICAL", 16, 28], ["Ceftriaxone", "TREATMENT", 0, 11], ["azithromycin", "TREATMENT", 16, 28]]], ["Her condition deteriorated, and on November 23, she was transferred to the intensive care unit (ICU) because of respiratory failure and hypotension.", [["respiratory", "ANATOMY", 112, 123], ["respiratory failure", "DISEASE", 112, 131], ["hypotension", "DISEASE", 136, 147], ["respiratory failure", "PROBLEM", 112, 131], ["hypotension", "PROBLEM", 136, 147], ["deteriorated", "OBSERVATION_MODIFIER", 14, 26], ["respiratory", "ANATOMY", 112, 123], ["failure", "OBSERVATION", 124, 131], ["hypotension", "OBSERVATION", 136, 147]]], ["On November 24, acute respiratory distress syndrome developed, requiring respiratory and hemodynamic support.", [["respiratory", "ANATOMY", 22, 33], ["respiratory", "ANATOMY", 73, 84], ["respiratory distress syndrome", "DISEASE", 22, 51], ["acute respiratory distress syndrome", "PROBLEM", 16, 51], ["respiratory and hemodynamic support", "TREATMENT", 73, 108], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory distress", "OBSERVATION", 22, 42]]], ["Empiric oseltamivir and vancomycin were added to the treatment regimen.", [["oseltamivir", "CHEMICAL", 8, 19], ["vancomycin", "CHEMICAL", 24, 34], ["oseltamivir", "CHEMICAL", 8, 19], ["vancomycin", "CHEMICAL", 24, 34], ["oseltamivir", "SIMPLE_CHEMICAL", 8, 19], ["vancomycin", "SIMPLE_CHEMICAL", 24, 34], ["Empiric oseltamivir", "TREATMENT", 0, 19], ["vancomycin", "TREATMENT", 24, 34], ["the treatment regimen", "TREATMENT", 49, 70]]], ["Later that day, the baby was delivered by caesarean section because the patient was persistently hypoxemic while on maximal ventilator support.", [["hypoxemic", "DISEASE", 97, 106], ["baby", "ORGANISM", 20, 24], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["caesarean section", "TREATMENT", 42, 59], ["persistently hypoxemic", "PROBLEM", 84, 106], ["maximal ventilator support", "TREATMENT", 116, 142], ["hypoxemic", "OBSERVATION", 97, 106]]], ["Transient improvement in oxygenation was noted after the delivery.", [["the delivery", "TREATMENT", 53, 65], ["improvement", "OBSERVATION_MODIFIER", 10, 21], ["oxygenation", "OBSERVATION_MODIFIER", 25, 36]]], ["The newborn, who was noted to be healthy and had Apgar scores of 6 and 8 at 1 and 5 minutes, respectively, had no contact with the mother after birth.Case ReportNasopharyngeal aspirate samples were tested for influenza A(H1N1)pdm09 virus and MERS-CoV by real-time reverse transcription PCR (2), and multiple other laboratory and culture tests were conducted (Table).", [["ReportNasopharyngeal aspirate samples", "ANATOMY", 155, 192], ["ReportNasopharyngeal aspirate samples", "CANCER", 155, 192], ["influenza A(H1N1)pdm09 virus", "ORGANISM", 209, 237], ["MERS-CoV", "ORGANISM", 242, 250], ["H1N1)pdm09 virus", "SPECIES", 221, 237], ["influenza A(H1N1)pdm09 virus", "SPECIES", 209, 237], ["MERS-CoV", "SPECIES", 242, 250], ["Apgar scores", "TEST", 49, 61], ["Case ReportNasopharyngeal aspirate samples", "TEST", 150, 192], ["influenza", "PROBLEM", 209, 218], ["pdm09 virus", "PROBLEM", 226, 237], ["MERS", "TEST", 242, 246], ["transcription PCR", "TEST", 272, 289], ["culture tests", "TEST", 329, 342]]], ["Most yielded negative results, but on November 25, the regional laboratory reported the MERS-CoV real-time reverse transcription PCR results were positive.", [["the MERS", "TEST", 84, 92], ["CoV real", "TEST", 93, 101], ["reverse transcription PCR", "TEST", 107, 132]]], ["Laboratory testing was done by qualitative assay, using the 2012 novel human CoV (human coronavirus\u2013Erasmus Medical Center).", [["human", "ORGANISM", 71, 76], ["CoV", "ORGANISM", 77, 80], ["human", "ORGANISM", 82, 87], ["coronavirus", "ORGANISM", 88, 99], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 82, 87], ["coronavirus", "SPECIES", 88, 99], ["human CoV", "SPECIES", 71, 80], ["human coronavirus", "SPECIES", 82, 99], ["Laboratory testing", "TEST", 0, 18], ["qualitative assay", "TEST", 31, 48], ["human CoV (human coronavirus", "TREATMENT", 71, 99]]], ["The assay, performed according to a previously described method (3), contains reagents and enzyme for specific amplification of the region upstream of the envelope gene in the CoV genome.Case ReportOn November 26, oral ribavirin (400 mg and 600 mg morning and evening, respectively) and subcutaneous peginterferon-\u03b1 (180 \u00b5g 1\u00d7/wk) were initiated.", [["oral", "ANATOMY", 214, 218], ["ribavirin", "CHEMICAL", 219, 228], ["peginterferon-\u03b1", "CHEMICAL", 300, 315], ["ribavirin", "CHEMICAL", 219, 228], ["CoV", "ORGANISM", 176, 179], ["oral", "ORGANISM_SUBDIVISION", 214, 218], ["ribavirin", "SIMPLE_CHEMICAL", 219, 228], ["peginterferon-\u03b1", "SIMPLE_CHEMICAL", 300, 315], ["envelope gene", "DNA", 155, 168], ["CoV genome", "DNA", 176, 186], ["The assay", "TEST", 0, 9], ["enzyme", "TEST", 91, 97], ["oral ribavirin", "TREATMENT", 214, 228], ["subcutaneous peginterferon", "TREATMENT", 287, 313], ["envelope gene", "OBSERVATION", 155, 168], ["CoV genome", "OBSERVATION", 176, 186]]], ["On November 27, ribavirin was increased to 1,200 mg every 8 hours, and meropenem was begun.", [["ribavirin", "CHEMICAL", 16, 25], ["meropenem", "CHEMICAL", 71, 80], ["ribavirin", "CHEMICAL", 16, 25], ["meropenem", "CHEMICAL", 71, 80], ["ribavirin", "SIMPLE_CHEMICAL", 16, 25], ["meropenem", "SIMPLE_CHEMICAL", 71, 80], ["ribavirin", "TREATMENT", 16, 25], ["meropenem", "TREATMENT", 71, 80]]], ["Septic shock developed in the patient, requiring maximal vasopressors and ventilator support.", [["Septic shock", "DISEASE", 0, 12], ["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["Septic shock", "PROBLEM", 0, 12], ["maximal vasopressors", "TREATMENT", 49, 69], ["ventilator support", "TREATMENT", 74, 92], ["shock", "OBSERVATION", 7, 12], ["ventilator support", "OBSERVATION", 74, 92]]], ["Despite intensive support, the patient\u2019s condition continued to deteriorate; she died on December 2.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["intensive support", "TREATMENT", 8, 25]]], ["Cultures of blood, tracheal aspirate, and urine obtained on the day of death showed no growth; a chest radiograph revealed improvement in pulmonary edema and consolidation.Case ReportOn November 21, MERS-CoV pneumonia developed in the patient\u2019s husband.", [["blood", "ANATOMY", 12, 17], ["tracheal aspirate", "ANATOMY", 19, 36], ["urine", "ANATOMY", 42, 47], ["chest", "ANATOMY", 97, 102], ["pulmonary", "ANATOMY", 138, 147], ["death", "DISEASE", 71, 76], ["pulmonary edema", "DISEASE", 138, 153], ["pneumonia", "DISEASE", 208, 217], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 19, 36], ["urine", "ORGANISM_SUBSTANCE", 42, 47], ["pulmonary", "ORGAN", 138, 147], ["MERS-CoV", "ORGANISM", 199, 207], ["patient", "ORGANISM", 235, 242], ["patient", "SPECIES", 235, 242], ["Cultures", "TEST", 0, 8], ["blood", "TEST", 12, 17], ["tracheal aspirate", "TEST", 19, 36], ["urine", "TEST", 42, 47], ["a chest radiograph", "TEST", 95, 113], ["pulmonary edema", "PROBLEM", 138, 153], ["consolidation", "PROBLEM", 158, 171], ["CoV pneumonia", "PROBLEM", 204, 217], ["blood", "ANATOMY", 12, 17], ["tracheal", "ANATOMY", 19, 27], ["aspirate", "OBSERVATION", 28, 36], ["no", "UNCERTAINTY", 84, 86], ["chest", "ANATOMY", 97, 102], ["improvement", "OBSERVATION_MODIFIER", 123, 134], ["pulmonary", "ANATOMY", 138, 147], ["edema", "OBSERVATION", 148, 153], ["consolidation", "OBSERVATION", 158, 171], ["pneumonia", "OBSERVATION", 208, 217]]], ["He had no concurrent conditions and fully recovered after receiving an antimicrobial drug regimen similar to his wife\u2019s at a different facility.", [["concurrent conditions", "PROBLEM", 10, 31], ["an antimicrobial drug regimen", "TREATMENT", 68, 97], ["no", "UNCERTAINTY", 7, 9]]], ["The husband subsequently reported that he and his wife had visited a cattle farm (goats, sheep, and camels) 10 days before becoming sick (4) (Figure) but had not consumed camel meat or milk.", [["meat", "ANATOMY", 177, 181], ["milk", "ANATOMY", 185, 189], ["goats", "ORGANISM_SUBDIVISION", 82, 87], ["sheep", "ORGANISM_SUBDIVISION", 89, 94], ["camel", "ORGANISM", 171, 176], ["meat", "ORGANISM_SUBDIVISION", 177, 181], ["milk", "ORGANISM_SUBSTANCE", 185, 189], ["cattle", "SPECIES", 69, 75], ["goats", "SPECIES", 82, 87], ["sheep", "SPECIES", 89, 94], ["camel", "SPECIES", 171, 176], ["cattle", "SPECIES", 69, 75], ["goats", "SPECIES", 82, 87], ["sheep", "SPECIES", 89, 94], ["camel", "SPECIES", 171, 176]]], ["In addition, a mild cough without fever or other symptoms developed in the patient\u2019s 8-year-old son; MERS-CoV PCR testing of nasopharyngeal aspirate from the boy was positive.", [["nasopharyngeal aspirate", "ANATOMY", 125, 148], ["cough", "DISEASE", 20, 25], ["fever", "DISEASE", 34, 39], ["patient", "ORGANISM", 75, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 125, 148], ["boy", "ORGANISM", 158, 161], ["patient", "SPECIES", 75, 82], ["boy", "SPECIES", 158, 161], ["a mild cough", "PROBLEM", 13, 25], ["fever", "PROBLEM", 34, 39], ["other symptoms", "PROBLEM", 43, 57], ["CoV PCR testing", "TEST", 106, 121], ["nasopharyngeal aspirate", "TEST", 125, 148], ["mild", "OBSERVATION_MODIFIER", 15, 19], ["cough", "OBSERVATION", 20, 25], ["nasopharyngeal", "ANATOMY", 125, 139], ["aspirate", "OBSERVATION", 140, 148]]], ["He recovered uneventfully without intervention.", [["He", "ORGANISM", 0, 2], ["intervention", "TREATMENT", 34, 46]]], ["The younger sibling and newborn remained asymptomatic and tested negative for MERS-CoV.Case ReportPatients infected with MERS-CoV typically show signs of respiratory illness (2) and sometimes diarrhea.", [["respiratory", "ANATOMY", 154, 165], ["respiratory illness", "DISEASE", 154, 173], ["diarrhea", "DISEASE", 192, 200], ["newborn", "ORGANISM", 24, 31], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["MERS-CoV", "ORGANISM", 121, 129], ["MERS-CoV", "PROTEIN", 78, 86], ["MERS-CoV", "SPECIES", 78, 86], ["MERS-CoV", "SPECIES", 121, 129], ["asymptomatic", "PROBLEM", 41, 53], ["MERS", "PROBLEM", 78, 82], ["CoV", "PROBLEM", 83, 86], ["respiratory illness", "PROBLEM", 154, 173], ["sometimes diarrhea", "PROBLEM", 182, 200], ["respiratory illness", "OBSERVATION", 154, 173], ["diarrhea", "OBSERVATION", 192, 200]]], ["Complications include acute renal failure and acute respiratory distress syndrome with shock.", [["renal", "ANATOMY", 28, 33], ["respiratory", "ANATOMY", 52, 63], ["acute renal failure", "DISEASE", 22, 41], ["acute respiratory distress syndrome", "DISEASE", 46, 81], ["shock", "DISEASE", 87, 92], ["renal", "ORGAN", 28, 33], ["acute renal failure", "PROBLEM", 22, 41], ["acute respiratory distress syndrome", "PROBLEM", 46, 81], ["shock", "PROBLEM", 87, 92], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["renal", "ANATOMY", 28, 33], ["failure", "OBSERVATION", 34, 41], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory distress", "OBSERVATION", 52, 72], ["syndrome", "OBSERVATION", 73, 81], ["shock", "OBSERVATION", 87, 92]]], ["Immunocompromised patients may have atypical signs and symptoms.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["atypical signs and symptoms", "PROBLEM", 36, 63]]], ["Furthermore, several issues are relevant to MERS-CoV and other infectious diseases acquired during pregnancy: 1) pregnancy is associated with immunologic changes that may alter susceptibility to and severity of infectious diseases; 2) the effects of infection upon the fetus are not fully understood; and 3) prophylaxis and treatment appropriate for the general population might not be appropriate for pregnant women (5\u20138).", [["fetus", "ANATOMY", 269, 274], ["infectious diseases", "DISEASE", 63, 82], ["infectious diseases", "DISEASE", 211, 230], ["infection", "DISEASE", 250, 259], ["MERS-CoV", "ORGANISM", 44, 52], ["fetus", "ORGAN", 269, 274], ["women", "ORGANISM", 411, 416], ["women", "SPECIES", 411, 416], ["MERS-CoV", "SPECIES", 44, 52], ["other infectious diseases", "PROBLEM", 57, 82], ["pregnancy", "PROBLEM", 113, 122], ["immunologic changes", "PROBLEM", 142, 161], ["infectious diseases", "PROBLEM", 211, 230], ["infection", "PROBLEM", 250, 259], ["prophylaxis", "TREATMENT", 308, 319], ["treatment", "TREATMENT", 324, 333], ["the general population", "PROBLEM", 350, 372], ["infectious", "OBSERVATION", 211, 221], ["infection", "OBSERVATION", 250, 259]]], ["When the pregnant patient in our study sought medical care, she had atypical symptoms (fever and back pain, followed later by cough and shortness of breath).", [["back", "ANATOMY", 97, 101], ["fever", "DISEASE", 87, 92], ["back pain", "DISEASE", 97, 106], ["cough", "DISEASE", 126, 131], ["shortness of breath", "DISEASE", 136, 155], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["atypical symptoms", "PROBLEM", 68, 85], ["fever", "PROBLEM", 87, 92], ["back pain", "PROBLEM", 97, 106], ["cough", "PROBLEM", 126, 131], ["shortness of breath", "PROBLEM", 136, 155], ["back", "ANATOMY", 97, 101]]], ["It is unclear if the delay in initiating antimicrobial therapy may have contributed to the fatal outcome.Case ReportMERS-CoV infection developed in 2 of the patient\u2019s 4 other family members, an outcome compatible with the description of other small clusters among household members and close contacts.", [["infection", "DISEASE", 125, 134], ["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["the delay", "PROBLEM", 17, 26], ["antimicrobial therapy", "TREATMENT", 41, 62], ["the fatal outcome", "PROBLEM", 87, 104], ["Case ReportMERS-CoV infection", "PROBLEM", 105, 134], ["fatal", "OBSERVATION_MODIFIER", 91, 96], ["infection", "OBSERVATION", 125, 134]]], ["The spectrum of illness and symptomatology among the affected family is also noteworthy: the young child was mildly sick, whereas the pregnant mother died.", [["illness", "DISEASE", 16, 23], ["child", "ORGANISM", 99, 104], ["illness", "PROBLEM", 16, 23], ["symptomatology", "PROBLEM", 28, 42], ["mildly sick", "PROBLEM", 109, 120]]], ["This discrepancy in disease severity correlates with findings from other reports (9,10).Case ReportNo MERS-CoV transmission was documented between the patient and hospital staff; thus, the staff\u2019s use of contact and droplet precautions, including airborne precautions while performing aerosol-generating procedures, seems to have been effective (11,12).", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["This discrepancy in disease severity", "PROBLEM", 0, 36], ["droplet precautions", "TREATMENT", 216, 235], ["airborne precautions", "TREATMENT", 247, 267], ["aerosol-generating procedures", "TREATMENT", 285, 314], ["disease", "OBSERVATION", 20, 27]]], ["Of note, these precautions were implemented after the patient was transferred to the ICU.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["these precautions", "TREATMENT", 9, 26]]], ["No symptoms developed, and all staff tested negative for MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 57, 75], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["MERS-CoV", "SPECIES", 57, 65], ["symptoms", "PROBLEM", 3, 11], ["MERS", "PROBLEM", 57, 61], ["CoV infection", "PROBLEM", 62, 75], ["symptoms", "OBSERVATION", 3, 11], ["CoV", "ANATOMY", 62, 65], ["infection", "OBSERVATION", 66, 75]]], ["The lack of cross transmission in the exposed healthcare workers before implementation of protective measures supports the benefit of using standard precautions and the fact that transmission of MERS-CoV between humans remains limited (13).Case ReportAlthough, MERS-CoV infection and pregnancy were a fatal combination for the patient in our study, virus shedding ceased in the patient during therapy with ribavirin and peginterferon-\u03b1.", [["MERS-CoV infection", "DISEASE", 261, 279], ["ribavirin", "CHEMICAL", 406, 415], ["peginterferon-\u03b1.", "CHEMICAL", 420, 436], ["ribavirin", "CHEMICAL", 406, 415], ["MERS-CoV", "ORGANISM", 195, 203], ["humans", "ORGANISM", 212, 218], ["MERS-CoV", "ORGANISM", 261, 269], ["patient", "ORGANISM", 327, 334], ["patient", "ORGANISM", 378, 385], ["ribavirin", "SIMPLE_CHEMICAL", 406, 415], ["peginterferon-\u03b1.", "SIMPLE_CHEMICAL", 420, 436], ["humans", "SPECIES", 212, 218], ["patient", "SPECIES", 327, 334], ["patient", "SPECIES", 378, 385], ["MERS-CoV", "SPECIES", 195, 203], ["humans", "SPECIES", 212, 218], ["MERS-CoV", "SPECIES", 261, 269], ["protective measures", "TREATMENT", 90, 109], ["standard precautions", "TREATMENT", 140, 160], ["CoV infection", "PROBLEM", 266, 279], ["pregnancy", "PROBLEM", 284, 293], ["our study", "TEST", 338, 347], ["virus shedding", "PROBLEM", 349, 363], ["therapy", "TREATMENT", 393, 400], ["ribavirin", "TREATMENT", 406, 415], ["peginterferon", "TREATMENT", 420, 433], ["CoV", "OBSERVATION_MODIFIER", 266, 269], ["infection", "OBSERVATION", 270, 279]]], ["Knowledge about the use of these drugs is limited; thus, further studies are needed to understand the possible safety, efficacy, and optimal dosage and duration of this regimen.", [["these drugs", "TREATMENT", 27, 38], ["further studies", "TEST", 57, 72], ["this regimen", "TREATMENT", 164, 176]]], ["Few data exist regarding the use of ribavirin in pregnant humans; however, the drug is generally contraindicated in pregnancy (14,15) because of evidence of teratogenic and embryocidal effects in animal studies.", [["ribavirin", "CHEMICAL", 36, 45], ["ribavirin", "CHEMICAL", 36, 45], ["ribavirin", "SIMPLE_CHEMICAL", 36, 45], ["humans", "ORGANISM", 58, 64], ["humans", "SPECIES", 58, 64], ["humans", "SPECIES", 58, 64], ["ribavirin", "TREATMENT", 36, 45], ["teratogenic and embryocidal effects", "PROBLEM", 157, 192], ["animal studies", "TEST", 196, 210], ["teratogenic", "OBSERVATION", 157, 168]]], ["The potential role of cyclosporine, intravenous immune globulin, and high-frequency ventilation for treatment of MERS-CoV during pregnancy needs evaluation.Case ReportAfter the baby was delivered, the patient showed transient improvement, with improved oxygenation, followed by progressive worsening of clinical status and death.", [["intravenous", "ANATOMY", 36, 47], ["cyclosporine", "CHEMICAL", 22, 34], ["death", "DISEASE", 323, 328], ["cyclosporine", "CHEMICAL", 22, 34], ["cyclosporine", "SIMPLE_CHEMICAL", 22, 34], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 47], ["immune globulin", "GENE_OR_GENE_PRODUCT", 48, 63], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 113, 121], ["baby", "ORGANISM", 177, 181], ["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["MERS-CoV", "SPECIES", 113, 121], ["cyclosporine", "TREATMENT", 22, 34], ["intravenous immune globulin", "TREATMENT", 36, 63], ["high-frequency ventilation", "TREATMENT", 69, 95], ["MERS", "PROBLEM", 113, 117], ["CoV during pregnancy", "PROBLEM", 118, 138], ["evaluation", "TEST", 145, 155], ["progressive worsening of clinical status", "PROBLEM", 278, 318], ["death", "PROBLEM", 323, 328], ["transient", "OBSERVATION_MODIFIER", 216, 225], ["improvement", "OBSERVATION", 226, 237], ["progressive", "OBSERVATION_MODIFIER", 278, 289], ["worsening", "OBSERVATION_MODIFIER", 290, 299]]], ["It is unclear whether there is a pattern of delayed release of chemokines and activation of inflammatory cascades leading to delayed worsening of the clinical condition.", [["chemokines", "PROTEIN", 63, 73], ["delayed release of chemokines", "PROBLEM", 44, 73], ["inflammatory cascades", "PROBLEM", 92, 113], ["delayed worsening of the clinical condition", "PROBLEM", 125, 168], ["inflammatory", "OBSERVATION_MODIFIER", 92, 104], ["worsening", "OBSERVATION_MODIFIER", 133, 142]]], ["The patient was maintained on broad-spectrum antibacterial drugs with excellent pharmacokinetics.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["broad-spectrum antibacterial drugs", "TREATMENT", 30, 64], ["antibacterial drugs", "OBSERVATION", 45, 64]]], ["All cultures and screening for resistant pathogens remained negative, making it unlikely that the patient succumbed to a superimposed bacterial infection.ConclusionsPregnant women who seek medical care for pneumonia, influenza-like illness, or sepsis on the Arabian Peninsula may benefit from screening for MERS-CoV to ensure early diagnosis and management of this sometimes fatal disease.", [["cultures", "ANATOMY", 4, 12], ["bacterial infection", "DISEASE", 134, 153], ["pneumonia", "DISEASE", 206, 215], ["influenza-like illness", "DISEASE", 217, 239], ["sepsis", "DISEASE", 244, 250], ["patient", "ORGANISM", 98, 105], ["women", "ORGANISM", 174, 179], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 307, 315], ["patient", "SPECIES", 98, 105], ["women", "SPECIES", 174, 179], ["MERS-CoV", "SPECIES", 307, 315], ["All cultures", "TEST", 0, 12], ["screening", "TEST", 17, 26], ["resistant pathogens", "PROBLEM", 31, 50], ["a superimposed bacterial infection", "PROBLEM", 119, 153], ["pneumonia", "PROBLEM", 206, 215], ["influenza", "PROBLEM", 217, 226], ["illness", "PROBLEM", 232, 239], ["sepsis", "PROBLEM", 244, 250], ["screening", "TEST", 293, 302], ["management", "TREATMENT", 346, 356], ["this sometimes fatal disease", "PROBLEM", 360, 388], ["bacterial", "OBSERVATION_MODIFIER", 134, 143], ["infection", "OBSERVATION", 144, 153], ["pneumonia", "OBSERVATION", 206, 215], ["sepsis", "OBSERVATION", 244, 250]]], ["The immunologic and chemokine response to the infection needs close examination to help define the potential therapeutic role of antiinflammatory agents in this disease.ConclusionsMERS-CoV infection and pregnancy were a fatal combination in this case.", [["infection", "DISEASE", 46, 55], ["ConclusionsMERS-CoV infection", "DISEASE", 169, 198], ["ConclusionsMERS-CoV", "GENE_OR_GENE_PRODUCT", 169, 188], ["chemokine", "PROTEIN", 20, 29], ["ConclusionsMERS-CoV", "SPECIES", 169, 188], ["the infection", "PROBLEM", 42, 55], ["close examination", "TEST", 62, 79], ["antiinflammatory agents", "TREATMENT", 129, 152], ["this disease", "PROBLEM", 156, 168], ["ConclusionsMERS", "TEST", 169, 184], ["CoV infection", "PROBLEM", 185, 198], ["pregnancy", "PROBLEM", 203, 212], ["infection", "OBSERVATION", 46, 55], ["CoV", "OBSERVATION_MODIFIER", 185, 188], ["infection", "OBSERVATION", 189, 198]]], ["Death occurred despite treatment with a combined ribavirin and interferon regimen and despite clearance of virus shedding and radiographic evidence of improvement at death.", [["Death", "DISEASE", 0, 5], ["ribavirin", "CHEMICAL", 49, 58], ["interferon regimen", "CHEMICAL", 63, 81], ["death", "DISEASE", 166, 171], ["ribavirin", "CHEMICAL", 49, 58], ["ribavirin", "SIMPLE_CHEMICAL", 49, 58], ["interferon", "PROTEIN", 63, 73], ["Death", "PROBLEM", 0, 5], ["treatment", "TREATMENT", 23, 32], ["a combined ribavirin", "TREATMENT", 38, 58], ["interferon regimen", "TREATMENT", 63, 81], ["virus shedding", "PROBLEM", 107, 121], ["improvement at death", "PROBLEM", 151, 171], ["improvement", "OBSERVATION_MODIFIER", 151, 162]]], ["Thus, this regimen needs to be further studied in pregnant patients with MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 73, 91], ["patients", "ORGANISM", 59, 67], ["MERS-CoV", "ORGANISM", 73, 81], ["patients", "SPECIES", 59, 67], ["MERS-CoV", "SPECIES", 73, 81], ["this regimen", "TREATMENT", 6, 18], ["MERS", "PROBLEM", 73, 77], ["CoV infection", "PROBLEM", 78, 91], ["infection", "OBSERVATION", 82, 91]]]], "PMC2567325": [["BackgroundPublic health emergency (PHE) is an event or events that cause or may cause harm to the health of a community or nation [1].", [["PHE", "CHEMICAL", 35, 38]]], ["To prevent and/or minimize the harm caused by PHE, early detection and management are necessary.", [["PHE", "CHEMICAL", 46, 49], ["PHE", "CHEMICAL", 46, 49], ["PHE", "SIMPLE_CHEMICAL", 46, 49], ["management", "TREATMENT", 71, 81]]], ["As hospitals are the main location for PHE surveillance and treatment, their preparedness is critical for PHE's early detection and management [2].", [["PHE", "CHEMICAL", 39, 42], ["PHE", "CHEMICAL", 106, 109], ["PHE surveillance", "TEST", 39, 55], ["treatment", "TREATMENT", 60, 69]]], ["Evaluating the current status of PHE preparedness within the hospital system is the first step in improving a nation's preparedness for a PHE.", [["PHE", "CHEMICAL", 33, 36], ["PHE", "CHEMICAL", 138, 141]]], ["Yet, there is no national data on China's hospital PHE preparedness capacity aside from two studies that addressed the issues at local level [3,4].", [["PHE", "CHEMICAL", 51, 54], ["two studies", "TEST", 88, 99], ["no", "UNCERTAINTY", 14, 16]]], ["To understand the current status of hospital PHE preparedness in China, a sample survey of hospitals in four representative city/provinces were conducted between November 2004 and March 2005.Study design ::: MethodsThe survey used a cross-sectional study design to survey hospitals in different regions of China.", [["PHE", "CHEMICAL", 45, 48], ["Methods", "TREATMENT", 208, 215], ["a cross-sectional study", "TEST", 231, 254], ["China", "ANATOMY", 306, 311]]], ["Respondents were all secondary and tertiary hospitals(the detail of hospital classification see in appendix) in the city of Beijing and provinces of Shandong, Guangxi, and Hainan.", [["appendix", "ORGAN", 99, 107], ["appendix", "ANATOMY", 99, 107]]], ["The selection of hospitals in these four regions is intended to represent a variety of regional economic status.", [["variety", "OBSERVATION_MODIFIER", 76, 83], ["regional", "OBSERVATION_MODIFIER", 87, 95], ["economic status", "OBSERVATION", 96, 111]]], ["According to the Hospital Classification Method issued by the National Bureau of Statistics of China, the surveyed hospitals included general hospitals, hospitals of traditional Chinese medicine (TCM), hospitals of integrated traditional Chinese medicine and western medicine (TCM-WM), specialized hospitals, community health center, and medical emergency center (the definition of community health center and medical emergency center see in appendix) [6].", [["appendix", "ANATOMY", 442, 450]]], ["The study was approved by the Institutional Review Board (IRB) of the School of Basic Medicine, Peking Union Medical College in Beijing, China.Survey instruments ::: MethodsBased on a literature and government document review, a detailed methodological approach for research framework and questionnaire development was followed to inform the development of this study [3].", [["The study", "TEST", 0, 9], ["this study", "TEST", 357, 367]]], ["The questionnaire and the survey protocol (including field work manual and quality control procedures) were tested by a pilot study.", [["the survey protocol", "TEST", 22, 41], ["a pilot study", "TEST", 118, 131]]], ["For the purpose of this study, we analyzed the data focused on the following nine areas of interest: (1) hospital's demographic data (including region, SARS crisis experience, teaching function, hospital type, and number of medical staff in related departments); (2) hospital PHE preparation (emergency plans, response initiating time, accessibility, and revision and implementation of emergency plan); (3) response to a community PHE (cooperation with local organizations, relationship with the community PHE network, medical treatment, and rescue work in the community); (4) stockpiles of drugs and materials (stockpiles of drugs and other resources and personal protective equipment); (5)PHE detection and identification (syndrome surveillance); (6) procedures for medical treatment (protocol for diagnosis, treatment, and transfer of PHE victims); (7) laboratory diagnosis and management (laboratory regulation and management system, sample disposal and evaluation system, collection and disposal of suspected samples, and diagnosis of pathogen/etiology); (8) staff training (organization of PHE training, current training of medical staff, curriculum development and training effectiveness assessment); and (9) risk communication (organization for communication of risk psychological counseling to victim and medical staff, and communication with public).", [["samples", "ANATOMY", 1014, 1021], ["SARS", "DISEASE", 152, 156], ["PHE", "CHEMICAL", 276, 279], ["PHE", "CHEMICAL", 431, 434], ["PHE", "CHEMICAL", 691, 694], ["this study", "TEST", 19, 29], ["revision", "TREATMENT", 355, 363], ["medical treatment", "TREATMENT", 519, 536], ["drugs", "TREATMENT", 591, 596], ["drugs", "TREATMENT", 626, 631], ["personal protective equipment", "TREATMENT", 656, 685], ["PHE detection", "TEST", 691, 704], ["medical treatment", "TREATMENT", 768, 785], ["treatment", "TREATMENT", 811, 820], ["laboratory regulation", "TEST", 893, 914], ["management system", "TREATMENT", 919, 936], ["evaluation system", "TEST", 958, 975], ["pathogen", "PROBLEM", 1040, 1048], ["PHE training", "TREATMENT", 1096, 1108], ["current training", "TREATMENT", 1110, 1126], ["curriculum development", "TREATMENT", 1145, 1167], ["training effectiveness assessment", "TEST", 1172, 1205]]], ["Excluding aspect 1, items 2\u20139 (covering 88 survey questions) represent 8 types of PHE preparedness capacities.", [["PHE", "CHEMICAL", 82, 85], ["PHE preparedness capacities", "PROBLEM", 82, 109], ["8 types", "OBSERVATION_MODIFIER", 71, 78]]], ["Item scores were calculated by adding together \"yes\" answers.", [["Item scores", "TEST", 0, 11]]], ["Items scores were used as a proxy for measuring PHE preparedness in an institution.", [["PHE", "CHEMICAL", 48, 51], ["measuring PHE preparedness", "TREATMENT", 38, 64]]], ["A total item score was measured by calculating the score across all 8 items.", [["A total item score", "TEST", 0, 18]]], ["The higher the total item score, the better the hospital PHE preparedness capacity.", [["PHE", "CHEMICAL", 57, 60], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["Further analyses were conducted to understand the correlation between preparedness capacity and demographic information.", [["Further analyses", "TEST", 0, 16]]], ["The distribution of the related preparedness capacities across 10 categories of PHE [1] and 15 types of etiology was also assessed.Data collection procedures ::: MethodsA computerized questionnaire stored in a CD was sent to the targeted hospitals accompanied by an official letter from each of the four city and provincial health departments stating the importance of the survey and requiring that each hospital designates a department director to be responsible for coordinating the completion of the questionnaire.", [["PHE", "CHEMICAL", 80, 83], ["PHE", "CHEMICAL", 80, 83], ["the related preparedness capacities", "PROBLEM", 20, 55], ["PHE", "TEST", 80, 83], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["The data from returned questionnaires were then transferred into a database for analysis.Data analysis ::: MethodsA database was set up using Microsoft Excel 2003.", [["The data", "TEST", 0, 8], ["analysis", "TEST", 80, 88], ["Data analysis", "TEST", 89, 102]]], ["Data was checked, cleaned, and analyzed using SPSS software version 11.5.", [["Data", "TEST", 0, 4], ["SPSS software version", "TEST", 46, 67]]], ["Ninety-five percent confidence interval of means (95% CI) was used to describe PHE preparedness capacities.", [["PHE", "CHEMICAL", 79, 82], ["means", "TEST", 43, 48], ["PHE preparedness capacities", "PROBLEM", 79, 106]]], ["Categorical variables were analyzed with frequency and percentage.", [["Categorical variables", "TEST", 0, 21]]], ["Comparisons of mean score of each of eight PHE preparedness capacities among different types of hospitals were performed with P < 0.05 as statistical significance using parameter test (Independent-Samples T Test (two-tailed) or One-way Analysis of Variance) and/or non-parameter test (Mann-Whitney Test or Kruskal-Wallis Test) based on data distribution characteristics and homogeneity.Hospital demographic information ::: ResultsOf analyzed hospitals (318), 29.9% were in Beijing, 24.5% in Shandong, 40.6% in Guangxi and 5.0% in Hainan.", [["PHE", "CHEMICAL", 43, 46], ["mean score", "TEST", 15, 25], ["parameter test", "TEST", 169, 183], ["Samples T Test", "TEST", 197, 211], ["Variance", "TEST", 248, 256], ["non-parameter test", "TEST", 265, 283], ["Kruskal-Wallis Test", "TEST", 306, 325], ["Shandong", "TEST", 491, 499], ["Guangxi", "TEST", 510, 517]]], ["The mean number of physicians and nurses in emergency department and infectious-disease department were 24.3 and 12.0, respectively.", [["infectious-disease", "DISEASE", 69, 87]]], ["Table 1 shows the demographic characteristics of the analyzed hospitals.Hospital PHE preparation (Capacity 1) ::: ResultsOf 318 hospitals, 264(85.2%) had an emergency plan.", [["PHE", "CHEMICAL", 81, 84]]], ["Among the 264 hospitals that had an emergency plan, 92.6% reported that the institution possessed a protocol to initiate the emergency plan, 75.5% had a classification system for different PHE events, 55.3% had evaluated and revised their emergency plan at least once, and 79.6% reported that their emergency plan was accessible to all medical staff.", [["PHE", "CHEMICAL", 189, 192], ["different PHE events", "PROBLEM", 179, 199]]], ["As for organizational preparation, 93.3% of hospitals with an active emergency plan had a command center and designated personnel for PHE situations.", [["organizational preparation", "TREATMENT", 7, 33], ["PHE situations", "PROBLEM", 134, 148]]], ["There were statistical significance among tertiary grade A hospitals (95% CI: 9.8,10.9) and secondary grade B ones(95% CI:7.0,9.3), tertiary grade B hospitals(95% CI:9.8,11.9) and secondary grade B ones.", [["CI", "TEST", 74, 76], ["secondary grade B ones", "PROBLEM", 92, 114], ["CI", "TEST", 119, 121], ["tertiary grade B hospitals", "PROBLEM", 132, 158], ["CI", "TEST", 163, 165], ["secondary grade B ones", "PROBLEM", 180, 202]]], ["Comparison of eight aspects PHE preparedness capacities among different types of hospitals are showed in table 2 and table 3.Response to PHE in community (Capacity 2) ::: ResultsOf all analyzed respondents, 64.2% were designated as the local emergency hospital for PHE patient admissions and 53.0% of them were the designated hospitals to provide medical rescue services during a national disaster.", [["PHE", "CHEMICAL", 28, 31], ["PHE", "CHEMICAL", 137, 140], ["PHE", "CHEMICAL", 265, 268], ["PHE", "CHEMICAL", 137, 140], ["patient", "ORGANISM", 269, 276], ["patient", "SPECIES", 269, 276], ["medical rescue services", "TREATMENT", 347, 370]]], ["Of all analyzed respondents, 97.4% could promptly transport needed medical staff to the PHE field, 84.5% reported that they were prepared to respond to the needs of vulnerable people (including women, children, pregnant women and the disabled) during a PHE, however, only 49.8% had evaluated their ability to increase beds and equipment for PHE.", [["PHE", "CHEMICAL", 253, 256], ["PHE", "CHEMICAL", 341, 344], ["people", "ORGANISM", 176, 182], ["women", "ORGANISM", 194, 199], ["children", "ORGANISM", 201, 209], ["women", "ORGANISM", 220, 225], ["people", "SPECIES", 176, 182], ["women", "SPECIES", 194, 199], ["children", "SPECIES", 201, 209], ["women", "SPECIES", 220, 225]]], ["When performing a PHE preparedness drill, 22.9% of respondents reported that they would invite relevant community organizations to participate.", [["PHE", "CHEMICAL", 18, 21], ["a PHE preparedness drill", "TREATMENT", 16, 40]]], ["With regard to capacity comparison, the statistics test showed: the total item score of hospitals in Beijing(95% CI:5.9,6.9) was lower than that of hospitals in Shandong (95% CI:7.0,7.9) and Guangxi(95% CI:6.7,7.4); the score of teaching hospitals(95% CI:7.0,7.5) was higher than that of non-teaching hospitals(95% CI:5.7,6.6); and the score of tertiary grade A (95% CI:6.8,8.0) and B (95% CI:6.7,8.4) hospitals was higher than that of secondary grade B ones(95% CI:5.4,6.9), respectively.", [["the statistics test", "TEST", 36, 55], ["CI", "TEST", 113, 115], ["CI", "TEST", 175, 177], ["Guangxi", "TEST", 191, 198], ["CI", "TEST", 203, 205], ["CI", "TEST", 252, 254], ["CI", "TEST", 315, 317], ["CI", "TEST", 367, 369], ["B", "TEST", 383, 384], ["CI", "TEST", 390, 392], ["secondary grade B ones", "PROBLEM", 436, 458], ["CI", "TEST", 463, 465]]], ["In regards to other medical materials, 80.1% had stockpiles of materials for responding to PHE.", [["PHE", "CHEMICAL", 91, 94], ["PHE", "CHEMICAL", 91, 94], ["PHE", "SIMPLE_CHEMICAL", 91, 94]]], ["As for the stockpiles of drugs for infectious diseases, about 93.2%, 91.9% and 43.5% of responding hospitals had drug stockpiles for treating infectious diarrhea, influenza and botulismo toxin, respectively.", [["infectious diseases", "DISEASE", 35, 54], ["infectious diarrhea", "DISEASE", 142, 161], ["influenza", "DISEASE", 163, 172], ["botulismo toxin", "SIMPLE_CHEMICAL", 177, 192], ["drugs", "TREATMENT", 25, 30], ["infectious diseases", "PROBLEM", 35, 54], ["drug stockpiles", "TREATMENT", 113, 128], ["infectious diarrhea", "PROBLEM", 142, 161], ["influenza", "PROBLEM", 163, 172], ["botulismo toxin", "PROBLEM", 177, 192]]], ["When hospitals were compared on this item, statistical analysis showed that institutions in Beijing (95% CI:5.8,6.9) had a higher score than that of Shandong (95% CI:6.6,7.9).", [["statistical analysis", "TEST", 43, 63], ["CI", "TEST", 105, 107], ["CI", "TEST", 163, 165]]], ["Tertiary hospitals generally had a higher score than secondary ones.PHE detection and identification (Capacity 4) ::: ResultsAmong all the respondents, 55.5% reported that they had developed syndromic surveillance systems for certain diseases and 84.4% required that physicians on duty should report any abnormity to the hospital's presidents (the definition of abnormity see in appendix).", [["PHE", "CHEMICAL", 68, 71], ["appendix", "ORGAN", 379, 387], ["PHE detection", "TEST", 68, 81], ["syndromic surveillance systems", "PROBLEM", 191, 221], ["certain diseases", "PROBLEM", 226, 242], ["abnormity", "PROBLEM", 362, 371], ["appendix", "ANATOMY", 379, 387]]], ["Abnormity in admission diagnosis, routine microbiological tests, emergency room patients, and death with unknown causes were systematically monitored by 74.6% of institutions and 47.4% of hospitals shared their surveillance information with the local health authority.", [["death", "DISEASE", 94, 99], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["routine microbiological tests", "TEST", 34, 63], ["death", "PROBLEM", 94, 99]]], ["There were statistically significant differences between tertiary grade hospitals (Grade A 95% CI: 5.6,6.6; Grade B 95% CI: 5.6,7.3) and secondary grade B hospitals (95% CI:4.1,5.9) for this capacity, with tertiary hospitals scoring higher on their ability to detect and identify a PHE.Procedures for medical treatment (Capacity 5) ::: ResultsPhysicians in 80.2% of the responding institutions reported being familiarized with the latest treatment protocol for a PHE, 92.8% could transfer PHE victims to corresponding medical agencies for appropriate treatment, and 98.0% could provide training on the protocol system.", [["PHE", "CHEMICAL", 282, 285], ["PHE", "CHEMICAL", 463, 466], ["PHE", "CHEMICAL", 489, 492], ["PHE", "CHEMICAL", 282, 285], ["CI", "TEST", 95, 97], ["Grade B", "TEST", 108, 115], ["CI", "TEST", 120, 122], ["secondary grade B hospitals", "PROBLEM", 137, 164], ["CI", "TEST", 170, 172], ["this capacity", "TEST", 186, 199], ["medical treatment", "TREATMENT", 301, 318], ["the latest treatment protocol", "TREATMENT", 427, 456], ["a PHE", "TEST", 461, 466], ["appropriate treatment", "TREATMENT", 539, 560], ["the protocol system", "TREATMENT", 598, 617], ["statistically", "OBSERVATION_MODIFIER", 11, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["However, only 69.0% had specific procedures for patient transfer in a PHE.", [["PHE", "CHEMICAL", 70, 73], ["PHE", "CHEMICAL", 70, 73], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["As for infectious disease treatment protocol, 80.1% had protocols for SARS, but only 37.3% for brucellosis.", [["infectious disease", "DISEASE", 7, 25], ["SARS", "DISEASE", 70, 74], ["brucellosis", "DISEASE", 95, 106], ["infectious disease treatment protocol", "TREATMENT", 7, 44], ["SARS", "PROBLEM", 70, 74], ["brucellosis", "PROBLEM", 95, 106], ["brucellosis", "OBSERVATION", 95, 106]]], ["With regard to the capacity comparison between evaluated hospitals, statistical analysis revealed that hospitals in Shandong (95% CI:8.8,10.7) and Guangxi (95% CI:8.5,9.8) scored higher than those of Beijing (95% CI:6.5,8.1).", [["statistical analysis", "TEST", 68, 88], ["CI", "TEST", 130, 132], ["Guangxi", "TEST", 147, 154], ["CI", "TEST", 160, 162], ["CI", "TEST", 213, 215]]], ["Furthermore, TCM-WM hospitals (95% CI:8.9,13.7) scored higher than all other types of institutions.", [["CI", "TEST", 35, 37]]], ["Tertiary grade hospitals (Grade A 95% CI:8.2,10.2; Grade B 95% CI: 8.6,11.4) and teaching hospitals (95% CI:8.6,9.6) had better score than secondary grade B (95% CI:5.5,8.3)and non-teaching institutions (95% CI:6.8,8.5), respectively.Laboratory diagnosis and management (Capacity 6) ::: ResultsWe selected 15 kinds of infectious diseases/etiologies on which to assess laboratory diagnosis capacity, medical treatment procedures, and drug stockpile for infectious disease control.", [["infectious diseases", "DISEASE", 318, 337], ["infectious disease", "DISEASE", 452, 470], ["CI", "TEST", 38, 40], ["Grade B", "TEST", 51, 58], ["CI", "TEST", 63, 65], ["CI", "TEST", 105, 107], ["secondary grade B", "PROBLEM", 139, 156], ["CI", "TEST", 162, 164], ["CI", "TEST", 208, 210], ["infectious diseases", "PROBLEM", 318, 337], ["laboratory diagnosis capacity", "TEST", 368, 397], ["medical treatment procedures", "TREATMENT", 399, 427], ["drug stockpile", "TREATMENT", 433, 447], ["infectious disease control", "TREATMENT", 452, 478], ["infectious", "OBSERVATION", 318, 328]]], ["Our results showed that 59.0% of responding hospitals could isolate and identify salmonella and staphylococcus, but less than 5% reported that they could isolate and identify human H5N1 avian flu and SARS.", [["salmonella and staphylococcus", "DISEASE", 81, 110], ["H5N1 avian flu", "DISEASE", 181, 195], ["SARS", "DISEASE", 200, 204], ["human", "ORGANISM", 175, 180], ["H5N1 avian flu", "ORGANISM", 181, 195], ["human", "SPECIES", 175, 180], ["H5N1 avian flu", "SPECIES", 181, 195], ["human H5N1 avian flu", "SPECIES", 175, 195], ["salmonella", "PROBLEM", 81, 91], ["staphylococcus", "PROBLEM", 96, 110], ["SARS", "PROBLEM", 200, 204], ["staphylococcus", "OBSERVATION", 96, 110]]], ["As for the management of laboratory of results, 97.4% of respondents had strict laboratory operational regulations and 96.4% had personnel specially assigned to laboratory management.", [["laboratory management", "TREATMENT", 161, 182]]], ["When faced with an emergency, 76.7% could promptly enlarge the capacity of sample disposal, while only 33.5% had protocols to collect suspected samples.", [["samples", "ANATOMY", 144, 151]]], ["Disposal and transportation of suspected samples capabilities were 33.5% and 32.6%, respectively, but once laboratories were contaminated, only 9.1% had alternatives.", [["samples", "ANATOMY", 41, 48], ["suspected samples capabilities", "TEST", 31, 61], ["laboratories", "TEST", 107, 119]]], ["Statistical analysis showed that tertiary-grade A (95% CI:4.6,5.7) and B (95% CI:4.4,5.9) hospitals and hospitals with experience of SARS patients (95% CI:4.3,5.3) scored higher than those secondary-grade and without experience (95% CI:4.2,4.7), respectively.Staff training (Capacity 7) ::: ResultsAmong all the respondents, 94.5% reported that they had a training program for the following medical staff: infection managers (56.3%); emergency department physicians and nurses (92.2%); and infectious disease ward physicians and nurses (71.8%).", [["SARS", "DISEASE", 133, 137], ["infection", "DISEASE", 406, 415], ["infectious disease", "DISEASE", 490, 508], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["Statistical analysis", "TEST", 0, 20], ["CI", "TEST", 55, 57], ["B", "TEST", 71, 72], ["CI", "TEST", 78, 80], ["SARS", "PROBLEM", 133, 137], ["CI", "TEST", 152, 154], ["CI", "TEST", 233, 235], ["tertiary", "OBSERVATION_MODIFIER", 33, 41], ["without", "UNCERTAINTY", 209, 216]]], ["Staff training was supervised by a designated person in 82.3% of institutions and 65.8% had training curriculums, 66.5% of which was updated regularly.", [["person", "SPECIES", 46, 52]]], ["Effectiveness of PHE training was periodically assessed in 50.3% of respondents.", [["PHE", "CHEMICAL", 17, 20], ["PHE", "CHEMICAL", 17, 20], ["PHE", "SIMPLE_CHEMICAL", 17, 20], ["PHE training", "TREATMENT", 17, 29]]], ["For this capacity, statistical significance indicated that respondents in Shandong (95% CI:5.9,7.0) scored higher than participating institutions in Guangxi (95% CI:5.1,6.0).Risk communication (Capacity 8) ::: ResultsOf all respondents, 45.0% possessed expert panels to advise on PHE psychological counseling for medical staff and PHE victims.", [["PHE", "CHEMICAL", 280, 283], ["PHE", "CHEMICAL", 331, 334], ["this capacity", "PROBLEM", 4, 17], ["CI", "TEST", 88, 90], ["CI", "TEST", 162, 164]]], ["Medical staff in 12.1% of the analyzed hospitals were trained to assess the psychological impact of PHE.", [["PHE", "CHEMICAL", 100, 103], ["PHE", "CHEMICAL", 100, 103], ["PHE", "SIMPLE_CHEMICAL", 100, 103]]], ["If a PHE occurred, participating hospitals could: counsel victims and their family members (43.6%); offer teaching materials (51.0%); access additional psychological consultants (19.3%).", [["PHE", "CHEMICAL", 5, 8]]], ["With regards to communication capabilities, 39.4% of hospitals reported a mass media communication protocol, 43.9% possessed a designated spokesperson to deliver PHE information to the public, and 30.8% possessed personnel specially assigned to communicate information to the media, public, and local governments.", [["PHE", "CHEMICAL", 162, 165], ["communication capabilities", "TEST", 16, 42], ["a mass media communication protocol", "TREATMENT", 72, 107]]], ["Statistical analysis showed that hospitals in Shandong (95% CI:4.6,6.2) scored higher than those in Beijing (95% CI:3.4,4.4), Guangxi (95% CI:3.2,4.1) and Hainan (95% CI:2.2,5.3) on this capacity, with tertiary-grade hospitals (Grade A 95% CI: 4.7,6.0; Grade B 95% CI: 4.2,6.9) reporting better score than secondary ones (Grade A 95% CI: 3.2,4.0; Grade B 95% CI: 2.8,4.8).Comparisons of various PHE contents ::: ResultsFive aspects of preparedness capacities and various PHE events were described in crosstab, as shown in table 5.", [["PHE", "CHEMICAL", 395, 398], ["PHE", "CHEMICAL", 471, 474], ["PHE", "CHEMICAL", 395, 398], ["Statistical analysis", "TEST", 0, 20], ["CI", "TEST", 60, 62], ["CI", "TEST", 113, 115], ["Guangxi", "TEST", 126, 133], ["CI", "TEST", 139, 141], ["Hainan", "TEST", 155, 161], ["CI", "TEST", 167, 169], ["this capacity", "TEST", 182, 195], ["CI", "TEST", 240, 242], ["Grade", "TEST", 253, 258], ["B", "TEST", 259, 260], ["CI", "TEST", 265, 267], ["Grade", "TEST", 322, 327], ["CI", "TEST", 334, 336], ["Grade", "TEST", 347, 352], ["B", "TEST", 353, 354], ["CI", "TEST", 359, 361], ["preparedness capacities", "PROBLEM", 435, 458], ["various PHE events", "PROBLEM", 463, 481]]], ["Among all the respondents, 277 hospitals (95.5%) had emergency plans for infectious epidemics, and 50 ones (20.5%) for biochemical and nuclear terrorism.", [["nuclear", "ANATOMY", 135, 142], ["infectious epidemics", "DISEASE", 73, 93], ["nuclear", "CELLULAR_COMPONENT", 135, 142], ["infectious epidemics", "PROBLEM", 73, 93], ["biochemical and nuclear terrorism", "PROBLEM", 119, 152], ["nuclear terrorism", "OBSERVATION", 135, 152]]], ["Evaluation on infectious epidemic was performed by 93.7%, the percentage was relatively lower for bio-terrorism and nuclear terrorism threats (30.5%), In regards to expert consultation, 28.2% had attended local agency meetings on regulation and revision of emergency plans for infectious epidemic control and 93.3% had the available expert list for consultation on infectious epidemic, however, for terrorism, the percentage was only 23.1%.", [["Evaluation", "TEST", 0, 10], ["infectious epidemic", "PROBLEM", 14, 33], ["nuclear terrorism threats", "TEST", 116, 141], ["infectious epidemic control", "TREATMENT", 277, 304], ["infectious", "OBSERVATION_MODIFIER", 14, 24]]], ["Projects for admitting and treating infectious epidemic victims were common (71%), although only 13.3% of hospitals were involved in similar plans for dealing with bio-terror and nuclear threats.Limitations ::: DiscussionThe study has several limitations.", [["nuclear", "ANATOMY", 179, 186], ["The study", "TEST", 221, 230]]], ["First of all, the surveyed hospitals were restricted to four city and provinces, even some types of hospitals were rare (the number of the surveyed community health center and emergency center was just one, respectively), therefore, the results may not fully represent the PHE capacity of all hospitals in China.", [["PHE", "CHEMICAL", 273, 276]]], ["The inclusion of official documents from respective Health Bureaus, for example, may have encouraged respondents to complete survey but have also been interpreted as an official assessment of capacity leading some hospital representatives to overestimate PHE capacity.", [["PHE", "CHEMICAL", 255, 258], ["an official assessment", "TEST", 166, 188]]], ["Thirdly, only quantitative data were collected to measure certain capacities of PHE preparedness.", [["PHE", "CHEMICAL", 80, 83], ["PHE", "SIMPLE_CHEMICAL", 80, 83], ["quantitative data", "TEST", 14, 31], ["PHE preparedness", "TREATMENT", 80, 96]]], ["To a certain extent, this loss of respondents caused a loss of information.ConclusionAfter several years of construction and development, the capability of hospitals in China to deal with PHE, in particular infectious diseases control, has improved greatly [3,4].", [["PHE", "CHEMICAL", 188, 191], ["infectious diseases", "DISEASE", 207, 226], ["particular infectious diseases control", "PROBLEM", 196, 234], ["certain extent", "OBSERVATION_MODIFIER", 5, 19]]], ["Nevertheless, this research suggests that China has more progress to make before PHE preparedness is satisfactory.", [["PHE", "CHEMICAL", 81, 84], ["satisfactory", "OBSERVATION_MODIFIER", 101, 113]]], ["To enhance hospital preparation for dealing with PHE, governments at all levels should increase investment in the construction of infrastructure to create and sustain appropriate PHE capacity.", [["PHE", "CHEMICAL", 49, 52], ["PHE", "CHEMICAL", 179, 182], ["PHE, governments", "TREATMENT", 49, 65]]], ["On the other hand, hospitals at all levels should enhance their management, including updating and revising of emergency plans; strengthening communication and cooperation with other local agencies; enhancing the capacity of abnormity monitoring and laboratory diagnostic capability for infectious diseases; improving the treatment program for various PHE scenarios; and strengthening psychological intervention and risk communication capabilities.", [["infectious diseases", "DISEASE", 287, 306], ["emergency plans", "TREATMENT", 111, 126], ["abnormity monitoring", "TEST", 225, 245], ["infectious diseases", "PROBLEM", 287, 306], ["the treatment program", "TREATMENT", 318, 339], ["various PHE scenarios", "TREATMENT", 344, 365], ["strengthening psychological intervention", "TREATMENT", 371, 411]]], ["Finally PHE preparedness in relation to terrorism caused by nuclear radiation and bio-chemical substance was low in this study and should be further assessed for areas of need and improvement.AppendixAbnormity: Abnormity means the rapid increase of emergency room patients with acute asthma, flu, fever of unknown causes.AppendixHospital classification: According to \"the hospital classification system\" of the Ministry of Health of People's Republic of China, all hospitals in China are classified into primary, secondary, and tertiary hospitals based on their functions in providing medical care, medical education, and conducting medical research.", [["nuclear", "ANATOMY", 60, 67], ["PHE", "CHEMICAL", 8, 11], ["terrorism", "DISEASE", 40, 49], ["asthma", "DISEASE", 284, 290], ["flu", "DISEASE", 292, 295], ["fever", "DISEASE", 297, 302], ["PHE", "CHEMICAL", 8, 11], ["PHE", "SIMPLE_CHEMICAL", 8, 11], ["nuclear", "CELLULAR_COMPONENT", 60, 67], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["People", "SPECIES", 433, 439], ["terrorism", "PROBLEM", 40, 49], ["nuclear radiation", "TREATMENT", 60, 77], ["bio-chemical substance", "PROBLEM", 82, 104], ["this study", "TEST", 116, 126], ["acute asthma", "PROBLEM", 278, 290], ["flu", "PROBLEM", 292, 295], ["fever", "PROBLEM", 297, 302], ["medical education", "TREATMENT", 599, 616], ["radiation", "OBSERVATION", 68, 77], ["rapid", "OBSERVATION_MODIFIER", 231, 236], ["increase", "OBSERVATION_MODIFIER", 237, 245], ["acute", "OBSERVATION_MODIFIER", 278, 283], ["asthma", "OBSERVATION", 284, 290]]], ["A secondary hospital is defined as a regional hospital that provides comprehensive medical care, medical education, and medical research for the region.", [["comprehensive medical care", "TREATMENT", 69, 95], ["medical education", "TREATMENT", 97, 114]]], ["A tertiary hospital is defined as cross-regional, providing comprehensive and specialized medical care with a high level of medical education and research functions.", [["medical education", "TREATMENT", 124, 141]]], ["Secondary and tertiary hospitals are further classified into subgroups: Grade A, Grade B, and Grade C according to their service levels, size, medical technology, medical equipment, and management and medical quality [27].AppendixCommunity health center: community health center is a kind of primary health care delivery in China, most of which are transferred from secondary grade hospitals, and provide preventive, curative care, maternal and child care, rehabilitation and health education to local inhabitants by general practitioners, community nurses and public health workers.AppendixMedical emergency center: medical emergency center (First Aid Station) is a kind of emergency health care delivery in China, which provide emergency care, first aid, monitoring and treatment for all those patients with pre-hospital emergencies.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsJSH designed the study and developed the tools.", [["patients", "ORGANISM", 796, 804], ["patients", "SPECIES", 796, 804], ["Grade A, Grade B, and Grade C", "PROBLEM", 72, 101], ["medical equipment", "TREATMENT", 163, 180], ["primary health care delivery", "TREATMENT", 292, 320], ["curative care", "TREATMENT", 417, 430], ["maternal and child care", "TREATMENT", 432, 455], ["rehabilitation", "TREATMENT", 457, 471], ["emergency health care delivery", "TREATMENT", 675, 705], ["emergency care", "TREATMENT", 730, 744], ["treatment", "TREATMENT", 772, 781], ["pre-hospital emergencies", "TREATMENT", 810, 834], ["the study", "TEST", 947, 956], ["size", "OBSERVATION_MODIFIER", 137, 141]]], ["HZH participated in design of the study and development of the tools, and supervised the data collection and data entry.", [["HZH", "CHEMICAL", 0, 3], ["the study", "TEST", 30, 39], ["the data collection", "TEST", 85, 104]]], ["XML performed data checkup, data analysis and drafted the manuscript.", [["checkup", "TEST", 19, 26], ["data analysis", "TEST", 28, 41]]], ["All authors participated in discussion, revision and approved of the final manuscript.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication history", [["Pre-publication", "DISEASE", 86, 101], ["pre-publication", "DISEASE", 113, 128], ["Pre-publication", "DISEASE", 173, 188], ["revision", "TREATMENT", 40, 48]]]], "PMC2932768": [["IntroductionPorcine respiratory coronavirus (PRCV) is highly prevalent in pigs in Europe (Laude et al., 1993) and in a serological survey in 2008 in Belgium, 698/728 samples tested positive for PRCV (unpublished data).", [["samples", "ANATOMY", 166, 173], ["respiratory coronavirus", "DISEASE", 20, 43], ["IntroductionPorcine respiratory coronavirus", "ORGANISM", 0, 43], ["PRCV", "ORGANISM", 45, 49], ["pigs", "ORGANISM", 74, 78], ["samples", "CANCER", 166, 173], ["pigs", "SPECIES", 74, 78], ["IntroductionPorcine respiratory coronavirus", "SPECIES", 0, 43], ["PRCV", "SPECIES", 45, 49], ["pigs", "SPECIES", 74, 78], ["PRCV", "SPECIES", 194, 198], ["IntroductionPorcine respiratory coronavirus", "PROBLEM", 0, 43], ["a serological survey", "TEST", 117, 137], ["PRCV", "TEST", 194, 198], ["respiratory coronavirus", "OBSERVATION", 20, 43]]], ["The virus mainly infects the lower respiratory tract, targeting type-2 pneumocytes and, to a lesser extent, bronchiolar epithelium (Atanasova et al., 2008).", [["lower respiratory tract", "ANATOMY", 29, 52], ["type-2 pneumocytes", "ANATOMY", 64, 82], ["bronchiolar epithelium", "ANATOMY", 108, 130], ["lower", "ORGANISM_SUBDIVISION", 29, 34], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["type-2 pneumocytes", "CELL", 64, 82], ["bronchiolar epithelium", "TISSUE", 108, 130], ["The virus mainly infects the lower respiratory tract", "PROBLEM", 0, 52], ["type-2 pneumocytes", "PROBLEM", 64, 82], ["virus", "OBSERVATION", 4, 9], ["lower", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["pneumocytes", "OBSERVATION", 71, 82], ["lesser", "OBSERVATION_MODIFIER", 93, 99], ["extent", "OBSERVATION_MODIFIER", 100, 106], ["bronchiolar epithelium", "ANATOMY", 108, 130]]], ["Although PRCV infection is typically sub-clinical or mild under experimental conditions, it can contribute to naturally occurring respiratory disease, when combined with other viruses or bacteria (Brockmeier et al., 2002).IntroductionBacteria commonly colonise the lower respiratory tract during primary viral infection and their cell-wall components are also present in the dust generated within animal housing (Crook et al., 1991, Donham, 1991, Zhiping et al., 1996, Zucker et al., 2000).", [["respiratory", "ANATOMY", 130, 141], ["lower respiratory tract", "ANATOMY", 265, 288], ["cell", "ANATOMY", 330, 334], ["infection", "DISEASE", 14, 23], ["respiratory disease", "DISEASE", 130, 149], ["primary viral infection", "DISEASE", 296, 319], ["PRCV", "CANCER", 9, 13], ["lower", "ORGANISM_SUBDIVISION", 265, 270], ["respiratory tract", "ORGANISM_SUBDIVISION", 271, 288], ["cell", "CELL", 330, 334], ["PRCV", "SPECIES", 9, 13], ["PRCV infection", "PROBLEM", 9, 23], ["mild under experimental conditions", "PROBLEM", 53, 87], ["naturally occurring respiratory disease", "PROBLEM", 110, 149], ["other viruses", "PROBLEM", 170, 183], ["bacteria", "PROBLEM", 187, 195], ["IntroductionBacteria commonly colonise the lower respiratory tract", "PROBLEM", 222, 288], ["primary viral infection", "PROBLEM", 296, 319], ["infection", "OBSERVATION", 14, 23], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["respiratory disease", "OBSERVATION", 130, 149], ["lower", "ANATOMY_MODIFIER", 265, 270], ["respiratory tract", "ANATOMY", 271, 288], ["viral infection", "OBSERVATION", 304, 319]]], ["Some of the most important inflammatory components of the outer membrane of Gram-negative bacteria are lipopolysaccharides (LPS).", [["outer membrane", "ANATOMY", 58, 72], ["lipopolysaccharides", "CHEMICAL", 103, 122], ["LPS", "CHEMICAL", 124, 127], ["outer membrane", "CELLULAR_COMPONENT", 58, 72], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 103, 122], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["Gram", "TEST", 76, 80], ["lipopolysaccharides", "PROBLEM", 103, 122], ["inflammatory", "OBSERVATION_MODIFIER", 27, 39], ["outer membrane", "ANATOMY", 58, 72], ["negative bacteria", "OBSERVATION", 81, 98], ["lipopolysaccharides", "OBSERVATION_MODIFIER", 103, 122]]], ["PRCV acting in synergy with LPS from Escherichia coli induces severe respiratory disease with excessive production of pro-inflammatory cytokines, such as tumour necrosis factor (TNF)-\u03b1 and interleukin (IL)-1 in the lungs (Van Reeth et al., 2000).IntroductionGram-positive bacteria also release toxins such as lipoteichoic acids (LTA) that stimulate cytokine production (Ginsburg, 2002).", [["respiratory", "ANATOMY", 69, 80], ["lungs", "ANATOMY", 215, 220], ["PRCV", "CHEMICAL", 0, 4], ["LPS", "CHEMICAL", 28, 31], ["respiratory disease", "DISEASE", 69, 88], ["necrosis", "DISEASE", 161, 169], ["lipoteichoic acids", "CHEMICAL", 309, 327], ["LTA", "CHEMICAL", 329, 332], ["lipoteichoic acids", "CHEMICAL", 309, 327], ["PRCV", "SIMPLE_CHEMICAL", 0, 4], ["LPS", "SIMPLE_CHEMICAL", 28, 31], ["Escherichia coli", "ORGANISM", 37, 53], ["tumour necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 154, 184], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 189, 207], ["lungs", "ORGAN", 215, 220], ["lipoteichoic acids", "SIMPLE_CHEMICAL", 309, 327], ["LTA", "SIMPLE_CHEMICAL", 329, 332], ["pro-inflammatory cytokines", "PROTEIN", 118, 144], ["tumour necrosis factor (TNF)-\u03b1", "PROTEIN", 154, 184], ["interleukin (IL)-1", "PROTEIN", 189, 207], ["cytokine", "PROTEIN", 349, 357], ["Escherichia coli", "SPECIES", 37, 53], ["Escherichia coli", "SPECIES", 37, 53], ["LPS", "TREATMENT", 28, 31], ["Escherichia coli", "PROBLEM", 37, 53], ["severe respiratory disease", "PROBLEM", 62, 88], ["pro-inflammatory cytokines", "PROBLEM", 118, 144], ["tumour necrosis factor", "PROBLEM", 154, 176], ["TNF", "TEST", 178, 181], ["interleukin (IL)", "TREATMENT", 189, 205], ["IntroductionGram-positive bacteria", "PROBLEM", 246, 280], ["release toxins", "PROBLEM", 286, 300], ["lipoteichoic acids", "TEST", 309, 327], ["cytokine production", "PROBLEM", 349, 368], ["Escherichia coli", "OBSERVATION", 37, 53], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["respiratory disease", "OBSERVATION", 69, 88], ["excessive", "OBSERVATION_MODIFIER", 94, 103], ["production", "OBSERVATION_MODIFIER", 104, 114], ["pro-inflammatory cytokines", "OBSERVATION", 118, 144], ["tumour", "OBSERVATION_MODIFIER", 154, 160], ["necrosis", "OBSERVATION", 161, 169], ["lungs", "ANATOMY", 215, 220]]], ["Such bacteria and their cell-wall components can make up >80% of the total bacterial content of the dust found in pig housing whereas Gram-negative organisms constitute only 2% (Crook et al., 1991, Donham, 1991).", [["cell-wall components", "ANATOMY", 24, 44], ["cell", "CELL", 24, 28], ["pig", "ORGANISM", 114, 117], ["pig", "SPECIES", 114, 117], ["pig", "SPECIES", 114, 117], ["Such bacteria", "PROBLEM", 0, 13], ["their cell-wall components", "PROBLEM", 18, 44], ["the dust", "PROBLEM", 96, 104], ["Gram", "TEST", 134, 138], ["bacteria", "OBSERVATION", 5, 13], ["wall", "ANATOMY_MODIFIER", 29, 33]]], ["Staphylococcus spp. are among the most widely distributed Gram-positive micro-organisms, and the LTA they produce share pathophysiological properties and recognition mechanisms such as CD14 and Toll-like receptors (TLRs), with LPS (Ginsburg, 2002).", [["Staphylococcus spp.", "ORGANISM", 0, 19], ["Gram", "GENE_OR_GENE_PRODUCT", 58, 62], ["LTA", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD14", "GENE_OR_GENE_PRODUCT", 185, 189], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 194, 213], ["TLRs", "GENE_OR_GENE_PRODUCT", 215, 219], ["LPS", "SIMPLE_CHEMICAL", 227, 230], ["LTA", "PROTEIN", 97, 100], ["CD14", "PROTEIN", 185, 189], ["Toll-like receptors", "PROTEIN", 194, 213], ["TLRs", "PROTEIN", 215, 219], ["Staphylococcus spp.", "SPECIES", 0, 19], ["Staphylococcus spp.", "SPECIES", 0, 19], ["Staphylococcus spp.", "PROBLEM", 0, 19], ["positive micro-organisms", "PROBLEM", 63, 87], ["the LTA", "TEST", 93, 100], ["CD14", "TEST", 185, 189], ["positive micro-organisms", "OBSERVATION", 63, 87]]], ["LTA from S. aureus has powerful cytokine-inducing activity both in vitro (Morath et al., 2002, Kinsner et al., 2006, Deininger et al., 2007) and in vivo in cattle (Rainard et al., 2008).IntroductionThe objective of the present study was to assess whether LTA from S. aureus exacerbates disease and enhances pulmonary pro-inflammatory cytokine production in PRCV-infected pigs.", [["pulmonary", "ANATOMY", 307, 316], ["LTA", "CHEMICAL", 0, 3], ["LTA", "CHEMICAL", 255, 258], ["LTA", "GENE_OR_GENE_PRODUCT", 0, 3], ["S. aureus", "ORGANISM", 9, 18], ["cattle", "ORGANISM", 156, 162], ["LTA", "GENE_OR_GENE_PRODUCT", 255, 258], ["S. aureus", "ORGANISM", 264, 273], ["pulmonary", "ORGAN", 307, 316], ["PRCV", "ORGANISM", 357, 361], ["pigs", "ORGANISM", 371, 375], ["cytokine", "PROTEIN", 32, 40], ["cytokine", "PROTEIN", 334, 342], ["S. aureus", "SPECIES", 9, 18], ["cattle", "SPECIES", 156, 162], ["S. aureus", "SPECIES", 264, 273], ["pigs", "SPECIES", 371, 375], ["S. aureus", "SPECIES", 9, 18], ["cattle", "SPECIES", 156, 162], ["S. aureus", "SPECIES", 264, 273], ["PRCV", "SPECIES", 357, 361], ["pigs", "SPECIES", 371, 375], ["S. aureus", "PROBLEM", 9, 18], ["powerful cytokine", "TREATMENT", 23, 40], ["the present study", "TEST", 215, 232], ["LTA", "PROBLEM", 255, 258], ["S. aureus exacerbates disease", "PROBLEM", 264, 293], ["enhances pulmonary pro-inflammatory cytokine production", "PROBLEM", 298, 353], ["aureus", "OBSERVATION", 12, 18], ["aureus", "OBSERVATION", 267, 273], ["pulmonary", "ANATOMY", 307, 316], ["pro-inflammatory cytokine production", "OBSERVATION", 317, 353], ["infected pigs", "OBSERVATION", 362, 375]]], ["It was anticipated that the cytokines examined might participate in the pathogenesis of disease (IL-1, IL-6, TNF-\u03b1) and/or in the immunological response to infection (interferon [IFN]-\u03b3, IL-12/IL-23).", [["infection", "DISEASE", 156, 165], ["IL-1", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 109, 114], ["interferon [IFN]-\u03b3", "GENE_OR_GENE_PRODUCT", 167, 185], ["IL-12", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL-23", "GENE_OR_GENE_PRODUCT", 193, 198], ["cytokines", "PROTEIN", 28, 37], ["TNF", "PROTEIN", 109, 112], ["interferon [IFN]-\u03b3", "PROTEIN", 167, 185], ["IL", "PROTEIN", 193, 195], ["the cytokines", "TEST", 24, 37], ["disease", "PROBLEM", 88, 95], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["TNF", "TEST", 109, 112], ["infection", "PROBLEM", 156, 165], ["interferon [IFN", "TREATMENT", 167, 182], ["IL", "TEST", 187, 189], ["infection", "OBSERVATION", 156, 165]]], ["We also evaluated if there was any correlation between the concentrations of the induced cytokines and the severity of clinical signs or pulmonary lesions.Virus and lipoteichoic acid preparation ::: Materials and methodsA Belgian isolate of PRCV (91V44) was used on second passage in swine testis (ST) cells (Van Reeth and Pensaert, 1994); the inoculation dose was 107 50% tissue culture infective doses (TCID50)/pig.", [["pulmonary lesions", "ANATOMY", 137, 154], ["testis", "ANATOMY", 290, 296], ["ST) cells", "ANATOMY", 298, 307], ["tissue", "ANATOMY", 373, 379], ["pulmonary lesions", "DISEASE", 137, 154], ["lipoteichoic acid", "CHEMICAL", 165, 182], ["PRCV", "CHEMICAL", 241, 245], ["91V44", "CHEMICAL", 247, 252], ["lipoteichoic acid", "CHEMICAL", 165, 182], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 137, 154], ["Virus", "ORGANISM", 155, 160], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 165, 182], ["PRCV", "ORGANISM", 241, 245], ["swine", "ORGANISM", 284, 289], ["testis (ST) cells", "CELL", 290, 307], ["Van Reeth", "CELL", 309, 318], ["pig", "ORGANISM", 413, 416], ["cytokines", "PROTEIN", 89, 98], ["swine testis (ST) cells", "CELL_TYPE", 284, 307], ["swine", "SPECIES", 284, 289], ["pig", "SPECIES", 413, 416], ["PRCV", "SPECIES", 241, 245], ["swine", "SPECIES", 284, 289], ["pig", "SPECIES", 413, 416], ["the induced cytokines", "PROBLEM", 77, 98], ["clinical signs", "PROBLEM", 119, 133], ["pulmonary lesions", "PROBLEM", 137, 154], ["lipoteichoic acid preparation", "TREATMENT", 165, 194], ["the inoculation dose", "TEST", 340, 360], ["pig", "TREATMENT", 413, 416], ["pulmonary", "ANATOMY", 137, 146], ["lesions", "OBSERVATION", 147, 154], ["lipoteichoic acid", "OBSERVATION", 165, 182], ["testis", "ANATOMY", 290, 296]]], ["Based on previous experiments, the dose of LTA from S. aureus (Sigma\u2013Aldrich) was 200 \u03bcg/kg bodyweight, which, in contrast to a 20 \u03bcg/kg dose, results in moderate to severe inflammatory cell infiltration (see Appendix A, Supplementary material, Table 1).", [["cell", "ANATOMY", 186, 190], ["LTA", "CHEMICAL", 43, 46], ["Sigma\u2013Aldrich", "CHEMICAL", 63, 76], ["LTA", "SIMPLE_CHEMICAL", 43, 46], ["S. aureus", "ORGANISM", 52, 61], ["cell", "CELL", 186, 190], ["S. aureus", "SPECIES", 52, 61], ["S. aureus", "SPECIES", 52, 61], ["LTA", "TEST", 43, 46], ["S. aureus", "PROBLEM", 52, 61], ["moderate to severe inflammatory cell infiltration", "PROBLEM", 154, 203], ["aureus", "OBSERVATION", 55, 61], ["moderate", "OBSERVATION_MODIFIER", 154, 162], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["inflammatory cell infiltration", "OBSERVATION", 173, 203], ["Appendix", "ANATOMY", 209, 217]]], ["In both doses there was no extensive cytokine production.", [["cytokine", "PROTEIN", 37, 45], ["extensive cytokine production", "PROBLEM", 27, 56], ["no", "UNCERTAINTY", 24, 26], ["extensive", "OBSERVATION_MODIFIER", 27, 36], ["cytokine production", "OBSERVATION", 37, 56]]], ["The cytokine concentrations were higher than controls, but comparable with previous data using LPS alone and lower than in PRCV\u2013LPS-inoculated animals (Van Reeth et al., 2000, Van Gucht et al., 2006).", [["LPS", "CHEMICAL", 95, 98], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["PRCV", "ORGANISM", 123, 127], ["\u2013LPS", "SIMPLE_CHEMICAL", 127, 131], ["cytokine", "PROTEIN", 4, 12], ["PRCV", "SPECIES", 123, 127], ["The cytokine concentrations", "TEST", 0, 27], ["LPS", "TREATMENT", 95, 98]]], ["Virus and LTA were diluted in pyrogen-free phosphate-buffered saline (PBS) (Gibco) to obtain 3 mL of inoculum.Experimental design and sampling procedure ::: Materials and methodsTwenty-eight, 3-week-old, caesarean-derived, colostrum-deprived pigs from four sows were individually housed in sterile, Horsefall-type isolation units with positive-pressure ventilation.", [["LTA", "CHEMICAL", 10, 13], ["phosphate", "CHEMICAL", 43, 52], ["phosphate", "CHEMICAL", 43, 52], ["Virus", "ORGANISM", 0, 5], ["LTA", "SIMPLE_CHEMICAL", 10, 13], ["pyrogen-free phosphate-buffered saline", "SIMPLE_CHEMICAL", 30, 68], ["colostrum", "ORGANISM", 223, 232], ["pigs", "ORGANISM", 242, 246], ["sows", "ORGANISM", 257, 261], ["pigs", "SPECIES", 242, 246], ["pigs", "SPECIES", 242, 246], ["Virus", "PROBLEM", 0, 5], ["LTA", "TEST", 10, 13], ["buffered saline (PBS", "TREATMENT", 53, 73], ["inoculum", "PROBLEM", 101, 109], ["caesarean", "TREATMENT", 204, 213], ["positive-pressure ventilation", "TREATMENT", 335, 364], ["LTA", "OBSERVATION_MODIFIER", 10, 13], ["inoculum", "OBSERVATION", 101, 109], ["pressure ventilation", "OBSERVATION", 344, 364]]], ["The animals were fed commercial ultra-high-temperature-treated cow\u2019s milk.", [["milk", "ANATOMY", 69, 73], ["animals", "ORGANISM", 4, 11], ["cow", "ORGANISM", 63, 66], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["cow", "SPECIES", 63, 66], ["cow", "SPECIES", 63, 66], ["commercial ultra", "TEST", 21, 37]]], ["Twenty-four pigs were randomly assigned to three groups each containing eight animals.Experimental design and sampling procedure ::: Materials and methodsAll inoculations were performed via the intra-tracheal route as described previously (Van Gucht et al., 2006).", [["pigs", "ORGANISM", 12, 16], ["pigs", "SPECIES", 12, 16], ["pigs", "SPECIES", 12, 16], ["All inoculations", "TREATMENT", 154, 170]]], ["One group was inoculated with PRCV and 24 h later with LTA (PRCV\u2013LTA group).", [["LTA", "CHEMICAL", 55, 58], ["PRCV\u2013LTA", "CHEMICAL", 60, 68], ["LTA", "SIMPLE_CHEMICAL", 55, 58], ["PRCV", "SPECIES", 30, 34], ["PRCV", "TREATMENT", 30, 34], ["LTA", "TEST", 55, 58]]], ["The remaining two groups were inoculated with either PRCV (PRCV group) or LTA (LTA group), respectively, and served as controls.Experimental design and sampling procedure ::: Materials and methodsOne pig from each group was euthanased by intra-peritoneal injection of pentobarbital (Kela Laboratories) at the time-points indicated (Table 1).", [["intra-peritoneal", "ANATOMY", 238, 254], ["PRCV", "CHEMICAL", 53, 57], ["LTA", "CHEMICAL", 74, 77], ["pentobarbital", "CHEMICAL", 268, 281], ["pentobarbital", "CHEMICAL", 268, 281], ["LTA", "SIMPLE_CHEMICAL", 74, 77], ["pig", "ORGANISM", 200, 203], ["intra-peritoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 238, 254], ["pentobarbital", "SIMPLE_CHEMICAL", 268, 281], ["pig", "SPECIES", 200, 203], ["PRCV", "SPECIES", 53, 57], ["pig", "SPECIES", 200, 203], ["LTA (LTA group", "TREATMENT", 74, 88], ["pentobarbital", "TREATMENT", 268, 281]]], ["The four remaining pigs were sham-inoculated with PBS and euthanased 4 h later.", [["pigs", "ORGANISM", 19, 23], ["pigs", "SPECIES", 19, 23], ["PBS", "TREATMENT", 50, 53]]], ["The experimental procedure had the authorisation of the Ethical and Animal Welfare Committee of the Faculty of Veterinary Medicine of Ghent University (EC 2004/40; EC 2005/75).Experimental design and sampling procedure ::: Materials and methodsPost-mortem, bronchoalveolar lavage fluid (BALF) was collected from the right lung and cytological examination was carried out as previously described (Van Gucht et al., 2006).", [["bronchoalveolar lavage fluid", "ANATOMY", 257, 285], ["BALF", "ANATOMY", 287, 291], ["right lung", "ANATOMY", 316, 326], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 257, 285], ["BALF", "ORGANISM_SUBSTANCE", 287, 291], ["lung", "ORGAN", 322, 326], ["The experimental procedure", "TREATMENT", 0, 26], ["methodsPost-mortem", "TEST", 237, 255], ["bronchoalveolar lavage fluid (BALF)", "TEST", 257, 292], ["cytological examination", "TEST", 331, 354], ["bronchoalveolar lavage", "OBSERVATION", 257, 279], ["right", "ANATOMY_MODIFIER", 316, 321], ["lung", "ANATOMY", 322, 326]]], ["Tissue samples of approximately 1 cm3 were taken from the cranial, cardiac and diaphragmatic lobes of the left lung for virological and bacteriological examination.", [["Tissue samples", "ANATOMY", 0, 14], ["cranial", "ANATOMY", 58, 65], ["cardiac", "ANATOMY", 67, 74], ["diaphragmatic lobes", "ANATOMY", 79, 98], ["left lung", "ANATOMY", 106, 115], ["Tissue samples", "CANCER", 0, 14], ["cranial", "ORGAN", 58, 65], ["cardiac", "ORGAN", 67, 74], ["diaphragmatic lobes", "MULTI-TISSUE_STRUCTURE", 79, 98], ["lung", "ORGAN", 111, 115], ["Tissue samples", "TEST", 0, 14], ["bacteriological examination", "TEST", 136, 163], ["cranial", "ANATOMY_MODIFIER", 58, 65], ["cardiac", "ANATOMY", 67, 74], ["diaphragmatic", "ANATOMY", 79, 92], ["lobes", "ANATOMY_MODIFIER", 93, 98], ["left", "ANATOMY_MODIFIER", 106, 110], ["lung", "ANATOMY", 111, 115]]], ["Virus titration was performed on 20% suspensions of pooled samples from the three lung lobes of each animal.Clinical monitoring and scoring system ::: Materials and methodsThe pigs were clinically examined three times daily prior to and every hour after inoculation.", [["samples", "ANATOMY", 59, 66], ["lung lobes", "ANATOMY", 82, 92], ["Virus", "ORGANISM", 0, 5], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 82, 92], ["pigs", "ORGANISM", 176, 180], ["pigs", "SPECIES", 176, 180], ["pigs", "SPECIES", 176, 180], ["Virus titration", "TREATMENT", 0, 15], ["pooled samples", "TEST", 52, 66], ["Clinical monitoring", "TEST", 108, 127], ["The pigs", "TREATMENT", 172, 180], ["inoculation", "PROBLEM", 254, 265], ["three", "ANATOMY_MODIFIER", 76, 81], ["lung", "ANATOMY", 82, 86], ["lobes", "ANATOMY_MODIFIER", 87, 92]]], ["Clinical \u2018scores\u2019 were allocated for: respiratory rate (0, <60/min; 1, 60\u201390/min \u2013 mild tachypnoea; 2, >90/min \u2013 severe tachypnoea); laboured abdominal breathing (0, absent; 1, present); dyspnoea (0, absent; 1, present); depression (0, absent; 1, present), and anorexia (0, absent; 1, present).Clinical monitoring and scoring system ::: Materials and methodsAnorexia was assessed by fasting the pigs for 6\u20138 h prior to inoculation and then providing each animal with 150\u2013200 mL of milk following the inoculation procedure.", [["respiratory", "ANATOMY", 38, 49], ["abdominal", "ANATOMY", 142, 151], ["milk", "ANATOMY", 481, 485], ["tachypnoea", "DISEASE", 88, 98], ["tachypnoea", "DISEASE", 120, 130], ["abdominal breathing", "DISEASE", 142, 161], ["dyspnoea", "DISEASE", 187, 195], ["depression", "DISEASE", 221, 231], ["anorexia", "DISEASE", 261, 269], ["Anorexia", "DISEASE", 358, 366], ["pigs", "ORGANISM", 395, 399], ["milk", "ORGANISM_SUBSTANCE", 481, 485], ["pigs", "SPECIES", 395, 399], ["pigs", "SPECIES", 395, 399], ["respiratory rate", "TEST", 38, 54], ["mild tachypnoea", "PROBLEM", 83, 98], ["severe tachypnoea", "PROBLEM", 113, 130], ["laboured abdominal breathing", "PROBLEM", 133, 161], ["dyspnoea", "PROBLEM", 187, 195], ["depression", "PROBLEM", 221, 231], ["anorexia", "PROBLEM", 261, 269], ["Clinical monitoring", "TEST", 294, 313], ["Anorexia", "PROBLEM", 358, 366], ["inoculation", "TREATMENT", 419, 430], ["the inoculation procedure", "TREATMENT", 496, 521], ["abdominal breathing", "ANATOMY", 142, 161]]], ["Pigs that did not consume the milk were assigned an anorexia score of \u20181\u2019 (sham-inoculated animals had completely consumed their milk ration within 1 h).", [["milk", "ANATOMY", 30, 34], ["anorexia", "DISEASE", 52, 60], ["Pigs", "ORGANISM", 0, 4], ["milk", "ORGANISM_SUBSTANCE", 30, 34], ["milk", "ORGANISM_SUBDIVISION", 129, 133], ["Pigs", "SPECIES", 0, 4], ["an anorexia score", "TEST", 49, 66]]], ["A fresh quantity of milk was given to each pig every 4 h to prevent bacterial spoilage influencing consumption.", [["milk", "ANATOMY", 20, 24], ["milk", "ORGANISM_SUBSTANCE", 20, 24], ["pig", "ORGANISM", 43, 46], ["pig", "SPECIES", 43, 46], ["pig", "SPECIES", 43, 46], ["A fresh quantity of milk", "TREATMENT", 0, 24], ["bacterial spoilage influencing consumption", "PROBLEM", 68, 110], ["fresh", "OBSERVATION_MODIFIER", 2, 7], ["quantity", "OBSERVATION_MODIFIER", 8, 16], ["bacterial spoilage", "OBSERVATION", 68, 86]]], ["The total clinical score for each pig at each time-point was calculated by adding the scores for each clinical parameter.Post-mortem assessment of lung lesions ::: Materials and methodsImages of the macroscopically visible lesions were transcribed onto a lung diagram (Christensen et al., 1999) and the approximate percentage of the affected dorsal and ventral surfaces estimated.", [["lung lesions", "ANATOMY", 147, 159], ["lesions", "ANATOMY", 223, 230], ["lung", "ANATOMY", 255, 259], ["dorsal", "ANATOMY", 342, 348], ["ventral surfaces", "ANATOMY", 353, 369], ["lung lesions", "DISEASE", 147, 159], ["pig", "ORGANISM", 34, 37], ["lung lesions", "CANCER", 147, 159], ["lesions", "CANCER", 223, 230], ["lung", "ORGAN", 255, 259], ["dorsal", "TISSUE", 342, 348], ["pig", "SPECIES", 34, 37], ["pig", "SPECIES", 34, 37], ["Post-mortem assessment", "TEST", 121, 143], ["lung lesions", "PROBLEM", 147, 159], ["methodsImages", "TEST", 178, 191], ["the macroscopically visible lesions", "PROBLEM", 195, 230], ["a lung diagram", "TEST", 253, 267], ["total", "OBSERVATION_MODIFIER", 4, 9], ["lung", "ANATOMY", 147, 151], ["lesions", "OBSERVATION", 152, 159], ["macroscopically", "OBSERVATION_MODIFIER", 199, 214], ["visible", "OBSERVATION_MODIFIER", 215, 222], ["lesions", "OBSERVATION", 223, 230], ["lung", "ANATOMY", 255, 259], ["percentage", "OBSERVATION_MODIFIER", 315, 325], ["affected", "OBSERVATION_MODIFIER", 333, 341], ["dorsal", "OBSERVATION_MODIFIER", 342, 348], ["ventral", "OBSERVATION_MODIFIER", 353, 360], ["surfaces", "OBSERVATION_MODIFIER", 361, 369]]], ["The percentage of lung affected was calculated as the average of the percentages of the affected dorsal and ventral surfaces.Quantification of pro-inflammatory cytokines in BALF ::: Materials and methodsConcentrations of IL-1, IL-6 and TNF-\u03b1 were quantified in three separate bioassays and geometric means calculated (Helle et al., 1988, Van Reeth et al., 1999).", [["lung", "ANATOMY", 18, 22], ["dorsal", "ANATOMY", 97, 103], ["ventral surfaces", "ANATOMY", 108, 124], ["lung", "ORGAN", 18, 22], ["dorsal", "TISSUE", 97, 103], ["ventral surfaces", "TISSUE", 108, 124], ["IL-1", "GENE_OR_GENE_PRODUCT", 221, 225], ["IL-6", "GENE_OR_GENE_PRODUCT", 227, 231], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 236, 241], ["pro-inflammatory cytokines", "PROTEIN", 143, 169], ["BALF", "CELL_TYPE", 173, 177], ["IL-1, IL-6", "PROTEIN", 221, 231], ["TNF", "PROTEIN", 236, 239], ["IL", "TEST", 221, 223], ["IL", "TEST", 227, 229], ["TNF", "TEST", 236, 239], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["lung", "ANATOMY", 18, 22], ["affected", "OBSERVATION", 23, 31], ["average", "OBSERVATION_MODIFIER", 54, 61], ["percentages", "OBSERVATION_MODIFIER", 69, 80], ["affected", "OBSERVATION_MODIFIER", 88, 96], ["dorsal", "ANATOMY_MODIFIER", 97, 103], ["ventral", "ANATOMY_MODIFIER", 108, 115], ["surfaces", "ANATOMY_MODIFIER", 116, 124], ["pro-inflammatory cytokines", "OBSERVATION", 143, 169], ["BALF", "ANATOMY", 173, 177]]], ["IFN-\u03b3 was measured by ELISA (Biosource) and IL-12 using a DuoSet ELISA that detects the p40 sub-unit common to both IL-12 and IL-23 (R and D Systems).", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-12", "GENE_OR_GENE_PRODUCT", 44, 49], ["p40", "GENE_OR_GENE_PRODUCT", 88, 91], ["IL-12", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-23", "GENE_OR_GENE_PRODUCT", 126, 131], ["R", "GENE_OR_GENE_PRODUCT", 133, 134], ["D Systems", "SIMPLE_CHEMICAL", 139, 148], ["IFN-\u03b3", "PROTEIN", 0, 5], ["IL-12", "PROTEIN", 44, 49], ["p40 sub-unit", "DNA", 88, 100], ["IL", "PROTEIN", 116, 118], ["IL", "PROTEIN", 126, 128], ["IFN", "TEST", 0, 3], ["ELISA", "TEST", 22, 27], ["IL", "TEST", 44, 46], ["a DuoSet ELISA", "TEST", 56, 70], ["IL", "TEST", 116, 118], ["IL", "TEST", 126, 128]]], ["The assay did not discriminate between IL-12 and IL-23 (Novelli and Casanova, 2004, Bastos et al., 2004, Watford et al., 2004).Virological and bacteriological examination ::: Materials and methodsTitres of PRCV were determined on ST cells (Van Reeth and Pensaert, 1994) with a detection limit of 101.7 TCID50/g of tissue.", [["ST cells", "ANATOMY", 230, 238], ["tissue", "ANATOMY", 314, 320], ["IL-12", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-23", "GENE_OR_GENE_PRODUCT", 49, 54], ["PRCV", "SIMPLE_CHEMICAL", 206, 210], ["ST cells", "CELL", 230, 238], ["Van Reeth", "CELL", 240, 249], ["tissue", "TISSUE", 314, 320], ["IL", "PROTEIN", 39, 41], ["PRCV", "PROTEIN", 206, 210], ["ST cells", "CELL_TYPE", 230, 238], ["The assay", "TEST", 0, 9], ["IL", "TEST", 39, 41], ["bacteriological examination", "TEST", 143, 170], ["PRCV", "TREATMENT", 206, 210], ["a detection limit", "TEST", 275, 292]]], ["Routine bacteriological examination of lung tissue was performed as follows.", [["lung tissue", "ANATOMY", 39, 50], ["lung tissue", "TISSUE", 39, 50], ["Routine bacteriological examination of lung tissue", "TEST", 0, 50], ["lung tissue", "ANATOMY", 39, 50]]], ["Samples were plated on bovine blood agar and cultured aerobically.", [["Samples", "ANATOMY", 0, 7], ["blood", "ANATOMY", 30, 35], ["bovine", "ORGANISM", 23, 29], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["bovine", "SPECIES", 23, 29], ["bovine", "SPECIES", 23, 29], ["Samples", "TEST", 0, 7], ["bovine blood agar", "TEST", 23, 40]]], ["A \u2018nurse\u2019-colony of coagulase-positive Staphylococcus spp. was streaked diagonally on each plate.", [["coagulase-positive Staphylococcus spp", "GENE_OR_GENE_PRODUCT", 20, 57], ["coagulase", "PROTEIN", 20, 29], ["Staphylococcus spp", "SPECIES", 39, 57], ["Staphylococcus spp", "SPECIES", 39, 57], ["coagulase", "TEST", 20, 29], ["positive Staphylococcus spp", "PROBLEM", 30, 57], ["positive", "OBSERVATION_MODIFIER", 30, 38], ["Staphylococcus spp", "OBSERVATION", 39, 57], ["streaked", "OBSERVATION", 63, 71], ["diagonally", "ANATOMY_MODIFIER", 72, 82]]], ["The plates were inspected for bacterial growth after 48 and 72 h.", [["The plates", "TREATMENT", 0, 10], ["bacterial growth", "PROBLEM", 30, 46]]], ["Colonies were identified by standard techniques as reported by Van Gucht et al. (2003).Statistical analysis ::: Materials and methodsResults of the three inoculation procedures were compared using the Friedman test with \u2018time of euthanasia\u2019 as a stratification factor.", [["Colonies", "ANATOMY", 0, 8], ["Colonies", "CELL", 0, 8], ["the three inoculation procedures", "TREATMENT", 144, 176], ["the Friedman test", "TEST", 197, 214], ["euthanasia", "TREATMENT", 229, 239]]], ["Pair-wise comparisons (PRCV\u2013LTA vs. PRCV and PRCV\u2013LTA vs. LTA) were carried out using the Wilcoxon signed-rank sum test also stratified using time of euthanasia.", [["PRCV", "PROTEIN", 45, 49], ["PRCV\u2013LTA", "TREATMENT", 23, 31], ["PRCV", "TEST", 36, 40], ["PRCV\u2013LTA", "TREATMENT", 45, 53], ["LTA", "TEST", 58, 61], ["rank sum test", "TEST", 106, 119], ["euthanasia", "PROBLEM", 150, 160], ["euthanasia", "OBSERVATION", 150, 160]]], ["Statistical analysis was performed using StatXact software.Clinical signs and pulmonary viral load ::: ResultsNo clinical signs were observed or virus found in the four sham-inoculated controls.", [["pulmonary", "ANATOMY", 78, 87], ["pulmonary", "ORGAN", 78, 87], ["Statistical analysis", "TEST", 0, 20], ["Clinical signs", "TEST", 59, 73], ["clinical signs", "PROBLEM", 113, 127], ["virus", "PROBLEM", 145, 150], ["pulmonary", "ANATOMY", 78, 87], ["viral load", "OBSERVATION", 88, 98]]], ["Fig. 1illustrates the development of clinical signs in the experimental groups.", [["clinical signs in the experimental groups", "PROBLEM", 37, 78]]], ["Only 2/8 PRCV-only inoculated pigs developed mild depression and occasional anorexia 12\u201324 h post inoculation (PI), which persisted until 48 h PI.", [["PRCV", "CHEMICAL", 9, 13], ["depression", "DISEASE", 50, 60], ["anorexia", "DISEASE", 76, 84], ["PRCV", "GENE_OR_GENE_PRODUCT", 9, 13], ["pigs", "ORGANISM", 30, 34], ["pigs", "SPECIES", 30, 34], ["pigs", "SPECIES", 30, 34], ["mild depression", "PROBLEM", 45, 60], ["occasional anorexia", "PROBLEM", 65, 84], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["depression", "OBSERVATION", 50, 60], ["occasional", "OBSERVATION_MODIFIER", 65, 75], ["anorexia", "OBSERVATION", 76, 84]]], ["Of the eight LTA-only inoculated pigs, four developed mild (lasting <1 h) depression and anorexia at 2 h (n= 3) or at 8 h (n= 1) PI, respectively.", [["depression", "DISEASE", 74, 84], ["anorexia", "DISEASE", 89, 97], ["LTA", "SIMPLE_CHEMICAL", 13, 16], ["pigs", "ORGANISM", 33, 37], ["LTA", "PROTEIN", 13, 16], ["pigs", "SPECIES", 33, 37], ["pigs", "SPECIES", 33, 37], ["depression", "PROBLEM", 74, 84], ["anorexia", "PROBLEM", 89, 97], ["LTA", "OBSERVATION_MODIFIER", 13, 16], ["inoculated pigs", "OBSERVATION", 22, 37], ["mild", "OBSERVATION_MODIFIER", 54, 58]]], ["In contrast, the PRCV\u2013LTA-inoculated animals exhibited severe tachypnoea, dyspnoea, laboured abdominal breathing, depression, anorexia and occasional vomiting.", [["abdominal", "ANATOMY", 93, 102], ["PRCV\u2013LTA", "CHEMICAL", 17, 25], ["tachypnoea", "DISEASE", 62, 72], ["dyspnoea", "DISEASE", 74, 82], ["abdominal breathing", "DISEASE", 93, 112], ["depression", "DISEASE", 114, 124], ["anorexia", "DISEASE", 126, 134], ["vomiting", "DISEASE", 150, 158], ["PRCV\u2013LTA", "SIMPLE_CHEMICAL", 17, 25], ["animals", "ORGANISM", 37, 44], ["abdominal", "ORGANISM_SUBDIVISION", 93, 102], ["the PRCV\u2013LTA", "TEST", 13, 25], ["severe tachypnoea", "PROBLEM", 55, 72], ["dyspnoea", "PROBLEM", 74, 82], ["laboured abdominal breathing", "PROBLEM", 84, 112], ["depression", "PROBLEM", 114, 124], ["anorexia", "PROBLEM", 126, 134], ["occasional vomiting", "PROBLEM", 139, 158], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["tachypnoea", "OBSERVATION", 62, 72], ["dyspnoea", "OBSERVATION", 74, 82], ["abdominal breathing", "ANATOMY", 93, 112], ["depression", "OBSERVATION", 114, 124], ["anorexia", "OBSERVATION", 126, 134], ["occasional", "OBSERVATION_MODIFIER", 139, 149], ["vomiting", "OBSERVATION", 150, 158]]], ["These signs were evident in 7/8 pigs by 1 h PI and had begun to resolve 4\u20138 h PI (clinical scores relating to individual animals are detailed in Appendix A, Supplementary material, Table 3).Clinical signs and pulmonary viral load ::: ResultsThe three treatment groups differed significantly from each other (P= 0.0014) when the maximum scores/pig in each group were compared.", [["pulmonary", "ANATOMY", 209, 218], ["pigs", "ORGANISM", 32, 36], ["pulmonary", "ORGAN", 209, 218], ["pig", "ORGANISM", 343, 346], ["pigs", "SPECIES", 32, 36], ["pigs", "SPECIES", 32, 36], ["pig", "SPECIES", 343, 346], ["These signs", "TEST", 0, 11], ["h PI (clinical scores", "PROBLEM", 76, 97], ["individual animals", "PROBLEM", 110, 128], ["Clinical signs", "TEST", 190, 204], ["the maximum scores", "TEST", 324, 342], ["Appendix", "ANATOMY", 145, 153], ["pulmonary", "ANATOMY", 209, 218], ["viral load", "OBSERVATION", 219, 229]]], ["The PRCV\u2013LTA group had a significantly higher maximum score than either the LTA (P= 0.0156) or PRCV (P= 0.0156) group.Clinical signs and pulmonary viral load ::: ResultsVirus was detected in the lungs of all the PRCV-inoculated pigs.", [["pulmonary", "ANATOMY", 137, 146], ["lungs", "ANATOMY", 195, 200], ["pulmonary", "ORGAN", 137, 146], ["ResultsVirus", "GENE_OR_GENE_PRODUCT", 162, 174], ["lungs", "ORGAN", 195, 200], ["pigs", "ORGANISM", 228, 232], ["ResultsVirus", "PROTEIN", 162, 174], ["pigs", "SPECIES", 228, 232], ["PRCV", "SPECIES", 212, 216], ["pigs", "SPECIES", 228, 232], ["a significantly higher maximum score", "PROBLEM", 23, 59], ["the LTA", "TEST", 72, 79], ["P", "TEST", 81, 82], ["PRCV", "TEST", 95, 99], ["Clinical signs", "TEST", 118, 132], ["ResultsVirus", "TEST", 162, 174], ["LTA", "OBSERVATION_MODIFIER", 9, 12], ["pulmonary", "ANATOMY", 137, 146], ["viral load", "OBSERVATION", 147, 157], ["lungs", "ANATOMY", 195, 200], ["inoculated pigs", "OBSERVATION", 217, 232]]], ["Titres were similar (P= 1.00) in the PRCV (4.1\u20137.3 log10 TCID50/g tissue) and PRCV\u2013LTA (4.8\u20138.0 log10 TCID50/g tissue) groups (individual animal titres detailed in Appendix A, Supplementary material, Table 2).", [["tissue", "ANATOMY", 66, 72], ["tissue", "ANATOMY", 111, 117], ["tissue", "TISSUE", 66, 72], ["PRCV\u2013LTA", "SIMPLE_CHEMICAL", 78, 86], ["tissue", "TISSUE", 111, 117], ["PRCV", "SPECIES", 78, 82], ["Titres", "TEST", 0, 6], ["the PRCV", "TEST", 33, 41], ["tissue", "TEST", 66, 72], ["PRCV", "TEST", 78, 82], ["LTA", "TEST", 83, 86], ["individual animal titres", "TEST", 127, 151], ["Appendix", "ANATOMY", 164, 172]]], ["Virus was not detected in animals in the LTA group.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5], ["not detected", "UNCERTAINTY", 10, 22], ["LTA", "ANATOMY_MODIFIER", 41, 44]]], ["No bacteria were cultured from any of the lungs from any group.Assessment of lung lesions and cytological examination of BALF ::: ResultsGrossly visible red regions of consolidation were scattered predominantly throughout the cranial and cardiac lobes of the PRCV-only and PRCV\u2013LTA inoculated groups.", [["lungs", "ANATOMY", 42, 47], ["lung lesions", "ANATOMY", 77, 89], ["BALF", "ANATOMY", 121, 125], ["cranial", "ANATOMY", 226, 233], ["cardiac lobes", "ANATOMY", 238, 251], ["lungs", "ORGAN", 42, 47], ["lung lesions", "CANCER", 77, 89], ["cranial", "ORGAN", 226, 233], ["cardiac lobes", "MULTI-TISSUE_STRUCTURE", 238, 251], ["PRCV\u2013LTA", "GENE_OR_GENE_PRODUCT", 273, 281], ["bacteria", "PROBLEM", 3, 11], ["lung lesions", "PROBLEM", 77, 89], ["cytological examination of BALF", "TEST", 94, 125], ["consolidation", "PROBLEM", 168, 181], ["bacteria", "OBSERVATION", 3, 11], ["lungs", "ANATOMY", 42, 47], ["lung", "ANATOMY", 77, 81], ["lesions", "OBSERVATION", 82, 89], ["Grossly", "OBSERVATION_MODIFIER", 137, 144], ["visible", "OBSERVATION_MODIFIER", 145, 152], ["regions", "OBSERVATION_MODIFIER", 157, 164], ["consolidation", "OBSERVATION", 168, 181], ["scattered", "OBSERVATION_MODIFIER", 187, 196], ["predominantly", "OBSERVATION_MODIFIER", 197, 210], ["cranial", "ANATOMY_MODIFIER", 226, 233], ["cardiac", "ANATOMY", 238, 245], ["lobes", "ANATOMY_MODIFIER", 246, 251], ["PRCV", "ANATOMY", 259, 263], ["LTA", "OBSERVATION_MODIFIER", 278, 281], ["inoculated", "OBSERVATION", 282, 292]]], ["Table 1 details the percentages of affected lung area, BALF cell counts and neutrophil influx as percent of BALF cells.", [["lung area", "ANATOMY", 44, 53], ["BALF cell", "ANATOMY", 55, 64], ["neutrophil", "ANATOMY", 76, 86], ["BALF cells", "ANATOMY", 108, 118], ["lung", "ORGAN", 44, 48], ["BALF cell", "CELL", 55, 64], ["neutrophil", "CELL", 76, 86], ["BALF cells", "CELL", 108, 118], ["neutrophil", "CELL_TYPE", 76, 86], ["BALF cells", "CELL_TYPE", 108, 118], ["affected lung area", "PROBLEM", 35, 53], ["BALF cell counts", "TEST", 55, 71], ["neutrophil influx", "TEST", 76, 93], ["BALF cells", "PROBLEM", 108, 118], ["lung", "ANATOMY", 44, 48], ["area", "ANATOMY_MODIFIER", 49, 53], ["BALF cell counts", "OBSERVATION", 55, 71], ["neutrophil influx", "OBSERVATION", 76, 93], ["BALF cells", "OBSERVATION", 108, 118]]], ["Lesions were not observed in the sham-inoculated animals.", [["Lesions", "PROBLEM", 0, 7], ["not observed", "UNCERTAINTY", 13, 25]]], ["The BALF cell count and the neutrophil percentages in these pigs ranged from 34 to 161 \u00d7 106 and from 0% to 0.9%, respectively.Assessment of lung lesions and cytological examination of BALF ::: ResultsIn the PRCV-only group, pulmonary lesions were seen in <=9.5% of the lung surface area.", [["BALF cell", "ANATOMY", 4, 13], ["neutrophil", "ANATOMY", 28, 38], ["lung lesions", "ANATOMY", 141, 153], ["BALF", "ANATOMY", 185, 189], ["pulmonary lesions", "ANATOMY", 225, 242], ["lung surface area", "ANATOMY", 270, 287], ["pulmonary lesions", "DISEASE", 225, 242], ["BALF cell", "CELL", 4, 13], ["neutrophil", "CELL", 28, 38], ["pigs", "ORGANISM", 60, 64], ["lung lesions", "CANCER", 141, 153], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 225, 242], ["lung", "ORGAN", 270, 274], ["neutrophil", "CELL_TYPE", 28, 38], ["pigs", "SPECIES", 60, 64], ["The BALF cell count", "TEST", 0, 19], ["the neutrophil percentages", "TEST", 24, 50], ["these pigs", "TEST", 54, 64], ["lung lesions", "PROBLEM", 141, 153], ["cytological examination of BALF", "TEST", 158, 189], ["the PRCV", "TEST", 204, 212], ["pulmonary lesions", "PROBLEM", 225, 242], ["BALF cell count", "OBSERVATION", 4, 19], ["neutrophil percentages", "OBSERVATION", 28, 50], ["lung", "ANATOMY", 141, 145], ["lesions", "OBSERVATION", 146, 153], ["pulmonary", "ANATOMY", 225, 234], ["lesions", "OBSERVATION", 235, 242], ["lung", "ANATOMY", 270, 274], ["surface", "ANATOMY_MODIFIER", 275, 282]]], ["The total BALF cell count and neutrophil percentage also remained constant despite individual animal variation.", [["BALF cell", "ANATOMY", 10, 19], ["neutrophil", "ANATOMY", 30, 40], ["BALF cell", "CELL", 10, 19], ["neutrophil", "CELL", 30, 40], ["neutrophil", "CELL_TYPE", 30, 40], ["The total BALF cell count", "TEST", 0, 25], ["neutrophil percentage", "TEST", 30, 51], ["total", "OBSERVATION_MODIFIER", 4, 9], ["BALF cell count", "OBSERVATION", 10, 25], ["neutrophil percentage", "OBSERVATION", 30, 51], ["animal variation", "OBSERVATION", 94, 110]]], ["Although the LTA group did not exhibit lesions, the total BALF cell count in 6/8 of these pigs and the neutrophil percentage in all eight animals exceeded the maximal values observed in sham-inoculated controls.", [["lesions", "ANATOMY", 39, 46], ["BALF cell", "ANATOMY", 58, 67], ["neutrophil", "ANATOMY", 103, 113], ["LTA", "GENE_OR_GENE_PRODUCT", 13, 16], ["lesions", "PATHOLOGICAL_FORMATION", 39, 46], ["BALF cell", "CELL", 58, 67], ["pigs", "ORGANISM", 90, 94], ["neutrophil", "CELL", 103, 113], ["neutrophil", "CELL_TYPE", 103, 113], ["pigs", "SPECIES", 90, 94], ["pigs", "SPECIES", 90, 94], ["the LTA group", "TEST", 9, 22], ["lesions", "PROBLEM", 39, 46], ["the total BALF cell count", "TEST", 48, 73], ["these pigs", "TEST", 84, 94], ["the neutrophil percentage", "TEST", 99, 124], ["the maximal values", "TEST", 155, 173], ["lesions", "OBSERVATION", 39, 46], ["total", "OBSERVATION_MODIFIER", 52, 57], ["BALF cell count", "OBSERVATION", 58, 73], ["neutrophil percentage", "OBSERVATION", 103, 124], ["inoculated controls", "OBSERVATION", 191, 210]]], ["The PRCV\u2013LTA group developed lung lesions 27 h after PRCV inoculation but the overall pattern of lesion development did not differ from that of the PRCV-only group (P= 1.0).Assessment of lung lesions and cytological examination of BALF ::: ResultsThe total BALF cell counts did not differ significantly between either the PRCV\u2013LTA and PRCV groups (P= 0.25), or between the PRCV\u2013LTA and LTA groups (P= 0.078).", [["lung lesions", "ANATOMY", 29, 41], ["lesion", "ANATOMY", 97, 103], ["lung lesions", "ANATOMY", 187, 199], ["BALF", "ANATOMY", 231, 235], ["BALF cell", "ANATOMY", 257, 266], ["lung lesions", "DISEASE", 29, 41], ["PRCV", "CHEMICAL", 148, 152], ["PRCV\u2013LTA", "GENE_OR_GENE_PRODUCT", 4, 12], ["lung lesions", "PATHOLOGICAL_FORMATION", 29, 41], ["lesion", "PATHOLOGICAL_FORMATION", 97, 103], ["lung lesions", "CANCER", 187, 199], ["BALF cell", "CELL", 257, 266], ["PRCV", "SPECIES", 53, 57], ["PRCV", "SPECIES", 322, 326], ["PRCV", "SPECIES", 373, 377], ["lung lesions", "PROBLEM", 29, 41], ["PRCV inoculation", "TREATMENT", 53, 69], ["lesion development", "PROBLEM", 97, 115], ["the PRCV", "TEST", 144, 152], ["lung lesions", "PROBLEM", 187, 199], ["cytological examination of BALF", "TEST", 204, 235], ["The total BALF cell counts", "TEST", 247, 273], ["P", "TEST", 348, 349], ["LTA", "OBSERVATION_MODIFIER", 9, 12], ["lung", "ANATOMY", 29, 33], ["lesions", "OBSERVATION", 34, 41], ["lesion", "OBSERVATION", 97, 103], ["lung", "ANATOMY", 187, 191], ["lesions", "OBSERVATION", 192, 199]]], ["The percentage of neutrophils in BALF in the PRCV\u2013LTA group, while significantly higher than in the PRCV group (P= 0.0078), was not significantly different from that in the LTA group (P= 0.039).Quantification of pro-inflammatory cytokines in BALF ::: ResultsThe concentrations of pro-inflammatory cytokines in BALF are illustrated in Fig. 2.", [["neutrophils", "ANATOMY", 18, 29], ["BALF", "ANATOMY", 33, 37], ["PRCV", "ANATOMY", 100, 104], ["BALF", "ANATOMY", 310, 314], ["neutrophils", "CELL", 18, 29], ["BALF", "CELL", 33, 37], ["PRCV", "CANCER", 100, 104], ["BALF", "CELL", 310, 314], ["neutrophils", "CELL_TYPE", 18, 29], ["BALF", "CELL_TYPE", 33, 37], ["pro-inflammatory cytokines", "PROTEIN", 212, 238], ["BALF", "CELL_TYPE", 242, 246], ["pro-inflammatory cytokines", "PROTEIN", 280, 306], ["BALF", "CELL_TYPE", 310, 314], ["neutrophils in BALF", "TEST", 18, 37], ["pro-inflammatory cytokines in BALF", "TREATMENT", 280, 314], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["neutrophils", "OBSERVATION", 18, 29], ["LTA", "OBSERVATION_MODIFIER", 50, 53], ["significantly", "OBSERVATION_MODIFIER", 67, 80], ["higher", "OBSERVATION_MODIFIER", 81, 87], ["significantly different", "OBSERVATION_MODIFIER", 132, 155], ["pro-inflammatory cytokines", "OBSERVATION", 212, 238], ["BALF", "ANATOMY", 242, 246], ["concentrations", "OBSERVATION_MODIFIER", 262, 276], ["pro-inflammatory cytokines", "OBSERVATION", 280, 306], ["BALF", "ANATOMY", 310, 314]]], ["No TNF-\u03b1, IL-6 or IL-12/IL-23 were detected in any of the sham-inoculated controls.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 3, 8], ["IL-6", "GENE_OR_GENE_PRODUCT", 10, 14], ["IL-12", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL-23", "GENE_OR_GENE_PRODUCT", 24, 29], ["controls", "ORGANISM", 74, 82], ["TNF", "PROTEIN", 3, 6], ["IL", "PROTEIN", 24, 26], ["TNF", "TEST", 3, 6], ["IL", "TEST", 10, 12], ["IL", "TEST", 18, 20], ["IL", "TEST", 24, 26], ["TNF", "ANATOMY", 3, 6]]], ["Only low levels of IL-1 (102 and 96 U/mL) and IFN-\u03b3 (10 and 12 pg/mL) were detected in 2/4 of the sham-inoculated controls.", [["IL-1", "GENE_OR_GENE_PRODUCT", 19, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 46, 51], ["controls", "ORGANISM", 114, 122], ["IL", "PROTEIN", 19, 21], ["IFN", "PROTEIN", 46, 49], ["IL", "TEST", 19, 21], ["IFN", "TEST", 46, 49], ["low levels", "OBSERVATION_MODIFIER", 5, 15], ["inoculated controls", "OBSERVATION", 103, 122]]], ["Inoculation of PRCV alone induced higher levels of IL-6 (4662\u201346,353 U/mL), IL-12/IL-23 (11\u2013121 pg/mL) and TNF-\u03b1 (124\u2013545 U/mL) than in the sham-inoculated pigs, and the concentrations of IL-1 (<40\u2013544 U/mL) and IFN-\u03b3 (0\u20132329 pg/mL) in 6/8 of the PRCV-inoculated animals were higher than the highest levels recorded in the sham-inoculates.Quantification of pro-inflammatory cytokines in BALF ::: ResultsInoculation of LTA alone resulted in the induction of IL-1, IL-6 and TNF-\u03b1 for a short period.", [["PRCV", "CHEMICAL", 15, 19], ["LTA", "CHEMICAL", 418, 421], ["PRCV", "ORGANISM", 15, 19], ["IL-6", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-12/IL-23", "GENE_OR_GENE_PRODUCT", 76, 87], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 107, 112], ["pigs", "ORGANISM", 156, 160], ["IL-1", "GENE_OR_GENE_PRODUCT", 188, 192], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 212, 217], ["PRCV", "ORGANISM", 247, 251], ["animals", "ORGANISM", 263, 270], ["LTA", "SIMPLE_CHEMICAL", 418, 421], ["IL-1", "GENE_OR_GENE_PRODUCT", 457, 461], ["IL-6", "GENE_OR_GENE_PRODUCT", 463, 467], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 472, 477], ["IL-6", "PROTEIN", 51, 55], ["TNF", "PROTEIN", 107, 110], ["IL", "PROTEIN", 188, 190], ["IFN", "PROTEIN", 212, 215], ["pro-inflammatory cytokines", "PROTEIN", 357, 383], ["BALF", "CELL_TYPE", 387, 391], ["LTA", "PROTEIN", 418, 421], ["IL-1, IL-6", "PROTEIN", 457, 467], ["TNF", "PROTEIN", 472, 475], ["pigs", "SPECIES", 156, 160], ["PRCV", "SPECIES", 15, 19], ["pigs", "SPECIES", 156, 160], ["PRCV", "SPECIES", 247, 251], ["IL", "TEST", 51, 53], ["IL", "TEST", 76, 78], ["TNF", "TEST", 107, 110], ["the concentrations of IL", "TEST", 166, 190], ["IFN", "TEST", 212, 215], ["the PRCV", "TEST", 243, 251], ["LTA", "TEST", 418, 421], ["the induction of IL", "TREATMENT", 440, 459], ["IL", "TREATMENT", 463, 465], ["TNF", "TREATMENT", 472, 475], ["higher", "OBSERVATION_MODIFIER", 276, 282], ["pro-inflammatory cytokines", "OBSERVATION", 357, 383], ["BALF", "ANATOMY", 387, 391]]], ["By 12 h PI, these cytokines were no longer detectable in these pigs.", [["pigs", "ORGANISM", 63, 67], ["cytokines", "PROTEIN", 18, 27], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 63, 67], ["these cytokines", "TEST", 12, 27], ["no longer", "UNCERTAINTY", 33, 42]]], ["The concentrations of IFN-\u03b3 in this group never exceeded those in sham-inoculated animals and remained constant throughout the experiment.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 22, 27], ["IFN", "PROTEIN", 22, 25], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["constant", "OBSERVATION_MODIFIER", 103, 111]]], ["The levels of IL-12/IL-23 in 3/8 LTA-inoculated animals exceeded the maximal levels observed in the sham-inoculates.", [["IL-12", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-23", "GENE_OR_GENE_PRODUCT", 20, 25], ["LTA", "SIMPLE_CHEMICAL", 33, 36], ["animals", "ORGANISM", 48, 55], ["IL", "PROTEIN", 20, 22], ["The levels", "TEST", 0, 10], ["IL", "TEST", 14, 16], ["IL", "TEST", 20, 22], ["LTA", "TEST", 33, 36], ["the maximal levels", "TEST", 65, 83]]], ["Cytokine concentrations were similar in the PRCV\u2013LTA and PRCV groups (P> 0.025), and the levels of IL-6, IL-12/IL-23 and IFN-\u03b3 were higher than those of the LTA group (P< 0.025).", [["PRCV", "ANATOMY", 57, 61], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["PRCV\u2013LTA", "CELL", 44, 52], ["PRCV", "CANCER", 57, 61], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["IL-12", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-23", "GENE_OR_GENE_PRODUCT", 111, 116], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 121, 126], ["LTA", "SIMPLE_CHEMICAL", 157, 160], ["Cytokine", "PROTEIN", 0, 8], ["IL-23", "PROTEIN", 111, 116], ["IFN", "PROTEIN", 121, 124], ["PRCV", "SPECIES", 44, 48], ["PRCV", "SPECIES", 57, 61], ["Cytokine concentrations", "TEST", 0, 23], ["P", "TEST", 70, 71], ["the levels", "TEST", 85, 95], ["IL", "TEST", 99, 101], ["IL", "TEST", 105, 107], ["IL", "TEST", 111, 113], ["IFN", "TEST", 121, 124]]], ["The concentrations of all cytokines peaked at 28/4 h after PRCV/LTA inoculation and at the end of the study the levels were still higher than in the sham-inoculated controls.DiscussionThe results of this experiment demonstrate that LTA from S. aureus enhances the clinical severity of PRCV infection in pigs in a manner similar to that of LPS from E. coli (Van Reeth et al., 2000).", [["PRCV", "CHEMICAL", 59, 63], ["LTA", "CHEMICAL", 64, 67], ["LTA", "CHEMICAL", 232, 235], ["PRCV", "CHEMICAL", 285, 289], ["infection", "DISEASE", 290, 299], ["LPS", "CHEMICAL", 339, 342], ["LTA", "GENE_OR_GENE_PRODUCT", 232, 235], ["S. aureus", "ORGANISM", 241, 250], ["PRCV", "CANCER", 285, 289], ["pigs", "ORGANISM", 303, 307], ["LPS", "SIMPLE_CHEMICAL", 339, 342], ["E. coli", "ORGANISM", 348, 355], ["cytokines", "PROTEIN", 26, 35], ["S. aureus", "SPECIES", 241, 250], ["pigs", "SPECIES", 303, 307], ["E. coli", "SPECIES", 348, 355], ["PRCV", "SPECIES", 59, 63], ["S. aureus", "SPECIES", 241, 250], ["PRCV", "SPECIES", 285, 289], ["pigs", "SPECIES", 303, 307], ["E. coli", "SPECIES", 348, 355], ["all cytokines", "PROBLEM", 22, 35], ["PRCV/LTA inoculation", "TREATMENT", 59, 79], ["the study", "TEST", 98, 107], ["the levels", "TEST", 108, 118], ["LTA", "PROBLEM", 232, 235], ["S. aureus", "PROBLEM", 241, 250], ["PRCV infection", "PROBLEM", 285, 299], ["LPS", "PROBLEM", 339, 342], ["E. coli", "PROBLEM", 348, 355], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["higher", "OBSERVATION_MODIFIER", 130, 136], ["aureus", "OBSERVATION", 244, 250], ["infection", "OBSERVATION", 290, 299]]], ["However, there was no evidence that this clinical exacerbation was associated with over-production of pro-inflammatory cytokines such as TNF-\u03b1, as previously hypothesised in the context of PRCV infection and LPS (Van Reeth et al., 2000).", [["infection", "DISEASE", 194, 203], ["LPS", "CHEMICAL", 208, 211], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 137, 142], ["PRCV", "ORGANISM", 189, 193], ["LPS", "SIMPLE_CHEMICAL", 208, 211], ["pro-inflammatory cytokines", "PROTEIN", 102, 128], ["TNF-\u03b1", "PROTEIN", 137, 142], ["PRCV", "SPECIES", 189, 193], ["this clinical exacerbation", "PROBLEM", 36, 62], ["pro-inflammatory cytokines", "PROBLEM", 102, 128], ["TNF", "TEST", 137, 140], ["PRCV infection", "PROBLEM", 189, 203], ["LPS", "PROBLEM", 208, 211], ["no evidence that", "UNCERTAINTY", 19, 35], ["pro-inflammatory cytokines", "OBSERVATION", 102, 128], ["infection", "OBSERVATION", 194, 203]]], ["The concentration of TNF-\u03b1 was higher in PRCV\u2013LPS-inoculated relative to PRCV- and LPS-inoculated controls, and there was a temporal association between peak TNF-\u03b1 production and the severity of clinical signs.", [["PRCV\u2013LPS", "CHEMICAL", 41, 49], ["LPS", "CHEMICAL", 83, 86], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["PRCV\u2013LPS", "SIMPLE_CHEMICAL", 41, 49], ["PRCV", "CELL", 73, 77], ["LPS", "SIMPLE_CHEMICAL", 83, 86], ["controls", "ORGANISM", 98, 106], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 158, 163], ["TNF", "PROTEIN", 21, 24], ["TNF", "PROTEIN", 158, 161], ["PRCV", "SPECIES", 73, 77], ["The concentration of TNF", "TEST", 0, 24], ["PRCV\u2013LPS", "TEST", 41, 49], ["PRCV", "TEST", 73, 77], ["LPS", "TEST", 83, 86], ["a temporal association", "PROBLEM", 122, 144], ["peak TNF", "TEST", 153, 161], ["clinical signs", "TEST", 195, 209], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["temporal", "OBSERVATION_MODIFIER", 124, 132]]], ["Other cytokines, in addition to TNF-\u03b1, were elevated in PRCV\u2013LTA-inoculated pigs and there was no significant difference in the concentration of this cytokine between the PRCV-only and the PRCV\u2013LTA groups.DiscussionDifferences in the modes of action of LTA and LPS may relate to the different ways these compounds are recognised by the host (Draing et al., 2008).", [["LTA", "CHEMICAL", 253, 256], ["LPS", "CHEMICAL", 261, 264], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 32, 37], ["PRCV\u2013LTA", "SIMPLE_CHEMICAL", 56, 64], ["pigs", "ORGANISM", 76, 80], ["LTA", "SIMPLE_CHEMICAL", 253, 256], ["LPS", "SIMPLE_CHEMICAL", 261, 264], ["cytokines", "PROTEIN", 6, 15], ["TNF", "PROTEIN", 32, 35], ["cytokine", "PROTEIN", 150, 158], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 76, 80], ["Other cytokines", "TEST", 0, 15], ["TNF", "TEST", 32, 35], ["PRCV\u2013LTA", "TEST", 56, 64], ["the PRCV", "TEST", 167, 175], ["LTA and LPS", "TREATMENT", 253, 264], ["cytokines", "OBSERVATION", 6, 15], ["elevated", "OBSERVATION_MODIFIER", 44, 52], ["no", "UNCERTAINTY", 95, 97], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["difference", "OBSERVATION", 110, 120]]], ["It is likely that LTA is recognised by TLR-2 (Hoogerwerf et al., 2008, Knapp et al., 2008, Meron-Sudai et al., 2008), whereas LPS recognition is mediated through TLR-4 (Triantafilou and Triantafilou, 2005).", [["LTA", "CHEMICAL", 18, 21], ["LPS", "CHEMICAL", 126, 129], ["LTA", "GENE_OR_GENE_PRODUCT", 18, 21], ["TLR-2", "GENE_OR_GENE_PRODUCT", 39, 44], ["LPS", "SIMPLE_CHEMICAL", 126, 129], ["TLR-4", "GENE_OR_GENE_PRODUCT", 162, 167], ["LTA", "PROTEIN", 18, 21], ["TLR", "PROTEIN", 39, 42], ["TLR", "PROTEIN", 162, 165], ["LTA", "PROBLEM", 18, 21], ["LPS recognition", "TEST", 126, 141], ["likely that", "UNCERTAINTY", 6, 17], ["LTA", "OBSERVATION_MODIFIER", 18, 21]]], ["Pure LTA appears to be a less potent cytokine-inducer than LPS and the ability of LTA to induce higher concentrations of cytokines has been attributed to its synergistic interactions with other bacterial components such as muramyl dipeptide (Yang et al., 2001), peptidoglycan or host macromolecules such as glycosphingolipids (Meron-Sudai et al., 2008).DiscussionRecently, the recognition of LTA has been shown to involve not only TLR-2 and CD14 (also a co-receptor for LPS), but also CD36.", [["LTA", "CHEMICAL", 5, 8], ["LPS", "CHEMICAL", 59, 62], ["LTA", "CHEMICAL", 82, 85], ["muramyl dipeptide", "CHEMICAL", 223, 240], ["LTA", "CHEMICAL", 392, 395], ["muramyl dipeptide", "CHEMICAL", 223, 240], ["LTA", "GENE_OR_GENE_PRODUCT", 5, 8], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["LTA", "SIMPLE_CHEMICAL", 82, 85], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 223, 240], ["peptidoglycan", "SIMPLE_CHEMICAL", 262, 275], ["glycosphingolipids", "SIMPLE_CHEMICAL", 307, 325], ["LTA", "GENE_OR_GENE_PRODUCT", 392, 395], ["TLR-2", "GENE_OR_GENE_PRODUCT", 431, 436], ["CD14", "GENE_OR_GENE_PRODUCT", 441, 445], ["LPS", "GENE_OR_GENE_PRODUCT", 470, 473], ["CD36", "GENE_OR_GENE_PRODUCT", 485, 489], ["cytokine", "PROTEIN", 37, 45], ["cytokines", "PROTEIN", 121, 130], ["LTA", "PROTEIN", 392, 395], ["TLR", "PROTEIN", 431, 434], ["CD14", "PROTEIN", 441, 445], ["CD36", "PROTEIN", 485, 489], ["LPS", "TREATMENT", 59, 62], ["LTA", "TREATMENT", 82, 85], ["higher concentrations of cytokines", "PROBLEM", 96, 130], ["its synergistic interactions", "PROBLEM", 154, 182], ["other bacterial components", "PROBLEM", 188, 214], ["muramyl dipeptide", "TREATMENT", 223, 240], ["peptidoglycan", "TREATMENT", 262, 275], ["host macromolecules", "TREATMENT", 279, 298], ["glycosphingolipids", "TREATMENT", 307, 325], ["TLR", "TEST", 431, 434], ["less potent", "OBSERVATION_MODIFIER", 25, 36]]], ["Blocking of this co-receptor and CD14 inhibited the binding of LTA and LTA-induced TNF-\u03b1 release by human monocytes (Nilsen et al., 2008).", [["monocytes", "ANATOMY", 106, 115], ["LTA", "CHEMICAL", 63, 66], ["LTA", "CHEMICAL", 71, 74], ["CD14", "GENE_OR_GENE_PRODUCT", 33, 37], ["LTA", "GENE_OR_GENE_PRODUCT", 63, 66], ["LTA", "SIMPLE_CHEMICAL", 71, 74], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["human", "ORGANISM", 100, 105], ["monocytes", "CELL", 106, 115], ["co-receptor", "PROTEIN", 17, 28], ["CD14", "PROTEIN", 33, 37], ["TNF", "PROTEIN", 83, 86], ["human monocytes", "CELL_TYPE", 100, 115], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["LTA", "TEST", 63, 66], ["LTA", "TEST", 71, 74], ["TNF", "TEST", 83, 86]]], ["Further research is required to determine if PRCV infection induces increased expression of LTA receptors such as TLR-2 and CD36, as has been shown for CD14 (Van Gucht et al., 2006).", [["PRCV", "CHEMICAL", 45, 49], ["infection", "DISEASE", 50, 59], ["PRCV", "ORGANISM", 45, 49], ["LTA receptors", "GENE_OR_GENE_PRODUCT", 92, 105], ["TLR-2", "GENE_OR_GENE_PRODUCT", 114, 119], ["CD36", "GENE_OR_GENE_PRODUCT", 124, 128], ["CD14", "GENE_OR_GENE_PRODUCT", 152, 156], ["LTA receptors", "PROTEIN", 92, 105], ["TLR-2", "PROTEIN", 114, 119], ["CD36", "PROTEIN", 124, 128], ["CD14", "PROTEIN", 152, 156], ["PRCV", "SPECIES", 45, 49], ["PRCV infection", "PROBLEM", 45, 59], ["LTA receptors", "PROBLEM", 92, 105], ["TLR", "TEST", 114, 117], ["infection", "OBSERVATION", 50, 59]]], ["In general, the mechanisms through which Gram-positive bacteria effect host immunological activation are less clearly understood than for Gram-negative infections (Sriskandan and Cohen, 1999, Draing et al., 2008).DiscussionIn general, bacterial cell-wall components are effective in inducing the production of chemokines such as IL-8.", [["cell-wall components", "ANATOMY", 245, 265], ["infections", "DISEASE", 152, 162], ["Gram-", "GENE_OR_GENE_PRODUCT", 41, 46], ["Gram", "GENE_OR_GENE_PRODUCT", 138, 142], ["cell", "CELL", 245, 249], ["IL-8", "GENE_OR_GENE_PRODUCT", 329, 333], ["chemokines", "PROTEIN", 310, 320], ["IL-8", "PROTEIN", 329, 333], ["Gram-positive bacteria effect host immunological activation", "PROBLEM", 41, 100], ["Gram-negative infections", "PROBLEM", 138, 162], ["bacterial cell-wall components", "TREATMENT", 235, 265], ["negative", "OBSERVATION_MODIFIER", 143, 151], ["infections", "OBSERVATION", 152, 162], ["bacterial cell", "OBSERVATION", 235, 249], ["wall", "ANATOMY_MODIFIER", 250, 254]]], ["Our finding that up to 81% of the total BALF cells were neutrophils in LTA-inoculated pigs indicates that this bacterial component may be highly effective in activating pulmonary neutrophil infiltration in this species.", [["BALF cells", "ANATOMY", 40, 50], ["neutrophils", "ANATOMY", 56, 67], ["pulmonary neutrophil", "ANATOMY", 169, 189], ["BALF cells", "CELL", 40, 50], ["neutrophils", "CELL", 56, 67], ["LTA", "SIMPLE_CHEMICAL", 71, 74], ["pigs", "ORGANISM", 86, 90], ["pulmonary neutrophil", "CELL", 169, 189], ["BALF cells", "CELL_TYPE", 40, 50], ["neutrophils", "CELL_TYPE", 56, 67], ["LTA", "PROTEIN", 71, 74], ["pigs", "SPECIES", 86, 90], ["pigs", "SPECIES", 86, 90], ["the total BALF cells", "TEST", 30, 50], ["neutrophils", "TEST", 56, 67], ["LTA", "TEST", 71, 74], ["this bacterial component", "PROBLEM", 106, 130], ["activating pulmonary neutrophil infiltration", "PROBLEM", 158, 202], ["BALF cells", "OBSERVATION", 40, 50], ["pulmonary", "ANATOMY", 169, 178], ["neutrophil infiltration", "OBSERVATION", 179, 202]]], ["A similar rapid influx of neutrophils into the milk of cows occurs following inoculation of 10\u2013100 \u03bcg LTA into the mammary gland (Rainard et al., 2008).", [["neutrophils", "ANATOMY", 26, 37], ["milk", "ANATOMY", 47, 51], ["mammary gland", "ANATOMY", 115, 128], ["neutrophils", "CELL", 26, 37], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["cows", "ORGANISM", 55, 59], ["LTA", "SIMPLE_CHEMICAL", 102, 105], ["mammary gland", "ORGAN", 115, 128], ["neutrophils", "CELL_TYPE", 26, 37], ["cows", "SPECIES", 55, 59], ["A similar rapid influx of neutrophils", "PROBLEM", 0, 37], ["inoculation", "TREATMENT", 77, 88], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["rapid", "OBSERVATION_MODIFIER", 10, 15], ["influx of neutrophils", "OBSERVATION", 16, 37], ["mammary gland", "ANATOMY", 115, 128]]], ["In this study the neutrophil influx was accompanied by increased secretion of TNF-\u03b1 and IL-1\u03b2 and of chemokines like CXCL-2 and IL-8.", [["neutrophil", "ANATOMY", 18, 28], ["neutrophil", "CELL", 18, 28], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 88, 93], ["CXCL-2", "GENE_OR_GENE_PRODUCT", 117, 123], ["IL-8", "GENE_OR_GENE_PRODUCT", 128, 132], ["TNF", "PROTEIN", 78, 81], ["IL-1\u03b2", "PROTEIN", 88, 93], ["chemokines", "PROTEIN", 101, 111], ["CXCL-2 and IL-8", "PROTEIN", 117, 132], ["this study", "TEST", 3, 13], ["increased secretion", "PROBLEM", 55, 74], ["TNF", "TEST", 78, 81], ["IL", "TEST", 88, 90], ["chemokines", "TEST", 101, 111], ["CXCL", "TEST", 117, 121], ["IL", "TEST", 128, 130], ["neutrophil influx", "OBSERVATION", 18, 35], ["increased", "OBSERVATION_MODIFIER", 55, 64]]], ["In the current study, the finding that the total BALF cell count and neutrophil percentages in the PRCV\u2013LTA pigs were slightly, though not significantly, lower than in LTA-inoculated animals during the first 8 h PI may possibly have been due to their more rapid and effective destruction in the dually-inoculated pigs (Medan et al., 2002, Fuchs et al., 2007, Zhang et al., 2008).DiscussionWe did not investigate the possible role of histamine in the pathogenesis of disease in our experimental model.", [["BALF cell", "ANATOMY", 49, 58], ["neutrophil", "ANATOMY", 69, 79], ["LTA", "CHEMICAL", 168, 171], ["histamine", "CHEMICAL", 433, 442], ["histamine", "CHEMICAL", 433, 442], ["BALF cell", "CELL", 49, 58], ["neutrophil", "CELL", 69, 79], ["pigs", "ORGANISM", 108, 112], ["LTA", "SIMPLE_CHEMICAL", 168, 171], ["PI", "SIMPLE_CHEMICAL", 212, 214], ["pigs", "ORGANISM", 313, 317], ["histamine", "SIMPLE_CHEMICAL", 433, 442], ["neutrophil", "CELL_TYPE", 69, 79], ["pigs", "SPECIES", 108, 112], ["pigs", "SPECIES", 313, 317], ["pigs", "SPECIES", 108, 112], ["pigs", "SPECIES", 313, 317], ["the current study", "TEST", 3, 20], ["the total BALF cell count", "TEST", 39, 64], ["neutrophil percentages", "TEST", 69, 91], ["LTA pigs", "TREATMENT", 104, 112], ["effective destruction", "PROBLEM", 266, 287], ["histamine", "TREATMENT", 433, 442], ["disease", "PROBLEM", 466, 473], ["BALF cell count", "OBSERVATION", 49, 64], ["neutrophil percentages", "OBSERVATION", 69, 91], ["slightly", "OBSERVATION_MODIFIER", 118, 126], ["effective", "OBSERVATION_MODIFIER", 266, 275], ["destruction", "OBSERVATION", 276, 287], ["disease", "OBSERVATION", 466, 473]]], ["In addition to mast cells, neutrophils can produce histamine during mycoplasma infection in mice (Xu et al., 2006).", [["mast cells", "ANATOMY", 15, 25], ["neutrophils", "ANATOMY", 27, 38], ["histamine", "CHEMICAL", 51, 60], ["mycoplasma infection", "DISEASE", 68, 88], ["histamine", "CHEMICAL", 51, 60], ["mast cells", "CELL", 15, 25], ["neutrophils", "CELL", 27, 38], ["histamine", "SIMPLE_CHEMICAL", 51, 60], ["mice", "ORGANISM", 92, 96], ["mast cells", "CELL_TYPE", 15, 25], ["neutrophils", "CELL_TYPE", 27, 38], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["mast cells", "PROBLEM", 15, 25], ["neutrophils", "TEST", 27, 38], ["histamine", "PROBLEM", 51, 60], ["mycoplasma infection", "PROBLEM", 68, 88], ["mast cells", "OBSERVATION", 15, 25], ["mycoplasma infection", "OBSERVATION", 68, 88]]], ["Histamine can interact with LPS in the expression of cyclo-oxygenase-2 and of prostaglandin I2 and E2 by human endothelial cells (Tan et al., 2007) and can also increase the sensitivity of these cells to the effects of Gram-positive and Gram-negative bacteria through inducing the expression of TLR-2, TLR-4 (Talreja et al., 2004), IL-8 and IL-6 (Li et al., 2001).", [["endothelial cells", "ANATOMY", 111, 128], ["cells", "ANATOMY", 195, 200], ["Histamine", "CHEMICAL", 0, 9], ["LPS", "CHEMICAL", 28, 31], ["prostaglandin I2", "CHEMICAL", 78, 94], ["E2", "CHEMICAL", 99, 101], ["Histamine", "CHEMICAL", 0, 9], ["prostaglandin I2", "CHEMICAL", 78, 94], ["Histamine", "SIMPLE_CHEMICAL", 0, 9], ["LPS", "SIMPLE_CHEMICAL", 28, 31], ["cyclo-oxygenase-2", "GENE_OR_GENE_PRODUCT", 53, 70], ["prostaglandin I2", "SIMPLE_CHEMICAL", 78, 94], ["E2", "SIMPLE_CHEMICAL", 99, 101], ["human", "ORGANISM", 105, 110], ["endothelial cells", "CELL", 111, 128], ["cells", "CELL", 195, 200], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 219, 232], ["Gram-", "GENE_OR_GENE_PRODUCT", 237, 242], ["TLR-2", "GENE_OR_GENE_PRODUCT", 295, 300], ["TLR-4", "GENE_OR_GENE_PRODUCT", 302, 307], ["IL-8", "GENE_OR_GENE_PRODUCT", 332, 336], ["IL-6", "GENE_OR_GENE_PRODUCT", 341, 345], ["cyclo-oxygenase", "PROTEIN", 53, 68], ["human endothelial cells", "CELL_TYPE", 105, 128], ["TLR", "PROTEIN", 295, 298], ["TLR", "PROTEIN", 302, 305], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["Histamine", "TREATMENT", 0, 9], ["LPS", "TREATMENT", 28, 31], ["cyclo-oxygenase", "TEST", 53, 68], ["prostaglandin I2", "TREATMENT", 78, 94], ["Gram-positive and Gram-negative bacteria", "PROBLEM", 219, 259], ["TLR", "TEST", 295, 298], ["TLR", "TEST", 302, 305], ["IL", "TEST", 332, 334], ["negative bacteria", "OBSERVATION", 242, 259]]], ["Furthermore, histamine-mediated respiratory disease closely resembles the pattern of clinical signs observed in our study (White et al., 1987, White, 1990).DiscussionHistamine causes broncho-constriction leading to dyspnoea, tachypnoea and laboured abdominal breathing.", [["respiratory", "ANATOMY", 32, 43], ["broncho", "ANATOMY", 183, 190], ["abdominal", "ANATOMY", 249, 258], ["histamine", "CHEMICAL", 13, 22], ["respiratory disease", "DISEASE", 32, 51], ["DiscussionHistamine", "CHEMICAL", 156, 175], ["broncho-constriction", "DISEASE", 183, 203], ["dyspnoea", "DISEASE", 215, 223], ["tachypnoea", "DISEASE", 225, 235], ["abdominal breathing", "DISEASE", 249, 268], ["histamine", "CHEMICAL", 13, 22], ["DiscussionHistamine", "CHEMICAL", 156, 175], ["histamine", "SIMPLE_CHEMICAL", 13, 22], ["DiscussionHistamine", "SIMPLE_CHEMICAL", 156, 175], ["abdominal", "ORGANISM_SUBDIVISION", 249, 258], ["histamine-mediated respiratory disease", "PROBLEM", 13, 51], ["clinical signs", "PROBLEM", 85, 99], ["our study", "TEST", 112, 121], ["DiscussionHistamine", "TREATMENT", 156, 175], ["broncho-constriction", "PROBLEM", 183, 203], ["dyspnoea", "PROBLEM", 215, 223], ["tachypnoea", "PROBLEM", 225, 235], ["laboured abdominal breathing", "PROBLEM", 240, 268], ["respiratory disease", "OBSERVATION", 32, 51], ["tachypnoea", "OBSERVATION", 225, 235], ["abdominal", "ANATOMY", 249, 258], ["breathing", "OBSERVATION", 259, 268]]], ["Moreover, its ability to induce the production of TNF-\u03b1, IL-6 and other cytokines may also contribute to the severity of these clinical features.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["TNF", "PROTEIN", 50, 53], ["IL-6", "PROTEIN", 57, 61], ["cytokines", "PROTEIN", 72, 81], ["TNF", "TEST", 50, 53], ["IL", "TEST", 57, 59], ["other cytokines", "TREATMENT", 66, 81]]], ["Leaving aside this speculation as to a possible role for histamine in our infection model, we can conclude that the severity of the induced disease was not linked to the effect of TNF-\u03b1, but most likely reflected an integrated, concerted interaction between the examined cytokines and possibly other (so far unidentified) mediators.ConclusionsTo our knowledge this is the first in vivo study to report the synergistic interaction between a virus and LTA in enhancing the severity of respiratory disease in the pig.", [["respiratory", "ANATOMY", 483, 494], ["histamine", "CHEMICAL", 57, 66], ["infection", "DISEASE", 74, 83], ["LTA", "CHEMICAL", 450, 453], ["respiratory disease", "DISEASE", 483, 502], ["histamine", "CHEMICAL", 57, 66], ["histamine", "SIMPLE_CHEMICAL", 57, 66], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 180, 185], ["LTA", "SIMPLE_CHEMICAL", 450, 453], ["pig", "ORGANISM", 510, 513], ["TNF", "PROTEIN", 180, 183], ["cytokines", "PROTEIN", 271, 280], ["pig", "SPECIES", 510, 513], ["pig", "SPECIES", 510, 513], ["histamine", "TREATMENT", 57, 66], ["the induced disease", "PROBLEM", 128, 147], ["TNF", "TEST", 180, 183], ["vivo study", "TEST", 381, 391], ["the synergistic interaction", "PROBLEM", 402, 429], ["a virus and LTA", "TREATMENT", 438, 453], ["respiratory disease", "PROBLEM", 483, 502], ["infection", "OBSERVATION", 74, 83], ["disease", "OBSERVATION", 140, 147], ["severity", "OBSERVATION_MODIFIER", 471, 479], ["respiratory disease", "OBSERVATION", 483, 502]]], ["Given that Gram-positive bacteria capable of producing LTA are commonly found in high quantities in the dust within pig accommodation, its role in the development of porcine respiratory disease complex merits further investigation.Conflict of interest statementNone of the authors of this paper has a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.", [["respiratory", "ANATOMY", 174, 185], ["LTA", "CHEMICAL", 55, 58], ["porcine respiratory disease", "DISEASE", 166, 193], ["Gram-", "GENE_OR_GENE_PRODUCT", 11, 16], ["LTA", "GENE_OR_GENE_PRODUCT", 55, 58], ["pig", "ORGANISM", 116, 119], ["porcine", "ORGANISM", 166, 173], ["people", "ORGANISM", 347, 353], ["LTA", "PROTEIN", 55, 58], ["porcine", "SPECIES", 166, 173], ["people", "SPECIES", 347, 353], ["pig", "SPECIES", 116, 119], ["Gram-positive bacteria", "PROBLEM", 11, 33], ["porcine respiratory disease", "PROBLEM", 166, 193], ["further investigation", "TEST", 209, 230], ["bacteria", "OBSERVATION", 25, 33], ["LTA", "OBSERVATION_MODIFIER", 55, 58], ["high quantities", "OBSERVATION_MODIFIER", 81, 96], ["dust", "OBSERVATION", 104, 108], ["pig accommodation", "OBSERVATION", 116, 133], ["porcine", "OBSERVATION_MODIFIER", 166, 173], ["respiratory disease", "OBSERVATION", 174, 193]]]], "PMC7214778": [["\u206f\u206fDear Editor,\u206f\u206fSmall interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded non-coding RNA molecules, which is 20-25 base pairs in length. siRNAs can regulate the expression of genes, by a phenomenon known as RNA interference (RNAi).", [["Small interfering RNA", "RNA", 16, 37], ["short interfering RNA", "RNA", 66, 87], ["silencing RNA", "RNA", 91, 104], ["double-stranded non-coding RNA molecules", "RNA", 120, 160], ["Small interfering RNA (siRNA)", "PROBLEM", 16, 45], ["short interfering RNA or silencing RNA", "PROBLEM", 66, 104], ["double-stranded non-coding RNA molecules", "PROBLEM", 120, 160], ["siRNAs", "TREATMENT", 199, 205], ["Small", "OBSERVATION_MODIFIER", 16, 21], ["interfering", "OBSERVATION", 22, 33]]], ["Based on the phenomenon, the siRNA based therapeutics have been developed and implemented for anticancer, antiviral, and genetic diseases (Liu et al., 2020[4]).\u206f\u206fIn December 2019, WHO reported the outbreak of a novel coronavirus, designated as SARS-CoV-2 or severe acute respiratory syndrome-related coronavirus.", [["anticancer", "ANATOMY", 94, 104], ["coronavirus", "DISEASE", 217, 228], ["acute respiratory syndrome-related coronavirus", "DISEASE", 265, 311], ["anticancer", "CANCER", 94, 104], ["coronavirus", "ORGANISM", 217, 228], ["SARS-CoV-2", "ORGANISM", 244, 254], ["severe acute respiratory", "ORGANISM", 258, 282], ["coronavirus", "ORGANISM", 300, 311], ["coronavirus", "SPECIES", 217, 228], ["SARS-CoV", "SPECIES", 244, 252], ["coronavirus", "SPECIES", 300, 311], ["SARS-CoV-2", "SPECIES", 244, 254], ["severe acute respiratory syndrome-related coronavirus", "SPECIES", 258, 311], ["the phenomenon", "PROBLEM", 9, 23], ["the siRNA", "TREATMENT", 25, 34], ["anticancer", "TREATMENT", 94, 104], ["antiviral", "TREATMENT", 106, 115], ["a novel coronavirus", "PROBLEM", 209, 228], ["severe acute respiratory syndrome", "PROBLEM", 258, 291], ["coronavirus", "PROBLEM", 300, 311], ["severe", "OBSERVATION_MODIFIER", 258, 264], ["acute", "OBSERVATION_MODIFIER", 265, 270], ["respiratory syndrome", "OBSERVATION", 271, 291], ["coronavirus", "OBSERVATION", 300, 311]]], ["This virus has currently spread across 212 countries which resulted in 2,416,135 active cases of infection, and approximately 165,939 mortalities, as per WHO (2020[9]).", [["infection", "DISEASE", 97, 106], ["This virus", "PROBLEM", 0, 10], ["infection", "PROBLEM", 97, 106], ["virus", "OBSERVATION", 5, 10], ["active", "OBSERVATION_MODIFIER", 81, 87], ["infection", "OBSERVATION", 97, 106]]], ["There are many drugs currently being tested which include antiviral (remdesivir, favipiravir, lopinavir, ritonavir, and arbidol), anti-malarial (hydroxychloroquine), and anticancer (interferon-alpha 2b) agents.", [["anticancer", "ANATOMY", 170, 180], ["remdesivir", "CHEMICAL", 69, 79], ["favipiravir", "CHEMICAL", 81, 92], ["lopinavir, ritonavir", "CHEMICAL", 94, 114], ["arbidol", "CHEMICAL", 120, 127], ["hydroxychloroquine", "CHEMICAL", 145, 163], ["interferon-alpha 2b", "CHEMICAL", 182, 201], ["remdesivir", "CHEMICAL", 69, 79], ["favipiravir", "CHEMICAL", 81, 92], ["lopinavir", "CHEMICAL", 94, 103], ["ritonavir", "CHEMICAL", 105, 114], ["arbidol", "CHEMICAL", 120, 127], ["hydroxychloroquine", "CHEMICAL", 145, 163], ["remdesivir", "SIMPLE_CHEMICAL", 69, 79], ["favipiravir", "SIMPLE_CHEMICAL", 81, 92], ["lopinavir", "SIMPLE_CHEMICAL", 94, 103], ["ritonavir", "SIMPLE_CHEMICAL", 105, 114], ["arbidol", "SIMPLE_CHEMICAL", 120, 127], ["anti-malarial", "SIMPLE_CHEMICAL", 130, 143], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 145, 163], ["anticancer", "CANCER", 170, 180], ["interferon-alpha 2b", "GENE_OR_GENE_PRODUCT", 182, 201], ["interferon", "PROTEIN", 182, 192], ["many drugs", "TREATMENT", 10, 20], ["antiviral (remdesivir", "TREATMENT", 58, 79], ["favipiravir", "TREATMENT", 81, 92], ["lopinavir", "TREATMENT", 94, 103], ["ritonavir", "TREATMENT", 105, 114], ["arbidol", "TREATMENT", 120, 127], ["anti-malarial (hydroxychloroquine)", "TREATMENT", 130, 164], ["anticancer (interferon", "TREATMENT", 170, 192], ["alpha 2b) agents", "TREATMENT", 193, 209], ["many", "OBSERVATION_MODIFIER", 10, 14], ["drugs", "OBSERVATION", 15, 20]]], ["These drug candidates are undergoing clinical trials, and their efficacy against SARS-CoV-2 has yet to be proven.", [["SARS", "DISEASE", 81, 85], ["SARS-CoV-2", "ORGANISM", 81, 91], ["SARS-CoV", "SPECIES", 81, 89], ["clinical trials", "TREATMENT", 37, 52], ["SARS", "PROBLEM", 81, 85]]], ["Under such a situation, siRNA based treatment can provide an effective solution in combating COVID-19 (Liu et al., 2020[4]).", [["siRNA based treatment", "TREATMENT", 24, 45], ["an effective solution", "TREATMENT", 58, 79]]], ["Some earlier studies revealed that siRNA candidates were effectively used against the outbreak of SARS and Middle-East Respiratory Syndrome (MERS), recapitulated in Table 1(Tab.", [["SARS", "DISEASE", 98, 102], ["Middle-East Respiratory Syndrome", "DISEASE", 107, 139], ["Middle-East Respiratory Syndrome (MERS)", "SPECIES", 107, 146], ["Some earlier studies", "TEST", 0, 20], ["siRNA candidates", "TREATMENT", 35, 51], ["SARS", "PROBLEM", 98, 102], ["Middle-East Respiratory Syndrome", "PROBLEM", 107, 139], ["Middle", "ANATOMY_MODIFIER", 107, 113], ["Respiratory Syndrome", "OBSERVATION", 119, 139]]], ["1) (References in Table 1: Weimin H, Li S, Aili L, 2003[8]; Tang QQ, Lu PY, Xie FY, Liu Y, Xu J, Woodle MC, 2004[6]; Wang Y, Liu L, Wang S, Zhang Y, 2006[7]; Zhang Y, Wang G, Li M, Wang H, Feng H, 2006[12]; Sun B, Zheng B, Lv W, Xu K, 2006[5]; Elm\u00e9n J, Wahlestedt C, Liang Z, S\u00f8rensen MA, \u00d8rum H, Koch T, 2014[2]).\u206f\u206fThe siRNAs identified successfully targeted the sequences which coded for the viral RNA-dependent RNA polymerase, helicase, proteolytic enzymes, and the nucleoprotein N of earlier SARS virus leading to a 50, 70, 90, and 95 % decrease in viral load, respectively.", [["SARS", "DISEASE", 496, 500], ["SARS virus", "ORGANISM", 496, 506], ["viral RNA-dependent RNA polymerase", "PROTEIN", 394, 428], ["helicase", "PROTEIN", 430, 438], ["proteolytic enzymes", "PROTEIN", 440, 459], ["nucleoprotein N", "PROTEIN", 469, 484], ["SARS virus", "SPECIES", 496, 506], ["References in Table", "TEST", 4, 23], ["Weimin", "TEST", 27, 33], ["Li S", "TEST", 37, 41], ["Aili", "TEST", 43, 47], ["MC", "TEST", 104, 106], ["Feng H", "TEST", 189, 195], ["Sun B", "TEST", 207, 212], ["Zheng B", "TEST", 214, 221], ["Lv W", "TEST", 223, 227], ["K", "TEST", 232, 233], ["Elm\u00e9n", "TEST", 244, 249], ["J", "TEST", 250, 251], ["Wahlestedt", "TEST", 253, 263], ["C", "TEST", 264, 265], ["Liang Z", "TEST", 267, 274], ["S\u00f8rensen", "TEST", 276, 284], ["MA", "TEST", 285, 287], ["\u00d8rum H", "TEST", 289, 295], ["Koch T", "TEST", 297, 303], ["The siRNAs", "TREATMENT", 316, 326], ["the sequences", "TEST", 360, 373], ["the viral RNA", "TEST", 390, 403], ["dependent RNA polymerase", "PROBLEM", 404, 428], ["proteolytic enzymes", "TEST", 440, 459], ["earlier SARS virus", "PROBLEM", 488, 506], ["viral load", "TEST", 553, 563], ["Lv", "ANATOMY", 223, 225], ["siRNAs", "OBSERVATION", 320, 326], ["viral load", "OBSERVATION", 553, 563]]], ["The viral genome of SARS-CoV-2 is 29 kbp in size and one of the largest genomes among the RNA virus.", [["SARS-CoV-2", "ORGANISM", 20, 30], ["viral genome", "DNA", 4, 16], ["SARS-CoV-2", "DNA", 20, 30], ["SARS-CoV", "SPECIES", 20, 28], ["The viral genome of SARS", "TEST", 0, 24], ["CoV", "TEST", 25, 28], ["kbp in size", "TEST", 37, 48], ["the RNA virus", "PROBLEM", 86, 99], ["viral genome", "OBSERVATION", 4, 16], ["29 kbp", "OBSERVATION_MODIFIER", 34, 40], ["size", "OBSERVATION_MODIFIER", 44, 48], ["one", "OBSERVATION_MODIFIER", 53, 56], ["largest", "OBSERVATION_MODIFIER", 64, 71], ["genomes", "OBSERVATION", 72, 79], ["RNA virus", "OBSERVATION", 90, 99]]], ["This genome consists of fourteen open reading frames (ORFs) which coded for twenty-seven structural and nonstructural proteins (Wu et al., 2020[10]).", [["open reading frames", "DNA", 33, 52], ["ORFs", "DNA", 54, 58], ["nonstructural proteins", "PROTEIN", 104, 126]]], ["At the 5' end, there are the two largest ORFs, namely ORF1a and ORF1b which are translated into a single large poly-protein by the ribosome through a frame-shift event.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 54, 59], ["ORF1b", "GENE_OR_GENE_PRODUCT", 64, 69], ["ribosome", "CELLULAR_COMPONENT", 131, 139], ["5' end", "DNA", 7, 13], ["ORFs", "DNA", 41, 45], ["ORF1a", "DNA", 54, 59], ["ORF1b", "DNA", 64, 69], ["poly-protein", "PROTEIN", 111, 123], ["the two largest ORFs", "PROBLEM", 25, 45], ["a single large poly-protein", "TREATMENT", 96, 123], ["two", "OBSERVATION_MODIFIER", 29, 32], ["largest", "OBSERVATION_MODIFIER", 33, 40], ["ORFs", "OBSERVATION", 41, 45], ["large", "OBSERVATION_MODIFIER", 105, 110], ["poly", "OBSERVATION", 111, 115]]], ["The ORF1a comprises of two viral cysteine proteases, namely papain-like protease (nsp3) and the main protease designated as 3-chymotrypsin-like protease or 3CL.", [["cysteine", "CHEMICAL", 33, 41], ["ORF1a", "GENE_OR_GENE_PRODUCT", 4, 9], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 60, 80], ["nsp3", "GENE_OR_GENE_PRODUCT", 82, 86], ["3-chymotrypsin-like protease", "GENE_OR_GENE_PRODUCT", 124, 152], ["3CL", "GENE_OR_GENE_PRODUCT", 156, 159], ["ORF1a", "PROTEIN", 4, 9], ["viral cysteine proteases", "PROTEIN", 27, 51], ["papain-like protease", "PROTEIN", 60, 80], ["nsp3", "PROTEIN", 82, 86], ["protease", "PROTEIN", 101, 109], ["3-chymotrypsin-like protease", "PROTEIN", 124, 152], ["3CL", "PROTEIN", 156, 159], ["two viral cysteine proteases", "TREATMENT", 23, 51], ["namely papain", "TREATMENT", 53, 66], ["protease (nsp3", "TREATMENT", 72, 86], ["the main protease", "TREATMENT", 92, 109], ["chymotrypsin-like protease", "TREATMENT", 126, 152], ["viral cysteine proteases", "OBSERVATION", 27, 51]]], ["Among two viral proteases the sequence which codes for the nsp3 has been reported to be less conserved (Liu et al., 2020[4]).", [["nsp3", "GENE_OR_GENE_PRODUCT", 59, 63], ["viral proteases", "PROTEIN", 10, 25], ["nsp3", "PROTEIN", 59, 63], ["the nsp3", "PROBLEM", 55, 63]]], ["However, the sequence which codes for the protease 3CL (nsp5) has been observed to be highly conserved among the annotated sequences (Wu et al., 2020[11]).", [["3CL", "GENE_OR_GENE_PRODUCT", 51, 54], ["nsp5", "GENE_OR_GENE_PRODUCT", 56, 60], ["protease 3CL", "PROTEIN", 42, 54], ["nsp5", "PROTEIN", 56, 60], ["the protease 3CL", "TEST", 38, 54]]], ["Currently, the protease has been considered as a major drug target for multiple antiviral agents, which are presently undergoing clinical trials.", [["protease", "PROTEIN", 15, 23], ["the protease", "TREATMENT", 11, 23], ["multiple antiviral agents", "TREATMENT", 71, 96], ["antiviral agents", "OBSERVATION", 80, 96]]], ["Thus, the sequence coding for nsp5 can be treated as a potential target for RNAi using siRNA based therapeutics.", [["nsp5", "GENE_OR_GENE_PRODUCT", 30, 34], ["nsp5", "PROTEIN", 30, 34], ["siRNA based therapeutics", "TREATMENT", 87, 111]]], ["Other potential targets include the viral RNA dependent RNA polymerase (Rd-Rp) which is located in the ORF1b, stretching from 13-16 kbp on the viral genome.", [["Rd-Rp", "GENE_OR_GENE_PRODUCT", 72, 77], ["ORF1b", "GENE_OR_GENE_PRODUCT", 103, 108], ["viral RNA dependent RNA polymerase", "PROTEIN", 36, 70], ["Rd", "PROTEIN", 72, 74], ["Rp", "PROTEIN", 75, 77], ["ORF1b", "DNA", 103, 108], ["viral genome", "DNA", 143, 155], ["the viral RNA dependent RNA polymerase", "PROBLEM", 32, 70], ["viral RNA", "OBSERVATION", 36, 45], ["viral genome", "OBSERVATION", 143, 155]]], ["Downstream to the sequences (from 16-18 kbp) the site coding for the viral helicase has been identified.", [["viral helicase", "PROTEIN", 69, 83], ["the sequences", "TEST", 14, 27], ["the viral helicase", "PROBLEM", 65, 83], ["viral helicase", "OBSERVATION", 69, 83]]], ["These two sites have been reported to be highly conserved among the annotated genome of SARS-CoV-2 along with the earlier genomes of beta coronaviruses like SARS and MERS (Wu et al., 2020[11]).", [["SARS", "DISEASE", 157, 161], ["SARS-CoV-2", "ORGANISM", 88, 98], ["beta coronaviruses", "ORGANISM", 133, 151], ["SARS-CoV-2", "DNA", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["beta coronaviruses", "SPECIES", 133, 151], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["beta coronaviruses", "PROBLEM", 133, 151], ["SARS", "PROBLEM", 157, 161], ["beta coronaviruses", "OBSERVATION_MODIFIER", 133, 151]]], ["Thus, these two sites can be considered to be potential targets for RNAi using siRNA.\u206f\u206fTo date, various delivery systems for siRNA have been identified which are broadly classified into nanoparticles based carriers and viral vectors.", [["RNAi using siRNA", "TREATMENT", 68, 84], ["various delivery systems", "TREATMENT", 96, 120], ["siRNA", "PROBLEM", 125, 130], ["viral vectors", "TREATMENT", 219, 232], ["viral vectors", "OBSERVATION", 219, 232]]], ["In 2003, siRNA based drug was developed by Sirnaomics, Inc. (Maryland, USA) for the outbreak of SARS-CoV and H5N1 influenza.", [["SARS-CoV and H5N1 influenza", "DISEASE", 96, 123], ["SARS-CoV", "ORGANISM", 96, 104], ["H5N1 influenza", "ORGANISM", 109, 123], ["H5N1 influenza", "SPECIES", 109, 123], ["SARS-CoV", "SPECIES", 96, 104], ["SARS", "PROBLEM", 96, 100], ["CoV", "PROBLEM", 101, 104], ["H5N1 influenza", "PROBLEM", 109, 123]]], ["Besides, in 2017, six siRNA have been developed by Alnylam Pharmaceuticals (USA) and Vir Biotechnology against infectious diseases.", [["infectious diseases", "DISEASE", 111, 130], ["infectious diseases", "PROBLEM", 111, 130]]], ["Further, Alnylam Pharmaceuticals (USA) has designed and synthesized over 350 siRNA targeting highly conserved regions of the available SARS-CoV-2 genome (Hodgson, 2020[3]).", [["Alnylam", "CHEMICAL", 9, 16], ["SARS-CoV-2 genome", "DNA", 135, 152]]], ["However, effective carriers must be identified for the successful delivery of the drug payload at the areas which are predominantly infected by the pathogen.\u206f\u206fFor SARS-CoV-2, the ciliated cells of the human lungs are the primary site for viral infection, with reports indicating viral transmission via contact, droplets of saliva or fomites from the infected person.", [["ciliated cells", "ANATOMY", 179, 193], ["lungs", "ANATOMY", 207, 212], ["saliva", "ANATOMY", 323, 329], ["fomites", "ANATOMY", 333, 340], ["viral infection", "DISEASE", 238, 253], ["ciliated cells", "CELL", 179, 193], ["human", "ORGANISM", 201, 206], ["lungs", "ORGAN", 207, 212], ["saliva", "ORGANISM_SUBSTANCE", 323, 329], ["ciliated cells", "CELL_TYPE", 179, 193], ["human", "SPECIES", 201, 206], ["person", "SPECIES", 359, 365], ["SARS-CoV", "SPECIES", 163, 171], ["human", "SPECIES", 201, 206], ["the drug payload", "TREATMENT", 78, 94], ["SARS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171], ["viral infection", "PROBLEM", 238, 253], ["drug payload", "OBSERVATION", 82, 94], ["predominantly", "OBSERVATION_MODIFIER", 118, 131], ["infected", "OBSERVATION", 132, 140], ["pathogen", "OBSERVATION", 148, 156], ["ciliated cells", "OBSERVATION", 179, 193], ["human", "ANATOMY_MODIFIER", 201, 206], ["lungs", "ANATOMY", 207, 212], ["viral", "OBSERVATION_MODIFIER", 238, 243], ["infection", "OBSERVATION", 244, 253], ["infected", "OBSERVATION", 350, 358]]], ["Therefore, techniques designed for optimal delivery of drugs onto the lung epithelial cells can provide better and timely results.", [["lung epithelial cells", "ANATOMY", 70, 91], ["lung epithelial cells", "CELL", 70, 91], ["lung epithelial cells", "CELL_TYPE", 70, 91], ["optimal delivery of drugs", "TREATMENT", 35, 60], ["the lung epithelial cells", "TREATMENT", 66, 91], ["lung", "ANATOMY", 70, 74], ["epithelial cells", "OBSERVATION", 75, 91]]], ["In this context, Conti and co-researchers have demonstrated an in vitro testing of poly (amidoamine) dendrimer nanocarriers for the potential aerosol-based delivery system of siRNA onto lung epithelial cells (Conti et al., 2014[1]).", [["lung epithelial cells", "ANATOMY", 186, 207], ["poly (amidoamine", "CHEMICAL", 83, 99], ["poly (amidoamine)", "CHEMICAL", 83, 100], ["poly (amidoamine) dendrimer nanocarriers", "SIMPLE_CHEMICAL", 83, 123], ["lung epithelial cells", "CELL", 186, 207], ["lung epithelial cells", "CELL_TYPE", 186, 207], ["poly (amidoamine) dendrimer nanocarriers", "TREATMENT", 83, 123], ["the potential aerosol-based delivery system", "TREATMENT", 128, 171], ["siRNA onto lung epithelial cells", "PROBLEM", 175, 207], ["lung", "ANATOMY", 186, 190], ["epithelial cells", "OBSERVATION", 191, 207]]], ["However, the nanocarrier delivery system has limits to its efficient delivery.", [["the nanocarrier delivery system", "TREATMENT", 9, 40], ["its efficient delivery", "TREATMENT", 55, 77]]], ["Hence, there is a need to overcome these limitations by formulating an effective delivery system that can offer unique advances to the field of inhaled siRNA formulation.\u206f\u206fDespite the pandemic outbreaks of COVID-19 and the high rate of transmission in humans, there is no specific treatment for the COVID-19 at present.", [["COVID-19", "CHEMICAL", 206, 214], ["humans", "ORGANISM", 252, 258], ["humans", "SPECIES", 252, 258], ["humans", "SPECIES", 252, 258], ["an effective delivery system", "TREATMENT", 68, 96], ["inhaled siRNA formulation", "TREATMENT", 144, 169], ["COVID", "TEST", 206, 211], ["the COVID", "TEST", 295, 304], ["no", "UNCERTAINTY", 269, 271]]], ["Thus, for the treatment of COVID-19 siRNA based therapy can be developed against the novel coronavirus SARS-CoV-2, where siRNAs can hit the highly conserved region of SARS-CoV-2 RNA and also can act as an inhibitor to suppress the genetic disorders of the lungs.", [["lungs", "ANATOMY", 256, 261], ["COVID-19 siRNA", "CHEMICAL", 27, 41], ["SARS", "DISEASE", 103, 107], ["COVID-19", "SIMPLE_CHEMICAL", 27, 35], ["coronavirus SARS-CoV-2", "ORGANISM", 91, 113], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 167, 177], ["lungs", "ORGAN", 256, 261], ["SARS-CoV-2 RNA", "RNA", 167, 181], ["coronavirus", "SPECIES", 91, 102], ["COVID-19 siRNA based therapy", "TREATMENT", 27, 55], ["the novel coronavirus SARS", "PROBLEM", 81, 107], ["CoV", "TEST", 108, 111], ["siRNAs", "PROBLEM", 121, 127], ["SARS", "PROBLEM", 167, 171], ["an inhibitor", "TREATMENT", 202, 214], ["the genetic disorders of the lungs", "PROBLEM", 227, 261], ["lungs", "ANATOMY", 256, 261]]], ["This approach could help to achieve a better treatment goal that can reduce the pandemic threat of COVID-19.Conflict of interestThe authors declare no conflict of interest.", [["COVID-19", "CHEMICAL", 99, 107], ["COVID", "TEST", 99, 104]]]], "f04518627b8397d11241046b09b3925ce3cd31ac": [["T he airway epithelium is a critical interface between the host and environment and a common site of genetic and acquired disease states such as asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF), and infectious diseases.", [["airway epithelium", "ANATOMY", 5, 22], ["pulmonary", "ANATOMY", 173, 182], ["asthma", "DISEASE", 145, 151], ["chronic obstructive pulmonary disease", "DISEASE", 153, 190], ["cystic fibrosis", "DISEASE", 192, 207], ["CF", "DISEASE", 209, 211], ["infectious diseases", "DISEASE", 218, 237], ["airway epithelium", "TISSUE", 5, 22], ["pulmonary", "ORGAN", 173, 182], ["genetic and acquired disease states", "PROBLEM", 101, 136], ["asthma", "PROBLEM", 145, 151], ["chronic obstructive pulmonary disease", "PROBLEM", 153, 190], ["cystic fibrosis (CF)", "PROBLEM", 192, 212], ["infectious diseases", "PROBLEM", 218, 237], ["airway", "ANATOMY", 5, 11], ["epithelium", "ANATOMY_MODIFIER", 12, 22], ["asthma", "OBSERVATION", 145, 151], ["chronic", "OBSERVATION_MODIFIER", 153, 160], ["obstructive", "OBSERVATION_MODIFIER", 161, 172], ["pulmonary", "ANATOMY", 173, 182], ["disease", "OBSERVATION", 183, 190], ["cystic", "OBSERVATION_MODIFIER", 192, 198], ["fibrosis", "OBSERVATION", 199, 207], ["infectious", "OBSERVATION_MODIFIER", 218, 228]]], ["Modifying airway epithelia with therapeutic proteins, gene expression cassettes, or genome-editing reagents offers great promise, but efficacious delivery is a common challenge.", [["airway epithelia", "ANATOMY", 10, 26], ["airway epithelia", "TISSUE", 10, 26], ["therapeutic proteins", "PROTEIN", 32, 52], ["gene expression cassettes", "DNA", 54, 79], ["Modifying airway epithelia", "PROBLEM", 0, 26], ["therapeutic proteins", "TREATMENT", 32, 52], ["gene expression cassettes", "TREATMENT", 54, 79], ["genome-editing reagents", "TREATMENT", 84, 107], ["efficacious delivery", "TREATMENT", 134, 154], ["airway", "ANATOMY", 10, 16]]], ["This is because the respiratory epithelium presents barriers through its specialized cell types, secreted host defense factors, and mucociliary transport 1 .", [["respiratory epithelium", "ANATOMY", 20, 42], ["cell", "ANATOMY", 85, 89], ["mucociliary", "ANATOMY", 132, 143], ["respiratory epithelium", "TISSUE", 20, 42], ["cell", "CELL", 85, 89], ["mucociliary transport 1", "GENE_OR_GENE_PRODUCT", 132, 155], ["secreted host defense factors", "PROTEIN", 97, 126], ["the respiratory epithelium", "PROBLEM", 16, 42], ["respiratory epithelium", "OBSERVATION", 20, 42], ["specialized cell types", "OBSERVATION", 73, 95], ["host defense", "OBSERVATION", 106, 118]]], ["While in vivo delivery with vector systems has advanced 2-7 , airway epithelia remain poorly transduced by many viral and non-viral approaches [8] [9] [10] [11] [12] .", [["airway epithelia", "ANATOMY", 62, 78], ["airway epithelia", "MULTI-TISSUE_STRUCTURE", 62, 78], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 143, 165], ["vector systems", "TREATMENT", 28, 42], ["many viral and non-viral approaches", "PROBLEM", 107, 142], ["airway epithelia", "ANATOMY", 62, 78]]]]}